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2 Thesis Abstract 
This thesis presents an approach to expose relationships between immune-mediated drug 
induced liver injury (IMDILI) and the three-dimensional structural features of toxic drug 
molecules and their metabolites. The series of analyses in the following chapters test the 
hypothesis that drugs (or their metabolites) which produce similar patterns of toxicity 
interact with targets within common toxicological pathways and that activation of the 
underlying mechanisms depends on structural similarity among toxic molecules.   
Chapter 1 provides an introduction to the vast and multifaceted literature surrounding drug 
induced liver injuries (DILI). It provides an overview of idiosyncratic DILI, including its 
classification and risk factors. The key mechanistic theories of DILI and the experimental 
approaches that have been undertaken in its study are also discussed, exposing the need for 
a multidisciplinary approach to the study for DILI. 
Chapter 2 describes the identification of a probe set of drugs with which to facilitate the 
study of IMDILI. Cases of IMDILI were identified from spontaneous adverse drug reaction 
(ADR) reports collected by Australia’s Therapeutic Goods Administration (TGA). Multivariate 
logistic regression was used to quantify the association between the occurrence of IMDILI 
and exposure to drugs of interest. 18 drugs were found to be significantly associated with 
IMDILI (P<0.00015, Bonferroni-adjusted limit for significance). 
By comparing the known and predicted interactions with each of the IMDILI probe drugs 
and examining the interactions that are common between the drugs, it should be possible 
to identify potential toxicity targets involved in the pathogenesis of IMDILI. Chapter 3 
describes the use of the network map tools SLAP (1) and STITCH (2) for this purpose. There 
were substantial differences in the results obtained from each search tool; hence it was 
difficult to ascertain whether any of the known and predicted proteins associated with the 
IMDILI probe set of drugs are potential toxicity targets involved in the pathogenesis of 
IMDILI. 
In Chapter 4 the IMDILI probe set of drugs, along with known and proposed metabolites 
were used as a training set for the development of a pharmacophore model. A 4-point 
pharmacophore hypothesis consisting of 2 hydrogen-bond acceptors, 1 hydrogen-bond 
donor and 1 ring moiety was found to be the best representation of structural similarities 
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within the training set. In external validation the model was able to differentiate between 
molecules in the Active and Inactive Test sets with sensitivity and specificity of 75% and 
92%, respectively. 
Chapter 5 describes a number of analyses in which the pharmacophore hypothesis derived 
in Chapter 4 is used as the starting point for identifying other drugs implicated in IMDILI as 
well as potential toxicity targets for IMDILI. Pharmacophore screening results demonstrated 
similarities between the probe IMDILI set of drugs and Toll-Like Receptor 7 (TLR7) agonists, 
suggesting TLR7 as a potential toxicity target. Similarly, molecular docking results suggested 
a potential role for the adaptive immune system protein HLA-B*5701 in the pathogenesis of 
IMDILI. 
Chapter 6 presents an experimental attempt to test whether or not the probe IMDILI set of 
drugs are able to activate TLR7 in vitro. A published experimental procedure (3) was 
adopted to assay for TLR7 activity. However, despite multiple attempts, the published 
results were not able to be replicated in the lab. Further work is required to develop a viable 
experimental setup. 
The series of studies that encompass this thesis highlights the potential for multidisciplinary 
approaches in the study of complex diseases. Importantly, linking information from clinical 
and chemical databases with knowledge from biological pathway and gene-association 
datasets can reveal potential mechanisms behind idiosyncratic drug reactions. 
Multidisciplinary approaches are particularly helpful for rare diseases where little 
knowledge is available, and may provide key insights into mechanisms of toxicity that 
cannot be gleaned from a single disciplinary study. 
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3 Abbreviations 
2D Two dimensional 
3D Three dimensional 
ABC transporter ATP-binding cassette transporter 
ADR Adverse Drug Reaction 
ALP Alkaline phosphatase 
ALT Alanine transaminase 
APCs Antigen Presenting Cells 
ASP Aspartate aminotransferase 
BDDCS Biopharmaceutical Drug Disposition and Classification System 
BSA Bovine Serum Albumin 
CER Comparisonwise Error Rate 
CI Confidence Interval 
CoMFA Comparative Molecular Field Analysis 
CoMMA Comparative Molecular Moment Analysis 
CoMSIA Comparative Molecular Similarity Indices 
COSTART Coding Symbols for a Thesaurus of Adverse Reaction Terms 
DAEN Database of Adverse Event Notifications 
DAMPs Danger-Associated Molecular Patterns 
DILI Drug induced liver injury 
DILIN Drug Induced Liver Injury Network 
DISCO DIStance Comparison 
DTT Dithiothreitol 
EER Experimentwise Error Rate 
FAERS FDA Adverse Event Reporting System 
FDA Food and Drug Administration 
GLDH Glutamate dehydrogenase 
GRIND Grid-Independent Descriptors 
GSH Glutathione 
HGLT Higher Level Group Term 
HLA-B Human Leukocyte Antigen, class I, B 
HLT Higher Level Term 
HMGB1 High mobility group box-1 
HQSAR Hologram Quantitative Structure Activity Relationship 
HTML Hyper Text Markup Language 
IC Information Component 
ICH International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use 
iDILI Idiosyncratic Drug Induced Liver Injury 
IDMT Intersite Distance Matching Tolerance 
IgE Immunoglobulin E 
IMDILI Immune-Mediated Drug Induced Liver Injury 
IRI International Resource Identifier 
IκB Inhibitor of kappa B 
K18 Keratin-18 
KEGG Kyoto Encyclopaedia of Genes and Genomes 
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LC-MS Liquid Chromatography-Mass Spectrometry 
LLT Lower Level Term 
LPS Lipopolysaccharides 
MAP kinases Mitogen-Activated Protein kinases 
MCMM/LMOD Mixed Monte-Carlo Multiple Minimum/Low Mode 
MedDRA Medical Dictionary for Regulatory Authorities 
MEER Maximum Experimentwise Error Rate 
miRNA Micro ribonucleic acid 
MyD88 Myeloid differentiation primary response gene 88 
NAPQI N-acetyl-p-benzoquinone imine 
NFκB Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NIDDK US National Institute of Diabetes and Digestive and Kidney Diseases 
NMR Nuclear Magnetic Resonance 
OMIM Online Mendelian Inheritance in Man 
OSVM Oren-Spedicato Variable Metric 
OWL Web Ontology Language 
PAMPs Pathogen-Associated Molecular Patterns 
PBS Phosphate-buffered saline 
PDB Protein Data Bank 
p-i hypothesis Pharmacological interaction hypothesis 
pIκB Phosphorylated Inhibitor of kappa B 
PPR Proportional Reporting Ratio 
PRCG Polak-Ribierer Conjugate Gradient 
PRR Pattern Recognition Receptors 
PT Preferred Term 
PVDF Polyvinylidene fluoride 
QSAR Quantitative Structure Activity Relationship 
RCSB Research Collaboratory for Structural Bioinformatics 
RDF Resource Description Framework 
RMSD Root Mean Square Deviation 
ROR Reporting Odds Ratio 
SDF Simple Data Format 
SDS Sodium Dodecyl Sulfate 
SLAP Semantic Link for Association Prediction 
SMARTS Smiles ARbitary Target Specification 
SMILES Simplified Molecular Input Line Entry System 
SOC System Organ Class 
ssRNA Single stranded ribonucleic acid 
STITCH Search Tool for InTeracting Chemicals 
TBST Tris Buffered Saline with Tween ® 
TGA Therapeutic Goods Administration 
TLRs Toll-Like Receptors 
TNFα Tumour Necrosis Factor alpha 
WHIM Weighted Holistic Invariant Molecular 
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1 Chapter 1: Drug Induced Liver Injury 
Drug induced liver injury (DILI) is an enigmatic problem that has continued to frustrate drug 
development and researchers despite many years of research. DILI is multifaceted, with 
consequences ranging far beyond the liver itself. The clinical significance of DILI can range 
from asymptomatic increases in liver enzyme activities to fulminant liver failure and death 
(4). Importantly, DILI is a leading cause for both the withdrawal of drugs from marketing, 
and the failure of drugs in preclinical trials (5). A multitude of risk factors have been 
identified, but the mechanisms of DILI remain unclear. In recent years there have been 
renewed efforts to provide new insights into DILI with some success. This chapter provides 
an overview of DILI and identifies key insights into risk factors and mechanisms of 
hepatotoxicity. 
1.1 Classification  
Two broad classifications of DILI have been identified, based on the incidence rate and 
predictability. Paracetamol (acetaminophen) hepatotoxicity is the best known example of 
predictable DILI. The majority of people who exceed the dose threshold will manifest 
hepatotoxicity and the mechanism of toxicity is well established (6). Paracetamol is 
metabolised to an electrophilic metabolite NAPQI (N-acetyl-p-benzoquinone imine). The 
body detoxifies this metabolite by conjugating it with glutathione (GSH). When hepatic GSH 
is depleted, NAPQI  binds to other proteins, leading to mitochondrial oxidant stress and 
apoptosis of liver cells (6). 
Some drugs exhibit what is termed idiosyncratic DILI (iDILI), where the mechanism of toxicity 
is poorly understood and hepatotoxicity occurs within the therapeutic dose range. These 
drugs are usually well tolerated by the majority of the population, with hepatotoxicity 
manifesting in an unpredictable minority (7). A prospective study carried out in Iceland 
reported a crude incidence for iDILI at 19.1 cases per 100,000 inhabitants (0.019%), 
occurring in 1 in 9480 patients taking diclofenac (0.011%), 1 in 133 patients taking 
azathioprine (0.75%) and 1 in 2350 (0.043%) of patients exposed to amoxicillin/clavulanic 
acid, one of the most commonly prescribed antibiotics (8). Other figures have estimated the 
prevalence of DILI due to amoxicillin/clavulanic acid to be 1 in 7143 patients (0.014%) (9). 
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A subset of iDILI is observed to occur with features of an immune reaction, with 20-30% of 
iDILI cases presenting with fever, rash and/or eosinophilia (10). Furthermore, genetic 
associations with immune system proteins have also been identified for some drugs (e.g. 
flucloxacillin DILI and HLA-B*5701 (11)). This led to iDILI being further divided into immune-
mediated DILI (IMDILI), where hepatotoxicity is associated with the immune response, and 
metabolic idiosyncrasy, which covers all other iDILI not seen to be immune mediated (12,13) 
(Figure 1.1). 
 
Figure 1.1 Classification of Drug Induced Liver Injury (DILI). 
Since the sub classification of iDILI is based on observed characteristics of the clinical 
presentation rather than any substantial knowledge of the underlying pathophysiology, 
some have questioned the usefulness of the distinction between IMDILI and metabolic 
idiosyncrasy (14). Indeed, some presentations of iDILI do not the display signs and 
symptoms of an immune reaction, but are nevertheless thought to be immune mediated 
from what is known regarding the mechanism of toxicity. For example, the now withdrawn 
first-in-class oral anticoagulant ximelagatran has been shown to cause increased alanine 
transaminase (ALT) activity with no indication of an immune mediated mechanism (15). 
However, genome-wide association studies revealed a link with proteins of the adaptive 
immune system thereby suggesting that the ximelagatran related hepatotoxicity is, in fact, 
immune mediated (16). Other examples include isoniazid DILI which is not typically 
associated with immunogenic components such as fever or rash, but for which recent 
evidence for the immune hypothesis has emerged, with the detection of antibodies to 
DILI
Predictable Idiosyncratic
Immune 
mediated
Metabolic 
idiosyncrasy
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isoniazid and cytochrome P450 enzymes in affected patients (17).  However, whether this 
finding points conclusively towards an  immune mediated mechanism is still unclear (18). 
1.1.1 Clinical manifestations 
IDILI covers all liver injuries that can be attributed to any drug; hence it is understandably an 
extremely broad end point. Differential diagnosis is extremely difficult  since the clinical and 
laboratory manifestations of iDILI can vary from drug to drug (19) and mimic other forms of 
liver disease (20), including viral hepatitis and autoimmune liver disease (21).  Currently, 
diagnosis is still dependent on the exclusion of all other possible causes and confounders 
(22). It is worth noting, however, that the presence of confounders does not exclude 
iDILI.  For example, the interaction of the drug with an existing underlying disease could 
precipitate DILI which would otherwise not have manifested.  
There is a wide spectrum of severity, ranging from asymptomatic elevations in liver 
transaminase activity to fulminant liver failure and death (4). The timeframe from exposure 
to clinical signs of DILI is also quite varied, ranging from days (e.g. fluconazole DILI (23)) to 
weeks (e.g. rivaroxaban DILI (24)) and months (e.g. troglitazone DILI (25)). Typically, delayed 
onset is a sign of immune involvement, due to the time the immune system needs to 
coordinate a response (26). However this is not always the case, since some iDILI may 
involve the interaction of a drug with a precipitating event that transpires sometime during 
drug therapy. 
1.2 Biomarkers 
Currently, the main biomarkers of hepatic injury are serum total bilirubin concentration, and 
the activity of the enzymes alkaline phosphatase (ALP), alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST). AST is found in a variety of organs, including liver, heart, 
kidney, muscle and brain, while ALT is more localised to the liver, although still not 
exclusively. Likewise, ALP can become elevated in hyperthyroidism, malignancy or bone 
disease (27). Hence, these are not exclusive biomarkers for DILI. Significant increases in 
enzyme activity can also occur in a number of liver diseases that are unrelated to DILI (e.g. 
due to a hepatic viral infection). 
In addition to the lack of specificity, elevations in ALT and AST activity occur after liver injury 
has already manifested; hence these biomarkers are of limited value in screening for, and 
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preventing, DILI. To complicate matters further, DILI can also occur without significant 
elevation in ALT and AST activities (28).  
Understandably then, the gold standard status of ALT and AST activity as identifiers of the 
risk of DILI has been challenged (29). Indeed, a recent study found the common clinical liver 
function tests to be highly variable in measuring hepatocellular injury of known 
hepatotoxins when cultured with human hepatocytes (28). There is an urgent need to 
develop novel, specific biomarkers able to provide an early signal to identify iDILI before 
acute liver injury occurs. A number of novel biomarkers for DILI are currently under 
development, including glutamate dehydrogenase (GLDH), High mobility group box-1 
(HMGB1) and Keratin-18 (K18) (27).  Other possibilities under consideration include 
cytokines and profiling based on data from omics approaches (30).   
MicroRNAs (miRNA) are also under development as potential biomarkers for DILI. These 
small, single stranded RNA (ssRNA) molecules are important in gene regulation (31). Some 
studies have shown that circulating miRNAs that had emerged from the liver due to cell 
damage had increased sensitivity to DILI when compared to ALT and AST activity (30). 
Microarrays have been developed for global miRNA profiling, and preliminary results in the 
use of miRNA as biomarkers for DILI are promising (32). 
Despite these advances many challenges still remain. Since none of these new biomarkers 
have been extensively validated in the clinical setting they are currently of limited practical 
value in detecting and preventing DILI (30). Also of concern is the translational ability of 
biomarkers for DILI from preclinical animal studies into human investigations (27). 
1.3 Associations & Risk Factors for iDILI 
There are a multitude of factors that have been associated with an increased risk of iDILI 
(Figure 1.2). These range from sex (33) and level of exercise (34) to metabolic enzymes, 
including cytochrome P450 and Phase 2 conjugation enzymes (35) and drug transporters 
(36,37). Examples include erythromycin DILI, which has been associated with genetic 
variation in ATP-binding cassette transporter (ABC transporter) expression, and sulindac 
DILI, which is thought to be due to the inhibition of hepatic biliary reuptake (38). 
Associations have also been drawn with genes encoding immune system proteins, such as 
Human Leukocyte Antigens (HLA) and interleukins (35). 
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Unfortunately it is still unclear the extents to which these risk factors interact, if at all, in 
contributing to the risk of DILI (39). Given the complexity and rarity of iDILI, systems level 
mapping of the risk factors may be required to deduce the critical elements of the 
toxicological pathway involved in this form of liver injury (40). 
 
Figure 1.2 Summary of associations and risk factors for idiosyncratic Drug Induced Liver Injury (iDILI). Part of the figure 
sourced from http://www.clker.com/; http://en.wikipedia.org/. 
1.3.1 Characteristics of medications 
Traditionally, iDILI has been thought to be independent of the dose of the causative drug, 
since these reactions lack the dose-toxicity response that is typical of direct hepatotoxins. 
Moreover, liver injury often only occurs in a small minority of people, with incidence rates 
thought to be between 2-20 per 100,000 patient-years (41), meaning that the causative 
drug is usually well tolerated by a majority of the exposed population over the spectrum of 
approved dose regimens. This also means that iDILI is not often revealed during clinical trial 
testing in drug development but is identified once the medicine is approved for marketing 
and taken by a substantially larger and clinically diverse patient cohort. 
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Nevertheless, the pharmacological basis of drug action confirms there must be some level of 
dose-response relationship, since intuitively the offending drugs and/or their metabolites 
must be present in sufficient quantities to initiate the toxicity reaction. In pursuit of this 
hypothesis, Lambert et al. discovered that drugs with daily doses greater than 50 mg are 
more likely to be associated with DILI, while drugs with daily doses less than 10 mg are less 
likely to be associated with hepatotoxicity (42). These researchers also noted a relationship 
between dose and prognosis, where DILI caused by drugs taken at higher daily doses were 
associated with poorer outcomes, such as death or liver transplantation (42). 
Subsequently, it was noted that in addition to high daily dose, hepatic metabolism and 
lipophilicity of the drug are also associated with an increased risk of DILI (43,44). Increasing 
lipophilicity is associated with greater permeability into hepatocytes, and is consistent with 
the hypothesis that increasing hepatic uptake and drug concentrations within the liver leads 
to an increased risk of DILI. 
Vuppalanchi et al. further investigated the relationship between drug properties and DILI 
phenotype, by grouping drugs into their Biopharmaceutical Drug Disposition and 
Classification System (BDDCS) class (45), which takes into account properties such as 
solubility and gastrointestinal permeability. This is an improvement upon the associations 
drawn with daily dose alone, since the daily dose, typically measured in milligrams, does not 
account for differences in the molecular weights of drugs. These authors found that, while 
drugs with high solubility and extensive metabolism were associated with selected aspects 
of the DILI phenotype (e.g. longer latency period and higher proportion of hepatocellular 
injury), the severity and clinical outcomes were unrelated to the drug’s BDDCS class. 
Instead, the outcomes of DILI may more likely be due to host-related factors, such as 
variations in the immune response and/or the ability to detoxify reactive intermediates, 
rather than directly attributable to the molecular and biopharmaceutical characteristics of 
the drug. The authors noted that this finding is contrary to that of Lambert et al., and 
suggested that this may be due to an inadequate sample size, and/or differences in the DILI 
registries studied (45). Nevertheless, given the current lack of mechanistic understanding 
behind DILI it is possible that characteristics of both the drug and host are important, and 
that toxicity occurs when susceptible individuals are exposed to drugs exhibiting particular 
molecular and biopharmaceutical properties. 
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The pharmacokinetic (e.g. metabolism) and physicochemical characteristics (e.g. 
lipophilicity, solubility) of drugs are ultimately dependent on the drug’s molecular structure, 
and so it comes as no surprise that links have also been drawn between structural features 
of drugs and DILI (46). A number of structural alerts have also been developed, designed to 
allow for the identification of potentially hepatotoxic compounds early in the drug discovery 
process (47). For example, a recent study by Liu et al. identified 12 SMiles ARbitrary Target 
Specification (SMARTS) notations that were significantly associated with DILI and largely 
absent from non-hepatotoxic compounds (48). However, if used alone for toxicity screening, 
structural alerts can result in a high false positive rate, leading to the unnecessary culling of 
potentially viable compounds for further development (49). 
1.3.2 Immune system involvement  
There is now a substantial body of evidence to suggest that many DILI are mediated by the 
immune system. Around 25% of DILI present with hypersensitivity features of fever, rash, 
eosinophilia and cytopaenia (10). The extent of immune system involvement may also be 
under reported, since many reactions are mild and resolve spontaneously. Even for cases of 
mild liver injury, unless transaminase activities are continuously monitored, asymptomatic 
increases in ALT and AST activity are likely to pass undetected. 
While the pattern of liver injury may be different, there is some evidence that the severity 
and duration of hepatotoxicity is related to the hypersensitivity phenotype (50).  This 
suggests the immune reaction is mediating the hepatotoxicity, rather than acting in 
response to liver injury caused by other means. However, in some cases (e.g. abacavir (51), 
β-lactam antibiotics and antiepileptic drugs among others (52)), DILI appears in the context 
of a generalised hypersensitivity syndrome. This confounds attempts to determine whether 
drug exposure initiated an immune response which subsequently resulted in liver injury or 
vice versa. Without the mechanistic knowledge of how toxicity pathways are initiated it will 
be profoundly difficult to develop in vitro or indeed any kind of predictive model to screen 
for potentially hepatotoxic compounds early in drug development, or to identify patients 
who are at risk. 
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1.3.2.1 Adaptive immune system  
Since some DILI occurs in the context of a generalised hypersensitivity syndrome, in cases 
where the association is drawn between HLA and drug induced hypersensitivity syndrome 
rather than explicitly regarding DILI, it may be difficult to judge whether the hepatotoxicity 
is immune-mediated, and whether the DILI is associated with that particular HLA genotype. 
For example, the FDA’s Livertox database (51) notes that raised liver transaminases can 
occur in up to 6% of patients exposed to abacavir, and that the DILI usually occurs in the 
context of a generalised hypersensitivity syndrome. Although it is known that abacavir 
hypersensitivity is associated with HLA-B*5701 (53), it is unclear whether this association 
extends to abacavir DILI. 
The adaptive immune system has two arms – cell mediated and humoral immune 
responses. There is evidence for the involvement of both arms of the adaptive immune 
system in DILI. For example, flucloxacillin DILI is thought to be mediated by T-cells (54), 
while for other drugs such as isoniazid, there are findings of anti-drug or auto antibodies 
against metabolising enzymes (55). 
Whether for cell mediated or humoral responses, initiation of the adaptive immune system 
requires antigen presentation and activation of T-cells. HLA reside on antigen-presenting 
cells (APCs) and mediate the interaction between the APC and the T cell receptor (56). 
Genome wide association studies have linked various adverse drug reactions, including a 
number of iDILI with particular HLA genotypes (57). Well known examples of HLA 
associations include: flucloxacillin DILI and HLA-B*5701; carbamazepine hypersensitivity and 
HLA-A*3101 (58); amoxicillin-clavulanic acid DILI and HLA class II (59); abacavir 
hypersensitivity and HLA-B*5701 (60). These associations suggest that either the drug is 
causing DILI by a non-immune mechanism and preferentially evoking an immune response 
in people with certain HLA genotypes, or that the adaptive immune system is mediating the 
toxicity. 
1.3.2.2 Innate immune system 
The role of the innate immune system in contributing to DILI is often overlooked. It is 
increasingly recognised that the adaptive system does not work in isolation, and that the 
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important interplay between innate and adaptive immunity in the defence of the body is 
also important in mediating DILI (61,62). 
1.3.3 Pattern Recognition Receptors  
Pattern Recognition Receptors (PRRs) are the effectors of the innate immune system. They 
detect highly conserved pathogen-associated molecular patterns (PAMPs) often associated 
with bacterial products (e.g. lipopolysaccharides). In addition to PAMPs, PRRs also recognise 
endogenous damage-associated molecular patterns (DAMPs), activating inflammatory 
processes in response to cell damage. 
1.3.3.1 Toll-like receptors 
Toll-like receptors (TLRs) are the classic PRRs that are found in mammals and their role in 
liver disease has been extensively studied and reviewed (63,64). The liver is the first organ 
exposed to high levels of pathogens and drugs entering the body from the gastrointestinal 
tract via the hepatic portal vein. Understandably then, the liver has a high concentration of 
immune cells which remove pathogens and antigens before they can enter the systemic 
circulation. Kupffer cells are specialised macrophages which line the sinusoids and engulf 
dead red blood cells and bacteria. Both Kupffer cells and hepatocytes are among the 
numerous cells within the liver that have been found to express TLRs and have 
demonstrated responses to TLR ligands (63).  
TLR4 was the first mammalian TLR to be characterised and specifically responds to 
lipopolysaccharides (LPS) from Gram negative bacteria (65,66). The toxicity of LPS appears 
to be dose dependent, with larger LPS doses resulting in a strong inflammatory response 
(67). Moderate doses are non-toxic alone, but can result in liver injury when co-
administered with drugs – they are commonly used for this purpose in the development of 
animal models of DILI (68–70). Low LPS doses, ironically, have been shown to have a 
protective effect against toxicity induced by paracetamol’s highly reactive metabolite and 
chemicals such as carbon tetrachloride and concanavalin-A (71,72). Again, this highlights the 
complex mechanisms behind DILI and the difficulties in identifying the biological targets and 
pathways responsible for toxicity. 
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TLR9 appears to be critical in mediating acetaminophen DILI in mice (73), and TLR7 and TLR3 
have been associated with hypersensitivity reactions and are known to enhance the 
response mounted by the adaptive immune system (74,75). 
1.4 Mechanistic theories of IMDILI 
Over the years a number of theories have been proposed to explain the mechanisms behind 
IMDILI. The major hypotheses are summarised in Figure 1.3 and are discussed in the 
following sections. 
 
Figure 1.3 Summary of the major mechanistic theories of iDILI. Parent drugs may be metabolised into reactive 
metabolites. These metabolites act as haptens, covalently binding to cellular proteins. These dysfunctional proteins are 
identified as ‘foreign’ and presented by antigen presenting cells (APCs) to T cells to initiate an adaptive immune 
response. Alternatively, the parent drug may reversibly bind at the immunologic synapse between APCs and T cells to 
initiate the immune response with a pharmacological interaction (p-i). The danger hypothesis proposes that in addition 
to antigen presentation, a secondary ‘danger’ signal is required for immune activation – antigen presentation without 
this secondary signal results in tolerance. The danger signal may be the result of mild direct toxicity from the drug, or 
from an underlying condition, such as alcohol induced liver injury or a concomitant bacterial or viral infection. Part of 
the figure sourced from http://www.clker.com/. 
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1.4.1 Mitochondria 
Mitochondria mediate many important processes within cells, ranging from energy 
production to apoptosis and necrosis (76). It comes as no surprise then that mitochondria 
also play a central role in DILI (77). Mitochondrial toxicity offers an alternative to the 
immune-mediated hypotheses described below.  
Drugs and metabolites are known to impair mitochondrial function in a variety of ways, 
including the direct inhibition of β-oxidation leading to steatosis; inhibition of mitochondrial 
DNA transcription and protein synthesis, as well the disruption of mitochondrial membranes 
leading to cell death (77). 
Valproic acid resembles medium chain fatty acids and can compete with fatty acids in 
mitochondria during the β-oxidation process (77). Other drugs (e.g. troglitazone) damage 
mitochondrial DNA leading to apoptosis (78).  
Since all pro-apopotic signals are thought to converge on mitochondria (77), it can be 
difficult to determine whether mitochondrial toxicity is the cause of DILI, or whether 
mitochondria are merely mediating the toxicity due to another mechanism. This uncertainty 
means that the mitochondrial hypothesis is not an exclusivist theory; it may hold in 
conjunction with the hapten, danger, and pharmacological interaction (p-i) hypotheses 
described below.  
1.4.2 Hapten hypothesis 
Drugs with a molecular weight smaller than 1000 Daltons are thought to be too small to act 
as an antigen and elicit an immune response since they may not be able to activate T cells 
via antigen presentation (26). Rather, low molecular weight drugs can be metabolised into 
reactive intermediates which subsequently bind to cellular proteins, such as the 
metabolising enzyme that formed them. The body then mounts an immune response 
against these dysfunctional proteins, resulting in inflammation and organ injury. This is the 
basis of the hapten hypothesis (26). 
There is a large amount of circumstantial evidence for the hapten hypothesis. Pencillin 
based antibiotics have a chemically reactive β-lactam ring which can form covalent bonds 
with proteins. The body then mounts a humoral immune response, creating 
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immunoglobulin E (IgE) which mediates the hypersensitivity reaction (79). Similarly, 
halothane is metabolised into the reactive metabolite trifluroacetyl chloride, which then 
covalently binds to cellular proteins (14). 
One complication regarding the hapten hypothesis is that drugs implicated in DILI do not 
always form reactive metabolites. Hence, while the hapten hypothesis may explain the DILI 
of some drugs, it is by no means the only possible mechanism of hepatotoxicity. 
1.4.3 Danger hypothesis 
The danger concept, proposed by Matzinger in 1994, challenged the traditional view of 
immunology where the immune system is tolerant towards ‘self’, and hostile against ‘non-
self’ (80). Instead, the immune system activates in response to danger, regardless of its 
origin. Matzinger argues that for the traditional view to hold, a mechanism must exist to 
induce tolerance to tissue specific antigens on organs (e.g. liver and kidneys), and yet still 
allow for an immune response to tissue specific viruses. Such a mechanism, if it exists, must 
necessarily be very complex, and must allow the immune system to develop tolerance to a 
huge number of self-proteins (80), let alone that of symbiotic micro flora. The problem is 
much simplified if the immune system simply responds to ‘danger’ (e.g. exposure to 
hydrophobic regions of proteins signalling tissue damage (81)). 
For IMDILI, the danger hypothesis postulates that, in addition to the presence of foreign 
antigen, a second, so-called ‘danger signal’, signifying cellular toxicity, is required for the 
activation of the adaptive immune response (62). A danger signal may result from mild 
cellular damage caused by a drug’s direct toxicity. This leads to the release of DAMPs, with 
subsequent activation of the adaptive immune system to potentiate and exacerbate the 
reaction. 
1.4.4 Pharmacological interaction (p-i) hypothesis 
Based on the observation that some drugs are able to stimulate an immune response in the 
absence of chemical reactivity or metabolite formation, Pichler proposed the 
pharmacological interaction (p-i) hypothesis as an alternative to the hapten and pro-hapten 
hypotheses (82). The p-i concept is a modification of the hapten hypothesis where, rather 
than reactive metabolites, it is the parent drug itself that bridges the junction between 
antigen presenting cells and T-cell receptors to initiate the adaptive immune response.  
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The p-i hypothesis may be important in mediating the toxicity of ximelagatran, since its 
chemical structure resembles that of a peptide and may be able to bind directly to HLA (83).  
Recent evidence also suggests that some flucloxacillin DILI may be mediated through a p-i 
mechanism (84). 
1.5 Study methodologies 
Given the complexity of DILI and the length of time it has been an active field of research, it 
comes as no surprise that each research group has tackled the problem differently, 
according to their area of expertise and availability of resources. Many methodological 
approaches have been utilised in the study of iDILI, ranging from in vitro studies on cell lines 
(6) to the use of microfluidic liver biochips (85), in vivo animal models (e.g. zebra-fish (86) 
and rabbits (87)), bioinformatics approaches (88) and epidemiological approaches (89) 
(Figure 1.4).  
 
Figure 1.4 Idiosyncratic Drug Induced Liver Injury (iDILI) has been studied through a multitude of methodologies, yet 
many mysteries remain regarding the mechanisms of toxicity and the bioloical targets and pathways involved. Part of 
the figure sourced from http://www.clker.com/; http://en.wikipedia.org/. 
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1.5.1 Models of hepatotoxicity 
While in vitro and in vivo models of iDILI exist, they are far from perfect (90). Unless models 
are able to capture and account for the large number of risk factors and proteins associated 
with iDILI, it is likely that a generalizable, predictive model of iDILI will remain elusive. 
Hartung recently described the frustrations associated with translating in vitro and animal 
studies into humans in his Food for Thought article aptly titled: Look Back in Anger – What 
Clinical Studies Tell Us About Preclinical Work (91). It is this disparity in results between 
preclinical and clinical studies, and indeed between clinical trials and post-marketing 
surveillance, that is responsible for the billions of dollars ‘wasted’ in pharmaceutical 
research and development. With the deficiencies in in vivo models, researchers are aiming 
at reducing reliance on animal models, moving instead towards in silico screening and the 
use of bioinformatics tools (91,92). 
1.5.1.1 In vitro methods 
In vitro assays have long been established as efficient and cost effective alternatives to in 
vivo toxicological studies. Typically, the reaction of interest is studied under controlled 
conditions, and various factors are varied in a systematic manner to determine their 
influence on the reaction. 
While in vitro methods, particularly high throughput assays, are commonly used to 
investigate iDILI, debates ensue over the suitability of different cell types for these kinds of 
studies (93). The three most commonly used cell lines are primary hepatocytes, 
immortalised cell lines and hepatocellular carcinoma cell lines. Primary hepatocytes are 
thought to be the gold standard, as they are the closest representation of the human liver 
out of the three options. However, primary hepatocytes are short lived, hard to culture and 
difficult to obtain since sacrificing the animal is required. Another disadvantage of human 
primary hepatocytes is a lack of reproducibility across various donors. Moreover, the health 
of the donors can affect results. HepG2 (liver hepatocellular carcinoma) is a commonly used 
hepatocellular cell line used in toxicological studies. While these cells are relatively 
inexpensive and easy to obtain, they have a low expression of phase I enzymes, and as such, 
may not accurately reflect the situation in vivo, especially if metabolic activation is required. 
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Not surprisingly, using different types of hepatocytes can give different results in toxicity 
testing (94). 
To overcome some of the problems associated with using single cell lines, researchers have 
attempted co-culture models, where two or more cell lines are cultured simultaneously. 
Atienzar et al. developed a co-culture approach where dog primary hepatocytes were 
uniformly dispersed with stromal cells. Cell viability and glutathione concentrations were 
used to quantify the level of toxicity. The resultant co-culture system maintained metabolic 
capabilities for up to two weeks, which they suggest is sufficient for use in long term 
metabolism studies (95).  
Liver cells have a particular architecture that facilitates their role in detoxification. The move 
towards 3D models of liver cells comes amid increasing recognition that simple toxicological 
assays using single cell lines or even a co-culture of cells are unable to replicate in vivo 
toxicity (96). Since iDILI is influenced by a multitude of risk factors, a working model must be 
able to capture and distil the complexity of the various pathways involved in iDILI.  
As a step towards this, Ramaigari et al. developed a liver 3D model where HepG2 carcinoma 
cells were organised into multiple polarised spheroids. HepG2 cells in spheroid form 
regained some metabolic capability, as well as other functions such as storage of glycogen 
and transportation of bile salts. This increase in functionality appeared to translate into 
increased sensitivity in DILI screening (97). Similarly, Aritomi et al. found that although 
conventional cultures of HepG2 cells were unsuitable for modelling paracetamol DILI, 3D 
cultures of HepG2 cells in nano-culture plates were able to replicate key features of 
paracetamol DILI, including the creation of reactive metabolites (98). 
Adding another level of complexity, newer 3D models allow cells to aggregate and develop 
structures and communication networks. Bhushan et al. created a 3D co-culture of cells that 
effectively mimics a functional unit of the human liver. This liver-on-a-chip technology 
comprises of 4 different cell types: hepatocytes, endothelial, stellate and Kupffer cells. 
Preliminary work to prepare the model for use in early DILI detection appears to be 
promising (99). Similarly, Larson et al. also reports the use of liver microtissues for long term 
toxicity studies (100). 
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The success of these approaches highlights the need to move beyond traditional assays 
which focus on a single reaction and towards big picture approaches which better reflect 
the complexity of in vivo systems. 
1.5.1.2 In vivo methods 
One frustrating aspect of iDILI is the inability to reproduce the human manifestations of 
toxicity in animal models. In part, this may be due to differences between the test animal 
and humans, but it is also likely that, just as in humans, iDILI is rare and idiosyncratic in 
animals - i.e. host related susceptibility factors are required to enhance the intrinsic toxicity 
of a drug that will otherwise pass unnoticed. Knowledge of the susceptibility factors, 
proteins and pathways involved in the toxicity will be critical to developing an animal model 
that can replicate iDILI in humans (13). 
There are many difficulties with animal studies, including poor reproducibility and 
difficulties translating the results into humans or even between species (91). Traditionally, 
regulatory sciences have used high doses in animals to test for toxicity. This approach may 
be of limited benefit for toxicity which does not appear to be dose dependent.  
One method by which researchers have attempted to improve translatability between 
animals and humans is to make use of chimeric rodents with humanized livers. These are 
created by transplanting human hepatocytes into immunocompromised mice. The 
metabolic capabilities of these models are similar to that in humans, and so have been 
utilised in a number of pharmacological studies, as well as in the study of liver infections 
(101). However, chimeric mice failed to reproduce the liver injury caused by troglitazone, 
which was withdrawn due to iDILI. This may be due to the lack of B- and T- lymphocytes in 
chimeric mice, and hence their inability to model immune-mediated DILI (102).  
Given the limitations of animal models and with continual improvements in technology, the 
FDA is looking to replace animal studies with in silico and in vitro toxicity assays in the near 
future (92). 
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1.5.1.3 In silico methods 
Rapid advancements in computing technology and capacity have seen many researchers 
turn to in silico modelling as a cost effective alternative to in vitro and in vivo studies. For 
DILI, computational modelling has proven to be very versatile, with applications ranging 
from developing structural alerts for identifying hepatotoxic drugs by using the formation of 
reactive metabolites (49) to Quantitative Structure Toxicity Studies and mathematical 
modelling of mechanistic interactions between compounds and the liver (103). In addition, 
in silico technologies are often used in conjunction with bioinformatics and systems 
approaches in order to make sense of the large volumes of data generated by these 
techniques.  
One disadvantage with in silico methodologies is that when hypotheses are generated, there 
is still a need to test the hypothesis with in vitro or in vivo assays. Hence in silico 
technologies are most helpfully applied to preliminary screenings or in a setting where the 
technology has already been validated by another method. 
1.5.2 Bioinformatics approaches  
Bioinformatics or so-called ‘omics’ approaches have recently become popular because of 
the large amount of data that can be generated using these approaches, and the increasing 
availability of the technology to analyse such data. Bioinformatics techniques attempt to 
capture a snapshot of the biological content in the sample at a moment in time. By 
comparing the data captured during periods of disease and the ‘normal’ state, it is possible 
to use these snapshots as biomarkers of various diseases. 
Proteomics qualitatively and quantitatively measures the proteins that are present in a cell 
or in the extra cellular matrix. A sample of biological fluid is taken and then put through 
liquid chromatography-mass spectrometry (LC-MS). Identification of constituents is done by 
comparing the results to the spectra of known proteins. However, this is by no means an 
easy task since the level and range of proteins present in biological fluids can vary based on 
the timing and site of collection. Rodriguez-Suarez et al. analysed the proteomes of 
extracellular vesicles secreted by primary hepatocytes (104). By cataloguing the proteins 
secreted by hepatocytes that have been exposed to hepatotoxins, these researchers 
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discovered patterns in protein expression that differed between healthy and damaged 
hepatocytes which could be developed into novel non-invasive biomarkers of DILI (104). 
The Centre for Omic Sciences defines transcriptomics as ‘the study of transcriptomes – the 
complete set of RNA transcripts produced by the genome at any one time’ 
(omicscentre.com). The contribution of transcriptomics in the study of ADRs has been 
summarised in a recent review by Fernandez et al. (105). In short, researchers have found 
patterns in gene expression which differ between samples obtained from intoxicated and 
healthy patients. Blood borne gene expression markers can then serve as biomarkers of 
ADRs, including DILI (105). Similarly, Benet et al. investigated transcription factor expression 
profiles for cells exposed to known steatotic drugs and were able to identify three 
transcription factors as predictive biomarkers of drug induced hepatic steatosis (106).  
Although omics technologies are now commonly used in academia and industry, relative 
few research groups have utilised approaches combining multiple methods (107,108). In a 
recent review, Khan et al. argue that a holistic approach, combining proteomics, 
transcriptomics, metabolomics etc. is useful as a means of gathering comprehensive 
information, and that the use of bioinformatics tools may eventually revolutionise the drug 
discovery paradigm (88). 
1.5.3 Epidemiological approaches 
Due to the rare incidence of DILI, there is a need to identify cases by which to study the 
pathophysiology of the disease. Post-marketing data collected by pharmaceutical companies 
or regulatory authorities consists of adverse drug reaction (ADR) reports, and typically 
contain information on patient demographics, information on suspected drugs and details 
of the experienced ADR. Using case/non-case methodology, researchers can measure the 
strength of an association between particular ADRs (e.g. DILI) and drug exposure and hence 
identify DILI cases out of population data. Networks and registries have also been set up 
specifically to collect DILI cases for study.  
Table 1.1 lists some examples of DILI associations that have been found by analysing 
pharmacovigilance databases around the world. 
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Table 1.1 Examples of DILI studies conducted using various data sources. 
Data source Study focus 
Portuguese, French, 
Spanish, Italian 
pharmacovigilance system 
Hepatotoxicity with agometaline and newer 
antidepressents (109) 
Spanish DILI registry Characteristics of DILI cases (10) 
U.S. DILI network Characteristics of statin DILI (110) 
U.S. DILI network DILI due to herbal products (111) 
 
1.6 Struggles & Challenges 
The lack of understanding of the biological targets and pathways behind IMDILI makes it 
difficult to develop models to study the disease. The various study methodologies have 
revealed glimpses of the diverse associations and risk factors influencing IMDILI. The 
challenge in moving forward will be to integrate the current knowledge of IMDILI into a 
unified picture. It is becoming increasing clear that IMDILI is a multidimensional problem, 
and that multidisciplinary experimental approaches are required to solve it. 
1.7 Rationale for project and hypothesis 
This thesis presents an approach to expose relationships between IMDILI and the three-
dimensional structural features of toxic drug molecules and their metabolites. The analyses 
focus on immune mediated DILI (IMDILI) since these reactions have defined clinical 
characteristics, allowing for the identification of cases from population adverse drug event 
data.  
The series of analyses in the following chapters test the hypothesis that drugs (or their 
metabolites) which produce similar patterns of toxicity interact with targets within common 
toxicological pathways and that activation of the underlying mechanisms depends on 
structural similarity among toxic molecules.   
Firstly, a probe set of drugs for IMDILI must be identified. Any similarities within this set of 
drugs in terms of common biological pathways or structural features are then identified. 
These similarities can subsequently be used to reveal potential targets in the toxicity 
pathway of drugs implicated in IMDILI.   
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2 Chapter 2: Identification of probe IMDILI drugs 
2.1 Introduction 
2.1.1 Pharmacovigilance 
There are many gaps in the current understanding of immune-mediated drug-induced liver 
injury (IMDILI). Inconsistencies in cross species translation necessitate in vivo human 
toxicological data to aid in the understanding of the mechanisms of toxicity (13). Such data 
is first made available when the drug progresses from preclinical animal studies into human 
clinical trials. However, clinical trials are typically conducted in a relatively small number of 
otherwise healthy individuals and as such are inadequately powered to detect rare adverse 
drug reactions (ADRs). Hence drug regulatory authorities such as the US Food and Drug 
Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA) usually 
require pharmaceutical companies to collect post-marketing information regarding the 
safety and efficacy of their drug once it is approved for marketing and made available to a 
significantly larger and diverse patient population. 
Spontaneous ADR reports collected by drug regulatory authorities and by pharmaceutical 
companies as part of their monitoring responsibilities are collated and stored in 
pharmacovigilance databases. While valuable, the usability of information contained in 
these databases is highly dependent on the quality of the data, which in turn is dependent 
on the skill and clinical expertise of the reporter. 
Reports typically consist of information regarding patient demographics (e.g. age, sex), a list 
of drugs suspected of causing the ADR, drug information (e.g. drug name, brand name, 
dosage, batch number), and a list of ADRs reported. 
ADRs are described using sets of standardised terminology. An example is the Coding 
Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) (112), which was 
subsequently superseded by the Medical Dictionary for Regulatory Authorities (MedDRA) 
(113). 
MedDRA was developed by the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) to facilitate the 
sharing of regulatory information internationally for medical products used by humans 
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(113). It lists each ADR in a hierarchy of terms and is available in multiple languages. Body 
systems are grouped into System Organ Classes (SOC), which are further subdivided into 
Higher Level Group Terms (HLGT), Higher Level Terms (HLT), Preferred Terms (PT) and Lower 
Level Terms (LLT), with each layer giving a more specific description of the ADR (Figure 2.1). 
 
Figure 2.1 Example of Adverse Drug Reaction (ADR) terms classified under the MedDRA Hierarchy. (113) 
2.1.1.1 Data sources  
To facilitate the study of DILI, cases of DILI are required. Case information can be obtained 
from the post-marketing, pharmacovigilance databases described above. Alternatively, 
there are also large databases dedicated to collecting and storing DILI information, such as 
the Drug Induced Liver Injury Network (DILIN) (https://dilin.dcri.duke.edu/) and LiverTox 
(livertox.nih.gov/). 
The Drug Induced Liver Injury Network (DILIN) was established in 2003 by the US National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Its aim is ‘to collect and 
analyze cases of severe liver injury caused by prescription drugs, over-the-counter drugs, 
and alternative medicines, such as herbal products and supplements’.  Since 2008, the 
investigators have published close to 30 publications over a spectrum of topics ranging from 
causality assessment, (114) to characteristics of DILI, (4,45,115) to drugs, herbs and 
supplements implicated in DILI (110,111). 
Lowest Level Term
Feeling queasy
Preferred  Term
Nausea
High Level Term
Nausea and vomiting symptoms
High Level Group Term
Gastrointestinal signs and symptoms
System Organ Class
Gastrointestinal disorders
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The LiverTox database is another initiative of the NIDDK, in conjunction with the DILIN and 
the U.S. National Library of Medicine. It provides “up-to-date, accurate, and easily accessed 
information on the diagnosis, cause, frequency, patterns, and management of liver injury 
attributable to prescription and non-prescription medications, herbals and dietary 
supplements” (116). It is a helpful resource summarising the known evidence from current 
scientific literature. Monographs typically contain sections on background regarding the 
drug; evidence for hepatotoxicity; mechanism of injury and outcome and management 
advice. Each of these drug monographs are reviewed by at least one external researcher, 
many of whom are investigators in the DILIN (51). 
The U.S. Food and Drug Administration (FDA) stores ADR reports in its own database, the 
FDA Adverse Event Reporting System (FAERS). The database consists of adverse events and 
medication errors cases that are voluntarily reported by health care professionals or 
consumers. Although large and publicly available, the quality of the reports in the FAERS is 
poor. The lack of standardisation of drug names, misspellings and duplicated cases mean 
that extensive data cleaning is required before the database is analysable (117). The work 
undertaken to prepare the FDA database for analysis was published in the journal 
Pharmacoepidemiology and drug safety (117) (Appendix 1:  Peer Reviewed Scientific 
Publications arising from this thesis). 
Australia's drug regulatory authority, the Therapeutic Goods Administration (TGA), also 
collects reports of ADRs as part of its monitoring activity. The database collated by the TGA 
contains ADR reports from 1971 to the present.  Each drug is entered as both the brand 
name and the generic name with standardised spelling. Cases are reviewed by a health care 
professional before inclusion into the database. Reports include information on patient 
demographics; drug exposure (generic name, dose, frequency, dose form) and adverse 
reaction terms coded as MedDRA preferred terms (PT) and lower level terms (LLT). 
At the time of the analyses described below, two subsets of this TGA ADR data were 
available; one which contains 240,137 spontaneous ADR reports to the end of 2008 and the 
other 247,391 ADR reports to the end of 2011. The seemingly relatively modest increase in 
the numbers of reports between the two datasets is due to the inclusion of non-general 
market drugs (e.g. drugs undergoing clinical trial or medicines made available through the 
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TGA’s Special Access Scheme) in the 2008 dataset. In the 2011 dataset, non-general market 
cases were removed by the TGA on the basis that the data was usually incomplete with 
regard to patient, reaction or reporter information, and/or not comparable to other data. 
The following analyses focus on the TGA database since it is perceived to be of greater 
accuracy and reliability than the FAERS data. The subset of spontaneous ADR reports to 
2008 was chosen in order to capture as much data as possible, including the reports from 
clinical trials. 
2.1.1.2 Disproportionality analyses 
Due to the immense number of spontaneous ADR reports, it would take much meticulous 
and time consuming work to manually examine each report for cases of ADR. Moreover, 
there is a need to quantify the strength of association between drug exposure and ADR 
outcomes to determine if such associations are statistically significant and to inform clinical 
practice guidelines which govern the use of the drugs under scrutiny. 
Disproportionality analyses test the statistical null hypothesis that there is no difference in 
the incidence of reported exposure to a drug of interest between cases and non-cases. A 
number of statistical measures are available, including the Reporting Odds Ratio (ROR), 
Proportional Reporting Ratio (PRR), Yule’s Q, the Poisson probability, Chi-square test and 
Bayesian measures such as the Information Component (IC) (118). 
From a 2 x 2 contingency table (Table 2.1), disproportionality measures quantify the 
‘disproportionality’ between based on the frequency that would be expected in each cell of 
the table if there was no association between the ADR and drug exposure and the actual 
frequency. 
Table 2.1 Two by two contingency table of ADR reports. The table displays the frequency distribution of variables. ‘a’ is 
the number of reports containing the drug of interest and the ADR of interest. ‘b’ is the total number of reports for the 
drug of interest, excluding those with the ADR of interest. ‘c’ is the total number of reports for the ADR of interest, 
excluding those with the drug of interest. ‘d’ is the number of reports that do not contain the drug of interest nor the 
ADR of interest. 
 Reports with ADR of 
interest 
All other reports 
Reports with drug exposure a b 
All other reports c d 
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The PRR (Equation 1) compares the proportion of reports of a particular ADR versus reports 
for all other ADRs in cases with exposure to the drug of interest against cases without. If 
there is no association between the drug of interest and the ADR of interest, then one 
would expect a PRR of 1 (119). 
The ROR (Equation 2) measures the strength of association between exposure and outcome 
in case control studies. Rather than testing to see if drug exposure increases the risk of an 
ADR, case-control studies determine if the outcome of ADR is significantly associated with 
exposure to a drug (120). Lewallen and Courtright defined the ROR as “the ratio of the odds 
of an exposure in the case group to the odds of an exposure in the control group” (120). A 
ROR of 1 would be expected if there was no association between exposure and outcome. 
The properties of the different measures of disproportionality and the concordance 
between them have been compared by van Puijenbroek et al. (118). The level of 
concordance was high between all measures and particularly high when there were 4 or 
more reports containing the ADR and drug combination. The ROR offers the advantage that 
different adjustments are possible in logistic regression, such as the use of interaction terms 
(118). 
The ROR was chosen as the measure of disproportionality for the following analyses since it 
is a transparent measure that is not influenced by non-selective underreporting of drugs or 
adverse drug reactions (118). 
 
Proportional Reporting Ratio (PRR) 
𝑃𝑅𝑅 =
𝑎
𝑎+𝑏
𝑐
𝑐+𝑑
 
 
Reporting Odds Ratio (ROR) 
𝑅𝑂𝑅 =
𝑎
𝑐
𝑏
𝑑
= 𝑎𝑑/𝑏𝑐 
(1) 
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2.1.1.3 Logistic regression 
Since the outcome variable of interest (IMDILI) is binary, logistic regression can be used to 
describe the relationship between IMDILI and other variables (i.e. drugs of interest and 
confounding factors). Logistic regression describes the probability that the outcome occurs 
(Y = 1) based on variables in the equation. If the probability that Y = 1 is written as p, then 
the probability that Y = 0 is (1 – p).  Equation 3 gives the general logistic regression equation. 
The ROR for each variable (X1, X2,…) is given by the coefficients (B1, B2,…) respectively. 
General logistic regression equation 
ln (
𝑝
1−𝑝
) = 𝐵𝑜 + 𝐵1𝑋1 + 𝐵2𝑋2 + ⋯ 
Stepwise regression describes regression models that are built using an automated 
procedure to examine the impact of each of the covariates on the model. Forward stepwise 
regression begins with no variables in the equation. Each variable is then examined, and the 
variable that improves the model the most is added into the equation. The process is then 
repeated until the addition of variables no longer improves the model. 
The overall ‘fit’ of the model can be measured by the likelihood ratio test which is based on 
the chi-square statistic (Equation 4). If the addition of a variable to the equation improves 
the model, the deviance (D) should decrease, indicating that the expected values from the 
model are closer to the observed values.  
The likelihood ratio test (121) 
𝜒2 = 𝐷 (𝑓𝑜𝑟 𝑡ℎ𝑒 𝑚𝑜𝑑𝑒𝑙 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑡ℎ𝑒 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒) − 𝐷 (𝑓𝑜𝑟 𝑡ℎ𝑒 𝑚𝑜𝑑𝑒𝑙 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒) 
 
2.1.2 Correction for multiple testing 
In the present study, the null hypothesis (Ho) is that there is no difference in the incidence of 
reported exposure to a drug of interest between cases and non-cases. Setting a statistical 
significance level aids in making a decision regarding whether or not to reject the null 
hypothesis by quantifying the probability that the observed results are due to chance. 
Typically, a significance level (α) of 5% is deemed to be reasonable. A 5% significance level 
(3) 
(4) 
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(or p < 0.05) means that if the null hypothesis is true, then there is < 5% chance that the 
observed results are due to chance. 
There are two types of error that can be made when using significance levels. A type 1 error 
occurs when the null hypothesis is rejected, even though it is in fact true. This can happen 
when the significance level is set too high. Conversely, a type 2 error occurs when the null 
hypothesis is accepted, even though it is false. This can happen when the significance level is 
set too low. Therefore, care needs to be taken in choosing an appropriate significance level 
for the study. 
The need for adjusting the significance level in multiple testing has been described by 
Bender and Lange (122): 
“If one significance test at level α is performed, the probability of the type 1 error 
(i.e., rejecting the individual null hypothesis although it is in fact true) is the 
comparisonwise error rate (CER) α, also called individual level or individual error rate. 
Hence, the probability of not rejecting the true null hypothesis is (1-α). If k 
independent tests are performed, the probability of not rejecting all k null hypotheses 
when in fact all are true is (1-α)k. Hence, the probability of rejecting at least one of 
the k independent null hypotheses when in fact all are true is the experimentwise 
error rate (EER) under the complete null hypothesis EER = 1 -  (1 - α)k, also called 
global level, or familywise error rate (considering the family of k tests as one 
experiment). If the number k of tests increases, the EER also increases. For α = 0.05 
and k = 100 tests EER amounts to 0.994. Hence, in testing 100 independent true null 
hypotheses one can almost be sure to get at least one false significant result. The 
expected number of false significant tests in this case is 100 x 0.05 = 5.”  
The aim of this chapter is to develop a probe set of IMDILI drugs for use in further analyses. 
Hence the interest is in controlling the maximum experimentwise error rate (MEER). This is 
defined as “the probability of rejecting falsely at least one true individual null hypothesis, 
irrespective of which and how many of the other individual null hypotheses are true”(122). 
In other words, the aim is to minimise the probability of finding an association between a 
drug and IMDILI when in fact there is no association. 
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The simplest procedure to adjust for multiple testing is the Bonferroni correction, where the 
experimental significance level is divided by the number of independent tests (122). 
2.1.3 Rationale 
Since the diagnosis of IMDILI is based upon the exclusion of all other conditions, as 
described in Chapter 1, there is a degree of uncertainty in evaluating a drug’s potential to 
cause IMDILI. While drugs associated with IMDILI may be identified from the literature, 
sometimes these associations are drawn from case reports or there may be conflicting 
evidence as to a drug’s IMDILI potential. To facilitate further study of the biological 
mechanisms behind IMDILI it is necessary to derive a set of probe drugs with definite IMDILI 
potential. This chapter aims to achieve this high degree of confidence by identifying drugs 
associated with IMDILI from a pharmacovigilance database and then confirming this 
association with the literature.  
2.2 Methods 
2.2.1 Pharmacovigilance data source 
Pharmacovigilance data was obtained from Australia's Database of Adverse Event 
Notifications (DAEN) (http://www.tga.gov.au/safety/daen.htm#.UzAVgc4VXjs). The subset 
of data used from the DAEN contained 240,137 spontaneous ADR reports voluntarily 
reported to the TGA from 1972 to December 2008.  Reports were excluded when data were 
absent for patient age, sex, drug name or adverse reaction term. This led to 37,293 reports 
being excluded, leaving 204,844 ADR records for analysis. 
2.2.2 Case definition 
Cases of IMDILI were defined as reports which included a combination of at least one 
MedDRA preferred term indicative of liver injury (e.g. hepatic failure) and at least one 
MedDRA preferred term which indicated an immunological reaction (e.g. drug allergy). The 
full list of MedDRA terms used in the case definition is presented in Table 2.2. Non-cases 
were defined as all reports which do not meet the case definition.  
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Table 2.2 List of MedDRA preferred terms (PT) used to define cases of immune medicated drug induced liver injury 
(IMDILI). Cases of IMDILI were defined as reports which included at least one MedDRA PT describing liver injury and at 
least one MedDRA PT which indicated an immunological reaction. 
Liver injury preferred terms Immunological reaction preferred terms 
Cholestasis Allergic hepatitis 
Hepatitis cholestatic Dermatitis allergic 
Jaundice Hypersensitivity 
Jaundice acholuric Skin reaction 
Jaundice cholestatic Stevens-Johnson syndrome 
Jaundice hepatocellular Type I hypersensitivity 
Hepatobiliary disease Type II hypersensitivity 
Liver disorder Type III immune complex mediated reaction 
Mitochondrial hepatopathy Type IV hypersensitivity reaction 
Hepatic function abnormal Allergy to chemicals 
Hypertransaminasaemia Drug eruption 
Acute hepatic failure Drug hypersensitivity 
Chronic hepatic failure Drug rash with eosinophilia and systemic 
symptoms 
Hepatic failure Toxic skin eruption 
Allergic hepatitis Idiopathic urticaria 
Autoimmune hepatitis Urticaria 
Cholestatic liver injury Autoimmune disorder 
Chronic hepatitis Immune system disorder 
Hepatitis Butterfly rash 
Hepatitis acute Fixed eruption 
Hepatitis chronic active Rash 
Hepatitis chronic persistent Rash generalised 
Hepatitis fulminant Rash macular 
Hepatitis toxic Rash maculo-papular 
Hepatocellular injury Rash morbilliform 
Hepatotoxicity Systemic lupus erythematosus rash 
Mixed liver injury Eosinophilia 
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Liver injury preferred terms Immunological reaction preferred terms 
Mitochondrial toxicity Hepatic infiltration eosinophilic 
Alanine aminotransferase Hyperpyrexia 
Alanine aminotransferase abnormal  
Alanine aminotransferase increased  
Aspartate aminotransferase  
Aspartate aminotransferase abnormal  
Aspartate aminotransferase increased  
Liver function test  
Liver function test abnormal  
Mitochondrial aspartate aminotransferase 
increased 
 
Transaminases  
Transaminases abnormal  
Transaminases increased  
 
2.2.3 Drug exposure 
Where literature evidence of IMDILI exists for at least one member of the drug class, all 
drugs from a therapeutic class were selected for inclusion in disproportionality analyses. 
Therapeutic classes were defined according to the Australian Medicines Handbook 
(Adelaide, Australia, 2010). The full list of 328 drugs that were included is presented in Table 
2.4. 
Drug exposure was defined as case reports which contained at least 1 entry of the drug. 
Variations in dosage form and different salt forms were grouped. 
2.2.4 Confounders 
There are a number of variables which may confound potential toxicity signals from drugs. 
These were entered as covariates in the logistic regression. This allowed the identification of 
all the factors which are significantly associated with IMDILI. Table 2.3 lists the confounders 
included in the analysis. 
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Table 2.3 List of confounders included in the logistic regression analysis. 
Confounder Rationale 
Age (as a continuous variable) Increasing age is associated with polypharmacy 
and deteriorating liver function.  
Sex Females are at an increased risk of DILI 
Antivirals indicated for viral hepatitis These were used as surrogate markers of 
underlying liver disease 
 
2.2.5 Statistical analysis 
Statistical analyses were conducted using the SPSS 20.0.0 software (SPSS Inc. Chicago, IL, 
USA). 
Univariate analyses were carried out to quantify the association between each drug with 
IMDILI. Those drugs that were significantly associated with IMDILI were then included in 
multivariate logistic regression analysis. This was carried out using the forward stepwise 
inclusion method based on the likelihood ratio. The ROR and 95% confidence interval (95% 
CI) were reported.  
To minimise the risk of type-1 error associated with multiple tests, the overall alpha level 
was set at 0.00015 following the use of the Bonferroni Correction to account for the 328 
drugs investigated simultaneously (122).  
2.2.6 Antibiotic/Non-antibiotic Stratification 
The results of the multiple logistical regression analysis were divided into two groups: non-
antibiotic IMDILI drugs and antibiotic IMDILI drugs. The interaction between the non-
antibiotic IMDILI drugs group and antibiotic use (excluding the antibiotic IMDILI drugs) was 
investigated using logistic regression analysis. Multivariate logistic regression analysis was 
carried out using the forward stepwise inclusion method based on the likelihood ratio 
statistic. The ROR and 95% confidence interval (95% CI) were reported. 
2.2.7 Literature confirmation of toxicity classification 
A literature investigation was performed for each of the drugs significantly associated with 
IMDILI as identified by the multivariate logistic regression. A Medline search was conducted 
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using the Subject Heading “Drug Induced Liver Injury”. This was then combined with a 
search using the drug name. Hits were reviewed for evidence of hepatotoxicity presenting 
with immune features. The relevant drug monographs from the LiverTox database were also 
reviewed. 
2.3 Results 
2.3.1 Frequencies of reports 
The total numbers of reports for each of the drugs of interest are listed in Table 2.4. 
780 cases of IMDILI were identified. 
Table 2.4 Full list of drugs included in the disproportionality analysis, showing the total number of reports of this drug in 
the database. Therapeutic classes are taken from the Australian Medicines Handbook (2010). 
Therapeutic class Drug Frequency 
Inhaled anaesthetics Desflurane 10 
Inhaled anaesthetics Isoflurane 167 
Inhaled anaesthetics Methoxyflurane 6 
Inhaled anaesthetics Sevoflurane 105 
Antifungals Fluconazole 597 
Antifungals Itraconazole 127 
Antifungals Ketoconazole 254 
Antifungals Miconazole 152 
Antifungals Posaconazole 14 
Antifungals Voriconazole 108 
Other antifungals Amphotericin 533 
Other antifungals Caspofungin 27 
Other antifungals Flucytosine 39 
Other antifungals Griseofulvin 334 
Other antifungals Nystatin 595 
Other antifungals Pentamidine 69 
Other antifungals Terbinafine 724 
Antiretrovirals Abacavir 181 
Antiretrovirals Didanosine 239 
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Therapeutic class Drug Frequency 
Antiretrovirals Emtricitabine 8 
Antiretrovirals Lamivudine 706 
Antiretrovirals Stavudine 333 
Antiretrovirals Zidovudine 275 
Antiretrovirals Efavirenz 127 
Antiretrovirals Etravirine 1 
Antiretrovirals Nevirapine 235 
Antiretrovirals Atazanavir 44 
Antiretrovirals Darunavir 12 
Antiretrovirals Fosamprenavir 0 
Antiretrovirals Indinavir 307 
Antiretrovirals Lopinavir (includes combination 
with ritonavir) 
53 
Antiretrovirals Ritonavir (includes combination 
with lopinavir) 
185 
Antiretrovirals Saquinavir 80 
Antiretrovirals Tipranavir 5 
Antiretrovirals Enfuvirtide 16 
Antiretrovirals Maraviroc 0 
Antiretrovirals Raltegravir 9 
Antiretrovirals Tenofovir 108 
Antivirals for viral hepatitis Adefovir 23 
Antivirals for viral hepatitis Entecavir 7 
Antivirals for viral hepatitis Interferon alpha 774 
Antivirals for viral hepatitis Ribavirin 347 
Antituberculous drugs Ethambutol 290 
Antituberculous drugs Isoniazid 382 
Antituberculous drugs Pyrazinamide 180 
Antituberculous drugs Rifampicin 598 
Cephalosporins Cefaclor 1492 
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Therapeutic class Drug Frequency 
Cephalosporins Cefalotin 0 
Cephalosporins Cefepime 122 
Cephalosporins Cefotaxime 561 
Cephalosporins Cefoxitin 161 
Cephalosporins Ceftazidime 281 
Cephalosporins Ceftriaxone 1272 
Cephalosporins Cefuroxime 74 
Cephalosporins Cephalexin 1699 
Cephalosporins Cephazolin 727 
Macrolides Azithromycin 294 
Macrolides Clarithromycin 307 
Macrolides Erythromycin 2107 
Macrolides Roxithromycin 1282 
Penicillins Amoxicillin alone 2340 
Penicillins Clavulanic acid (in combination 
with amoxicillin or ticarcillin) 
2654 
Penicillins Ampicillin 1678 
Penicillins Benzathine penicillin 32 
Penicillins Benzylpenicillin 731 
Penicillins Dicloxacillin 388 
Penicillins Flucloxacillin 2679 
Penicillins Phenoxymethylpenicillin 437 
Penicillins Piperacillin 227 
Penicillins Procaine penicillin 209 
Penicillins Ticarcillin alone 105 
Quinolones Ciprofloxacin 1164 
Quinolones Moxifloxacin 78 
Quinolones Norfloxacin 548 
Tetracyclines Doxycycline 1360 
Tetracyclines Minocycline 602 
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Therapeutic class Drug Frequency 
Tetracyclines Tetracycline 254 
Other antibacterials Aztreonam 39 
Other antibacterials Chloramphenicol 422 
Other antibacterials Colistin 34 
Other antibacterials Daptomycin 0 
Other antibacterials Hexamine hippurate 135 
Other antibacterials Linezolid 51 
Other antibacterials Nitrofurantoin 685 
Other antibacterials Sodium fusidate 221 
Other antibacterials Sulfadiazine 86 
Other antibacterials Tigecycline 5 
Other antibacterials Trimethoprim 964 
Other antibacterials Sulfamethoxazole (& 
trimethoprim) 
4370 
ACE inhibitors Captopril 5639 
ACE inhibitors Enalapril 4622 
ACE inhibitors Fosinopril 732 
ACE inhibitors Lisinopril 1325 
ACE inhibitors Perindopril 2092 
ACE inhibitors Quinapril 449 
ACE inhibitors Ramipril 1668 
ACE inhibitors Trandolapril 428 
Sartans Candesartan 769 
Sartans Eprosartan 96 
Sartans Irbesartan 2643 
Sartans Losartan 312 
Sartans Olmesartan 21 
Sartans Telmisartan 586 
Sartans Valsartan 4 
Endothelin antagonists Ambrisentan 0 
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Therapeutic class Drug Frequency 
Endothelin antagonists Bosentan 82 
Other antihypertensives Clonidine 627 
Other antihypertensives Diazoxide 30 
Other antihypertensives Hydralazine 575 
Other antihypertensives Methyldopa 1973 
Other antihypertensives Minoxidil 85 
Other antihypertensives Moxonidine 20 
Other antihypertensives Nitroprusside (sodium) 9 
Statins Atorvastatin 3728 
Statins Fluvastatin 313 
Statins Pravastatin 1143 
Statins Rosuvastatin 262 
Statins Simvastatin 4978 
Fibrates Fenofibrate 126 
Fibrates Gemfibrozil 889 
Antiarrhythmics Adenosine 3 
Antiarrhythmics Amiodarone 1396 
Antiarrhythmics Atropine 602 
Antiarrhythmics Digoxin 5034 
Antiarrhythmics Disopyramide 188 
Antiarrhythmics Esmolol 4 
Antiarrhythmics Flecainide 211 
Antiarrhythmics Isoprenaline 11 
Antiarrhythmics Lignocaine 761 
Antiarrhythmics Sotalol 534 
Other antianginal drugs Ivabradine 0 
Other antianginal drugs Nicorandil 151 
Other antianginal drugs Perhexiline 249 
Retinoids (oral) Acitretin 85 
Retinoids (oral) Isotretinoin 498 
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Therapeutic class Drug Frequency 
Antithyroid drugs Carbimazole 405 
Antithyroid drugs Propylthiouracil 137 
Other drugs for erectile dysfunction Alprostadil 139 
Other drugs for erectile dysfunction Papaverine 12 
Immunosuppressants (RA) Azathioprine 801 
Immunosuppressants (RA) Cyclosporin 753 
Immunosuppressants (RA) Leflunomide 876 
Immunosuppressants (RA) Methotrexate 1612 
Nonsteroidal Anti-androgens Bicalutamide 37 
Nonsteroidal Anti-androgens Flutamide 132 
Nonsteroidal Anti-androgens Nilutamide 25 
TNF-alpha antagonists Adalimumab 139 
TNF-alpha antagonists Etanercept 187 
TNF-alpha antagonists Infliximab 220 
Tyrosine kinase inhibitors Dasatinib 27 
Tyrosine kinase inhibitors Erlotinib 10 
Tyrosine kinase inhibitors Gefitinib 25 
Tyrosine kinase inhibitors Imatinib 161 
Tyrosine kinase inhibitors Lapatinib 6 
Tyrosine kinase inhibitors Nilotinib 2 
Tyrosine kinase inhibitors Pazopanib 0 
Tyrosine kinase inhibitors Sorafenib 8 
Tyrosine kinase inhibitors Sunitinib 240 
Barbiturates Phenobarbitone 235 
Barbiturates Primidone 182 
Other antiepileptics Acetazolamide 2952 
Other antiepileptics Carbamazepine 229 
Other antiepileptics Ethosuximide 35 
Other antiepileptics Gabapentin 567 
Other antiepileptics Lacosamide 0 
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Therapeutic class Drug Frequency 
Other antiepileptics Lamotrigine 655 
Other antiepileptics Levetiracetam 124 
Other antiepileptics Oxcarbazepine 35 
Other antiepileptics Phenytoin 2491 
Other antiepileptics Pregabalin 247 
Other antiepileptics Sulthiame 42 
Other antiepileptics Tiagabine 37 
Other antiepileptics Topiramate 235 
Other antiepileptics Valproate  2204 
Other antiepileptics Vigabatrin 323 
Other antiepileptics Zonisamide 0 
Other drugs for neurological 
conditions 
Baclofen 302 
Other drugs for neurological 
conditions 
Botulinum toxin 55 
Other drugs for neurological 
conditions 
Dantrolene 26 
Other drugs for neurological 
conditions 
Modafinil 14 
Other drugs for neurological 
conditions 
Riluzole 47 
Other drugs for neurological 
conditions 
Ropinirole 13 
Other drugs for neurological 
conditions 
Tetrabenazine 28 
ADHD drugs Atomoxetine 71 
ADHD drugs Dexamphetamine 111 
ADHD drugs Methylphenidate 186 
Antidepressants Phenelzine 157 
Antidepressants Tranylcypromine 151 
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Therapeutic class Drug Frequency 
Antidepressants Citalopram 1081 
Antidepressants Escitalopram 360 
Antidepressants Fluoxetine 1540 
Antidepressants Fluvoxamine 405 
Antidepressants Paroxetine 2089 
Antidepressants Sertraline 4609 
Antidepressants Amitriptyline 1823 
Antidepressants Clomipramine 232 
Antidepressants Dothiepin 844 
Antidepressants Doxepin 947 
Antidepressants Imipramine 653 
Antidepressants Nortriptyline 224 
Antidepressants Trimipramine 167 
Antidepressants Agomelatine 0 
Antidepressants Desvenlafaxine 2 
Antidepressants Duloxetine 41 
Antidepressants Mianserin 584 
Antidepressants Mirtazapine 812 
Antidepressants Moclobemide 977 
Antidepressants Reboxetine 206 
Antidepressants Venlafaxine 1772 
Antipsychotics Amisulpride 305 
Antipsychotics Aripiprazole 206 
Antipsychotics Asenapine 0 
Antipsychotics Chlorpromazine 816 
Antipsychotics Clozapine 4657 
Antipsychotics Droperidol 307 
Antipsychotics Flupenthixol 170 
Antipsychotics Fluphenazine 364 
Antipsychotics Haloperidol 1088 
Chapter 2: Identification of probe IMDILI drugs 
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Therapeutic class Drug Frequency 
Antipsychotics Olanzapine 1361 
Antipsychotics Paliperidone 4 
Antipsychotics Pericyazine 157 
Antipsychotics Quetiapine 594 
Antipsychotics Risperidone 1114 
Antipsychotics Sertindole 0 
Antipsychotics Trifluoperazine 427 
Antipsychotics Ziprasidone 90 
Antipsychotics Zuclopenthixol 164 
Anxiolytics and hypnotics Alprazolam 563 
Anxiolytics and hypnotics Bromazepam 80 
Anxiolytics and hypnotics Clobazam 124 
Anxiolytics and hypnotics Diazepam 3179 
Anxiolytics and hypnotics Flunitrazepam 248 
Anxiolytics and hypnotics Lorazepam 399 
Anxiolytics and hypnotics Nitrazepam 1582 
Anxiolytics and hypnotics Oxazepam 1740 
Anxiolytics and hypnotics Temazepam 2786 
Anxiolytics and hypnotics Triazolam 16 
Anxiolytics and hypnotics Buspirone 31 
Anxiolytics and hypnotics Melatonin 19 
Anxiolytics and hypnotics Zolpidem 1248 
Anxiolytics and hypnotics Zopiclone 125 
Antigout Allopurinol 3463 
Antigout Colchicine 540 
Antigout Probenecid 303 
NSAIDs Celecoxib 3882 
NSAIDs Diclofenac 2643 
NSAIDs Etoricoxib 1589 
NSAIDs Ibuprofen 1589 
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Therapeutic class Drug Frequency 
NSAIDs Indomethacin 1971 
NSAIDs Ketoprofen 3763 
NSAIDs Ketorolac 216 
NSAIDs Mefenamic 107 
NSAIDs Meloxicam 720 
NSAIDs Naproxen 2365 
NSAIDs Parecoxib 90 
NSAIDs Piroxicam 1468 
NSAIDs Sulindac 877 
NSAIDs Tiaprofenic 360 
Other antirheumatics Hydroxychloroquine 456 
Other antirheumatics Penicillamine 239 
Other antirheumatics Sulfasalazine 960 
 
2.3.2 Multivariate Logistic Regression 
Multivariate logistic regression identified 18 drugs (representing 12 drug classes) that were 
significantly associated with IMDILI (P<0.00015, Bonferroni-adjusted limit for significance) 
(Figure 2.2). 
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Figure 2.2 Adjusted Reporting Odds Ratio (with 95% CI) for drugs significantly associated with immune-mediated drug 
induced liver injury as identified from Australia's post-marketing adverse drug reaction surveillance system. (P<0.00015 
– Bonferroni adjusted). 
2.3.3 Antibiotics/non-antibiotic stratification 
The results of the antibiotics stratification are shown in Table 2.5. The non-antibiotic IMDILI 
drugs group and the antibiotics group were positively correlated with IMDILI (ROR > 1), 
while there appears to be a negative association when antibiotics are taken concurrently 
with IMDILI drugs. 
Table 2.5 Results of binary logistic regression for antibiotic stratification (p<0.05). 
 Significance (p) ROR 
Non-antibiotic IMDILI drugs <0.001 10.2 (8.7-12.0) 
Antibiotics (excluding antibiotic IMDILI drugs) <0.001 2.0 (1.6-2.5) 
Antibiotics by IMDILI drugs   0.001 0.5 (0.3-0.8) 
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2.4 Discussion 
As with all pharmacovigilance datasets, the present data is limited by the information 
contained in the spontaneous ADR case reports. The most important consideration for the 
present study is that one cannot be certain of the causal relationship between a drug and an 
ADR. This may result in the misclassification of a drug’s IMDILI potential. For example, it is 
common for patients to be on multiple medications concurrently. In the event of an ADR, 
the case reporter would need to take a comprehensive medical history before attempting to 
identify the drug responsible for the ADR. Hence it is possible that the medication 
responsible for the ADR was not included in the ADR report due to either: 1) it was missed in 
the patient history gathering, or 2) the reporter falsely attributed the ADR to another drug 
and neglected to include the drug truly responsible.  
Misclassification can also occur at the analytical level. Within each case report there are 
often multiple medications and multiple ADRs, and it can difficult to identify which drugs are 
responsible for particular ADRs. Since drug exposure was defined as any case report 
containing at least entry of the drug, it is possible that IMDILI due to a particular drug was 
falsely attributed to another medication within the same report. 
Of the 18 drugs significantly associated with IMDILI in the analysis, 11 have been reported to 
cause IMDILI in the literature (Table 2.6). 
Table 2.6 Evidence for IMDILI for each of the drugs identified as IMDILI through multivariate logistic regression analysis. 
Data is sourced from the livertox database (http://livertox.nih.gov/) which provides “up-to-date, accurate, and easily 
accessed information on the diagnosis, cause, frequency, patterns, and management of liver injury attributable to 
prescription and non-prescription medications, herbals and dietary supplements” (116). 
Drug Evidence for IMDILI from the livertox database 
(http://livertox.nih.gov/) 
Allopurinol Acute liver injury associated with fever, rash, eosinophilia and 
systemic symptoms. 
Carbamazepine Hypersensitivity reactions linked to HLA-B*1502. Liver involvement 
is common in the hypersensitivity syndrome. 
Celecoxib Hepatotoxicity may be linked to previous sulfonamide allergy. 
Immunoallergic features are not uncommon in presentations of 
liver injury. 
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Drug Evidence for IMDILI from the livertox database 
(http://livertox.nih.gov/) 
Clavulanic acid Hepatotoxicity of amoxicillin/clavulanic acid is thought to be due to 
the clavulanic acid component, is linked with multiple HLA-
haplotypes and associated with rash, fever, arthralgias and 
eosinophilia. 
Flucloxacillin Liver injury is increased in the presence of HLA-B*5701 genotype. 
Lamotrigine Liver injury occurs as part of a systemic hypersensitivity syndrome, 
presenting with fever, rash, vomiting and nausea. 
Nevirapine Liver injury is more common in people with higher CD4 T cells and 
has been associated with HLA genotypes. 
Phenytoin Liver injury resembles immunoallergic hepatotoxicity, occurring the 
context of a systemic hypersensitivity syndrome. 
Propylthiouracil Liver injury has delayed onset and presentation with fever, rash 
and eosinophilia is not uncommon. 
Sulfasalazine Liver injury has features of hypersensitivity, including fever and 
rash. 
Sulindac Liver injury commonly presents with features of immunoallergic 
hepatitis. 
 
Surprisingly, neither age nor sex was found to be significantly associated with IMDILI. 
Although increased age and female sex are known risk factors for DILI (123), it is possible 
that their signals were not strong enough to pass the statistical significance cut-off of 
0.00015. Similarly, none of the drugs indicated for viral hepatitis were significantly 
associated. The final logistic regression equation did however contain 5 antibiotics. This 
raises the question regarding whether this is a true association of IMDILI with each 
antibiotic, or whether the risk of IMDILI is increased in the presence of an underlying 
bacterial infection, of which the antibiotics are acting as a surrogate marker. 
From Table 2.5, it is noted that while patients who experienced IMDILI were more likely to 
have taken a non-antibiotic IMDILI drug or an antibiotic, they were less likely to have been 
on both a non-antibiotic IMDILI drug and an antibiotic concurrently. The high odds ratio for 
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the non-antibiotic IMDILI drugs is expected, since these were the drugs that were identified 
as significantly associated with IMDILI in the initial multivariate logistic regression. The odds 
ratio of 2.0 (1.6-2.5) for the antibiotics group is somewhat suprising, given that the 5 IMDILI 
antibiotics were excluded from this analysis. This may be evidence that the antibiotics are 
acting as a surrogate marker for an underlying bacterial infection which is increasing the risk 
of IMDILI. However, if this is the case, then one would expect a potentiation or synergistic 
effect between non-antibiotic IMDILI drugs and the antibiotic group, resulting in a ROR that 
is greater than 1 for the antibiotics by IMDILI drugs interaction term. Unexpectly, the ROR 
for the interaction term is 0.50 (0.33-0.76), indicating that somehow, antibiotics may have a 
protective effect against the hepatotoxicity induced by IMDILI drugs. Ironically, this may also 
be explained by the underly bacterial infection hypothesis where the antibiotic is decreasing 
the bacterial load in the body, thereby reducing the potentiation effect. Further 
investigation is required in order to clarify the role that antibiotics play in the mechanism of 
IMDILI. 
2.5 Conclusion 
The research described in this chapter has identified a set of probe drugs for IMDILI. The 
next steps involve searching for similarities between the biological pathways and molecular 
structures of these probe drugs. As such, there is a need to be certain of the IMDILI 
potential of each of the drugs in our probe set. For this reason, literature confirmation and 
refinement of toxicity classification was an important step in of the method and acted as a 
safety net to filter out potentially false signals generated from the pharmacovigilance data. 
Once their toxicity was confirmed, the drugs of interest became a powerful set of probe 
molecules by which to study IMDILI. 
The following drugs were used as the probe set for IMDIL: allopurinol (a), carbamazepine 
(b), celecoxib (c), clavulanic acid (d), flucloxacillin (e), lamotrigine (f), nevirapine (g), 
phenytoin (h), propylthiouracil (i), sulfasalazine (j), sulindac (k). 
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2.6 Publication 
The work that was undertaken to clean the FDA database for use has been published in the 
journal Pharmacoepidemiology and drug safety (117). The full publication is presented in 
Appendix 1:  Peer Reviewed Scientific Publications arising from this thesis. 
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3 Chapter 3: Searching for similarities: Network map tools  
3.1 Introduction 
There is an immense diversity in the research that is happening across the globe, ranging 
from the arts to the environmental sciences, computer sciences and life sciences.  As the 
volume of data increases, the process of locating and accessing relevant information 
becomes exponentially more difficult. To reduce duplications and increase research efficacy, 
it is of vital importance not merely to be able to share information over the internet, but 
also to have systems in place which allow information to be searched and accessed quickly 
and easily. 
3.1.1 The Semantic Web 
The use of search engines such as Google or Yahoo is a common way by which to search for 
information on the internet. The results are presented as a list of links to HTML pages. 
Human interpretation is then required to determine which links are relevant and access the 
information. 
The Semantic Web was envisaged by Berners-Lee as a network of data and information that 
is easily read and interpretable by computers (124). Rather than having human eyes sift 
through all the available data on the internet and using the human mind to identify relevant 
information, agents can be programed to extract and interpret information from various 
sources before presenting it in a human friendly form. An idealised application of the 
Semantic Web was illustrated with the example of a young couple who needed to make an 
appointment with a specialist doctor (124).  
A software program (a semantic web ‘agent’) on the couple’s mobile phone could go online 
and search for webpages of doctors with the required speciality within a certain radius of 
the specified postcode. From there, the agent would identify those doctors which had free 
appointment times which coincided with free times in the couple’s calendar stored on the 
phone. A consolidated list of suitable doctors, the addresses of the surgeries and available 
appointment times would then be displayed. The aim of such an automated process would 
be to delegate to computers any task that does not require human judgement. 
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In the above example, most of the information required to make the appointment, such as 
doctors’ addresses and available appointment times are readily available through the 
websites of doctors and medical centres. However, they are generally only interpretable by 
human readers. For example, on the doctor’s webpage, a human would scroll down to find 
the doctor’s qualifications and the hyperlink for the appointment times. Conversely, it 
would be very difficult for an automated process to identify which texts on the page 
pertained to a doctor’s qualification and which links are related to appointment times.  
One method to overcome this problem would be to enforce a standardised layout for all 
webpages, which would be impractical. Alternatively, data could be collected from various 
sources into a centralised repository. However, this is still restrictive and limits access to 
data not contained within the repository. Moreover, such a repository will quickly become 
unmanageable as it increases in size and scope. 
The Semantic Web offers a solution by proposing a series of standards, such that computers 
can ‘interpret’ data in ways that previously required human intervention. These standards 
include the Resource Description Framework (RDF) format for documents and Web 
Ontology Language (OWL) for ontologies, which are lists defining the concepts and 
relationships used to describe and represent an area of concern (124,125). 
RDF encodes meaning in triplets; a subject, predicate and object. For example: 
<Sam> <is a> <person>. 
<Sam> <is a friend of> <Dai>.  
<Sam> <likes to play> <Souls>. 
< Souls> <was recommended by> <Dai>. 
<Souls> < is a prequel to> <Souls 2>. 
The above relationships demonstrate that the same resource can be referenced multiple 
times. Sam is the subject three times and Souls appears as the subject of two and the object 
of another triple. These relationships can be also expressed as an RDF graph with the 
subjects and objects as nodes and the predicates as arcs (Figure 3.1). 
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Figure 3.1 Informal graph of sample Resource Description Framework (RDF) triplets. The relationship is phrased 
directionally from the subject to the object. 
One of the goals of implementing RDF is to allow the automatic merging of information 
from multiple sources (126). The use of RDF triples serves as the starting point for merging 
data. However, merely standardising the format is insufficient, since there are many terms 
which have different meanings depending on the context (e.g. the term ‘virus’ in biology 
compared with computing science refers to completely different things). To overcome this, 
RDF assigns International Resource Identifiers (IRI) to identify the specific resource to which 
the term refers. For example, DBpedia (127) uses IRIs of the form 
http://dbpedia.org/resource/Name to denote the thing described by the corresponding 
Wikipedia article (126). The use of IRIs to define terms grants flexibility, since new 
vocabularies or ontologies can be created to define new concepts. 
The use of RDF has three underlying principles (126): 
1. The IRIs used to name the subject, predicate and object are “global” in scope, 
naming the same thing each time they are used. 
2. Each triple is “true” exactly when the predicate relation actually exists between the 
subject and the object. 
3. An RDF graph is “true” exactly when all the triples in it are “true”. 
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From these principles, systems can be designed to draw logical inferences; given a set of 
“true” input triples, a system can deduce that other triples must, logically, also be true. 
3.1.2 Network Pharmacology 
Network pharmacology challenges the traditional ‘one-drug one target’ drug discovery 
paradigm, where drugs are designed with high specificity with the aim of activating the 
single biological target that is responsible for the disease.  In a News and Views article, 
Andrew Hopkins briefly summarises a number of studies indicating that many drugs (e.g. β-
lactam and fluoroquinolone antibiotics, antipsychotic and cancer drugs) exhibit their 
pharmacological action by acting on multiple proteins (128). Moreover, studies on biological 
systems have revealed many built in redundancies, resulting in networks which are resilient 
to change. These realisations have led to the development of a paradigm shift imtowards 
‘systems’ approaches to drug design and development (128). In this view, an understanding 
of the physiological network is key to identifying the nodes which must be targeted 
simultaneously in order to overcome the built-in redundancies. 
The rise of ‘systems thinking’ approaches has encouraged researchers to look not only at 
single drug-protein interactions but to also consider the how the interaction fits into the big 
picture of the body’s functioning. This has sparked a number of ambitious projects, including 
The Human Interactome Project, an initiative of the Center for Cancer Systems Biology, 
which seeks to characterise the protein-protein interactions between all proteins in the 
human body (129). 
3.1.3 Data Repositories 
With the rise of omics methodologies and technological advances, large amounts of 
information have become publically available on the internet. Accordingly, a number of 
repositories have been compiled to store and index this information (Table 3.1). 
While each database summarises the relevant information for the topic of interest, the 
information may still be difficult to use for researchers seeking to, for example, draw links 
between a drug, its adverse drug reactions and biological pathways since the data is 
scattered across several different databases. To overcome this barrier, the information 
contained in various data repositories need to be linked together so that researchers can 
draw inferences from data spread across different sources.  
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The Bio2RDF project is a system that applies semantic web technology to bioinformatics 
databases, with one of its main goals to covert publically available databases into RDF 
format (130). Chem2bio2RDF (http://cheminfov.informatics.indiana.edu:8080/) is a 
semantic framework that builds upon the work of Bio2RDF by creating an RDF resource for 
integrated chemical and biological information (131). A network is created, with each node 
representing a data source. Nodes are linked if there is cross referencing between the data 
sources (131). As on May 2015, 24 databases have been linked (Table 3.1). 
Table 3.1 List of databases included in Chem2bio2RDF. 
Database Type Description 
Binding Database (132) Experimental BindingDB is a public, web-accessible database 
of measured binding affinities, focusing chiefly 
on the interactions of proteins considered to 
be drug-targets with small, drug-like molecules 
Binding MOAD (133) Experimental Binding MOAD's goal is to be the largest 
collection of well resolved protein crystal 
structures with clearly identified biologically 
relevant ligands, annotated with 
experimentally determined binding data 
extracted from literature. 
BioGRID (134) Organisation An online interaction repository 
Carcinogen (135) Organisation An international resource of the results of 
6540 chronic, long-term animal cancer tests on 
1547 chemicals. 
ChEBI (136) Experimental A freely available dictionary of molecular 
entities focused on “small” chemical 
compounds 
ChEMBL (137,138) Literature An open large-scale bioactivity database. 
Comparative 
Toxicogenomics 
Database (CTD) (139) 
Literature Provides manually curated information about 
chemical–gene/protein interactions, chemical–
disease and gene–disease relationships.  
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Database Type Description 
Drug Combination 
Database (DCDB) 
(140,141) 
Literature A database devoted to the research and 
development of multi-component drugs. 
Database of Interacting 
Proteins (DIP) (142) 
Experimental Catalogues experimentally determined 
interactions between proteins. 
DrugBank (143) Literature A unique bioinformatics and cheminformatics 
resource that combines detailed drug data 
with comprehensive drug target information. 
UNIPROT (144)  A catalogue of information on proteins. 
HUGO Gene 
Nomenclature 
Committee (HGNC) (145) 
Organisation A committee responsible for approving unique 
symbols and names for human loci, including 
protein coding genes, ncRNA genes and 
pseudogenes. 
Human Protein 
Reference Database 
(HPRD) (146,147) 
Literature Represents a centralised platform to visually 
depict and integrate information pertaining to 
domain architecture, post-translational 
modifications, interaction networks and 
disease association for each protein in the 
human proteome. 
KEGG: Kyoto 
Encyclopaedia of Genes 
and Genomes (148) 
Literature A database resource for understanding high-
level functions and utilities of the biological 
system. 
PDSP (149) Literature A database of Ki values for receptors and 
targets. 
Manually Annotated 
Targets and Drugs 
Online Resource 
(MATADOR) (150,151) 
Literature A resource for protein-chemical interactions. 
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Database Type Description 
Online Mendelian 
Inheritance in Man 
(OMIM) (152) 
Literature An Online Catalogue of Human Genes and 
Genetic Disorders 
Protein Data Bank in 
Europe (PDBe) 
Literature The European resource for the collection, 
organisation and dissemination of data on 
biological macromolecular structures 
PharmGKB (153) Literature A comprehensive resource that curates 
knowledge about the impact of genetic 
variation on drug response for clinicians and 
researchers. 
PubChem (154,155) Experimental A bioassay collection. 
PubMed (156) Literature A collection of citations for biomedical 
literature from MEDLINE. 
Reactome (157) Literature A free, open-source, curated and peer 
reviewed pathway database. 
SIDER (158) Literature Contains information on marketed medicines 
and their recorded adverse drug reactions. The 
information is extracted from public 
documents and package inserts. 
Therapeutic Target 
Database (TTD) (159) 
Literature Provides information about the known and 
explored therapeutic protein and nucleic acid 
targets, the targeted disease, pathway 
information and the corresponding drugs 
directed at each of these targets. 
 
3.1.4 Semantic Link for Association Prediction (SLAP) 
Semantic Link for Association Prediction (SLAP) is a Drug Target Prediction tool developed by 
the creators of Chem2Bio2RDF (1). Network pharmacology proponents have already 
stressed the importance profiling the effects of drugs on multiple protein targets (160). 
Large scale analyses of the effects of drugs on biological pathway systems are needed to 
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reveal the relationships between ADRs and protein targets (131). These analyses are 
facilitated by the use of semantic linked data, such as the Chem2Bio2RDF repository (1). 
Using knowledge of existing links, ‘missing’ links between nodes can sometimes be 
predicted by comparing the topology of nodes, such as sharing a certain number of 
neighbouring nodes or similar shortest paths between nodes. These concepts are commonly 
utilised in social media and advertising contexts. For example, social media programs may 
suggest people as ‘friends’ based on the number of ‘mutual friends’ and supermarkets may 
conduct targeted advertising based on a consumer’s purchasing history. 
SLAP is a statistical model which queries a heterogeneous network of 290,000 nodes and 
720,000 edges containing data on drug target interactions. Drug-target interaction 
information were extracted from datasets included in the Chem2Bio2RDF set (1). ‘Missing 
links’ in the network, i.e. drug-protein interactions for which there is as yet no experimental 
evidence, are predicted based on analysing the topology of neighbouring nodes. The 
strength of the predicted association is reported as an association score, which is calculated 
from the number of shortest paths and the properties of the links between the nodes (1). 
The SLAP methodology was validated by comparing the association scores of 1000 known 
drug target pairs from DrugBank (143) with that of 1000 random pairs of drugs and targets 
sampled from DrugBank. For each drug target pair, their direct link was first removed, so 
that only the neighbourhood properties were used in the score calculation (1).  
SLAP was able to correctly identify drug-target pairs in the data and was shown to 
outperform similar link prediction methods used in social networking (1). The method offers 
the advantage of considering pathway relationships from a systems level, rather than just 
known binding affinity data. In addition to direct drug target interactions, SLAP is also 
capable of identifying indirect interactions, such as changes in gene expression levels. Hence 
it is a useful tool with which to compare the biological functions of drugs. 
SLAP is publically available online at http://cheminfov.informatics.indiana.edu:8080/slap/. 
Compounds can be queried by drug name, SMILES string or their PubChem ID. Proteins can 
be queried by their name, UniProt ID or Gene Symbol. Results are presented in tabular 
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format, listing known and predicted interactions along with an association score calculated 
by SLAP. 
3.1.5 Search Tool for InTeracting CHemicals (STITCH) 
The Search Tool for InTeracting CHemicals (STITCH) is another searchable, online database 
of known and predicted interactions between chemicals and proteins (161). A consolidated 
set of chemicals was derived from the PubChem database. Associations between chemicals 
were classified into 4 groups: reactions from pathway databases, literature associations, 
similar structures and similar activities (161). Chemical-protein interactions were imported 
from the PDSP Ki Database and the Protein Data Bank (PDB). Interactions between 
metabolites and proteins were extracted pathway databases such as KEGG, Reactome and 
the NCI-Nature Pathway Interaction Database. Drug target relations were imported from 
DrugBank and MATADOR. Literature associations were obtained by text-mining the 
MEDLINE and OMIM databases. The full list of databases included in STITCH is presented in 
Table 3.2. 
Table 3.2 List of databases included in STITCH 4.0. 
Database Description 
ChEMBL (137) A freely available dictionary of 
molecular entities focused on “small” 
chemical compounds 
PDSP (149) A database of Ki values for receptors 
and targets. 
Protein Data Bank (PDB) (162) An information portal to biological 
macromolecular structures. 
DrugBank (143) A unique bioinformatics and 
cheminformatics resource that 
combines detailed drug data with 
comprehensive drug target 
information. 
GLIDA (163) A database for those who work in the 
field of GPCRs-related drug discover 
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Database Description 
and need information on both GPCRs 
and their known ligands. 
Manually Annotated Targets and 
Drugs Online Resource (MATADOR)  
(150,151) 
A resource for protein-chemical 
interactions. 
Therapeutic Target Database (TTD) 
(159) 
Provides information about the known 
and explored therapeutic protein and 
nucleic acid targets, the targeted 
disease, pathway information and the 
corresponding drugs directed at each of 
these targets 
Comparative Toxicogenomics 
Database (CTD) (139) 
Provides manually curated information 
about chemical–gene/protein 
interactions, chemical–disease and 
gene–disease relationships. 
KEGG: Kyoto Encyclopaedia of 
Genes and Genomes (148) 
A database resource for understanding 
high-level functions and utilities of the 
biological system. 
NCI/Nature Pathway Interaction 
Database (164) 
Biomolecular interactions and cellular 
processes assembled into authoritative 
human signalling pathways 
Reactome (157) A free, open-source, curated and peer 
reviewed pathway database.  
BioCyc (165) A collection of 5711 Pathway/Genome 
Databases (PGDBs) plus software tools 
for understanding their data. 
 
The STITCH database is publically available at the web portal http://stitch.embl.de/.Drugs 
can be entered by chemical name or generic name. STITCH returns the top predicted 
interacting partners in tabular format. The output from STITCH can be viewed in Confidence 
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View, where stronger associations are represented by thicker lines; Evidence View, where 
different coloured lines are used to represent the type of evidence for the interaction and 
Actions View, where modes of action are differentiated by colour. Associations between 
chemicals and proteins are predicted by text mining of the scientific literature, and the 
results are ranked by a confidence score. 
Databases which contain manually annotated interactions receive high sores and 
interactions based on experimental information are scored by the confidence or relevance 
of the reported information (161). 
STITCH is a well-known source of data and is queried more than 100 times each week (166), 
and has been used in published studies including those to identify targets of anti-
tuberculosis compounds in Mycobacterium tuberculosis (167), study the conservation of 
protein-chemical interactions between yeast species (168) and as a benchmark for 
predicted drug-target interactions (169,170). 
3.2 Rationale 
From Chapter 2, a number of drugs that are implicated in IMDILI have been identified. Once 
ingested, each of these drugs will pass through the pharmacokinetic stages of absorption, 
disposition, metabolism and excretion. Through these processes the drug will interact with 
many biological proteins, in addition to the protein interactions that occur as part of the 
drug’s pharmacological action. Logically, adverse drug reactions to the drug must be 
initiated by one or more of these interactions. By comparing the known and predicted 
interactions with each of the IMDILI probe drugs and examining the interactions that are 
common between the drugs, it should be possible to identify potential toxicity targets 
involved in the pathogenesis of IMDILI (Figure 3.2). In light of the current hypotheses 
regarding the mechanisms behind IMDILI, it is hypothesised that interactions with proteins 
involved in the activation of the immune system would be shared among a high proportion 
of the investigated drugs. 
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Figure 3.2 Schematic representation of the methodological approach. When ingested, each drug will interact with 
various body proteins. By comparing the known and predicted interactions with each of our IMDILI probe drugs, and 
examining the interactions that are common, it should be possible to identify potential toxicity targets involved in the 
pathogenesis of IMDILI. 
 
3.3 Methods 
3.3.1 SLAP for Drug Target Prediction 
The Pubchem Compound Identifiers of the probe IMDILI set of drugs (allopurinol, 
carbamazepine, celecoxib, clavulanic acid, flucloxacillin, lamotrigine, nevirapine, phenytoin, 
propylthiouracil, sulfasalazine, sulindac) were obtained. These were then used to query the 
SLAP tool for Drug Target Prediction (http://cheminfov.informatics.indiana.edu:8080/slap/). 
3.3.2 STITCH 4.0 
Each of the IMDILI set of drugs was entered by name into the STITCH 4.0 web portal 
(http://stitch.embl.de/).  
STITCH was asked to return at most 50 predicted functional partners in Homo sapiens. 
Interactions are only listed if they are of at least medium confidence (score > 0.400). 
3.1 Results 
SLAP and STITCH identified a total of 333 known and predicted protein interaction partners 
for the probe set of IMDILI drugs. 58 proteins were identified by both the SLAP and STITCH 
analyses. 110 proteins were identified by the SLAP analysis only. 165 proteins were 
identified by the STITCH analysis only. The full list of identified proteins and a brief 
description of their function is presented in Appendix 2: Consolidated list of proteins. 
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3.1.1 SLAP for Drug Target Prediction  
The 284 incidences of interactions between dug set and the 165 proteins identified by SLAP 
to be known and predicted interacting partners with the IMDILI probe set of drugs are 
summarised in Table 3.3. The full list of known and predicted proteins, along with the SLAP 
association score, is presented in Appendix 3: Results of SLAP. 
No protein interactions were predicted for clavulanic acid, flucloxacillin, nevirapine and 
sulindac. Celecoxib had the highest number of known and predicted interactions at 126, 
followed by carbamazepine with 63 predicted interactions; lamotrigine with 41 and 
phenytoin with 34.  
The highest number of probe IMDILI drugs predicted to interact with a particular protein 
was 4. There were six proteins with 4 interactions; ABCB1, ABCC2 CYP3A4, HRH1, KCNH2 
and SCN1A. The same 4 drugs were predicted to interact with each of these proteins: 
carbamazepine, celecoxib, lamotrigine and phenytoin. 
Table 3.3 Summary of the SLAP results, showing the proteins which are known and predicted to interact with the IMDILI 
probe set of drugs. 
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Total 
ABCB1   1 1     1   1       4 
ABCB11   1                   1 
ABCC1   1       1   1       3 
ABCC2   1 1     1   1       4 
ABCC4     1                 1 
ABCG2   1       1   1       3 
ADAM17     1                 1 
ADRA1A     1     1           2 
ADRA1B     1                 1 
ADRA1D     1                 1 
ADRA2A   1 1                 2 
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Total 
ADRA2B     1                 1 
ADRA2C     1                 1 
ADRB1     1                 1 
ADRB2     1                 1 
AKT1     1                 1 
AKT2     1                 1 
ALOX5     1                 1 
AR   1 1                 2 
ASL     1                 1 
BCL2     1                 1 
BCL2L1     1                 1 
CA1     1             1   2 
CA10     1                 1 
CA11     1             1   2 
CA12     1             1   2 
CA13     1             1   2 
CA14     1             1   2 
CA2     1             1   2 
CA3     1             1   2 
CA4     1             1   2 
CA5A     1             1   2 
CA5B     1             1   2 
CA7     1             1   2 
CA8     1                 1 
CA9     1             1   2 
CACNA1C           1   1       2 
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Total 
CACNA1
D 
          1           1 
CACNA1F           1           1 
CACNA1
G 
          1   1       2 
CACNA1
H 
          1   1       2 
CACNA1I           1   1       2 
CACNA1S           1           1 
CALM1           1           1 
CASP1     1                 1 
CASP3     1                 1 
CASP7     1                 1 
CCL2     1                 1 
CCND1     1                 1 
CCR5     1     1           2 
CDK2     1                 1 
CDK4     1                 1 
CHRM1     1                 1 
CHRM2     1                 1 
CHRM3     1                 1 
CHRM4     1                 1 
CHRM5     1                 1 
CHRNA7   1 1                 2 
CNR1     1                 1 
CNR2     1                 1 
CYP11B1   1                   1 
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Total 
CYP17A1   1           1       2 
CYP19A1   1 1         1       3 
CYP1A2   1 1           1     3 
CYP2A6   1           1       2 
CYP2B6   1 1         1       3 
CYP2C18   1                   1 
CYP2C8   1 1         1       3 
CYP2C9   1 1         1       3 
CYP3A4   1 1     1   1       4 
CYP4A11               1       1 
DDC     1                 1 
DHFR           1           1 
DRD1   1 1     1           3 
DRD2   1 1     1           3 
DRD3   1 1                 2 
DRD4   1 1                 2 
DRD5   1 1                 2 
EPHX2   1           1       2 
ESR1   1                   1 
FGF1     1                 1 
FGF2     1                 1 
FPR1   1       1   1       3 
GRIN2B           1           1 
GSTA1   1                   1 
GSTM1   1                   1 
GSTP1   1 1                 2 
HNMT     1                 1 
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Total 
HRH1   1 1     1   1       4 
HRH2     1                 1 
HRH3     1                 1 
HRH3           1           1 
HRH4     1                 1 
HTR1A   1 1                 2 
HTR1B   1 1                 2 
HTR1D   1 1                 2 
HTR1E   1 1                 2 
HTR1F   1 1                 2 
HTR2A   1                   1 
HTR2A     1     1           2 
HTR2B   1 1                 2 
HTR2C   1 1     1           3 
HTR3A   1 1                 2 
HTR4   1 1                 2 
HTR6   1 1                 2 
HTR7   1 1                 2 
IL1B 1   1             1   3 
JUN   1               1   2 
KCNH2   1 1     1   1       4 
KCNMA1     1                 1 
KCNQ1           1           1 
MAOA   1                   1 
MAPK1     1                 1 
MAPK12     1                 1 
MAPK14     1                 1 
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Total 
MMP1     1                 1 
MMP11     1                 1 
MMP13     1                 1 
MMP14     1                 1 
MMP2     1                 1 
MMP3     1                 1 
MMP7     1                 1 
MMP8     1                 1 
MMP8                   1   1 
MMP9     1                 1 
NFKB1   1 1             1   3 
NFKB2   1 1             1   3 
NISCH     1                 1 
NR1I2   1           1       2 
NR1I3   1                   1 
NR3C1   1                   1 
NR3C2   1                   1 
OPRK1     1                 1 
OPRM1     1                 1 
PDPK1     1                 1 
PGR   1 1         1       3 
PLA2G4A     1                 1 
PNMT     1                 1 
PPARA     1                 1 
PPARD     1                 1 
PPARG     1                 1 
PRKACA     1                 1 
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PTGER1     1                 1 
PTGER2     1                 1 
PTGER3     1                 1 
PTGER4     1                 1 
PTGS1   1                   1 
PTGS1     1                 1 
PTGS2   1 1                 2 
ROCK1     1                 1 
ROCK2     1                 1 
SCN10A   1       1   1       3 
SCN11A           1   1       2 
SCN1A   1 1     1   1       4 
SCN1B           1   1       2 
SCN2A   1       1   1       3 
SCN2B           1   1       2 
SCN3A   1       1   1       3 
SCN3B           1   1       2 
SCN4A   1       1   1       3 
SCN4B           1   1       2 
SCN5A   1       1   1       3 
SCN9A   1       1   1       3 
SLC12A1     1                 1 
SLC12A3     1                 1 
SLC22A6     1                 1 
SLC6A2           1           1 
SLC6A3     1     1           2 
SLC6A4   1 1     1           3 
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Total 
TNF     1                 1 
TP53   1 1                 2 
TPH1     1             1   2 
                          
TOTAL: 1 63 126 0 0 41 0 34 1 18 0 284 
 
3.1.2 STITCH 4.0 
The 327 incidences of interactions with the 223 proteins identified by STITCH to be known 
and predicted interacting partners with the IMDILI probe set of drugs are summarised in 
Table 3.4. The full list of known and predicted proteins, along with the SLAP association 
score, is presented in Appendix 4: Results from STITCH 4.0. An example of the output is 
show in Figure 3.3. 
Celecoxib and sulindac had the highest number of known and predicted interactions at 50 
each, followed by phenytoin with 48 and carbamazepine with 42.  
The highest number of probe IMDILI drugs predicted to interact with a particular protein 
was 7. This was attained by CYP3A4, which was predicted to interact with carbamazepine, 
celecoxib, flucloxacillin, lamotrigine, nevirapine, phenytoin and propylthiouracil. 
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Figure 3.3 Predicted protein functional partners for allopurinol as determined by STITCH 4.0. 
Table 3.4 Summary of the STITCH 4.0 results, showing the proteins which are known and predicted to interact with the 
IMDILI probe set of drugs. 
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Total 
ABCB1  1       1   1       3 
ABCC1     1                 1 
ABCC2  1           1   1   3 
ABCC4     1                 1 
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Total 
ABCG2                   1   1 
ACAT1                   1   1 
AKR1C1                     1 1 
AKR1C2                     1 1 
AKR1C3                     1 1 
AKT1     1                 1 
ALB     1         1       2 
ALOX15                   1   1 
ALOX15B                   1   1 
ALOX5     1             1   2 
ALOX5AP                   1   1 
AOX1 1                     1 
APRT 1                     1 
AR     1                 1 
ATIC                   1   1 
BAX                     1 1 
BDNF  1                   1 
BIRC5                     1 1 
C8orf4                     1 1 
CA12     1                 1 
CA13     1                 1 
CA2     1                 1 
CA5B     1                 1 
CA6     1                 1 
CA9     1                 1 
CASP3     1             1 1 3 
CASP8     1               1 2 
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CASP9     1             1   2 
CAV1     1                 1 
CCND1     1               1 2 
CD248       1               1 
CD4             1         1 
CD59       1               1 
CD79A                 1     1 
CDIPT       1               1 
CDK2     1                 1 
CDKN1A     1               1 2 
CFLAR     1                 1 
CHUK                   1   1 
CRH 1               1     2 
CRP 1                 1   2 
CTNNB1                     1 1 
CTSB               1       1 
CTSL1               1       1 
CXCL10 1                     1 
CYP11B1               1       1 
CYP17A1   1       1           2 
CYP19A1     1     1   1       3 
CYP1A1                 1   1 2 
CYP1A2   1         1       1 3 
CYP2A13               1       1 
CYP2A6           1 1         2 
CYP2B6   1       1 1 1       4 
CYP2C18   1           1       2 
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Total 
CYP2C19   1           1       2 
CYP2C8   1 1         1       3 
CYP2C9   1 1       1 1       4 
CYP2D6     1       1 1       3 
CYP2D7P1               1       1 
CYP2E1           1   1       2 
CYP3A4   1 1   1 1 1 1 1     7 
CYP3A43   1                   1 
CYP3A5   1         1 1   1   4 
CYP3A7   1         1 1       3 
DBH           1     1     2 
DDIT3     1                 1 
DGCR2     1                 1 
DIABLO                     1 1 
DIF 1   1                 2 
DIO1                 1     1 
DIO2                 1     1 
DIO3                 1     1 
DPH2               1       1 
DPH3               1       1 
DRD2           1           1 
EGFR     1               1 2 
EGR1                     1 1 
ENSG000001674
94 
                  1   1 
ENSG000001689
37 
                  1   1 
Chapter 3: Searching for similarities: Network map tools 
70 
 
  
al
lo
p
u
ri
n
o
l 
ca
rb
am
az
ep
in
e 
ce
le
co
xi
b
 
cl
av
u
la
n
ic
 a
ci
d
 
fl
u
cl
o
xa
ci
lli
n
 
la
m
o
tr
ig
in
e 
n
ev
ir
ap
in
e 
p
h
en
yt
o
in
 
p
ro
p
yl
th
io
u
ra
ci
l 
su
lf
as
al
az
in
e 
su
lin
d
ac
 
Total 
ENSG000002044
90 
                  1   1 
ENSG000002289
78 
1                     1 
EPHX1   1                   1 
EPX                 1     1 
ERBB2   1                 1 2 
FASLG 1                     1 
FASN     1                 1 
FMO3                     1 1 
G6PD                 1     1 
GDF15     1               1 2 
GNAT3                 1     1 
GNLY           1           1 
GSTM1   1                   1 
HDAC3   1                   1 
HIF1A 1                 1   2 
HLA-C         1             1 
HMBS   1                   1 
HPRT1 1                     1 
HSD3B2   1       1           2 
HSPA5                     1 1 
ICAM1     1             1   2 
IDO1 1                     1 
IGF1R     1                 1 
IKBKB                   1 1 2 
IL10 1                     1 
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Total 
IL1A     1         1       2 
IL1B                   1   1 
IL6     1       1         2 
ILK                     1 1 
IMPA1   1                   1 
INS     1       1 1       3 
ITGA2               1       1 
JUN     1                 1 
KCNA5                 1     1 
KCNH2           1   1       2 
KCNK18           1           1 
LEF1                     1 1 
MAPK1               1       1 
MAPK14     1                 1 
MAPK3               1     1 2 
MAPK8                     1 1 
MC2R           1           1 
MDK                     1 1 
MGMT               1       1 
MLXIPL 1                     1 
MMP7                     1 1 
MMP9     1             1   2 
MPO 1               1 1   3 
MTHFR                   1   1 
NAT2                   1   1 
NFKB1                     1 1 
NFKB2                   1   1 
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Total 
NFKBIA               1   1 1 3 
NFKBIZ               1       1 
NOS1 1             1       2 
NOS2 1                 1   2 
NOS3 1                     1 
NR1I2   1           1       2 
NR1I3               1       1 
NR3C1           1           1 
ODC1                 1     1 
ORM1   1                   1 
ORM2   1                   1 
PARP1 1                   1 2 
PCNA     1                 1 
PDPK1     1                 1 
PLAU     1                 1 
PNP 1                     1 
POMC   1                   1 
PPARD                     1 1 
PPARG     1             1   2 
PPIG   1           1       2 
PRB3                 1     1 
PTEN                 1     1 
PTGER4                     1 1 
PTGS1     1             1 1 3 
PTGS2 1   1             1 1 4 
PTH               1       1 
RALBP1   1                   1 
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Total 
RELA                   1 1 2 
REN                 1   1 2 
S100A4                     1 1 
SAT1                     1 1 
SCN10A   1       1   1       3 
SCN11A   1       1   1       3 
SCN1A   1       1   1       3 
SCN1B   1           1       2 
SCN2A           1   1       2 
SCN2B   1                   1 
SCN3A   1       1   1       3 
SCN4A   1       1   1       3 
SCN5A   1       1   1       3 
SCN7A   1       1   1       3 
SCN8A   1       1   1       3 
SCN9A   1       1           2 
SERPINA7                 1     1 
SHBG   1           1       2 
SLC22A1                     1 1 
SLC22A11                     1 1 
SLC22A2                     1 1 
SLC22A6                     1 1 
SLC22A7 1                   1 2 
SLC22A8 1                     1 
SLC2A6 1                     1 
SLC2A9 1                     1 
SLC46A1                   1   1 
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Total 
SLC7A11                   1   1 
SLCO1C1               1       1 
SP1     1               1 2 
SRC                     1 1 
SST   1           1       2 
ST6GAL1         1             1 
STAR                 1     1 
STAT3                     1 1 
SULT1E1                     1 1 
TAS2R1                 1     1 
TAS2R10                 1     1 
TAS2R14                 1     1 
TAS2R30                 1     1 
TAS2R38                 1     1 
TAS2R4                 1     1 
TBXAS1                   1   1 
TFAP2A   1                   1 
TG                 1     1 
THRA                   1   1 
TMSB10                 1     1 
TNF 1   1                 2 
TNFRSF10B 1   1               1 3 
TNFRSF1B                   1   1 
TNFSF10                     1 1 
TPO                 1     1 
TRH                 1     1 
TSHR                 1     1 
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Total 
UGT1A3           1           1 
UGT1A4           1           1 
UGT2B7   1                   1 
VEGFA     1                 1 
VEGFC     1                 1 
XDH 1                     1 
YWHAE                     1 1 
                          
TOTAL: 27 42 50 3 3 27 11 48 30 36 50 327 
 
3.2 Discussion 
Although SLAP incorporates more databases than STITCH, overall STITCH predicted more 
protein interacting partners than SLAP. This is an unexpected result since most the 
databases included in STITCH are also included in the SLAP set. 
Even more surprising is the small degree of overlap between the predicted proteins. Given 
the substantial number of data sources, one would expect similar proteins to be predicted 
as interacting partners for each drug. In contrast, substantial differences were apparent in 
the number of proteins reported for each drug and also the proteins that were returned, 
with only 17-20% concordance between the two search tools. 
These discrepancies may be due to the differences in how predicted functional partners are 
calculated; SLAP bases calculations on the topology of the nodes in the network while 
STITCH extracts interaction data from the indexed data sources and full-text articles freely 
available from PubMed Central or publishers’ websites (2). 
Metabolic enzymes, such as the cytochrome P450 enzymes, and drug transporters had the 
highest number of interactions. This is not unexpected, given that these are enzymes known 
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to process large numbers of drugs. Even then the majority of identified proteins were only 
thought to interact with 3 or 4 of the 11 IMDILI drugs included in the analyses. Moreover, 
these 3-4 drugs tend to be of the same therapeutic class (e.g. carbamazepine, lamotrigine 
and phenytoin from the SLAP results). This suggests that these proteins are shared because 
of the drugs’ common pharmacological action, rather than a toxicological pathway. No 
protein targets were found to be common to all the drugs in the probe set. 
3.3 Conclusion 
In this chapter, the known and predicted protein interactions for each of the IMDILI probe 
drugs were examined. However, due to the apparent lack of overlap between protein 
interactions, it is difficult to ascertain whether any of the known and predicted proteins 
associated with the IMDILI probe set of drugs are potential toxicity targets involved in the 
pathogenesis of IMDILI. 
Nevertheless, large scale drug-target prediction tools such as SLAP and STITCH are 
important resources for the research community due to their ability to search and integrate 
well-known publically available databases. The results from the use of these search tools 
can be unexpectedly varied and hence further investigations, such as in vitro assays, are 
needed to confirm whether the predicted proteins for the input drugs are true drug-target 
pairs. 
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4 Chapter 4: Searching for similarities: Pharmacophore modelling 
4.1 Computer Aided Drug Design 
Technological advances in the past two decades have seen the rise of computer aided drug 
design where state-of-the art technologies are used to speed up the process of drug-design 
and development (171). While traditional approaches relied on trial and error to uncover 
pharmacologically active compounds, computer aided drug design utilises structure-based 
and/or ligand-based screening for specific targets. This allows for more efficient and cost 
effective drug discovery. 
Powerful tools, such as X-ray crystallography and Nuclear Magnetic Resonance spectroscopy 
(NMR) have characterised the structure of many biological molecules. Knowledge of the 
structure of biological targets allows for the use of structure-based computer aided drug 
design techniques. The interaction between ligands and targets can be studied to aid in the 
identification of other molecules with activity on the target. Moreover, by establishing the 
mode of binding, new compounds can be designed with the required functional groups to 
agonise/antagonise the target site. 
However, the structure of the receptor is not always available in these situations; hence the 
use of ligand-based computer aided drug design techniques is required to create models by 
comparing characteristics of known and active ligands. 
While seemingly unusual, there has been growing interest in the use of in silico drug design 
technologies in toxicology. New computational technologies are transforming the field of 
regulatory science, with the FDA working towards replacing animal studies with a 
combination of in silico and in vitro approaches (92). 
Ursem and colleagues, in work led by the US Food and Drug Administration (FDA), recently 
combined pharmacovigilance data with in silico QSAR modelling techniques (172–174) to 
generate predictive models for idiosyncratic hepatobiliary and urinary tract adverse 
reactions.  Toxicity was classified by clustering adverse event terms under broad endpoints 
(e.g. liver disorder) and drug-event association signals were quantified using 
disproportionality analysis. This information was subsequently used to create QSAR models 
which predicted drug induced hepatobiliary and urinary tract toxicity in humans with low to 
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moderate sensitivity (172). The researchers propose that this approach has utility in 
directing or prioritising pharmacovigilance activities by regulators, sponsors and 
researchers.  While this application of QSAR promises to be a useful decision-support tool in 
drug development, the toxicity signals used to develop QSAR models were derived from 
broad toxicity endpoints which may arise from interactions of different molecules with 
different targets and pathways. These models therefore do not necessarily shed light on the 
mechanisms underlying the toxicity. 
4.1.1 Quantitative Structure Activity Relationships 
Both a drug’s pharmacodynamics (the drug’s action on the body) and pharmacokinetic (the 
body’s action on the drug) properties are based on the drug’s physiochemical properties, 
which in turn are derived from the drug’s molecular structure. Recognition of this led to the 
development of Quantitative Structure Activity Relationships (QSAR) (175).  
In QSAR modelling, the physicochemical properties of compounds are quantified into a 
number of QSAR descriptors. These can be grouped into measures of steric, electrostatic 
and hydrophobicity (Table 4.1). 
Regression analyses can then be used to estimate the relationship between the dependent 
variable, typically biological activity, with the independent variables, which are the QSAR 
descriptors (Equation 5). Techniques such as multiple linear regression and principle 
component analysis assign coefficients to the variables in the equation, quantifying the 
impact of each descriptor on biological activity.  
Table 4.1 Examples of Quantitative Structure Activity Relationship (QSAR) descriptors (176). 
Property grouping Examples of QSAR descriptors 
Steric van der Waals radii; molecular volume, surface area; molecular 
weight; hashed fingerprints; structural keys; counts of specific 
atoms, rings or other features; molecular connectivity χ indices; 
atom pairs topological torsions; polar surface area 
Electrostatic Polarity, ionisation properties; calculated molar refractivity; κ 
shape indices; electrotopological indices; dipole moment 
Hydrophobic cLogP; octanol/water partition coefficient 
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General QSAR equation 
𝐵𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 𝑓(𝑝ℎ𝑦𝑠𝑖𝑐𝑜𝑐ℎ𝑒𝑚𝑖𝑐𝑎𝑙 𝑝𝑟𝑜𝑝𝑒𝑟𝑡𝑖𝑒𝑠) 
Once a model has been built using a set of molecules (the training set), it needs to be 
validated on a test set of molecules. A leave-one-out or leave-some-out cross-validation can 
be used where a subset of the training set will be ‘left out’ during the model creation 
process and used as the test set. The process is then systematically repeated using a 
different subset until all molecules of the training set have been ‘left out’. The cross-
validation process provides some measure of the predictive ability and robustness of the 
model. The cross-validated correlation coefficient q2 is calculated by Equation 6. A QSAR 
model with a high q2, (q2 > 0.5) is considered by some researchers to be highly predictive 
(177). Once statistical stability has been achieved, i.e. the model is a good predictor of 
training set data, the model can then be externally validated with a group of molecules not 
used in generating the model (177). 
Cross-validated correlation coefficient (q2). yi, ?̂?i, ?̅?i, are the actual, estimated and average activities respectively. 
𝑞2 = 1 −  
𝛴(𝑦𝑖−?̂?𝑖)
2
𝛴(𝑦𝑖−?̅?𝑖)2
 
Fragment based 2D QSAR methods are examples of advances in QSAR modelling which have 
built upon the traditional method described above. Hologram QSAR (HQSAR) splits 
compounds into molecular fragments. These fragments contain topological and 
compositional information regarding the molecule and hence can be used as structural 
descriptors as part of the QSAR equation (178). 
The QSAR methods described so far are what have been termed 2D QSAR methods since all 
the descriptors can be calculated from the molecular formula alone. Unlike 2D QSAR 
methods, 3D QSAR approaches require knowledge of the bioactive conformations of 
molecules and can be broadly categorised into alignment-dependent methods and 
alignment-independent methods (179). 
Comparative Molecular Field Analysis (CoMFA) is a popular alignment-dependent 3D QSAR 
approach. Bioactive conformers of the training set compounds are aligned on a grid. A 
probe atom is then used to quantify the steric and electrostatic energies at each grid point 
for each molecule using Lennard-Jones and Coulombic functions (180). Comparative 
(6) 
(5) 
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Molecular Similarity Indices (CoMSIA) uses a Gaussian distance function instead of the 
Lennard Jones and Coulombic functions in calculating the energies and also expands the 
molecular fields to include hydrophobic, hydrogen bond acceptor and hydrogen bond donor 
properties in addition to steric and electrostatic parameters (181,182). The major weakness 
of CoMFA, CoMSIA and indeed all alignment-dependent 3D QSAR methods is the need for 
ligands to be aligned with respect to all the other ligands in the set (179). An absolute 
orientation of a single conformation needs to be identified for each ligand, and this is 
assumed to be the aligned conformation that will bind to the receptor in vivo. This can be a 
difficult task, especially in the absence of a co-crystallised receptor-ligand complex, or 
dissimilar ligands. 
Improvements on the CoMFA method include Topomer CoMFA , where automated 
alignment tools are used to generate both a conformation and orientation of a molecular 
fragment from the 2D structure (183). 3D QSAR methods which are completely alignment-
independent are also available. Examples include comparative molecular moment analysis 
(CoMMA) (184), Weighted Holistic Invariant Molecular (WHIM) (185) and GRid-Independent 
descriptors (GRIND) (186). 
The weakness of QSAR lies in the ability to identify only molecules that are similar to the 
training set. Since the equation considers the molecule as a whole, it is difficult to create 
meaningful QSAR models when there are large structural variations within the training set. 
Although molecules may belong to different structural classes of compounds, they may still 
share a 3D arrangement of molecular features which allow them to interact with a common 
receptor. 
4.1.2 Pharmacophore perception 
A pharmacophore is a set of features that is common to a group of molecules with activity 
on a target. The IUPAC defines a pharmacophore as "an ensemble of steric and electronic 
features that is necessary to ensure the optimal supramolecular interactions with a specific 
biological target and to trigger (or block) its biological response" (187). An example of a 
pharmacophore is presented in Figure 4.1. The quality of pharmacophore models is 
dependent upon the structural diversity as well as the size of the training set. Successful 
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pharmacophore models have been generated from a training set of around 15-20 
compounds (188). 
 
Figure 4.1 Example of a pharmacophore containing 2 hydrogen bond acceptors (red), 1 hydrogen bond donor (blue) and 
1 ring moiety (orange). 
The concept of feature groups is based on bioisosteres, which are chemical substituents or 
functional groups with similar chemical and biological properties. Features which are 
typically included in pharmacophore analyses include: hydrogen bond acceptors (HBA), 
hydrogen bond donors (HBD), hydrophobes (H), ring structures, positively and negatively 
charged groups. Examples of bioisoteric groups which have these properties are given in 
Table 4.2.  
By studying the structure-activity relationship between the feature groups and biological 
activity, it is possible to extrapolate structural information about the biological receptor. 
Assuming the 3D arrangement of pharmacophore features is critical for receptor binding 
these features will reflect complementary sites at the receptor. For this assumption to be 
true, the conformation of the molecule aligned to the pharmacophore must also be the 
bioactive conformation. Hence a thorough sampling of low energy conformations is of vital 
importance to ensure that the molecule’s bioactive conformation is among the set of 
conformations input into the pharmacophore perception program. 
DISCO (DIStance COmparison) is one of the earliest programs able to automate the 
pharmacophore searching process (189). Each conformation from an inputted set is 
transformed into a set of interpoint distances between pharmacophore features. The Bron-
Kerbosh clique-detection algorthim is used for distance comparisons to determine the 
maximum common substructure common to the training set compounds. A weakness with 
this approach is that a compound needs to be specified as the reference for the 
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conformational comparisons, which makes it difficult to find a common pharmacophore if 
all the compounds of the training set are highly flexible (189). 
 
Table 4.2 Examples of pharmacophoric bioisotere groups. 
Pharmacophore Group Example Structures 
Hydrogen Bond Donor 
                       
Hydrogen Bond 
Acceptor         
Hydrogen Bond Donor 
and Acceptor 
                          
Acid (Negative 
Ionizable) 
         
Base (Positive 
Ionizable)           
Hydrophobic / 
Aromatic      
Atoms not considered 
pharmacophoric 
              
 
Newer pharmacophore perception software includes Catalyst (190,191), GASP (192) and 
Schrödinger's Phase (193). The work outlined here utilised the Phase program so discussion 
will focus on the methods of pharmacophore determination available with this software. 
4.1.3 Schrödinger's Phase program 
Schrödinger's Phase program (version 3.4, Schrödinger, LLC, New York, NY, 2012.) utilises 
state-of-the-art algorithms for pharmacophore perception, structure alignment activity 
prediction and 3D database searching (194). It has been widely utilised for pharmacophore 
perception and 3D QSAR modelling from the development of novel breast cancer 
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drugs(195,196) to virtual screening of potentially new anti-diabetic compounds (197) and 
identifying the critical functional groups for anti-tubercular activity (198). 
The Phase workflow for building pharmacophore models from a set of known ligands has 
four steps (with a fifth optional step) (Figure 4.2). Each step is described in further detail 
below. Briefly, a set of molecules with affinity for a common receptor are inputted. These 
molecules are converted into 3D and energy minimized. Low energy conformations are 
generated and pharmacophore sites created. Pharmacophore hypotheses common to 
multiple ligands are then identified. 
 
Figure 4.2 Overview of Phase workflow for building pharmacopohore models from a set of ligands. 
4.1.3.1 Prepare ligands 
4.1.3.1.1 2D to 3D conversion 
Pharmacophore development requires all atom 3D representations of molecules. Hence any 
structures which are presented in 2D (e.g. sdf files downloaded from the DrugBank 
database) must first be converted into 3D. This can be done by minimisation or through the 
use of the LigPrep (Ligand Preparation) program (199). The use of LigPrep is recommended 
to prepare ligands for further analyses, since it is also able to ionise molecules at designated 
pH (typically 7.0 ± 2) and generate stereoisomers. 
4.1.3.1.2 Energy Minimisation 
Energy minimisation of the output molecules can be conducted with Macromodel (200). A 
number of methods are available for energy minimisation including Polak-Ribiere Conjugate 
Gradient (PRCG), Truncated Newton Conjugate Gradient (TNCG), Oren-Spedicato Variable 
Metric (OSVM) and Steepest Descent (SD). Of these, PRCG is thought to be best general 
method for minimization (200) and was therefore used in this study. 
Prepare ligands
Create 
pharmacophore 
sites
Develop 
pharmacophore 
hypotheses
Score hypotheses
Build QSAR 
models (optional)
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4.1.3.1.3 Conformer generation 
Low energy conformations can be generated externally and imported or produced as part of 
the Phase workflow. The two methods for conformer generation offered by Phase are 
Mixed Monte-Carlo Multiple Minimum/Low Mode (MCMM/LMOD) and ConfGen. These are 
further explained below. 
During the MCMM search, random changes are made in torsion angles. Hence this method 
is highly efficient in performing global searching, decreasing the risk of ‘becoming stuck’ on 
a local minima rather than the global minimum. However, if more than 10-15 flexible 
torsions are present, the complexity of the search will increase, leading to increased 
searching times (200).  
In the ConfGen (201,202)  methodology, molecules are divided into a core and a periphery. 
The Phase user manual defines peripheral groups as those that “have only one rotatable 
bond between terminal groups and the rest of the molecule. All the non-peripheral 
rotatable bonds are assigned to the core”. All core configurations are generated during the 
search process before the peripheral configurations are varied. Although two sampling 
options are available (Rapid and Thorough), the Phase manual notes that a Thorough 
conformational search does not significantly improve the final pharmacophore model 
compared with a Rapid search (203). 
4.1.3.1.4 Ligand groupings 
Once all the molecules have been prepared, the “pharm set” for pharmacophore perception 
must be defined. This can be done by manually assigning molecules to the “active” or 
“inactive” set, or an activity threshold can be set to automatically assign the pharm set 
based on an imported activity value. 
It is also possible to group multiple ligands such that they will be seen as “the same ligand” 
in the Develop pharmacophore hypotheses step – i.e. only one ligand in the group needs to 
match for the purpose of finding common pharmacophores. 
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4.1.3.2 Create pharmacophore sites 
To find commonalities between active ligands, the areas within each ligand which are 
capable of interacting with a receptor are identified. Phase supports 6 types of 
pharmacophore feature by default: 
 Hydrogen bond acceptor (A) 
 Hydrogen bond donor (D) 
 Hydrophobic group (H) 
 Negatively charged group (N) 
 Positively charged group (P) 
 Aromatic ring (R) 
Excluding hydrophobic groups and aromatic rings, each of these features is defined by a set 
of Smiles ARbitary Target Specification (SMARTS) patterns, a language for describing 
substructures within molecules developed by Daylight Chemical Information Systems (204). 
SMARTS uses rules that are straightforward extensions of SMILES. Tables outlining SMARTS 
primitives are presented in Appendix 5: SMARTS notation primitives. 
Within each set, the pharmacophore features are further categorised by the physical 
characteristics of the site; namely point, vector and group. Vector characteristics are helpful 
for features which have direction. For example, oxygen atoms have lone pairs of electrons 
which point in specific directions. 
If deemed inappropriate, default feature definitions can be ignored. Users can also define 
additional features using SMARTS patterns if required. 
Once the feature set has been finalised, Phase creates and stores the site points for each 
conformer of each ligand (Figure 4.3).  
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Figure 4.3 Total pharmacophore sites for allopurinol. Hydrogen bond acceptors (A) are shown in red; hydrogen bond 
donors (D) are shown in blue; hydrophobic sites (H) are shown in green; aromatic rings (R) are represented by an orange 
ring. 
4.1.3.3 Develop common pharmacophore hypotheses 
In this step, Phase uses a tree-based partitioning technique to group together similar 
pharmacophores by their intersite distances, i.e. the distance between two pharmacophore 
features. A k-point pharmacophore is represented by a vector of n distances, where  
n = (k(k-1))/2. Each of the n distances is filtered through a binary decision tree into 
categories of user defined length. The length of each category is termed the final box size. 
From the final box size and the user specified maximum tree depth, the size of the initial box 
size is calculated (Initial box size = Final box size ^ Maximum tree depth).  The final box size 
and the tree depth need to be set such that the initial box is large enough to encompass the 
largest molecule under consideration. Figure 4.4 shows an example of a tree with final box 
size of 2Å and a tree depth of 3. This gives an initial box size of 23=8Å. 
 
Figure 4.4 Sample Phase binary decision tree with final box size 2Å and tree depth 3. This gives an initial box size of 
23=8Å. 
Families of pharmacophores that have the same number of pharmacophore feature types 
are termed variants. For example pharmacophores belonging to the AADR variant will 
0<d<8
0<d<4
0<d<2 2<d<4
4<d<8
4<d<6 6<d<8
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contain 2 hydrogen bond acceptors, 1 hydrogen bond donor and 1 ring. Similarly, 
pharmacophores in the ADHR variant will contain 1 hydrogen bond acceptor, 1 hydrogen 
bond donor, 1 hydrophobe and 1 ring. 
The number of pharmacophore sites in the hypotheses and the number of ligands that 
much match to form a valid hypothesis is set by the user.  Partial matching is not possible. 
i.e. compounds are required to match all k sites of a k-point pharmacophore.  
Users can also specify a minimum intersite distance. This is the minimum distance which 
must be present between any two pharmacophore features. Any pharmacophore 
hypotheses with features closer than this distance will be rejected in the selection process. 
4.1.3.4 Score hypotheses 
From the previous step, several sets of pharmacophores will be produced. Each set will 
contain pharmacophores which have similar intersite distances, with each pharmacophore 
based on a different reference ligand. For each pharmacophore in the set, all of the other 
ligands are aligned with the reference ligand using a standard least squares procedure. 
Alignments are scored on their root mean squared deviations (RMSD) from site positions, a 
vector score, and a volume score. The pharmacophore and its corresponding reference 
ligand in the set which produces the highest scoring ligand alignments is taken as the 
pharmacophore hypothesis for that set.  
Following this step, a percentage cut-off to the overall alignment score can be used to 
eliminate low scoring hypotheses. 
The remaining hypotheses are then ranked based on volume and selectivity scoring. The 
volume score is calculated as the proportion of overlap between the reference ligand and 
non-reference ligands for each hypothesis, based on van der Waals models of non-hydrogen 
atoms (Equation 7). The selectivity score is a rough estimate of the rarity of the hypothesis, 
or the proportion of all molecules that will match the hypothesis. 
Volume score formula used to determine the quality of pharmacophore alignments. Taken from the Phase user manual. 
𝑆𝑣𝑜𝑙 =
𝑉𝑐𝑜𝑚𝑚𝑜𝑛(𝑖)
𝑉𝑡𝑜𝑡𝑎𝑙(𝑖)
 (7) 
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Within the Score Actives dialogue box, there is an option to set the allowed Root Mean 
Square deviation of intersite distances. This is the RMSD of the pharmacophore site distance 
from any contributing ligand to those of the reference ligand. Lower RMSD reflects stricter 
criteria, requiring alignments to more closely reflect that of the reference ligand. 
4.1.3.5 Advanced pharmacophore screening 
Phase provides a functionality to screen compounds using pharmacophore hypotheses. A 
hypothesis can be used to search a prepared database of 3D structures. Conformations can 
be generated externally and included as part of a database, or Phase can generate 
conformers using ConfGen (202) during the search process. 
Structures are searched for the required pharmacophore sites and intersite distances 
needed to match the input pharmacophore hypothesis. Conformers which fulfil these 
requirements are aligned to the hypothesis as a ‘hit’. Hits are assigned fitness scores based 
on the quality of the alignment to the pharmacophore hypothesis. 
There is an option to set the intersite distance matching tolerance (IDMT). This is the 
maximum allowed deviation from the pharmacophore site. Lower IDMT reflects stricter 
criteria, requiring alignments to more closely reflect that of the pharmacophore hypothesis. 
4.2 Rationale 
In this chapter, relationships between IMDILI and the three-dimensional structural features 
of toxic drug molecules and their metabolites are exposed. Pharmacophore perception tools 
are used to identify whether there are similarities in molecular structures between toxic 
drugs.  
In the following analyses a molecule's biological activity is defined as its IMDILI potential - 
i.e. active drugs are drugs that have known IMDILI potential and inactive drugs are drugs 
that are not known to cause IMDILI. 
4.3 Methods 
High molecular weight drugs tend to have high numbers of functional groups due to the 
increased number of atoms especially in less accessible regions of the molecule (e.g. in the 
centre). As such, inclusion of these drugs will increase the rate of false positives in the 
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identification of relevant pharmacophore features. For this reason, drugs with molecular 
weight >500 Da were excluded from all in silico analyses. 
Platform dependent differences have been noted from previous experiences so to ensure 
consistency of results, the pharmacophore perception process was repeated on four 
different computers across Linux (Ubuntu 12.04), MacOSX (Version 10.6.8) and Windows 
(Windows 7) platforms. 
4.3.1 Literature confirmation of toxicity classification 
The correct assignment of activity is essential for the development and validation of 
pharmacophore models. The IMDILI potential (or lack thereof) of the all drugs included in 
the pharmacophore analyses was confirmed by reviewing published literature. A drug was 
only included in the training set if there was published evidence of DILI with immune 
features (e.g. fever, rash or eosinophilia), or if genetic studies have identified associations 
with proteins known to activate the adaptive immune system (Table 2.6). This acted as a 
validation step to filter out potentially false signals generated from the pharmacovigilance 
data. 
4.3.2 Identification of metabolites 
Since drug metabolites are known to be involved in at least some DILI, all drugs were 
grouped with their known and proposed metabolites. Published literature was reviewed to 
identify known and proposed metabolites of all drugs in the training set. The full list of drugs 
and metabolites included in the training set for pharmacophore perception is presented in 
Table 4.3. 
Table 4.3 List of drugs and metabolites included in the training set for pharmacophore perception. Metabolites have 
been assigned an arbitrary number and are named as M(𝒙). E.g. Allopurinol M1 denotes allopurinol metabolite 1. 
Drug/metabolite Structure 
Allopurinol 
 
 
Allopurinol M1 (205) 
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Drug/metabolite Structure 
Allopurinol M2 
(205) 
 
Allopurinol M3 (205) 
 
 
Allopurinol M4 (205) 
 
 
Carbamazepine 
 
 
Carbamazepine M1 
(206) 
 
 
Carbamazepine M2 
(206) 
 
 
Carbamazepine M3 
(206) 
 
 
Carbamazepine M4 
(206) 
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Drug/metabolite Structure 
Carbamazepine M5 
(206) 
 
 
Carbamazepine M6 
(206) 
 
 
Celecoxib 
 
Celeboxicb M1 (207) 
 
 
Celeboxib M2 (207) 
 
 
Clavulanic acid 
 
Clavulanic acid M1 
(208) 
 
 
Clavulanic acid M2 
(208) 
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Drug/metabolite Structure 
Flucloxacillin 
 
Flucloxacillin M1 
(209) 
 
 
Flucloxacillin M2 
(209) 
 
 
Flucloxacillin M3 
(209) 
 
 
Lamotrigine 
 
Lamotrigine M1 (210) 
 
 
Lamotrigine M2 (210) 
 
 
Nevirapine 
 
Nevirapine M1 (211) 
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Drug/metabolite Structure 
Nevirapine M2 (211) 
 
 
Nevirapine M3 (211) 
 
 
Nevirapine M4 (211) 
 
 
Nevirapine M5 (211) 
 
 
Phenytoin 
 
Phenytoin M1(212) 
 
 
Phenytoin M2 (212) 
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Drug/metabolite Structure 
Phenytoin M3 (212) 
 
 
Phenytoin M4 (212) 
 
 
  
Phenytoin M6 (212) 
 
 
Propylthiouracil 
 
Propylthiouracil M2 
(213) 
 
 
Propylthiouracil M6 
(213) 
 
 
Propylthiouracil M7 
(213) 
  
Propylthiouracil M8 
(213) 
 
 
Propylthiouracil M9 
(213) 
 
 
Sulfasalazine 
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Drug/metabolite Structure 
Sulfasalazine M1 
(214) 
 
 
Sulfasalazine M2 
(214) 
 
 
Sulfasalazine M3 
(214) 
 
 
Sulfasalazine M4 
(214) 
  
Sulfasalazine M5 
(214) 
  
Sulfasalazine M6 
(214) 
 
 
Sulindac 
 
Sulindac M1 (215) 
 
 
Sulindac M2 (215) 
 
 
 
4.3.3 Prepare ligands 
All molecules were built with the molecular modelling and graphical user interface package, 
Maestro (version 9.3, Schrödinger, LLC, New York, NY, 2012.). Parent drug structures were 
downloaded in Simple Data Format (sdf) from the DrugBank database (www.drugbank.ca). 
Metabolites were drawn in using Maestro’s 2D sketcher tool. 
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The LigPrep program (version 2.8, Schrödinger, LLC, New York, NY, 2013) was used to 
convert the downloaded sdf files from 2D to 3D. Molecules were ionised at physiological pH 
7 (± 2.0). LigPrep was asked to generate one low energy ring conformation for each ligand 
using the OPLS_2005 forcefield (216). Specified chiralities were retained and unspecified 
chiralities were varied up to a maximum of 32 stereoisomers per ligand. 
The global minimal energy state of all molecules was determined with MacroModel (version 
9.9, Schrödinger, LLC, New York, NY, 2012).  Structures were minimised using the PRCG 
method. The convergence threshold was set to 0.05, based on gradient. Up to a maximum 
of 5000 iterations were allowed. The OPLS_2005 forcefield was used with a constant solvent 
dielectric of 1.0. Subsequently each molecule was visually inspected to confirm that 
minimisation had given chemically correct structures. These were then imported into a 
Phase run. 
Conformers were generated within the Phase workflow, using the OPLS_2005 forcefield 
with a distance-dependent electrostatic treatment. The ConfGen search method was used 
with Rapid sampling of the conformational space. Redundant conformers were eliminated 
using a RMSD cutoff of 0.5Å.  
Each drug of the training set was grouped with its known and proposed metabolites as an 
active ligand group. 
4.3.4 Create pharmacophore sites 
 Pharmacophore sites were identified using both point and vector geometries. The feature 
definitions used in the pharmacophore perception are presented in Appendix 6: Definitions 
of the pharmacophore features included in the genernation of pharmacophore hypotheses. 
4.3.5 Develop common pharmacophore hypothesis 
Phase was asked to identify common pharmacophore hypotheses with a maximum of 7 and 
a minimum of 4 site points. Hypotheses were required to match at least 9 of 11 active 
groups (82%). 
The initial box size was set to 32Å, with a final box size of 1Å and maximum tree depth of 5. 
The minimum intersite distance was set to 2Å. 
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4.3.6 Scoring actives 
Hypotheses were scored using the survival formula. The maximum RMSD of the intersite 
distances of any contributing ligand from those of the reference ligand was set at 1.2Å. 
4.3.7 External Validation 
4.3.7.1 Compilation of active test set 
Drugs withdrawn from the market because of DILI concerns as identified by Guengerich 
(217) were included in the active test set (Table 4.4). 
4.3.7.2 Compilation of inactive test set 
Australia’s DAEN database was searched for drugs with >200 case reports, none of which 
contain ADR descriptors indicative of DILI. Six drugs met these criteria, and were included in 
the inactive test set. Since the number of inactive drugs was significantly smaller than the 
number of active drugs (in the training and test sets), a second set of inactives was 
identified from the literature. Chen et al. (43) lists two datasets of drugs and the DILI 
potential of each drug as identified by two different sources.  
The 7 drugs identified in both data sources as without DILI potential were added into the 
inactive test set (Table 4.4). 
4.3.7.3 Molecular preparation 
The Test set molecules were prepared in the same manner as the Training Set. The IMDILI 
potential (or lack thereof) of each drug was confirmed by reviewing published literature. A 
drug was only included in the active test set if there was published evidence of DILI with 
immune features (e.g. fever, rash or eosinophilia), or if there were genetic associations with 
proteins known to activate the adaptive immune system. Drugs were excluded from the 
inactive test set if there was literature evidence of any hepatotoxicity (not necessarily 
immune mediated). Published literature was reviewed to identify known and proposed 
metabolites of all drugs in both test sets. The full list of drugs and metabolites included in 
both test sets is presented in Table 4.4. 
Molecules were built and minimised in the same manner as the Training Set (see section 
4.3.3 Prepare ligands). Conformations were generated as part of the Screening workflow. 
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Table 4.4 List of drugs and metabolites included in the active and inactive test sets. 
Set Drug/metabolite Structure 
Active test set Bromfenac 
 
 Bromfenac M1 (218) 
 
 
 Bromfenac M2a (218) 
 
 
 Bromfenac M3 (218) 
 
 
 Chlormezanone 
 
 
 Chlormezanone M1 
(219,220) 
 
 
 Chlormezanone M2 
(219,220) 
 
 
 Chlormezanone M3 
(219,220) 
  
 Chlormezanone M4 
(219,220) 
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Set Drug/metabolite Structure 
 Chlormezanone M5 
(219,220) 
 
 
 Chlormezanone M6 
(219,220) 
 
 
 Lumiracoxib 
 
 Lumiracoxib M1 
(221,222) 
 
 
 Lumiracoxib M2 
(221,222) 
 
 
 Lumiracoxib M3 
(221,222) 
 
 
 Lumiracoxib M4 
(221,222) 
 
 
 Lumiracoxib M5 
(221,222) 
 
 
 Lumiracoxib M6 
(221,222) 
 
 
 Lumiracoxib M7 
(221,222) 
 
 
Chapter 4: Searching for similarities: Pharmacophore modelling 
100 
 
Set Drug/metabolite Structure 
 Lumiracoxib M8 
(221,222) 
 
 
 Lumiracoxib M9 
(221,222) 
 
 
 Lumiracoxib M10 
(221,222) 
 
 
 Lumiracoxib M11 
(221,222) 
 
 
 Lumiracoxib M12 
(221,222) 
 
 
 Lumiracoxib M13 
(221,222) 
 
 
 Lumiracoxib M14 
(221,222) 
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Set Drug/metabolite Structure 
 Lumiracoxib M15 
(221,222) 
 
 
 Lumiracoxib 
M16(221,222) 
 
 
 Lumiracoxib M17 
(221,222) 
 
 
 Lumiracoxib M18 
(221,222) 
 
 
 Nomifensine 
 
 
 Nomifensine M1 
(223–225) 
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Set Drug/metabolite Structure 
 Nomifensine M2 
(223–225) 
 
 
 Nomifensine M3 
(223–225) 
 
 
 Nomifensine M4a 
(223–225) 
 
 
 Nomifensine M4ia 
(223–225) 
 
 
 Nomifensine M4ib 
(223–225) 
 
 
 Nomifensine M4ic 
(223–225) 
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Set Drug/metabolite Structure 
 Nomifensine M5 
(223–225) 
 
 
 Nomifensine M5i 
(223–225) 
 
 
 Oxyphenisatin 
 
 Pemoline 
 
 Tienilic acid 
 
 Tienilic acid M1 
(226–229) 
 
 
 Tienilic acid M1i 
(226–229) 
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Set Drug/metabolite Structure 
 Tienilic acid M2 
(226–229) 
 
 
 Tienilic acid M2i 
(226–229) 
 
 
 Tienilic acid M3 
(226–229) 
 
 
 Tienilic acid M3i 
(226–229) 
 
 
 Tienilic acid M4 
(226–229) 
 
 
 Tienilic acid M4i 
(226–229) 
  
 Tienilic acid M5 
(226–229) 
 
 
 Ximelagatran 
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Set Drug/metabolite Structure 
 Ximelagatran M1 
(230–233) 
 
 
 Ximelagatran M2 
(230–233) 
 
 
 Ximelagatran M3 
(230–233) 
 
 
 Ximelagatran M4 
(230–233) 
 
 
 Ximelagatran M5 
(230–233) 
 
 
 Ximelagatran M6 
(230–233) 
 
 
Inactive test set  Alprazolam 
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Set Drug/metabolite Structure 
 Alprazolam M1 (234) 
 
 
 Alprazolam M2 (234) 
 
 
 Aripiprazole 
 
 Baclofen 
 
 Baclofen M1 (235) 
 
 
 Fluvoxamine 
 
 Fluvoxamine M1 
(236,237) 
 
 
 Fluvoxamine M2 
(236,237) 
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Set Drug/metabolite Structure 
 Ketorolac 
 
 Ketorolac M1 (238) 
 
 
 Pregablin 
 
 Betaine 
 
 Clemastine 
 
 Clemastine M1 (239–
241) 
 
 
 Clemastine M2 (239–
241) 
 
 
 Clemastine M3 (239–
241) 
 
 
 Clemastine M4a 
(239–241) 
 
 
 Clemastine M4b 
(239–241) 
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Set Drug/metabolite Structure 
 Clemastine M4c 
(239–241) 
  
 Clemastine M6 (239–
241) 
 
 
 Clemastine M7 (239–
241) 
 
 
 Diphenhydramine 
 
 Diphenhydramine M1 
(242,243) 
 
 
 Diphenhydramine M2 
(242,243) 
 
 Diphenhydramine M3 
(242,243) 
 
 
 Diphenhydramine M4 
(242,243) 
 
 
 Diphenhydramine M5 
(242,243) 
 
 
 Diphenhydramine M6 
(242,243) 
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Set Drug/metabolite Structure 
 Isoproterenol 
 
 Isoproterenol M1 
(244) 
 
 
 Methysergide 
 
 Methysergide M1 
(245,246) 
 
 
 Oxybutynin 
 
 Oxybutynin M1 (247–
249) 
 
 
 Phenoxybenzamin 
 
 
4.3.7.4 Advanced Pharmacophore Screening of Test set 
The Phase (version 3.4, Schrödinger, LLC, New York, NY, 2012) Advanced Pharmacophore 
Screening tool was used to screen the active and inactive test sets for matches. The intersite 
distance matching tolerance was set to 2Å. The predictive performance measures 
sensitivity, specificity, accuracy, Matthews Correlation Coefficient, positive prediction value 
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and negative predictive value were calculated based on the number of drug/metabolite 
groups containing at least one molecule matching the pharmacophore hypothesis (250). 
4.4 Results 
The largest number of occurrences for each pharmacophore feature among the training set 
are listed in Table 4.5.  
Table 4.5 The largest number of occurrences for each pharmacophore feature among the training set molecules. 
Pharmacophore feature Largest number of occurrences among 
molecules of training set 
Hydrogen bond acceptor 8 
Hydrogen bond donor 4 
Hydrophobe 3 
Negative ionisable 1 
Positive ionisable 0 
Ring 2 
 
No 7, 6 or 5 point hypotheses were found to be common for the required number of active 
groups (9 out of 11). 
 
Of the 4 point pharmacophore hypotheses that were returned, the AADR and AADD variants 
were identified as high performing, based on the Phase survival score and visual inspection. 
Each of the hypotheses within these two variants was used to screen the active and inactive 
Test sets. The screening results for the AADR and AADD variants are presented in Table 4.6 
and Table 4.7 respectively. 
 
It is interesting to note that typically, only 2 of the 9 training set drug/metabolite groups 
which match the pharmacophore include the parent drug. The majority of the molecules 
which match the pharmacophore hypotheses are metabolites rather than parent drugs. This 
trend is also observed in the Test tests. 
 
Out of all the pharmacophore hypotheses investigated, the highest scoring was the 
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AADR.4989 hypothesis. This hypothesis had a Matthew's Correlation Coefficient of 0.69, 
which indicates a strong positive relationship. The model was able to differentiate between 
molecules in the Active and Inactive Test sets with sensitivity and specificity of 75% and 92% 
respectively. Hence, this hypothesis was taken to the be one that best captures the 
structural similarities between the molecules implicated in IMDILI and will henceforth be 
referred to as the toxicophore hypothesis. The site measurements for the toxicophore 
hypothesis are presented in Figure 4.5. 
 
Figure 4.5 Primary toxicophore hypothesis common to drugs/metabolites implicated in IMDILI. The hypothesis consists 
of 2 hydrogen bond acceptors (A), 1 hydrogen bond donor (D) and 1 ring structure (R). a) The toxicophore superimposed 
on its model ligand N4-acetylsulfapyridine. b) Site measurements for the pharmacophore. c) Schematic of the 
pharmacophore site measurements. 
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Table 4.6 List of molecules that match AADR pharmacophore hypotheses. “P” = only the parent drug matches the 
pharmacophore. “P+M” = both parent and metabolite drug molecules match the pharmacophore. “M” = only metabolite 
molecules match the pharmacophore hypothesis. 
  AADR.4989 AADR.3653 AADR.5301 AADR.3975 AADR.22 
T
ra
in
in
g
 S
e
t 
Allopurinol M M M M M 
Carbamazepine M M M M P+M 
Celecoxib P+M P+M P+M P+M P+M 
Clavulanic acid      
Flucloxacillin M M M M M 
Lamotrigine M M M M M 
Nevirapine M M M M P+M 
Phenytoin M M M M P+M 
Propylthiouracil M M M M M 
Sulfasalazine P+M P+M P+M P+M P+M 
Sulindac      
 TOTAL (of 11) 9 9 9 9 9 
       
A
c
ti
v
e
 T
e
s
t 
S
e
t 
Bromfenac P+M P+M P+M P+M P+M 
Chlormezanone  M   M 
Lumiracoxib P+M P+M M M P+M 
Nomifensine M M M M M 
Oxyphenisatin P P P  P 
Pemoline     P 
Tienilic acid M P+M P+M  P+M 
Ximelagatran P+M P+M P+M P+M P+M 
 TOTAL (of 8) 6 7 6 4 8 
       
In
a
c
ti
v
e
 T
e
s
t 
S
e
t 
Alprazolam      
Aripiprazole      
Baclofen      
Betaine hydrochloride      
Clemastine     M 
Diphenhydramine  M   M 
Fluvoxamine      
Isoproterenol P+M P+M P+M P+M P+M 
Ketorolac      
Methysergide  M M   
Oxybutynin     P 
Phenoxybenzaine      
Pregabalin      
 TOTAL (of 13) 1 3 2 1 4 
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  AADR.4989 AADR.3653 AADR.5301 AADR.3975 AADR.22 
       
 M
o
d
e
l 
S
ta
ti
s
ti
c
s
 
Matthew’s Correlation 
Coefficient 
0.69 0.63 0.60 0.48 0.68 
Accuracy 0.86 0.81 0.81 0.76 0.81 
Sensitivity 0.75 0.88 0.75 0.50 1.00 
Specificity 0.92 0.77 0.85 0.92 0.69 
Positive predictive value 0.86 0.70 0.75 0.80 0.67 
Negative predictive 
value 
0.86 0.91 0.85 0.75 1.00 
True positive 6 7 6 4 8 
False positive 1 3 2 1 4 
False negative 2 1 2 4 0 
True negative 12 10 11 12 9 
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Table 4.7 List of molecules that match AADD pharmacophore hypotheses. “P” = only the parent drug matches the 
pharmacophore. “P+M” = both parent and metabolite drug molecules match the pharmacophore. “M” = only metabolite 
molecules match the pharmacophore hypothesis. 
  AADD.428 AADD.3709 AADD.2715 AADD.4634 AADD.2702 AADD.3220 
T
ra
in
in
g
 S
e
t 
Allopurinol M M M M M M 
Carbamazepine M M M M M M 
Celecoxib       
Clavulanic acid P P+M P+M P+M P+M P+M 
Flucloxacillin P+M P+M P+M P+M P+M P+M 
Lamotrigine M M M M M M 
Nevirapine M M M M M M 
Phenytoin M M M M M M 
Propylthiouracil M M M M M M 
Sulfasalazine M M M M M M 
Sulindac       
 TOTAL (of 11) 9 9 9 9 9 9 
        
A
c
ti
v
e
 T
e
s
t 
S
e
t 
Bromfenac M M M M M P+M 
Chlormezanone M M M M M M 
Lumiracoxib M M M M M P+M 
Nomifensine  M M M M M 
Oxyphenisatin      P 
Pemoline       
Tienilic acid M P M M M M 
Ximelagatran P+M P+M P+M P+M P+M P+M 
 TOTAL (of 8) 5 6 6 6 6 7 
        
In
a
c
ti
v
e
 T
e
s
t 
S
e
t 
Alprazolam       
Aripiprazole       
Baclofen       
betaine 
hydrochloride 
      
Clemastine       
Diphenhydramine M M M M M M 
Fluvoxamine       
Isoproterenol  P P+M P+M P+M P+M 
Ketorolac       
Methysergide       
Oxybutynin M M M M M M 
Phenoxybenzaine       
Pregabalin       
 TOTAL (of 13) 2 3 3 3 3 3 
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  AADD.428 AADD.3709 AADD.2715 AADD.4634 AADD.2702 AADD.3220 
 M
o
d
e
l 
S
ta
ti
s
ti
c
s
 
Matthew’s Correlation 
Coefficient 
0.49 0.51 0.51 0.51 0.51 0.63 
Accuracy 0.76 0.76 0.76 0.76 0.76 0.81 
Sensitivity 0.63 0.75 0.75 0.75 0.75 0.88 
Specificity 0.85 0.77 0.77 0.77 0.77 0.77 
Positive predictive 
value 
0.71 0.67 0.67 0.67 0.67 0.70 
Negative predictive 
value 
0.79 0.83 0.83 0.83 0.83 0.91 
True positive 5 6 6 6 6 7 
False positive 2 3 3 3 3 3 
False negative 3 2 2 2 2 1 
True negative 11 10 10 10 10 10 
4.5 Discussion 
The research outlined in this chapter has exposed relationships between the three-
dimensional structural features of drugs and their metabolites and IMDILI. Parent or 
metabolite structures for many drugs implicated in IMDILI share common molecular 
features (in the form of a 4-point pharmacophore) that are largely not present in non-
hepatotoxic drugs. This is consistent with the hypothesis that one of the prerequisites for 
IMDILI is possession of structural features that interact with common targets within 
common pathways to initiate or potentiate the toxicity reaction. 
 
The prominence of metabolites among the matches to the pharmacophore is an interesting 
observation, since metabolites are not always taken into account in previous work of a 
similar nature (172). The literature has identified increased hepatic metabolism as a risk 
factor for IMDILI (see section 1.3.1 Characteristics of medications), and hence it is logical to 
infer that metabolites may have a role in the pathogenesis of toxicity. This highlights the 
importance of taking hepatic metabolism into account when developing models; both in 
silico, to ensure known and proposed metabolites are included in the analyses and in vitro 
and in vivo, to ensure the experimental system has metabolic capabilities. 
Traditionally, QSAR and pharmacophore perception methodologies have focussed on a 
single drug class in order to refine and perfect one lead compound out of a pool of similar 
molecules. The drugs used in this analysis had considerably varied structures, with the 
Chapter 4: Searching for similarities: Pharmacophore modelling 
116 
 
training set alone covering 7 different therapeutic drug classes. Given the varied 
pharmacological effects of these drugs it is unlikely that the common pharmacophore 
hypothesis is related to the drugs’ mechanisms of action; rather the 3D arrangements of 
structural features may reflect as yet unidentified receptors in a shared toxicity pathway. 
Similarly, traditional drug discovery attempts have generally focussed on designing drugs 
with specific agonist/antagonist activity on a single target. Network pharmacology 
acknowledges the inherent resistance and redundancies built into many biological systems 
and proposes that instead of targeting single receptors, drugs need to exhibit activity on 
multiple targets within a pathway to achieve the desired effect. In this view, the drug design 
process aims to optimise multiple structure-activity relationships at once (128).   
Given the complexity and variety of risk factors influencing IMDILI (see section 1.3 
Associations & Risk Factors for iDILI), it is likely that there is more than one receptor of 
importance within the toxicity pathway of IMDILI. One possibility is that the toxicophore 
hypothesis mirrors the active sites of multiple biological targets. Alternatively, there may be 
multiple pharmacophores which are important, with each corresponding to a different 
biological target within the toxicity pathway. For example, the toxicophore hypothesis may 
reflect the structural configuration needed to activate an adaptive immune system protein, 
and a second pharmacophore hypothesis, such as one of the high scoring AADD variants 
from Table 4.7, may reflect the structural configuration needed to active a protein of the 
innate immune system, with toxicity manifesting only when both proteins have been 
activated. 
 
Such a so-called multiple toxicophore hypothesis would be difficult to test using in vitro and 
in vivo experimental systems since the system would have to replicate the complex 
interaction between the innate and adaptive immune systems. The first step towards 
testing such a hypothesis would be to identify possible biological targets using in silico 
screening. Secondly, the ability of implicated drugs to activate these targets separately can 
be tested in vitro. Finally, an in vivo experimental system can be developed to examine 
whether activating a combination of proteins will lead to IMDILI. 
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4.6 Conclusion 
This chapter has identified a 4-point toxicophore hypothesis that captures the structural 
similarities between the molecules implicated in IMDILI. Presumably, this three-dimensional 
arrangement of molecular features is important in the activation of the toxicity pathway for 
IMDILI, and may reflect the features required to activate one or more biological proteins 
within this pathway. 
Using the toxicophore as a starting point, the following chapters of the thesis will begin this 
process of identifying potential toxicity targets for IMDILI. 
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5 Chapter 5: The Search for Potential Toxicity Targets 
5.1 Virtual Screening 
Virtual screening describes the process by which compound libraries are searched for 
potential leads in the drug discovery process. This can take various forms depending on the 
search criteria. The previous chapters of this thesis have identified: 
1. Literature evidence for the involvement of both adaptive and innate immunity in 
IMDILI. 
2. A set of probe molecules for investigating IMDILI. 
3. A 4-point pharmacophore hypothesis common to drugs implicated in IMDILI. This 4-
point pharmacophore hypothesis will be referred to as the primary toxicophore 
hypothesis. 
5.2 Pharmacophore based virtual screening of the DrugBank database 
5.2.1 Introduction 
Pharmacophore based virtual screening can be undertaken to search compound libraries for 
molecules which contain the 3D arrangement of molecular features, or pharmacophore, 
required for biological activity. 
A number of tools, both commercial and open source are available for pharmacophore 
screening. There are typically two different types of scoring algorithms that are used during 
the screening process (251): 
Root Mean Square Deviation (RMSD) based methods measure the distance of the feature 
group in the molecule to the centre of the pharmacophore feature. Molecules with chemical 
features which align to the pharmacophore within the specified distance tolerances are 
considered hits. 
Overlay based methods take into consideration the radii of the feature and the atoms 
involved. Hits are identified when the radii of the pharmacophoric feature of the molecule 
overlap with the radii of the pharmacophore. 
The work in this section was undertaken using two RMSD based pharmacophore screening 
programs: Schrödinger’s Phase (193) and Pharmer (252). 
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5.2.1.1 Phase 
Phase offers the option of generating conformations during the search process. Compounds 
are filtered based on their pharmacophore feature frequencies. For example if the input 
pharmacophore is AADR, hits must have at least 2 hydrogen bond acceptors, 1 hydrogen 
bond donor and 1 ring. Compounds which do not have the required features are eliminated 
from the search. Conformers are eliminated if the distances between pharmacophore sites 
are insufficiently close to those of the hypothesis. Conformations which survive this process 
are aligned to the pharmacophore hypothesis. Whether an alignment is identified as a hit to 
the pharmacophore is determined by the Intersite Distance Matching Tolerance (IDMT). This 
is the RMSD of the intersite distances between the molecule under investigation and the 
reference ligand used to generate the pharmacophore hypothesis (203); i.e. the distance 
between the molecule and the centre of the pharmacophoric feature. The default is 2.0Å. 
Since all compounds in the database are investigated, the computational resource required 
for the search increases in proportion to the size of the database queried. 
5.2.1.2 Pharmer 
Pharmer is a computational approach to pharmacophore screening that scales more with 
the complexity of the pharmacophore search, rather than the size of the database. 
Pharmacophore features in compounds are identified using SMARTS patterns. The spatial 
relationships between each of the features within a compound are stored as a series of 
coordinate triangles. The pharmacophore search query is broken down into triplets of 
features.  The compound database is then searched for all the feature triangles that are able 
to match each triplet. The triangles are then reassembled to produce the compound and the 
conformation that is able to align to the pharmacophore. Using this method millions of 
compounds in a library can be searched within a few seconds (252). 
Matches to the pharmacophore are determined by the radii of the pharmacophoric 
features; i.e. the distance between the molecule and the center of the pharmacophoric 
feature, which is the same as the Phase software. The default is 0.5Å. 
5.2.2 Datasource 
DrugBank is an open data drug and drug target database (143). As of 2/06/2015 the 
database contains a total of 7759 drug entries, including small molecule approved drugs, 
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protein/peptide approved drugs, nutraceuticals and experimental drugs. The full database is 
available for download (www.drugbank.ca/downloads#structures). 
5.2.3 Rationale 
Previous chapters of this work have identified a toxicophore hypothesis that is able to 
differentiate between drugs implicated in IMDILI and drugs devoid of DILI. Therefore, drugs 
with structural elements which are able to match the toxicophore should be more likely to 
be associated with IMDILI than drugs which do not match the hypothesis. 
Examining the number of matches to the toxicophore within the DrugBank database will 
give an indication of the specificity of the hypothesis and may aid in identifying drugs 
associated with IMDILI which were not identified in Chapter 2 of this thesis. 
To examine the implications of differences in the default feature tolerances values between 
the two programs (Phase: 2.0Å; Pharmer 0.5Å), the screening was repeated using three 
different tolerance settings: 0.5Å, 1.0Å and 2.0Å. 
5.2.4 Methods 
5.2.4.1 Molecular preparation 
Since Pharmer does not have molecular manipulation tools, all molecules were prepared 
with Schrödinger software and subsequently exported for use in Pharmer. 
All drugs held in the DrugBank database as of 20/08/13 were downloaded as a single sdf file 
and imported into Maestro (253). Drugs with MW > 500 Daltons were excluded from further 
analyses.  
The global minimal energy state of all molecules was determined with MacroModel (version 
9.9, Schrödinger, LLC, New York, NY, 2012).  Structures were minimised using the PRCG 
method (see section 4.1.3.1.2 Energy Minimisation). The convergence threshold was set to 
0.05, based on gradient. Up to a maximum of 5000 iterations were allowed. The OPLS_2005 
forcefield was used with a constant solvent dielectric of 1.0. Subsequently each molecule 
was visually inspected to confirm that minimisation had given chemically correct structures. 
The LigPrep (199) program was used to perform the 2D to 3D conversion for any structures 
not adequately minimised by the minimisation process using MacroModel (see examples in 
Figure 5.1 and Figure 5.2).  
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Conformations were generated with Confgen (202) using rapid sampling of the 
conformational space. Redundant conformers were eliminated using a RMSD cutoff of 0.5Å.   
Structures were subsequently exported as a single sdf file. 
 
Figure 5.1 Output of multiple minimisation, showing distorted conformation of Rhodamine with intersecting rings. 
(Potential Energy: 12,857kcal). 
 
Figure 5.2 Output of multiple minimisation, showing distorted conformation of ipratropium with a methyl group inside a 
ring structure. (Potential Energy: 4154kcal). 
5.2.4.2 Pharmacophore screening 
The Phase Advanced Pharmacophore Screening tool and the Pharmer program were used to 
screen the DrugBank dataset for matches to the toxicophore hypothesis. 
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5.2.4.2.1 Phase 
The site measurements of the toxicophore hypothesis (Figure 4.5) and the prepared 
DrugBank structures were imported into a Maestro project. The Phase Advanced 
Pharmacophore Screening tool was used to screen the DrugBank molecules for matches to 
the toxicophore. 
Since conformations had already been generated during the Molecular Preparation step, the 
“Use existing conformers” option was selected during the pharmacophore screening. 
Matches were required to align with all 4 site points of the toxicophore hypothesis. 
The analysis was repeated with 3 different settings for the intersite distance matching 
tolerance: 0.5Å, 1.0Å or 2.0Å (default). 
5.2.4.2.2 Pharmer 
The site measurements of the toxicophore hypothesis were manually entered into the 
Pharmer software. The sdf file containing the DrugBank molecules was used to create a 
pharmer database. Matches were required to align with all 4 site points of the toxicophore 
hypothesis. The analysis was repeated with 3 different settings for the radii of the 
pharmacophore features: 0.5Å (default), 1.0Å or 2.0Å. 
5.2.5 Results 
The number of drugs returned as hits to the pharmacophore are presented in Table 5.1. For 
both Phase and Pharmer, decreasing the pharmacophore feature tolerance results in a 
lower number of matches to the pharmacophore. The Phase screen runs returned less 
matches than the Pharmer runs at the higher pharmacophore feature tolerance settings (all 
except 0.5Å). The full lists of drugs that match the toxicophore as determined by Phase and 
Pharmer at the smallest feature tolerance setting are presented in Appendix 7: List of 
DrugBank molecules which match the toxicophore hypothesis (Table 15.1 and Table 15.2 
respectively). 
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Table 5.1 Results of DrugBank screen carried out using the Phase Advanced Pharmacophore Screening (193)and Pharmer 
(252) programs. The number of molecules within the DrugBank database which were returned as hits to the primary 
toxicophore hypothesis is shown for each run. 
Run Phase: Intersite Distance Matching Tolerance (Å)  
Pharmer: Radii of feature (Å) 
# DrugBank Matches 
(out of 5757) 
Phase 1 2.0 (default) 2040 
Phase 2 1.0 705 
Phase 3 0.5 333 
   
Pharmer 1 2.0 2383 
Pharmer 2 1.0 1014 
Pharmer 3 0.5 (default) 61 
 
5.2.6 Discussion 
From Figure 5.1 and Figure 5.2, it is interesting to note that sometimes molecular 
manipulation software can return structures with high potential energies that are unlikely to 
exist in vivo. This highlights the need to visually inspect molecules with unusually high 
energies to confirm that structures have been reasonably energy minimised.  
While the number of hits appear to be comparable between the two programs at 
IDMT/radii settings of 2.0Å and 1.0Å, it is important to take into account the differences 
between the two settings. Since the IDMT used by Phase relates to the deviation of the 
distance between the centres of two pharmacophoric sites, it is approximately equivalent to 
twice the radii of feature used by Pharmer, which relates to the distance deviation from 1 
site point only. Hence, an IDMT of 2.0Å in Phase would approximately correspond with a 
1.0Å setting in Pharmer. When this is taken into account, Pharmer is returning substantially 
fewer hits than Phase at the corresponding tolerance settings. 
The Phase run with the default IDMT of 2.0Å returned 2040 hits, which is a substantial 
proportion (35%) of the DrugBank database. Since these molecules contain the toxicophore 
hypothesis, they share structural features with drugs which are implicated in IMDILI. Hence, 
they may also be capable of activating the required biological pathways which lead to 
IMDILI. The rare incidence of IMIDLI is related to patient exposure, rather than the number 
of drugs implicated – i.e. it is possible for a large number of drugs to be implicated in IMDILI, 
with IMDILI manifesting in only a small minority of people who are exposed to the drugs. 
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One of the aims of this section was to identify drugs which are associated with IMDILI. In the 
absence of an in vitro confirmation assay, it is difficult to determine whether the returned 
hits are drugs which have true hepatotoxic potential. Similarly, without the means to verify 
the results, it is difficult to determine the optimal tolerance setting for the pharmacophore 
screening process.  Until a reliable screening assay is developed, the use of the toxicophore 
as a screening tool will remain limited.  
5.3 Screening of Toll-Like Receptor 7 agonists 
5.3.1 Introduction 
TLRs have a role in liver injury, with recent research linking TLR9 and liver fibrosis (254) and 
TLR 2 with neutrophil recruitment in acute and chronic liver injury (255). 
Lipopolysachharides from Gram-negative bacterial cell walls, TLR4 ligands, have also been 
known to potentiate DILI of trovafloxacin in animal models (256). TLR7, a cytoplasmic 
endosomal TLR, the subtype investigated in this study, is similar to TLR9 and is one of the 
few TLRs for which there are known small molecule modulators. All TLRs, with the exception 
of TLR3, are known to activate the MyD88 pathway (257), the downstream effects of which 
include the production of inflammatory cytokines and the expression of costimulatory 
molecules required for the activation of the adaptive immune system (65). 
5.3.2 Rationale 
Loxoribine, a model TLR7 agonist, possesses an arrangement of structural features that is 
consistent with the primary toxicophore hypothesis identified in the previous chapter of this 
thesis. Moreover loxoribine, abacavir and allopurinol (from the training set used in the 
pharmacophore perception) all share an imidazopyridine-like ring structure which is also 
present in the purine derived nucleobases adenine and guanine (Figure 5.3). Since TLR7 has 
a role in the identification of ssRNA from viruses (64), TLR7 agonists can share structural 
similarities with the nucleobases (258). This suggests that TLR7 may be a potential IMDILI 
toxicity target. If this is the case, it is expected that the pharmacophore hypothesis would be 
more prevalent in a group of molecules with known TLR7 activity than in a group devoid of 
this activity.  
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In this section two related analyses were undertaken: 1) Screening of a set of TLR7 agonists 
using the toxicophore hypothesis, and 2) Development of a pharmacophore hypothesis from 
the set of TLR7 agonists. 
 
Figure 5.3 Chemical structures of a) abacavir, b) allopurinol, c) loxoribine, d) adenine and e) guanine with the 
imidazopyridine-like ring structure highlighted. 
5.3.3 Methods 
5.3.3.1 Molecular Preparation 
Structures of 36 compounds, including 23 TLR7 agonists and 13 without activity on TLR7, 
were identified from Yoo et al.(258) and drawn into Masetro using the 2D sketcher tool 
(253). The structures used in the analyses are presented in Table 5.2. 
 
Table 5.2 Structures of Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines as described by Yoo et al. (207) 
Compound R1 R2 
5 H H 
6a COCH3 H 
6b COC3H7 H 
11a C4H9 H 
11b CH2C6H5 H 
17 H Cl 
19a H NH2 
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Compound R1 R2 
19b H NHC4H9 
19c H NHC7H15 
19d H 
 
19e H NHC6H5 
19f H NHCH2C6H5 
19g H 
 
19h H 
 
19i H 
 
19j H 
 
19k H 
 
19l H 
 
19m H 
 
19n H 
 
19o H 
 
19p H 
 
19q H 
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Compound R1 R2 
19r H 
 
19s H 
 
23a H C4H9 
23b H C6H5 
23c H 
 
23d H 
 
23e H 
 
23f H 
 
23g H 
  
23h H 
 
23i H 
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Compound R1 R2 
23j H 
 
30 Full 
molecule: 
 
 
The global minimal energy state of all molecules was determined with MacroModel (200).  
Structures were minimised using the PRCG method (see section 4.1.3.1.2 Energy 
Minimisation). The convergence threshold was set to 0.05, based on gradient. Up to a 
maximum of 5000 iterations were allowed. The OPLS_2005 forcefield was used with a 
constant dielectric of 1.0. Subsequently each molecule was visually inspected to confirm 
that minimisation had given chemically correct structures. 
5.3.3.2 Screening of TLR7 agonists using the toxicophore hypothesis 
The Phase Advanced Pharmacophore Screening tool was used to screen the compounds for 
matches using the toxicophore hypothesis. The intersite distance matching tolerance was 
set to 2.0Å. Conformations were generated during the search using the Rapid Sampling 
method (see 4.1.3.1.3 Conformer generation). Matches were required to align with all 4 site 
points of the toxicophore hypothesis. 
The predictive performance measures: sensitivity, specificity, accuracy, Matthews 
Correlation Coefficient, positive predictive value and negative predictive value, were 
calculated. 
5.3.3.3 Development of a pharmacophore from TLR7 agonists 
A pharmacophore hypothesis was generated from these molecules using the methodology 
described in Chapter 4 (4.3.4 Create pharmacophore sites; 4.3.5 Develop common 
pharmacophore hypothesis and 4.3.6 Scoring actives). 
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5.3.4 Results 
5.3.4.1 Screening of a set of TLR7 agonists using the toxicophore hypothesis 
The results of the toxicophore screening are presented in Table 5.3. The toxicophore 
hypothesis matched 17 of 23 (74%) of compounds with activity on TLR7 and 4 of 13 (31%) of 
the inactives. This corresponds to a sensitivity and specificity of 74% and 54% respectively. 
The 5 most potent agonists according to Yoo et al. (258) (19f,g,k,l,m) are among those that 
match the pharmacophore.  
Table 5.3 List of compounds active and inactive on Toll-like Receptor 7 and whether or not the compounds match the 
primary toxicophore hypothesis. 
Compound Activity on TLR7 Matches Toxicophore 
5 Yes No 
6a No No 
6b No No 
11a No No 
11b No No 
17 No No 
19a Yes Yes 
19b Yes Yes 
19c Yes Yes 
19d Yes Yes 
19e Yes Yes 
19f Yes Yes 
19g Yes Yes 
19h Yes Yes 
19i Yes Yes 
19j Yes Yes 
19k Yes Yes 
19l Yes Yes 
19m Yes Yes 
19n No Yes 
19o Yes Yes 
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Compound Activity on TLR7 Matches Toxicophore 
19p Yes Yes 
19q Yes Yes 
19r Yes Yes 
19s No Yes 
23a Yes No 
23b No No 
23c No Yes 
23d No No 
23e No No 
23f No No 
23g Yes No 
23h Yes No 
23i No Yes 
23j Yes No 
30 Yes No 
 
5.3.4.2 Develop a pharmacophore hypothesis from the set of TLR7 agonists 
Phase identified 21 pharmacophore variants which matched 17 out of 23 TLR7 agonists: 
AAAA, AAAD, AAAH, AAAR, AADD, AADH, AADR, AAHR, AARR, ADDH, ADDR, ADHR, ADRR, 
AHRR, ARRR, DDHR, DDRR, DHRR, DRRR, HRRR, RRRR. 
The survival scores for these hypotheses ranged from 2.24 to 3.87. Among the top scoring 
hypotheses with a survival score of 3.87 is an AADR pharmacophore which was able to 
differentiate between compounds with activity on TLR7 and compounds without activity 
with a sensitivity of 74% and a specificity of 69%. The statistical performance values are 
presented in Table 5.4. This pharmacophore has similar site measurements (Figure 5.4) to 
the toxicophore hypothesis. Figure 5.5 depicts the significant overlap between this 
pharmacophore and the toxicophore hypothesis. 
 
Chapter 5: The Search for Potential Toxicity Targets 
131 
 
Table 5.4 Performance measures for an AADR pharmacophore hypothesis which matched 17 out of 23 TLR7 agonists. 
Performance measure Score 
True positive 17 
False positive 4 
False negative 6 
True negative 9 
MCC 0.42 
Accuracy 0.72 
Sensitivity 0.74 
Specificity 0.69 
Positive predictive value 0.81 
Negative predictive value 0.60 
 
 
Figure 5.4 Pharmacophore generated from 1H-imidazo[4,5-c]pyridine Toll-Like Receptor 7 agonists, matching 17 out of 
23 actives. 
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Figure 5.5 Superimposed images of the AADR pharmacophore generated from TLR7 agonists and the toxicophore 
hypothesis. 
5.3.5 Discussion 
Part 1 of this section revealed that the toxicophore was able to match 17 out of 23 TLR7 
agonists. Hence it is not surprising that a pharmacophore with similar site measurements to 
the toxicophore would be able to be perceived from the same set of TLR7 agonists. It is 
interesting to note however that the toxicophore-like hypothesis ranked among the top 
scoring hypotheses perceived in Part 2 of this section – i.e. not only is the hypothesis an 
adequate model for the requirements for TLR7 activity, it is one of the better models 
available. This strongly suggests that the IMDILI probe set of drugs, which also contains 
these pharmacophoric elements, may be able to activate TLR7. As such, TLR7 is identified as 
a potential target that is common to the toxicity pathways of these drugs. 
5.4 Structure based virtual screening (molecular docking) 
5.4.1 Introduction 
Molecular docking is a structure based drug design technique. If a protein structure is 
known, algorithms can be used to predict the interaction between ligands and the protein. 
Prediction of the ligand-receptor complex is difficult for a number of reasons: 
1. The binding site of the ligand may not be known. It has been shown that even 
compounds with similar mechanisms of action can have different binding modes. 
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2. Since both the ligand and the receptor site have flexibility, simulating the molecular 
dynamics of the in vivo ligand-receptor interaction is computationally demanding. 
3. It difficult to determine the in vivo binding conformation. A highly efficient scoring 
algorithm must be in place to allow the screening of large numbers of molecules in a 
reasonable amount of time. 
The strength of the interaction between the receptor and the ligand can be quantified by 
calculating the free energy of binding. This can be broken down in a number of ways, 
commonly in the form (259): 
Contributions to the binding free energy (259). 
𝛥𝐺𝑏𝑖𝑛𝑑  =  𝛥𝐺𝑠𝑜𝑙𝑣𝑒𝑛𝑡 + 𝛥𝐺𝑐𝑜𝑛𝑓 +  𝛥𝐺𝑖𝑛𝑡 + 𝛥𝐺𝑚𝑜𝑡𝑖𝑜𝑛 
Most of the methods available for molecular docking assume that the receptor site is rigid; 
conformational flexibility is allowed only for the ligand.  
Examples of molecular docking programs are DOCK (260), Flex-X (261,262), GOLD (263), 
SURFLEX (264), GLIDE (265). The work outlined here utilised the GLIDE program, so 
discussion will focus on the molecular docking methods available within this software. 
5.4.1.1 Schrödinger's GLIDE program 
Schrödinger's GLIDE (Grid-based Ligand Docking with Energetics) program simulates the 
interactions between one or more ligand molecules and a protein receptor (265). In GLIDE 
docking experiments, proteins are usually held rigidly – i.e. conformational changes in the 
protein are not considered. 
5.4.1.1.1 Protein preparation 
Before ligand-receptor interactions can be simulated, the receptor binding site must first be 
identified. If a co-crystal of a ligand-receptor complex is available, this can be examined to 
see if the binding site is likely to be shared among other ligands. If a number of co-
crystallised structures are available, a single reference complex is chosen. All the other 
complexes are then superimposed onto it. The user can then examine the superimposed 
ligands to determine if they would be a reasonable fit for the reference binding site – i.e. 
there are no major steric clashes. If this is not the case, then the sites can be taken as 
independent, and separate docking experiments would have to be performed. Similarly, if a 
(8) 
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number of binding sites are apparent from co-crystallised structures, separate docking 
experiments would have to be performed for each of these sites (266). 
Protein structural information is generally sourced from the Research Collaboratory for 
Structural Bioinformatics (RCSB) Protein Data Bank (PDB) (www.rcsb.org). Structural data is 
derived from X-ray crystallographic studies, and generally only consists of heavy atoms, 
waters molecules, cofactors and metal ions. Structures may also be multimeric, containing 
one or more sub units. Bond orders and ionisation states are unassigned, and terminal 
amide groups can be misaligned. These missing elements of PDB files need to be filled in 
before forcefields can be used to calculate ligand binding energies. 
Schrödinger provides a Protein Preparation Wizard to assist in identifying and resolving 
common problems in the PDB structure (267). PDB structures can be imported directly by 
the wizard. Waters not thought to be involved in ligand binding are deleted. Redundant 
subunits or protein chains not involved in ligand binding are also removed to increase 
computational efficiency. Missing information for residues near the active site and formal 
charges for metal ions and ligating groups can also be added in. Covalent bonds from the 
protein to any co-crystallised ligand cannot be handled by GLIDE and must be deleted (266). 
A restrained minimisation of the input protein coordinates is then run to reorient side-chain 
hydroxyl groups and resolve potential steric clashes. 
Following preparation, the protein structure should be checked for errors. This can be done 
by visually inspecting for steric clashes or by docking the native ligand.  
5.4.1.1.2 Ligand preparation 
Ligand structures used for docking must not be covalently bonded to the receptor and 
should be a form that is likely to exist in the in vivo environment. Typically this means all 
atom 3D structures which are ionised at physiological pH (7±2.0) and globally minimised to a 
low energy state. 
Schrödinger’s LigPrep program (199) is designed to prepare a large number of ligands for 
docking. In accordance with the Glide user manual, structures are refined through the 
following series of steps (266): 
Chapter 5: The Search for Potential Toxicity Targets 
135 
 
1. Convert structure format into 3D 
2. Add hydrogen atoms 
3. Neutralized charged groups 
4. Generate ionization states 
5. Generate tautomers 
6. Filter structures 
7. Generate alternative chiralities 
8. Generate low-energy ring conformations 
9. Remove problematic structures 
10. Optimize the geometries 
11. Convert output file to desired format 
5.4.1.1.3 Receptor Grid generation 
At the ligand binding site, the shape and properties of the receptor are represented by a 
series of grid points. Pre-calculating the values of these grid points decreases the time and 
computational resources required to process the docking of large numbers of molecules. If 
there is more than one receptor binding conformation, multiple grids may be required 
(266). The binding site can be identified either by selecting a co-crystallised ligand or by 
marking the relevant amino acid residues. 
While Glide does not allow for flexibility in the receptor during the docking process, slight 
‘give’ in the receptor and in the ligand can be modelled by modifying the van der Waals radii 
scaling of nonpolar atoms. Decreasing the van der Waals radii of nonpolar atoms lowers the 
penalties for close contacts and provides some leniency for receptor flexibility (266). 
5.4.1.1.4 Ligand docking 
Ligand docking is conducted using the OPLS_2005 forcefield. Three levels of docking 
precision are available: 
 HTVS (high-throughput virtual screening) is designed for the rapid screening of a 
huge number of ligands. Conformational sampling is restricted in order to decrease 
computational resources. 
 SP (standard precision) is used for screening large numbers of compounds of 
unknown quality. 
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 XP (extra precision) is intended for ligands that have been identified by Standard 
Precision docking as high scoring. XP mode utilises a custom scoring function 
combined with a powerful sampling method to identify false positives and improve 
the correlation between good poses and good scores. XP mode is considerably more 
computationally demanding than SP docking. XP descriptor information can be 
requested to allow for visualisation of the scoring terms at a later stage. 
A number of ligand sampling options are also available: 
 Score in place: with this option no docking or optimisation is conducted. The input 
coordinates for the ligand are used for scoring. Accurate initial placement of the 
ligand with respect to the receptor is required. 
 Refined in place: with this option, no docking is performed. Rather, Glide identifies 
the best-scoring pose that is geometrically similar to the input pose by optimising 
the ligand structure in the field of the receptor. 
 Rigid: in rigid docking, no conformations are generated; the input conformation of 
the ligand is only translated or rigidly rotated with respective to the binding site. 
 Flexible: in flexible sampling, conformations are generated during the docking 
process. This option was used for the analysis. 
5.4.1.1.5 Visualizing Docking results 
Poses are orientations of molecules that are aligned with respect to the receptor. Poses 
created during a docking run are saved into a pose viewer file. Such files can be viewed 
using the Ligand Interaction Diagram facility in Maestro (253). In addition to displaying the 
poses, Maestro can also display hydrogen bonds, contacts and interactions with residues. 
For XP runs, the results can be displayed and analysed with the Glide XP Visualizer (266). 
This displays a table of XP terms for each ligand and allows the selective evaluation of 
ligands.  The terms included in the XP scoring function are listed in  
Table 5.5. The GlideScore (GScore) is the sum of the XP terms and summarises the overall 
binding affinity of the ligand for the receptor (266). 
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Table 5.5 List of terms included in the Glide XP (extra precision) docking scoring function (266). 
XP Term Description 
LipophilicEvdW Lipophilic term derived from hydrophobic 
grid potential at the hydrophobic ligand 
atoms 
PhobEn Hydrophobic enclosure reward 
PhobEnHB Reward for hydrophobically packed H-bond 
PhoEnPairHB Reward for hydrophobically packed 
correlated H-bonds 
HBond ChemScore H-bond pair term 
Electro Electrostatic rewards; includes Coulomb 
and metal terms 
SiteMap SiteMap ligand-receptor non-H-bonding 
polar-hydrophobic terms 
π Stack Pi-pi stacking reward 
π Cat Reward for pi-cation interactions 
ClBr Reward for Cl or Br in a hydrophobic 
environment that pack against Asp or Glu 
LowMW Reward for ligands with low molecular 
weight 
Penalties Polar atom burial and desolvation 
penalties, and penalty for intro-ligand 
contacts 
BPenal Penalty for ligands with large hydrophobic 
contacts and low H-bond scores 
ExposPenal Penalty for solvent-exposed ligand groups; 
cancels van der Waals terms 
RotPenal Rotatable bond penalty 
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5.4.2 Methods 
The crystal structure of HLA-B*5701 complexed with peptide V and abacavir was obtained 
from the protein data bank (PDB: 3UPR Biological Assembly 1).  All waters were removed 
and the protein was optimized and minimised using Maestro's Protein Preparation Wizard. 
Flucloxacillin and its metabolites were drawn in using Maestro’s 2D sketcher tool (Table 
5.6). 
Drug Structure 
Flucloxacillin 
 
Flucloxacillin M1 
(209) 
 
 
Flucloxacillin M2 
(209) 
 
 
Flucloxacillin M3 
(209) 
 
 
Table 5.6 Structures of flucloxacillin and its metabolites. 
Ligprep (199) was used to ionise the molecules at physiological pH (7±2.0) and to energy 
minimise the structures. 
Glide (version 5.8, Schrödinger, LLC, New York, NY, 2012.)(265) was used to generate a 14Å 
cubic receptor grid centred on the crystallised abacavir. Scaling of van der Waals radii was 
set to 0.8 with a partial charge cut off of 0.15. 
Extra precision flexible docking of flucloxacillin and its metabolites was then conducted. 
Ligand interaction diagrams were generated using Maestro’s Ligand Interaction Diagram 
tool (253). 
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5.4.3 Results 
XP docking showed that flucloxacillin and its metabolites were able to interact with HLA-
B*5701 in the same binding pocket as abacavir (Figure 5.6). The pharmacophoric features 
were positioned to interact with complementary amino acid residues within the HLA binding 
groove. Three examples are given in Figure 5.7, Figure 5.8 and Figure 5.9. 
 
Figure 5.6 Abacavir (green) and flucloxacillin overlapped in the F-pocket of the HLA-B*5701 binding groove. 
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Figure 5.7 a) Ligand interaction diagrams showing the interactions between amino acids of HLA-B*5701, peptide V and 
abacavir. b) Abacavir superimposed on the AADR toxicophore hypothesis from Chapter 4. c) Schematic showing the 
chemical groups contributing to the pharmacophore. 
 
Figure 5.8 a) Ligand interaction diagrams showing the interactions between amino acids of HLA-B*5701, peptide V and 
flucloxacillin M1. b) Flucloxacillin M1 superimposed on the AADR pharmacophore hypothesis from Chapter. c) Schematic 
showing the chemical groups contributing to the pharmacophore. 
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Figure 5.9 a) Ligand interaction diagrams showing the interactions between amino acids of HLA-B*5701, peptide V and 
flucloxacillin M3. b) Flucloxacillin M3 superimposed on the AADR pharmacophore hypothesis from Chapter. c) Schematic 
showing the chemical groups contributing to the pharmacophore. 
5.4.4 Discussion 
The results from this section show that flucloxacillin and its metabolites are able to bind to 
the same binding pocket as abacavir. 
A recently published paper on abacavir hypersensitivity (53) provides evidence for a 
modified p-i hypothesis (see 1.4.4 Pharmacological interaction (p-i) hypothesis) which the 
authors termed the altered self-peptide repertoire model. In this model, abacavir binds in 
the F-pocket at the base of the HLA-B*5701 groove. The presence of abacavir alters the set 
of endogenous peptides presented to T-cells by HLA-B*5701, and this is thought to be the 
mechanism behind abacavir's observed HLA-B*5701 restricted hypersensitivity (53). The 
residues Tyr9, Tyr-74, Ile-95, Val97, Tyr99,Tyr123, Ile-124, Trp147, Ile3, Leu7, and Val9 were 
thought to be those important in abacavir binding (53).  
Interestingly, these residues also appear to be important in the binding of the penicilloic 
acid metabolites of flucloxacillin and of its 5-hydroxymethyl derivative (Figure 5.7, Figure 
5.8, Figure 5.9). This suggests that the metabolites of flucloxacillin are interacting with HLA-
B*5701 and the co-crystallised peptide in a similar manner to abacavir and hence T-cell 
activation via HLA-B*5701 may be a common toxicity pathway for both abacavir and 
flucloxacillin. This is consistent with recent literature which has demonstrated the 
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importance of cytotoxic T-cells in mediating flucloxacillin induced DILI in HLA-B*5701 
positive patients (268). 
Moreover, the residues that are associated with binding are positioned to interact with the 
structural elements in the abacavir and flucloxacillin metabolite molecules which contribute 
to the toxicophore hypothesis.  
Although HLA-B*5701 has not previously been associated with abacavir induced liver injury, 
patients exposed to abacavir have been known to develop DILI with immune features (51). 
Since HLA-B*5701 positive patients are at increased risk of abacavir induced hypersensitivity 
reactions, it is possible that HLA-B*5701 may also play a role in mediating abacavir induced 
liver injury. 
 
Similarly, since the toxicophore is shared by molecules which are implicated in IMDILI, and 
the structural elements contributing to the toxicophore appear to be important in the 
binding interaction with HLA-B*5701, HLA-B*5701 may be a potential toxicity target within 
the toxicity pathway. 
5.5 Conclusions 
Starting from a relationship between drug structure and hepatotoxicity in the form of a 4-
point toxicophore hypothesis, this chapter has used virtual screening methods to identify 
more drugs associated with IMDILI as well as biological targets which may be involved in the 
toxicity pathway, namely the immune-system proteins HLA-B*5701 and TLR7.  
There is evidence for a role of the toxicophore within the toxicity pathway, which supports 
the hypothesis that drugs (or their metabolites) which produce similar patterns of toxicity 
interact with targets within common toxicological pathways and that activation of the 
underlying mechanisms depends on structural similarity among toxic molecules. 
From the literature knowledge regarding the mechanisms of IMDIL, these are both plausible 
toxicity targets that warrant further investigation. This may take the form of in vitro assays 
to determine whether drugs of the training set are able to activate an immune response via 
HLA-B*5701 and TLR7. 
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5.6 Publication 
The work presented in this Chapter in conjunction with that of Chapters 2 and 4 has been 
published in the journal CPT Pharmacometrics and Systems Pharmacology (269). The full 
publication is presented in Appendix 1:  Peer Reviewed Scientific Publications arising from 
this thesis.  
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6 Chapter 6: Experimental verification 
6.1 Introduction 
The previous chapters have identified TLR7 as a potential toxicity target for drugs implicated 
in IMDILI. This chapter an experiment to test whether or not the probe IMDILI set of drugs 
are able to activate TLR7 in vitro. 
All TLRs, with the exception of TLR3 activate the MyD88 adaptor molecule and activation of 
NFκB and mitogen-activated protein kinases (MAP kinases) which leads to the induction of 
inflammatory cytokines (257). Within the signalling pathway, IκB has an inhibitory effect on 
NFκB. When IκB is phosphorlated, this inhibitory effect is removed and results in the 
production of inflammatory cytokines (3). 
Cherfils-Vicini et al. used a Western Blotting procedure to demonstrate that loxoribine is 
able to promote the phosphorylation of IκB through the activation of TLR7 (3). Western 
Blotting is a technique used in cell and molecular biology to semi-quantitatively identify the 
presence of specific proteins within cells. This technique is described in further detail below. 
6.1.1 Western Blotting 
The Western Blotting technique has been recently described in detail by Mahmood and 
Yang (270) and Yang and Ma (271). Briefly, this technique consists of the following 
elements: 
1. Sample preparation 
2. Gel electrophoresis 
3. Blotting 
4. Antibody incubation 
5. Detection 
6.1.1.1 Sample Preparation 
The proteins of interest need to be extracted from the cells. Samples taken from cell culture 
are cooled or frozen rapidly with protein inhibitors to prevent the proteins from denaturing. 
Tissue samples display a higher degree of structure and need to be homogenised using 
sonication or mechanical force before the proteins can be extracted. 
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Once extracted, the proteins are added into a buffer solution containing a dye and a 
detergent. The detergent, typically sodium dodecyl sulfate (SDS), surrounds the protein with 
a negative charge, which will become important at a later stage where an electric field is 
applied to move the proteins. The dye, typically bromophenol blue, is added to allow the 
researcher to visually gauge the progress of the separation. The samples are then boiled for 
1 to 5 minutes to denature the protein higher order structure and loaded side-by-side into 
wells on a gel. 
6.1.1.2 Gel Electrophoresis 
Typically polyacrylamide gels are used for gel electrophoresis. The proteins loaded into the 
gel have a negative charge and will travel towards the positive electrode when voltage is 
applied. The speed of the protein through the gel is dependent upon the size of the pores in 
the gel and the size of the proteins, thus separating a mixture of proteins into bands based 
on their molecular weight. Two lanes on the gel are generally reserved for a positive and a 
negative control.  The positive control, or a bench mark, can be a commercially available 
mixture of proteins of known molecular weights or a known source of the target protein. 
This serves as a marker to confirm the identity of the target protein. A negative control is a 
null cell line, and is used to confirm that the staining is not nonspecific. For example, actin 
can be included to ensure that there are a similar number of cells in each well for the 
western blot. 
6.1.1.3 Blotting 
Once the separation is complete, the proteins in the polyacrylamide gel need to be 
transferred to a membrane for further analyses. A membrane typically made of 
nitrocellulose or polyvinylidene fluoride (PVDF) is laid on the gel. A voltage is then applied 
perpendicularly to the surface of the gel to move the negatively charged proteins from the 
gel onto the membrane.  
6.1.1.4 Antibody incubation 
To allow for detection, a label-antibody is used to bind the proteins of interest. Before the 
antibody is applied, blocking is conducted, typically with 5% bovine serum albumin (BSA) or 
nonfat dried milk diluted in Tris Buffered Saline with Tween® (TBST), in order prevent 
antibodies from binding to the membrane non-specifically.  
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Following incubation with the antibody, the membrane must be washed thoroughly to 
remove unbound antibody and minimise background signals in the detection step. 
6.1.1.5 Detection 
The presence of proteins of interest can be determined by the strength of the colorimetric 
or photometric signal emitted by the label antibody. Western Blotting is considered a semi-
quantitative technique since it provides a relative comparison of protein levels rather than 
specifically measuring the quantity of protein present in the initial sample. 
6.2 Rationale 
The experiment was conducted using airway smooth muscle cells (A549) which are known 
to express a number of TLRs, including TLR7. Since the activation of TLRs is asociated with 
the phosphoroylation of IκB, phosphorylated IκB (pIκB) can be used as a surrogate measure 
of TLR activity. If an effect on IκB is demonstrated, the experiment can be repeated using 
TLR7 knockout cells. A lack of response will confirm that the effect is due to TLR7 rather 
than another TLR subtype. The aim of this experiment ito compare the ability of probe 
IMDILI drugs to phosphoralate IκB with that of loxoribine in order to test whether the probe 
set of IMDILI drugs are active on TLR7. 
6.3 Methods 
Eight compounds were included in the analysis (Table 6.1). Loxoribine was chosen as the 
active control. For the actives, abacavir and allopurinol were included because of their 
structural similarity to loxoribine. Flucloxacillin was included due to the potential shared 
toxicity pathway with abacavir. The remaining active, nevirapine, and the 3 inactive 
controls, clemastine; oxybutynin and baclofen were randomly chosen. All chemicals were 
purchased from Sigma-Aldrich. 
A549 airway smooth muscle cells were cultured as per Appendix 8: A549 Cell Culture. 
The cells were then stimulated with the compounds listed in Table 6.1 at a concentration of 
10µg/mL for 30 minutes.  
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Table 6.1 Compounds included in the in vitro analysis. 
Compound  
Loxoribine Active control 
Abacavir sulfate Active 
Allopurinol Active 
Flucloxacillin Active 
Nevirapine Active 
Clemastine fumarate Negative control 
Oxybutynin chloride Negative control 
Baclofen Negative control 
 
Cells were prepared for Western Blotting as follows: 
1. Remove supernatant from 6-well dishes. 
2. Wash with 2 x 2 mL sterile phosphate-buffered saline (PBS).   
3. Add 300 µL 1X sample buffer and dithiothreitol (DTT) to each well. 
4. Scrape and collect in small tubes. 
5. Boil for 5 minutes and store at -80°C. 
6. Boil samples again for 5 minutes when ready to use for Western blotting. 
The experiment was subsequently repeated with loxoribine only at a number of different 
concentrations: 10; 25 and 50 µg/mL.  For this second experiment, two time points for cell 
treatment (30 and 60 minutes) were used. 
A third run was conducted with the cells stimulated for 30 minutes at a concentration of 
20µg/mL. This run was conducted using only a subset of the drugs (loxoribine, abacavir, 
nevirapine, oxybutynin and flucloxacillin). 
6.4 Results 
Figure 6.1 shows the expression of IκB following an incubation period of 30 minutes with 
each compound at a concentration of 10 µg/mL. IκB is present in all cells with the exception 
of those treated with TNFα. Correspondingly, Figure 6.2 shows the presence of 
phosphorolated IκB (pIκB) in these cells. pIκB was only present in cells treated with TNFα. 
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Figure 6.1 Expression of IκB in A549 cells. Cells were stimulated for 30 minutes with the respective compounds. 
 
Figure 6.2 Expression of pIκB in A549 cells. Cells were stimulated for 30 minutes with the respective compounds. 
Figure 6.3 shows the expression of IκB following an incubation period of either 30 or 60 
minutes withTNFα or loxoribine at 10; 25 or 50 µg/mL. IκB is present in all cells with the 
exception of those treated with TNFα. Correspondingly, Figure 6.4 shows the presence of 
phosphorolated IκB (pIκB) in these cells. pIκB was only present in cells treated with TNFα. 
 
 
Figure 6.3 Expression of IκB in A549 cells. Cells were stimulated with loxoribine or TNFα for 30 minutes or 60 minutes at 
the respective concentrations. 
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Figure 6.4 Expression of pIκB in A549 cells. Cells were stimulated with loxoribine or TNFα for 30 minutes or 60 minutes 
at the respective concentrations. 
Figure 6.5 shows the expression of IκB following an incubation period of 30 minutes with 
each compound at a concentration of 10 µg/mL. IκB is present in all cells with the exception 
of those treated with TNFα. Correspondingly, Figure 6.6 shows the presence of 
phosphorolated IκB (pIκB) in these cells. pIκB was only present in cells treated with TNFα. 
 
 
Figure 6.5 Expression of IκB in A549 cells. Cells were stimulated for 30 minutes with the respective compounds at 
20µg/mL. 
 
Figure 6.6 Expression of pIκB in A549 cells. Cells were stimulated for 30 minutes with the respective compounds at 
20µg/mL. 
 
 
Chapter 6: Experimental verification 
150 
 
6.5 Discussion 
Although IκB was present in all the examined cells, none of the drugs were able to induce 
the phosphorylation of IκB. Neither varying the incubation time nor increasing the 
concentration of the drug increased the phosphorylation of IκB. The presence of pIκB in cells 
treated with TNFα was expected. TNFα is known to induce the phosphorylation of IκB and 
was used as the negative control in this experiment. 
Surprisingly, loxoribine, a model TLR7 agonist and the positive control for this experiment 
was also unable to induce the phosphorylation of IκB. This implies that the negative results 
for the tested drugs are due to a fault in the experimental setup rather than a true result 
indicating a lack of activity on TLR7. 
The inability to replicate the extent of loxoribine induced IκB phosphorylation that was 
reported by Cherfils-Vicini et al. (3) could be due to a number of experimental reasons. 
Likely suspects include differences in cell plating and/or experimental conditions, such as 
the room temperature. Further investigations are required to determine the exact 
differences responsible. 
Alternative strategies may include the use of macrophages instead of A549 cells. 
Immortalised macrophage cell lines derived from bone marrow are available. Endogenous 
macrophages activate in response to foreign material in the body. Hence, they may provide 
an indicator of whether the tested compounds are able to activate the innate immune 
system.  
6.6 Conclusion 
This chapter described an experimental attempt to test whether or not the probe IMDILI set 
of drugs are able to activate TLR7 in vitro. Although the in vitro confirmation studies were 
not successful, the failure was due to an inability to develop a satisfactory experimental 
setup, rather than a negative result. Hence one avenue for future work would be to develop 
an experimental system by which to confirm the results of the in silico studies. 
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7 Conclusions and Future work 
7.1 Overview 
A major barrier to the study of rare and multifactorial diseases, such as IMDILI, is the lack of 
data. Researchers are faced with the conundrum of developing methods for screening or 
identifying drugs with the potential to cause idiosyncratic hepatotoxicity without knowledge 
of the underlying pathophysiology, while concomitantly confronting the challenge of 
revealing the mechanisms behind the toxicity in the absence of reliable in vitro or in vivo 
experimental methods. 
The presented work has outlined a multidisciplinary stepwise approach for the study of 
IMDILI. This combination approach makes efficient use of existing data in order to generate 
new hypotheses regarding toxicological targets. The overall aim was to test the hypothesis 
that drugs which produce similar patterns of toxicity interact with targets within common 
toxicological pathways and that activation of the underlying mechanisms depends on 
structural similarity among toxic molecules. 
The structure-toxicity relationship derived in this thesis adds to the growing use of 
toxicophores within the pharmaceutical industry. A recent review has highlighted the 
implementation of a step to identify chemical sub-structures within drug molecules as an 
essential step in the preliminary screening process for new chemical entities (272). 
Importantly, the results from Chapter 4 demonstrate the need to consider the chemical 
structures of any proposed metabolites in the screening process. Although increased 
hepatic metabolism is a known risk factor for DILI, there has been little direct evidence to 
link chemically reactive metabolites with DILI (273). 
7.2 Summary of key findings 
Chapter 2 described the use of pharmacovigilance data collected by the TGA to identify a 
set of 18 drugs, representing 12 drug classes, which were found to be significantly 
associated with IMDILI. The IMDILI potential of the drugs used in the probe set was 
confirmed by reviewing the literature in order to increase the confidence that these drugs 
are truly associated with IMDILI. This set of drugs served as a probe set of drugs to facilitate 
the study of IMDILI. 
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Chapter 3 used the network map tools SLAP and STITCH to compare the known and 
predicted protein interactions for drugs in the probe set in the hope of identifying 
commonalities in the biological pathways of these drugs. There were substantial differences 
in the results obtained from each search tool. Hence it was difficult to ascertain whether any 
of the known and predicted proteins associated with the IMDILI probe set of drugs are 
potential toxicity targets involved in the pathogenesis of IMDILI. 
Chapter 4 described the use of drug design technologies to identify structural similarities 
between the IMDILI probe set of drugs and their metabolites. This relationship took the 
form of a four-point toxicophore hypothesis which consisted of 2 hydrogen-bond acceptors, 
1 hydrogen-bond donor and 1 ring moiety. In external validation this model was able to 
differentiate between molecules in the Active and Inactive Test sets with sensitivity and 
specific of 75% and 92% respectively. Presumably, this three-dimensional arrangement of 
molecular features is important in the activation of the toxicity pathway for IMDILI, and may 
reflect the features required to activate one or more biological proteins within this pathway. 
Chapter 5 made use of the toxicophore to explore biological proteins which may be involved 
in the toxicity pathway of IMDILI. Two putative targets within immune pathways that may 
interact to produce tissue injury in vulnerable individuals were identified; namely the major 
histocompatability complex (HLA) which is involved in activating T-cells as part of the 
adaptive immune response and TLR-7, a pattern-recognition receptor involved in the innate 
immune system, which may be involved in priming or augmenting the adaptive immune 
response. Both of these are plausible toxicity targets in light of what is already known 
regarding the involvement of both the adaptive and innate immune systems in the 
pathogenesis of DILI. 
Chapter 6 described an experimental attempt to test whether or not the probe IMDILI set of 
drugs are able to activate TLR7 in vitro. Although the in vitro confirmation studies were not 
successful, the failure was due to an inability to develop a satisfactory experimental setup, 
rather than a negative result. One avenue for future work would be to develop an 
experimental system by which to confirm the results of the in silico studies. 
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7.3 Closing remarks 
The series of studies that encompass this thesis highlights the potential for multidisciplinary 
approaches in the study of complex diseases. Importantly, linking information from clinical 
and chemical databases with knowledge from biological pathway and gene-association 
datasets can reveal potential mechanisms behind idiosyncratic drug reactions. 
Multidisciplinary approaches are particularly helpful for rare diseases where little 
knowledge is available, and may provide key insights into mechanisms of toxicity that 
cannot be gleaned from a single disciplinary study. 
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  Gene UniProct 
entry 
Category Protein Function 
Both ABCB1 p08183 Transport Multidrug resistance 
protein 1 
Energy-dependent efflux pump responsible for 
decreased drug accumulation in multidrug-resistant 
cells. 
SLAP ABCB11 o95342 Transport Bile salt export pump Involved in the ATP-dependent secretion of bile salts 
into the canaliculus of hepatocytes. 
Both ABCC1 p33527 Transport Multidrug resistance-
associated protein 1 
Mediates export of organic anions and drugs from the 
cytoplasm. Mediates ATP-dependent transport of 
glutathione and glutathione conjugates, leukotriene 
C4, estradiol-17-beta-o-glucuronide, methotrexate, 
antiviral drugs and other xenobiotics. Confers 
resistance to anticancer drugs. Hydrolyzes ATP with 
low efficiency. 
Both ABCC2 q92887 Transport Canalicular multispecific 
organic anion transporter 1 
Mediates hepatobiliary excretion of numerous organic 
anions. May function as a cellular cisplatin 
transporter. 
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Both ABCC4 o15439 Transport Multidrug resistance-
associated protein 4 
May be an organic anion pump relevant to cellular 
detoxification. 
Both ABCG2 q9unq0 Transport ATP-binding cassette sub-
family G member 2 
High-capacity urate exporter functioning in both renal 
and extrarenal urate excretion. Plays a role in 
porphyrin homeostasis as it is able to mediates the 
export of protoporhyrin IX (PPIX) both from 
mitochondria to cytosol and from cytosol to 
extracellular space, and cellular export of hemin, and 
heme. Xenobiotic transporter that may play an 
important role in the exclusion of xenobiotics from 
the brain. Appears to play a major role in the 
multidrug resistance phenotype of several cancer cell 
lines. Implicated in the efflux of numerous drugs and 
xenobiotics: mitoxantrone, the photosensitizer 
pheophorbide, camptothecin, methotrexate, 
azidothymidine (AZT), and the anthracyclines 
daunorubicin and doxorubicin. 
STITCH ACAT1 p24752 Metabolism Acetyl-CoA 
acetyltransferase, 
mitochondrial 
Plays a major role in ketone body metabolism. 
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SLAP ADAM17 p78536 Enzyme Disintegrin and 
metalloproteinase domain-
containing protein 17 
Cleaves the membrane-bound precursor of TNF-alpha 
to its mature soluble form. Responsible for the 
proteolytical release of soluble JAM3 from endothelial 
cells surface. Responsible for the proteolytic release 
of several other cell-surface proteins, including p75 
TNF-receptor, interleukin 1 receptor type II, p55 TNF-
receptor, transforming growth factor-alpha, L-
selectin, growth hormone receptor, MUC1 and the 
amyloid precursor protein. Acts as an activator of 
Notch pathway by mediating cleavage of Notch, 
generating the membrane-associated intermediate 
fragment called Notch extracellular truncation (NEXT). 
Plays a role in the proteolytic processing of ACE2. 
SLAP ADRA1A p35348 Receptor Alpha-1A adrenergic 
receptor 
This alpha-adrenergic receptor mediates its action by 
association with G proteins that activate a 
phosphatidylinositol-calcium second messenger 
system. Its effect is mediated by G(q) and G(11) 
proteins. Nuclear ADRA1A-ADRA1B heterooligomers 
regulate phenylephrine(PE)-stimulated ERK signaling 
in cardiac myocytes. 
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SLAP ADRA1B p35368 Receptor Alpha-1B adrenergic 
receptor 
This alpha-adrenergic receptor mediates its action by 
association with G proteins that activate a 
phosphatidylinositol-calcium second messenger 
system. Its effect is mediated by G(q) and G(11) 
proteins. Nuclear ADRA1A-ADRA1B heterooligomers 
regulate phenylephrine (PE)-stimulated ERK signaling 
in cardiac myocytes 
SLAP ADRA1D p25100 Receptor Alpha-1D adrenergic 
receptor 
This alpha-adrenergic receptor mediates its effect 
through the influx of extracellular calcium. 
SLAP ADRA2A p08913 Receptor Alpha-2A adrenergic 
receptor 
Alpha-2 adrenergic receptors mediate the 
catecholamine-induced inhibition of adenylate cyclase 
through the action of G proteins. The rank order of 
potency for agonists of this receptor is oxymetazoline 
> clonidine > epinephrine > norepinephrine > 
phenylephrine > dopamine > p-synephrine > p-
tyramine > serotonin = p-octopamine. For 
antagonists, the rank order is yohimbine > 
phentolamine = mianserine > chlorpromazine = 
spiperone = prazosin > propanolol > alprenolol = 
pindolol 
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SLAP ADRA2B p18089 Receptor Alpha-2B adrenergic 
receptor 
Alpha-2 adrenergic receptors mediate the 
catecholamine-induced inhibition of adenylate cyclase 
through the action of G proteins. The rank order of 
potency for agonists of this receptor is clonidine > 
norepinephrine > epinephrine = oxymetazoline > 
dopamine > p-tyramine = phenylephrine > serotonin > 
p-synephrine / p-octopamine. For antagonists, the 
rank order is yohimbine > chlorpromazine > 
phentolamine > mianserine > spiperone > prazosin > 
alprenolol > propanolol > pindolol. 
SLAP ADRA2C p11118825 Receptor Alpha-2C adrenergic 
receptor 
Alpha-2 adrenergic receptors mediate the 
catecholamine-induced inhibition of adenylate cyclase 
through the action of G proteins. 
SLAP ADRB1 p08588 Receptor Beta-1 adrenergic receptor Beta-adrenergic receptors mediate the 
catecholamine-induced activation of adenylate 
cyclase through the action of G proteins. This receptor 
binds epinephrine and norepinephrine with 
approximately equal affinity. Mediates Ras activation 
through G(s)-alpha- and cAMP-mediated signaling. 
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SLAP ADRB2 p07550 Receptor Beta-2 adrenergic receptor Beta-adrenergic receptors mediate the 
catecholamine-induced activation of adenylate 
cyclase through the action of G proteins. The beta-2-
adrenergic receptor binds epinephrine with an 
approximately 30-fold greater affinity than it does 
norepinephrine. 
STITCH AKR1C1 q04828 Enzyme Aldo-keto reductase family 
1 member C1 
Converts progesterone to its inactive form, 20-alpha-
dihydroxyprogesterone (20-alpha-OHP). In the liver 
and intestine, may have a role in the transport of bile. 
May have a role in monitoring the intrahepatic bile 
acid concentration. Has a low bile-binding ability. May 
play a role in myelin formation. 
STITCH AKR1C2 p52895 Enzyme Aldo-keto reductase family 
1 member C2 
Works in concert with the 5-alpha/5-beta-steroid 
reductases to convert steroid hormones into the 3-
alpha/5-alpha and 3-alpha/5-beta-tetrahydrosteroids. 
Catalyzes the inactivation of the most potent 
androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) 
to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-
diol). Has a high bile-binding ability. 
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STITCH AKR1C3 p42330 Enzyme Aldo-keto reductase family 
1 member C3 
Catalyzes the conversion of aldehydes and ketones to 
alcohols. Catalyzes the reduction of prostaglandin 
(PG) D2, PGH2 and phenanthrenequinone (PQ) and 
the oxidation of 9-alpha,11-beta-PGF2 to PGD2. 
Functions as a bi-directional 3-alpha-, 17-beta- and 
20-alpha HSD. Can interconvert active androgens, 
estrogens and progestins with their cognate inactive 
metabolites. Preferentially transforms 
androstenedione (4-dione) to testosterone. 
Both AKT1 p31749 Kinase RAC-alpha 
serine/threonine-protein 
kinase 
AKT1 is one of 3 closely related serine/threonine-
protein kinases (AKT1, AKT2 and AKT3) called the AKT 
kinase, and which regulate many processes including 
metabolism, proliferation, cell survival, growth and 
angiogenesis. This is mediated through serine and/or 
threonine phosphorylation of a range of downstream 
substrates. Over 100 substrate candidates have been 
reported so far, but for most of them, no isoform 
specificity has been reported. AKT is responsible of 
the regulation of glucose uptake by mediating insulin-
induced translocation of the SLC2A4/GLUT4 glucose 
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transporter to the cell surface. Phosphorylation of 
PTPN1 at 'Ser-50' negatively modulates its 
phosphatase activity preventing dephosphorylation of 
the insulin receptor and the attenuation of insulin 
signaling. Phosphorylation of TBC1D4 triggers the 
binding of this effector to inhibitory 14-3-3 proteins, 
which is required for insulin-stimulated glucose 
transport. AKT regulates also the storage of glucose in 
the form of glycogen by phosphorylating GSK3A at 
'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of 
its kinase activity. Phosphorylation of GSK3 isoforms 
by AKT is also thought to be one mechanism by which 
cell proliferation is driven. AKT regulates also cell 
survival via the phosphorylation of MAP3K5 
(apoptosis signal-related kinase). Phosphorylation of 
'Ser-83' decreases MAP3K5 kinase activity stimulated 
by oxidative stress and thereby prevents apoptosis. 
AKT mediates insulin-stimulated protein synthesis by 
phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', 
thereby activating mTORC1 signaling and leading to 
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both phosphorylation of 4E-BP1 and in activation of 
RPS6KB1. AKT is involved in the phosphorylation of 
members of the FOXO factors (Forkhead family of 
transcription factors), leading to binding of 14-3-3 
proteins and cytoplasmic localization. In particular, 
FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 
'Ser-319'. FOXO3 and FOXO4 are phosphorylated on 
equivalent sites. AKT has an important role in the 
regulation of NF-kappa-B-dependent gene 
transcription and positively regulates the activity of 
CREB1 (cyclic AMP (cAMP)-response element binding 
protein). The phosphorylation of CREB1 induces the 
binding of accessory proteins that are necessary for 
the transcription of pro-survival genes such as BCL2 
and MCL1. AKT phosphorylates 'Ser-454' on ATP 
citrate lyase (ACLY), thereby potentially regulating 
ACLY activity and fatty acid synthesis. Activates the 3B 
isoform of cyclic nucleotide phosphodiesterase 
(PDE3B) via phosphorylation of 'Ser-273', resulting in 
reduced cyclic AMP levels and inhibition of lipolysis. 
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Phosphorylates PIKFYVE on 'Ser-318', which results in 
increased PI3P-5 activity. The Rho GTPase-activating 
protein DLC1 is another substrate and its 
phosphorylation is implicated in the regulation cell 
proliferation and cell growth. AKT plays a role as key 
modulator of the AKT-mTOR signaling pathway 
controlling the tempo of the process of newborn 
neurons integration during adult neurogenesis, 
including correct neuron positioning, dendritic 
development and synapse formation. Signals 
downstream of phosphatidylinositol 3-kinase (PI3K) to 
mediate the effects of various growth factors such as 
platelet-derived growth factor (PDGF), epidermal 
growth factor (EGF), insulin and insulin-like growth 
factor I (IGF-I). AKT mediates the antiapoptotic effects 
of IGF-I. Essential for the SPATA13-mediated 
regulation of cell migration and adhesion assembly 
and disassembly. May be involved in the regulation of 
the placental development. Phosphorylates 
STK4/MST1 at 'Thr-120' and 'Thr-387' leading to 
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inhibition of its: kinase activity, nuclear translocation, 
autophosphorylation and ability to phosphorylate 
FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 
'Thr-384' leading to inhibition of its: cleavage, kinase 
activity, autophosphorylation at Thr-180, binding to 
RASSF1 and nuclear translocation. Phosphorylates 
SRPK2 and enhances its kinase activity towards SRSF2 
and ACIN1 and promotes its nuclear translocation. 
Phosphorylates RAF1 at 'Ser-259' and negatively 
regulates its activity. Phosphorylation of BAD 
stimulates its pro-apoptotic activity. Phosphorylates 
KAT6A at 'Thr-369' and this phosphorylation inhibits 
the interaction of KAT6A with PML and negatively 
regulates its acetylation activity towards p53/TP53. 
AKT1-specific substrates have been recently 
identified, including palladin (PALLD), which 
phosphorylation modulates cytoskeletal organization 
and cell motility; prohibitin (PHB), playing an 
important role in cell metabolism and proliferation; 
and CDKN1A, for which phosphorylation at 'Thr-145' 
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induces its release from CDK2 and cytoplasmic 
relocalization. These recent findings indicate that the 
AKT1 isoform has a more specific role in cell motility 
and proliferation. Phosphorylates CLK2 thereby 
controlling cell survival to ionizing radiation. 
SLAP AKT2 p31751 Kinase RAC-beta 
serine/threonine-protein 
kinase 
AKT2 is one of 3 closely related serine/threonine-
protein kinases (AKT1, AKT2 and AKT3) called the AKT 
kinase, and which regulate many processes including 
metabolism, proliferation, cell survival, growth and 
angiogenesis. This is mediated through serine and/or 
threonine phosphorylation of a range of downstream 
substrates. Over 100 substrate candidates have been 
reported so far, but for most of them, no isoform 
specificity has been reported. AKT is responsible of 
the regulation of glucose uptake by mediating insulin-
induced translocation of the SLC2A4/GLUT4 glucose 
transporter to the cell surface. Phosphorylation of 
PTPN1 at 'Ser-50' negatively modulates its 
phosphatase activity preventing dephosphorylation of 
the insulin receptor and the attenuation of insulin 
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signaling. Phosphorylation of TBC1D4 triggers the 
binding of this effector to inhibitory 14-3-3 proteins, 
which is required for insulin-stimulated glucose 
transport. AKT regulates also the storage of glucose in 
the form of glycogen by phosphorylating GSK3A at 
'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of 
its kinase activity. Phosphorylation of GSK3 isoforms 
by AKT is also thought to be one mechanism by which 
cell proliferation is driven. AKT regulates also cell 
survival via the phosphorylation of MAP3K5 
(apoptosis signal-related kinase). Phosphorylation of 
'Ser-83' decreases MAP3K5 kinase activity stimulated 
by oxidative stress and thereby prevents apoptosis. 
AKT mediates insulin-stimulated protein synthesis by 
phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', 
thereby activating mTORC1 signaling and leading to 
both phosphorylation of 4E-BP1 and in activation of 
RPS6KB1. AKT is involved in the phosphorylation of 
members of the FOXO factors (Forkhead family of 
transcription factors), leading to binding of 14-3-3 
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proteins and cytoplasmic localization. In particular, 
FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 
'Ser-319'. FOXO3 and FOXO4 are phosphorylated on 
equivalent sites. AKT has an important role in the 
regulation of NF-kappa-B-dependent gene 
transcription and positively regulates the activity of 
CREB1 (cyclic AMP (cAMP)-response element binding 
protein). The phosphorylation of CREB1 induces the 
binding of accessory proteins that are necessary for 
the transcription of pro-survival genes such as BCL2 
and MCL1. AKT phosphorylates 'Ser-454' on ATP 
citrate lyase (ACLY), thereby potentially regulating 
ACLY activity and fatty acid synthesis. Activates the 3B 
isoform of cyclic nucleotide phosphodiesterase 
(PDE3B) via phosphorylation of 'Ser-273', resulting in 
reduced cyclic AMP levels and inhibition of lipolysis. 
Phosphorylates PIKFYVE on 'Ser-318', which results in 
increased PI3P-5 activity. The Rho GTPase-activating 
protein DLC1 is another substrate and its 
phosphorylation is implicated in the regulation cell 
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proliferation and cell growth. AKT plays a role as key 
modulator of the AKT-mTOR signaling pathway 
controlling the tempo of the process of newborn 
neurons integration during adult neurogenesis, 
including correct neuron positioning, dendritic 
development and synapse formation. Signals 
downstream of phosphatidylinositol 3-kinase (PI3K) to 
mediate the effects of various growth factors such as 
platelet-derived growth factor (PDGF), epidermal 
growth factor (EGF), insulin and insulin-like growth 
factor I (IGF-I). AKT mediates the antiapoptotic effects 
of IGF-I. Essential for the SPATA13-mediated 
regulation of cell migration and adhesion assembly 
and disassembly. May be involved in the regulation of 
the placental development.One of the few specific 
substrates of AKT2 identified recently is PITX2. 
Phosphorylation of PITX2 impairs its association with 
the CCND1 mRNA-stabilizing complex thus shortening 
the half-life of CCND1. AKT2 seems also to be the 
principal isoform responsible of the regulation of 
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glucose uptake. Phosphorylates C2CD5 on 'Ser-197' 
during insulin-stimulated adipocytes. AKT2 is also 
specifically involved in skeletal muscle differentiation, 
one of its substrates in this process being ANKRD2. 
Down-regulation by RNA interference reduces the 
expression of the phosphorylated form of BAD, 
resulting in the induction of caspase-dependent 
apoptosis. Phosphorylates CLK2 on 'Thr-343'. 
STITCH ALB p02768 Binding Serum albumin Serum albumin, the main protein of plasma, has a 
good binding capacity for water, Ca2+, Na+, K+, fatty 
acids, hormones, bilirubin and drugs. Its main function 
is the regulation of the colloidal osmotic pressure of 
blood. Major zinc transporter in plasma, typically 
binds about 80% of all plasma zinc. 
STITCH ALOX15 p16050 Enzyme Arachidonate 15-
lipoxygenase 
Non-heme iron-containing dioxygenase that catalyzes 
the stereo-specific peroxidation of free and esterified 
polyunsaturated fatty acids generating a spectrum of 
bioactive lipid mediators. Converts arachidonic acid 
into 12-hydroperoxyeicosatetraenoic acid/12-HPETE 
and 15-hydroperoxyeicosatetraenoic acid/15-HPETE. 
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Also converts linoleic acid to 13-
hydroperoxyoctadecadienoic acid. May also act on 
(12S)-hydroperoxyeicosatetraenoic acid/(12S)-HPETE 
to produce hepoxilin A3. Probably plays an important 
role in the immune and inflammatory responses. 
Through the oxygenation of membrane-bound 
phosphatidylethanolamine in macrophages may favor 
clearance of apoptotic cells during inflammation by 
resident macrophages and prevent an autoimmune 
response associated with the clearance of apoptotic 
cells by inflammatory monocytes. In parallel, may 
regulate actin polymerization which is crucial for 
several biological processes, including macrophage 
function. May also regulate macrophage function 
through regulation of the peroxisome proliferator 
activated receptor signaling pathway. Finally, it is also 
involved in the cellular response to IL13/interleukin-
13. In addition to its role in the immune and 
inflammatory responses, may play a role in epithelial 
wound healing in the cornea maybe through 
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production of lipoxin A4. May also play a role in 
endoplasmic reticulum stress response and the 
regulation of bone mass. 
STITCH ALOX15B o15296 Enzyme Arachidonate 15-
lipoxygenase B 
Non-heme iron-containing dioxygenase that catalyzes 
the stereo-specific peroxidation of free and esterified 
polyunsaturated fatty acids generating a spectrum of 
bioactive lipid mediators. Converts arachidonic acid to 
15S-hydroperoxyeicosatetraenoic acid/(15S)-HPETE. 
Also acts on linoleic acid to produce 13-
hydroxyoctadecadienoic acid/13-HPODE. Has no 
detectable 8S-lipoxygenase activity but reacts with 
(8S)-HPETE to produce (8S,15S)-diHPETE. May 
regulate progression through the cell cycle and cell 
proliferation. May also regulate cytokine secretion by 
macrophages and therefore play a role in the immune 
response. May also regulate macrophage 
differentiation into proatherogenic foam cells. 
Both ALOX5 p09917 Enzyme Arachidonate 5-
lipoxygenase 
Catalyzes the first step in leukotriene biosynthesis, 
and thereby plays a role in inflammatory processes. 
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STITCH ALOX5AP p20292 Binding Arachidonate 5-
lipoxygenase-activating 
protein 
Required for leukotriene biosynthesis by ALOX5 (5-
lipoxygenase). Anchors ALOX5 to the membrane. 
Binds arachidonic acid, and could play an essential 
role in the transfer of arachidonic acid to ALOX5. 
Binds to MK-886, a compound that blocks the 
biosynthesis of leukotrienes. 
STITCH AOX1 q06278 Metabolism Aldehyde oxidase Oxidase with broad substrate specificity, oxidizing 
aromatic azaheterocycles, such as N1-
methylnicotinamide and N-methylphthalazinium, as 
well as aldehydes, such as benzaldehyde, retinal, 
pyridoxal, and vanillin. Plays a key role in the 
metabolism of xenobiotics and drugs containing 
aromatic azaheterocyclic substituents. Participates in 
the bioactivation of prodrugs such as famciclovir, 
catalyzing the oxidation step from 6-deoxypenciclovir 
to penciclovir, which is a potent antiviral agent. Is 
probably involved in the regulation of reactive oxygen 
species homeostasis. May be a prominent source of 
superoxide generation via the one-electron reduction 
of molecular oxygen. Also may catalyze nitric oxide 
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(NO) production via the reduction of nitrite to NO 
with NADH or aldehyde as electron donor. May play a 
role in adipogenesis. 
STITCH APRT p07741 Enzyme Adenine 
phosphoribosyltransferase 
Catalyzes a salvage reaction resulting in the formation 
of AMP, that is energically less costly than de novo 
synthesis. 
Both AR p10275 Receptor Androgen receptor Steroid hormone receptors are ligand-activated 
transcription factors that regulate eukaryotic gene 
expression and affect cellular proliferation and 
differentiation in target tissues. Transcription factor 
activity is modulated by bound coactivator and 
corepressor proteins. Transcription activation is 
down-regulated by NR0B2. Activated, but not 
phosphorylated, by HIPK3 and ZIPK/DAPK3. 
SLAP ASL p04424 Enzyme Argininosuccinate lyase argininosuccinate lyase activity 
STITCH ATIC p31939 Enzyme Bifunctional purine 
biosynthesis protein PURH 
Bifunctional enzyme that catalyzes 2 steps in purine 
biosynthesis 
STITCH BAX q07812 Regulator Apoptosis regulator BAX Accelerates programmed cell death by binding to, and 
antagonizing the apoptosis repressor BCL2 or its 
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adenovirus homolog E1B 19k protein. Under stress 
conditions, undergoes a conformation change that 
causes translocation to the mitochondrion 
membrane, leading to the release of cytochrome c 
that then triggers apoptosis. Promotes activation of 
CASP3, and thereby apoptosis. 
SLAP BCL2 p10415 Regulator Apoptosis regulator Bcl-2 Suppresses apoptosis in a variety of cell systems 
including factor-dependent lymphohematopoietic and 
neural cells. Regulates cell death by controlling the 
mitochondrial membrane permeability. Appears to 
function in a feedback loop system with caspases. 
Inhibits caspase activity either by preventing the 
release of cytochrome c from the mitochondria 
and/or by binding to the apoptosis-activating factor 
(APAF-1) 
SLAP BCL2L1 q07817 Regulator Bcl-2-like protein 1 Potent inhibitor of cell death. Inhibits activation of 
caspases. Appears to regulate cell death by blocking 
the voltage-dependent anion channel (VDAC) by 
binding to it and preventing the release of the caspase 
activator, CYC1, from the mitochondrial membrane. 
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Also acts as a regulator of G2 checkpoint and 
progression to cytokinesis during mitosis.Isoform Bcl-
X(L) also regulates presynaptic plasticity, including 
neurotransmitter release and recovery, number of 
axonal mitochondria as well as size and number of 
synaptic vesicle clusters. During synaptic stimulation, 
increases ATP availability from mitochondria through 
regulation of mitochondrial membrane ATP synthase 
F1F0 activity and regulates endocytic vesicle retrieval 
in hippocampal neurons through association with 
DMN1L and stimulation of its GTPase activity in 
synaptic vesicles.Isoform Bcl-X(S) promotes apoptosis. 
STITCH BDNF p23560 Regulator Brain-derived neurotrophic 
factor 
During development, promotes the survival and 
differentiation of selected neuronal populations of 
the peripheral and central nervous systems. 
Participates in axonal growth, pathfinding and in the 
modulation of dendritic growth and morphology. 
Major regulator of synaptic transmission and plasticity 
at adult synapses in many regions of the CNS. The 
versatility of BDNF is emphasized by its contribution 
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to a range of adaptive neuronal responses including 
long-term potentiation (LTP), long-term depression 
(LTD), certain forms of short-term synaptic plasticity, 
as well as homeostatic regulation of intrinsic neuronal 
excitability. 
STITCH BIRC5 o15392 Regulator Baculoviral IAP repeat-
containing protein 5 
Multitasking protein that has dual roles in promoting 
cell proliferation and preventing apoptosis. 
Component of a chromosome passage protein 
complex (CPC) which is essential for chromosome 
alignment and segregation during mitosis and 
cytokinesis. Acts as an important regulator of the 
localization of this complex; directs CPC movement to 
different locations from the inner centromere during 
prometaphase to midbody during cytokinesis and 
participates in the organization of the center spindle 
by associating with polymerized microtubules. The 
complex with RAN plays a role in mitotic spindle 
formation by serving as a physical scaffold to help 
deliver the RAN effector molecule TPX2 to 
microtubules. May counteract a default induction of 
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apoptosis in G2/M phase. The acetylated form 
represses STAT3 transactivation of target gene 
promoters. May play a role in neoplasia. Inhibitor of 
CASP3 and CASP7. Isoform 2 and isoform 3 do not 
appear to play vital roles in mitosis. Isoform 3 shows a 
marked reduction in its anti-apoptotic effects when 
compared with the displayed wild-type isoform. 
STITCH C8orf4 q9nr00 Regulator Uncharacterized protein 
C8orf4 
May decrease apoptosis. 
SLAP CA1 p00915 Enzyme Carbonic anhydrase 1 Reversible hydration of carbon dioxide. Can hydrates 
cyanamide to urea. 
SLAP CA10 q9ns85 Uncertain Carbonic anhydrase-
related protein 10 
Does not have a catalytic activity. 
SLAP CA11 o75493 Uncertain Carbonic anhydrase-
related protein 11 
Does not have a catalytic activity. 
Both CA12 o43570   Carbonic anhydrase 12 Reversible hydration of carbon dioxide. 
Both CA13 q8n1q1 Enzyme Carbonic anhydrase 13 Reversible hydration of carbon dioxide. 
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SLAP CA14 q9ulx7 Enzyme Carbonic anhydrase 14 Reversible hydration of carbon dioxide. 
Both CA2 p00918 Enzyme Carbonic anhydrase 2 Essential for bone resorption and osteoclast 
differentiation (By similarity). Reversible hydration of 
carbon dioxide. Can hydrate cyanamide to urea. 
Involved in the regulation of fluid secretion into the 
anterior chamber of the eye. Contributes to 
intracellular pH regulation in the duodenal upper 
villous epithelium during proton-coupled peptide 
absorption. Stimulates the chloride-bicarbonate 
exchange activity of SLC26A6. 
SLAP CA3 p07451 Enzyme Carbonic anhydrase 3 Reversible hydration of carbon dioxide. 
SLAP CA4 p22748 Enzyme Carbonic anhydrase 4 Reversible hydration of carbon dioxide. May stimulate 
the sodium/bicarbonate transporter activity of 
SLC4A4 that acts in pH homeostasis. It is essential for 
acid overload removal from the retina and retina 
epithelium, and acid release in the choriocapillaris in 
the choroid 
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SLAP CA5A p35218 Enzyme Carbonic anhydrase 5A, 
mitochondrial 
Reversible hydration of carbon dioxide. Low activity. 
Both CA5B q9y2d0 Enzyme Carbonic anhydrase 5B, 
mitochondrial 
Reversible hydration of carbon dioxide. 
STITCH CA6 p23280 Enzyme Carbonic anhydrase 6 Reversible hydration of carbon dioxide. Its role in 
saliva is unknown. 
SLAP CA7 p43166 Enzyme Carbonic anhydrase 7 Reversible hydration of carbon dioxide. 
SLAP CA8 p35219 Uncertain Carbonic anhydrase-
related protein 
Does not have a carbonic anhydrase catalytic activity. 
Both CA9 q16790 Enzyme Carbonic anhydrase 9 Reversible hydration of carbon dioxide. Participates in 
pH regulation. May be involved in the control of cell 
proliferation and transformation. Appears to be a 
novel specific biomarker for a cervical neoplasia 
SLAP CACNA1C q13936 Ion channel Voltage-dependent L-type 
calcium channel subunit 
alpha-1C 
Voltage-sensitive calcium channels (VSCC) mediate 
the entry of calcium ions into excitable cells and are 
also involved in a variety of calcium-dependent 
processes, including muscle contraction, hormone or 
neurotransmitter release, gene expression, cell 
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motility, cell division and cell death. The isoform 
alpha-1C gives rise to L-type calcium currents. Long-
lasting (L-type) calcium channels belong to the 'high-
voltage activated' (HVA) group. They are blocked by 
dihydropyridines (DHP), phenylalkylamines, 
benzothiazepines, and by omega-agatoxin-IIIA 
(omega-Aga-IIIA). They are however insensitive to 
omega-conotoxin-GVIA (omega-CTx-GVIA) and 
omega-agatoxin-IVA (omega-Aga-IVA). Calcium 
channels containing the alpha-1C subunit play an 
important role in excitation-contraction coupling in 
the heart. The various isoforms display marked 
differences in the sensitivity to DHP compounds. 
Binding of calmodulin or CABP1 at the same 
regulatory sites results in an opposit effects on the 
channel function. 
SLAP CACNA1D q01668 Ion channel Voltage-dependent L-type 
calcium channel subunit 
alpha-1D 
Voltage-sensitive calcium channels (VSCC) mediate 
the entry of calcium ions into excitable cells and are 
also involved in a variety of calcium-dependent 
processes, including muscle contraction, hormone or 
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neurotransmitter release, gene expression, cell 
motility, cell division and cell death. The isoform 
alpha-1D gives rise to L-type calcium currents. Long-
lasting (L-type) calcium channels belong to the 'high-
voltage activated' (HVA) group. They are blocked by 
dihydropyridines (DHP), phenylalkylamines, 
benzothiazepines, and by omega-agatoxin-IIIA 
(omega-Aga-IIIA). They are however insensitive to 
omega-conotoxin-GVIA (omega-CTx-GVIA) and 
omega-agatoxin-IVA (omega-Aga-IVA). 
SLAP CACNA1F o60840 Ion channel Voltage-dependent L-type 
calcium channel subunit 
alpha-1F 
Voltage-sensitive calcium channels (VSCC) mediate 
the entry of calcium ions into excitable cells and are 
also involved in a variety of calcium-dependent 
processes, including muscle contraction, hormone or 
neurotransmitter release, gene expression, cell 
motility, cell division and cell death. The isoform 
alpha-1F gives rise to L-type calcium currents. Long-
lasting (L-type) calcium channels belong to the 'high-
voltage activated' (HVA) group. They are blocked by 
dihydropyridines (DHP), phenylalkylamines, 
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benzothiazepines, and by omega-agatoxin-IIIA 
(omega-Aga-IIIA). They are however insensitive to 
omega-conotoxin-GVIA (omega-CTx-GVIA) and 
omega-agatoxin-IVA (omega-Aga-IVA). 
SLAP CACNA1G o43497 Ion channel Voltage-dependent T-type 
calcium channel subunit 
alpha-1G 
Voltage-sensitive calcium channels (VSCC) mediate 
the entry of calcium ions into excitable cells and are 
also involved in a variety of calcium-dependent 
processes, including muscle contraction, hormone or 
neurotransmitter release, gene expression, cell 
motility, cell division and cell death. The isoform 
alpha-1G gives rise to T-type calcium currents. T-type 
calcium channels belong to the "low-voltage activated 
(LVA)" group and are strongly blocked by mibefradil. A 
particularity of this type of channel is an opening at 
quite negative potentials and a voltage-dependent 
inactivation. T-type channels serve pacemaking 
functions in both central neurons and cardiac nodal 
cells and support calcium signaling in secretory cells 
and vascular smooth muscle. They may also be 
involved in the modulation of firing patterns of 
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neurons which is important for information 
processing as well as in cell growth processes. 
SLAP CACNA1H o95180 Ion channel Voltage-dependent T-type 
calcium channel subunit 
alpha-1H 
Voltage-sensitive calcium channels (VSCC) mediate 
the entry of calcium ions into excitable cells and are 
also involved in a variety of calcium-dependent 
processes, including muscle contraction, hormone or 
neurotransmitter release, gene expression, cell 
motility, cell division and cell death. The isoform 
alpha-1H gives rise to T-type calcium currents. T-type 
calcium channels belong to the "low-voltage activated 
(LVA)" group and are strongly blocked by nickel and 
mibefradil. A particularity of this type of channels is 
an opening at quite negative potentials, and a 
voltage-dependent inactivation. T-type channels serve 
pacemaking functions in both central neurons and 
cardiac nodal cells and support calcium signaling in 
secretory cells and vascular smooth muscle. They may 
also be involved in the modulation of firing patterns 
of neurons which is important for information 
processing as well as in cell growth processes. 
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SLAP CACNA1I q9p0x4 Ion channel Voltage-dependent T-type 
calcium channel subunit 
alpha-1I 
Voltage-sensitive calcium channels (VSCC) mediate 
the entry of calcium ions into excitable cells and are 
also involved in a variety of calcium-dependent 
processes, including muscle contraction, hormone or 
neurotransmitter release, gene expression, cell 
motility, cell division and cell death. Isoform alpha-1I 
gives rise to T-type calcium currents. T-type calcium 
channels belong to the "low-voltage activated (LVA)" 
group and are strongly blocked by nickel and 
mibefradil. A particularity of this type of channels is 
an opening at quite negative potentials, and a 
voltage-dependent inactivation. T-type channels serve 
pacemaking functions in both central neurons and 
cardiac nodal cells and support calcium signaling in 
secretory cells and vascular smooth muscle. They may 
also be involved in the modulation of firing patterns 
of neurons which is important for information 
processing as well as in cell growth processes. Gates 
in voltage ranges similar to, but higher than alpha 1G 
or alpha 1H (By similarity). 
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SLAP CACNA1S q13698 Ion channel Voltage-dependent L-type 
calcium channel subunit 
alpha-1S 
Voltage-sensitive calcium channels (VSCC) mediate 
the entry of calcium ions into excitable cells and are 
also involved in a variety of calcium-dependent 
processes, including muscle contraction, hormone or 
neurotransmitter release, gene expression, cell 
motility, cell division and cell death. The isoform 
alpha-1S gives rise to L-type calcium currents. Long-
lasting (L-type) calcium channels belong to the 'high-
voltage activated' (HVA) group. They are blocked by 
dihydropyridines (DHP), phenylalkylamines, 
benzothiazepines, and by omega-agatoxin-IIIA 
(omega-Aga-IIIA). They are however insensitive to 
omega-conotoxin-GVIA (omega-CTx-GVIA) and 
omega-agatoxin-IVA (omega-Aga-IVA). Calcium 
channels containing the alpha-1S subunit play an 
important role in excitation-contraction coupling in 
skeletal muscle. 
SLAP CALM1 p62158 Regulator Calmodulin Calmodulin mediates the control of a large number of 
enzymes, ion channels, aquaporins and other proteins 
by Ca2+. Among the enzymes to be stimulated by the 
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calmodulin-Ca2+ complex are a number of protein 
kinases and phosphatases. Together with CCP110 and 
centrin, is involved in a genetic pathway that 
regulates the centrosome cycle and progression 
through cytokinesis. 
SLAP CASP1 p29466 Enzyme Caspase-1 Thiol protease that cleaves IL-1 beta between an Asp 
and an Ala, releasing the mature cytokine which is 
involved in a variety of inflammatory processes. 
Important for defense against pathogens. Cleaves and 
activates sterol regulatory element binding proteins 
(SREBPs). Can also promote apoptosis. 
Both CASP3 p42574 Enzyme Caspase-3 Involved in the activation cascade of caspases 
responsible for apoptosis execution. At the onset of 
apoptosis it proteolytically cleaves poly(ADP-ribose) 
polymerase (PARP) at a '216-Asp-|-Gly-217' bond. 
Cleaves and activates sterol regulatory element 
binding proteins (SREBPs) between the basic helix-
loop-helix leucine zipper domain and the membrane 
attachment domain. Cleaves and activates caspase-6, 
-7 and -9. Involved in the cleavage of huntingtin. 
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Triggers cell adhesion in sympathetic neurons through 
RET cleavage. 
SLAP CASP7 p55210 Enzyme Caspase-7 Involved in the activation cascade of caspases 
responsible for apoptosis execution. Cleaves and 
activates sterol regulatory element binding proteins 
(SREBPs). Proteolytically cleaves poly(ADP-ribose) 
polymerase (PARP) at a '216-Asp-|-Gly-217' bond. 
Overexpression promotes programmed cell death. 
STITCH CASP8 q14790 Enzyme Caspase-8 Most upstream protease of the activation cascade of 
caspases responsible for the TNFRSF6/FAS mediated 
and TNFRSF1A induced cell death. Binding to the 
adapter molecule FADD recruits it to either receptor. 
The resulting aggregate called death-inducing 
signaling complex (DISC) performs CASP8 proteolytic 
activation. The active dimeric enzyme is then 
liberated from the DISC and free to activate 
downstream apoptotic proteases. Proteolytic 
fragments of the N-terminal propeptide (termed 
CAP3, CAP5 and CAP6) are likely retained in the DISC. 
Cleaves and activates CASP3, CASP4, CASP6, CASP7, 
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CASP9 and CASP10. May participate in the GZMB 
apoptotic pathways. Cleaves ADPRT. Hydrolyzes the 
small-molecule substrate, Ac-Asp-Glu-Val-Asp-|-AMC. 
Likely target for the cowpox virus CRMA death 
inhibitory protein. Isoform 5, isoform 6, isoform 7 and 
isoform 8 lack the catalytic site and may interfere with 
the pro-apoptotic activity of the complex. 
STITCH CASP9 p55211 Enzyme Caspase-9 Involved in the activation cascade of caspases 
responsible for apoptosis execution. Binding of 
caspase-9 to Apaf-1 leads to activation of the 
protease which then cleaves and activates caspase-3. 
Promotes DNA damage-induced apoptosis in a 
ABL1/c-Abl-dependent manner. Proteolytically 
cleaves poly(ADP-ribose) polymerase (PARP). 
Isoform 2 lacks activity is an dominant-negative 
inhibitor of caspase-9. 
STITCH CAV1 q03135 Immune 
activation 
Caveolin-1 May act as a scaffolding protein within caveolar 
membranes. Interacts directly with G-protein alpha 
subunits and can functionally regulate their activity 
(By similarity). Involved in the costimulatory signal 
Appendix 2: Consolidated list of proteins 
209 
 
essential for T-cell receptor (TCR)-mediated T-cell 
activation. Its binding to DPP4 induces T-cell 
proliferation and NF-kappa-B activation in a T-cell 
receptor/CD3-dependent manner. Recruits CTNNB1 
to caveolar membranes and may regulate CTNNB1-
mediated signaling through the Wnt pathway. 
SLAP CCL2 p13500 Chemotatic C-C motif chemokine 2 Chemotactic factor that attracts monocytes and 
basophils but not neutrophils or eosinophils. 
Augments monocyte anti-tumor activity. Has been 
implicated in the pathogenesis of diseases 
characterized by monocytic infiltrates, like psoriasis, 
rheumatoid arthritis or atherosclerosis. May be 
involved in the recruitment of monocytes into the 
arterial wall during the disease process of 
atherosclerosis. 
Both CCND1 p24385 Regulator G1/S-specific cyclin-D1 Regulatory component of the cyclin D1-CDK4 (DC) 
complex that phosphorylates and inhibits members of 
the retinoblastoma (RB) protein family including RB1 
and regulates the cell-cycle during G1/S transition. 
Phosphorylation of RB1 allows dissociation of the 
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transcription factor E2F from the RB/E2F complex and 
the subsequent transcription of E2F target genes 
which are responsible for the progression through the 
G1 phase. Hypophosphorylates RB1 in early G1 phase. 
Cyclin D-CDK4 complexes are major integrators of 
various mitogenenic and antimitogenic signals. Also 
substrate for SMAD3, phosphorylating SMAD3 in a 
cell-cycle-dependent manner and repressing its 
transcriptional activity. Component of the ternary 
complex, cyclin D1/CDK4/CDKN1B, required for 
nuclear translocation and activity of the cyclin D-CDK4 
complex. Exhibits transcriptional corepressor activity 
with INSM1 on the NEUROD1 and INS promoters in a 
cell cycle-independent manner. 
SLAP CCR5 p51681 Receptor C-C chemokine receptor 
type 5 
Receptor for a number of inflammatory CC-
chemokines including MIP-1-alpha, MIP-1-beta and 
RANTES and subsequently transduces a signal by 
increasing the intracellular calcium ion level. May play 
a role in the control of granulocytic lineage 
proliferation or differentiation. Acts as a coreceptor 
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(CD4 being the primary receptor) for HIV-1 R5 
isolates. 
STITCH CD248 q9hcu0   Endosialin May play a role in tumor angiogenesis 
STITCH CD4 p01730 Immune 
activation 
T-cell surface glycoprotein 
CD4 
Accessory protein for MHC class-II antigen/T-cell 
receptor interaction. May regulate T-cell activation. 
Induces the aggregation of lipid rafts. 
STITCH CD59 p13987 Immune 
activation 
CD59 glycoprotein Potent inhibitor of the complement membrane attack 
complex (MAC) action. Acts by binding to the C8 
and/or C9 complements of the assembling MAC, 
thereby preventing incorporation of the multiple 
copies of C9 required for complete formation of the 
osmolytic pore. This inhibitor appears to be species-
specific. Involved in signal transduction for T-cell 
activation complexed to a protein tyrosine kinase. 
The soluble form from urine retains its specific 
complement binding activity, but exhibits greatly 
reduced ability to inhibit MAC assembly on cell 
membranes. 
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STITCH CD79A p11912 Immune 
activation 
B-cell antigen receptor 
complex-associated 
protein alpha chain 
Required in cooperation with CD79B for initiation of 
the signal transduction cascade activated by binding 
of antigen to the B-cell antigen receptor complex 
(BCR) which leads to internalization of the complex, 
trafficking to late endosomes and antigen 
presentation. Also required for BCR surface 
expression and for efficient differentiation of pro- and 
pre-B-cells. Stimulates SYK autophosphorylation and 
activation. Binds to BLNK, bringing BLNK into 
proximity with SYK and allowing SYK to phosphorylate 
BLNK. Also interacts with and increases activity of 
some Src-family tyrosine kinases. Represses BCR 
signaling during development of immature B-cells. 
STITCH CDIPT o14735 Enzyme CDP-diacylglycerol--inositol 
3-phosphatidyltransferase 
Catalyzes the biosynthesis of phosphatidylinositol 
(PtdIns) as well as PtdIns:inositol exchange reaction. 
May thus act to reduce an excessive cellular PtdIns 
content. The exchange activity is due to the reverse 
reaction of PtdIns synthase and is dependent on CMP, 
which is tightly bound to the enzyme. 
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Both CDK2 p24941 Kinase Cyclin-dependent kinase 2 Serine/threonine-protein kinase involved in the 
control of the cell cycle; essential for meiosis, but 
dispensable for mitosis. Phosphorylates CTNNB1, 
USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, 
NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. 
Triggers duplication of centrosomes and DNA. Acts at 
the G1-S transition to promote the E2F transcriptional 
program and the initiation of DNA synthesis, and 
modulates G2 progression; controls the timing of 
entry into mitosis/meiosis by controlling the 
subsequent activation of cyclin B/CDK1 by 
phosphorylation, and coordinates the activation of 
cyclin B/CDK1 at the centrosome and in the nucleus. 
Crucial role in orchestrating a fine balance between 
cellular proliferation, cell death, and DNA repair in 
human embryonic stem cells (hESCs). Activity of CDK2 
is maximal during S phase and G2; activated by 
interaction with cyclin E during the early stages of 
DNA synthesis to permit G1-S transition, and 
subsequently activated by cyclin A2 (cyclin A1 in germ 
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cells) during the late stages of DNA replication to 
drive the transition from S phase to mitosis, the G2 
phase. EZH2 phosphorylation promotes H3K27me3 
maintenance and epigenetic gene silencing. 
Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 
prevents oxidative stress-mediated Ras-induced 
senescence by phosphorylating MYC. Involved in G1-S 
phase DNA damage checkpoint that prevents cells 
with damaged DNA from initiating mitosis; regulates 
homologous recombination-dependent repair by 
phosphorylating BRCA2, this phosphorylation is low in 
S phase when recombination is active, but increases 
as cells progress towards mitosis. In response to DNA 
damage, double-strand break repair by homologous 
recombination a reduction of CDK2-mediated BRCA2 
phosphorylation. Phosphorylation of RB1 disturbs its 
interaction with E2F1. NPM1 phosphorylation by 
cyclin E/CDK2 promotes its dissociates from 
unduplicated centrosomes, thus initiating centrosome 
duplication. Cyclin E/CDK2-mediated phosphorylation 
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of NPAT at G1-S transition and until prophase 
stimulates the NPAT-mediated activation of histone 
gene transcription during S phase. Required for 
vitamin D-mediated growth inhibition by being itself 
inactivated. Involved in the nitric oxide- (NO) 
mediated signaling in a nitrosylation/activation-
dependent manner. USP37 is activated by 
phosphorylation and thus triggers G1-S transition. 
CTNNB1 phosphorylation regulates insulin 
internalization. Phosphorylates FOXP3 and negatively 
regulates its transcriptional activity and protein 
stability (By similarity). 
SLAP CDK4 p11802 Kinase Cyclin-dependent kinase 4 Ser/Thr-kinase component of cyclin D-CDK4 (DC) 
complexes that phosphorylate and inhibit members of 
the retinoblastoma (RB) protein family including RB1 
and regulate the cell-cycle during G1/S transition. 
Phosphorylation of RB1 allows dissociation of the 
transcription factor E2F from the RB/E2F complexes 
and the subsequent transcription of E2F target genes 
which are responsible for the progression through the 
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G1 phase. Hypophosphorylates RB1 in early G1 phase. 
Cyclin D-CDK4 complexes are major integrators of 
various mitogenenic and antimitogenic signals. Also 
phosphorylates SMAD3 in a cell-cycle-dependent 
manner and represses its transcriptional activity. 
Component of the ternary complex, cyclin 
D/CDK4/CDKN1B, required for nuclear translocation 
and activity of the cyclin D-CDK4 complex. 
STITCH CDKN1A p38936 Regulator Cyclin-dependent kinase 
inhibitor 1 
May be the important intermediate by which 
p53/TP53 mediates its role as an inhibitor of cellular 
proliferation in response to DNA damage. Binds to 
and inhibits cyclin-dependent kinase activity, 
preventing phosphorylation of critical cyclin-
dependent kinase substrates and blocking cell cycle 
progression. Functions in the nuclear localization and 
assembly of cyclin D-CDK4 complex and promotes its 
kinase activity towards RB1. At higher stoichiometric 
ratios, inhibits the kinase activity of the cyclin D-CDK4 
complex. 
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STITCH CFLAR o15519 Regulator CASP8 and FADD-like 
apoptosis regulator 
Apoptosis regulator protein which may function as a 
crucial link between cell survival and cell death 
pathways in mammalian cells. Acts as an inhibitor of 
TNFRSF6 mediated apoptosis. A proteolytic fragment 
(p43) is likely retained in the death-inducing signaling 
complex (DISC) thereby blocking further recruitment 
and processing of caspase-8 at the complex. Full 
length and shorter isoforms have been shown either 
to induce apoptosis or to reduce TNFRSF-triggered 
apoptosis. Lacks enzymatic (caspase) activity. 
SLAP CHRM1 p11229 Receptor Muscarinic acetylcholine 
receptor M1 
The muscarinic acetylcholine receptor mediates 
various cellular responses, including inhibition of 
adenylate cyclase, breakdown of phosphoinositides 
and modulation of potassium channels through the 
action of G proteins. Primary transducing effect is Pi 
turnover. 
SLAP CHRM2 p08172 Receptor Muscarinic acetylcholine 
receptor M2 
The muscarinic acetylcholine receptor mediates 
various cellular responses, including inhibition of 
adenylate cyclase, breakdown of phosphoinositides 
and modulation of potassium channels through the 
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action of G proteins. Primary transducing effect is 
adenylate cyclase inhibition. Signaling promotes 
phospholipase C activity, leading to the release of 
inositol trisphosphate (IP3); this then triggers calcium 
ion release into the cytosol. 
SLAP CHRM3 p20309 Receptor Muscarinic acetylcholine 
receptor M3 
The muscarinic acetylcholine receptor mediates 
various cellular responses, including inhibition of 
adenylate cyclase, breakdown of phosphoinositides 
and modulation of potassium channels through the 
action of G proteins. Primary transducing effect is Pi 
turnover. 
SLAP CHRM4 p08173 Receptor Muscarinic acetylcholine 
receptor M4 
The muscarinic acetylcholine receptor mediates 
various cellular responses, including inhibition of 
adenylate cyclase, breakdown of phosphoinositides 
and modulation of potassium channels through the 
action of G proteins. Primary transducing effect is 
inhibition of adenylate cyclase. 
SLAP CHRM5 p08912 Receptor Muscarinic acetylcholine 
receptor M5 
The muscarinic acetylcholine receptor mediates 
various cellular responses, including inhibition of 
adenylate cyclase, breakdown of phosphoinositides 
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and modulation of potassium channels through the 
action of G proteins. Primary transducing effect is Pi 
turnover. 
SLAP CHRNA7 q494w8 Ion channel CHRNA7-FAM7A fusion 
protein 
extracellular ligand-gated ion channel activity 
STITCH CHUK o15111 Kinase Inhibitor of nuclear factor 
kappa-B kinase subunit 
alpha 
Serine kinase that plays an essential role in the NF-
kappa-B signaling pathway which is activated by 
multiple stimuli such as inflammatory cytokines, 
bacterial or viral products, DNA damages or other 
cellular stresses. Acts as part of the canonical IKK 
complex in the conventional pathway of NF-kappa-B 
activation and phosphorylates inhibitors of NF-kappa-
B on serine residues. These modifications allow 
polyubiquitination of the inhibitors and subsequent 
degradation by the proteasome. In turn, free NF-
kappa-B is translocated into the nucleus and activates 
the transcription of hundreds of genes involved in 
immune response, growth control, or protection 
against apoptosis. Negatively regulates the pathway 
by phosphorylating the scaffold protein TAXBP1 and 
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thus promoting the assembly of the A20/TNFAIP3 
ubiquitin-editing complex (composed of 
A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and 
RNF11). Therefore, CHUK plays a key role in the 
negative feedback of NF-kappa-B canonical signaling 
to limit inflammatory gene activation. As part of the 
non-canonical pathway of NF-kappa-B activation, the 
MAP3K14-activated CHUK/IKKA homodimer 
phosphorylates NFKB2/p100 associated with RelB, 
inducing its proteolytic processing to NFKB2/p52 and 
the formation of NF-kappa-B RelB-p52 complexes. In 
turn, these complexes regulate genes encoding 
molecules involved in B-cell survival and lymphoid 
organogenesis. Participates also in the negative 
feedback of the non-canonical NF-kappa-B signaling 
pathway by phosphorylating and destabilizing 
MAP3K14/NIK. Within the nucleus, phosphorylates 
CREBBP and consequently increases both its 
transcriptional and histone acetyltransferase 
activities. Modulates chromatin accessibility at NF-
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kappa-B-responsive promoters by phosphorylating 
histones H3 at 'Ser-10' that are subsequently 
acetylated at 'Lys-14' by CREBBP. Additionally, 
phosphorylates the CREBBP-interacting protein 
NCOA3. 
SLAP CNR1 p21554 Receptor Cannabinoid receptor 1 Involved in cannabinoid-induced CNS effects. Acts by 
inhibiting adenylate cyclase. Could be a receptor for 
anandamide. Inhibits L-type Ca2+ channel current. 
Isoform 2 and isoform 3 have altered ligand binding. 
SLAP CNR2 p34972 Receptor Cannabinoid receptor 2 Heterotrimeric G protein-coupled receptor for 
endocannabinoid 2-arachidonoylglycerol mediating 
inhibition of adenylate cyclase. May function in 
inflammatory response, nociceptive transmission and 
bone homeostasis. 
STITCH CRH p06850 Hormone Corticoliberin This hormone from hypothalamus regulates the 
release of corticotropin from pituitary gland. 
STITCH CRP p02741 Immune 
functions 
C-reactive protein Displays several functions associated with host 
defense: it promotes agglutination, bacterial capsular 
swelling, phagocytosis and complement fixation 
through its calcium-dependent binding to 
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phosphorylcholine. Can interact with DNA and 
histones and may scavenge nuclear material released 
from damaged circulating cells. 
STITCH CTNNB1 p35222 Regulator Catenin beta-1 Key downstream component of the canonical Wnt 
signaling pathway. In the absence of Wnt, forms a 
complex with AXIN1, AXIN2, APC, CSNK1A1 and 
GSK3B that promotes phosphorylation on N-terminal 
Ser and Thr residues and ubiquitination of CTNNB1 via 
BTRC and its subsequent degradation by the 
proteasome. In the presence of Wnt ligand, CTNNB1 is 
not ubiquitinated and accumulates in the nucleus, 
where it acts as a coactivator for transcription factors 
of the TCF/LEF family, leading to activate Wnt 
responsive genes. Involved in the regulation of cell 
adhesion. Acts as a negative regulator of centrosome 
cohesion. Involved in the 
CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin 
internalization. Blocks anoikis of malignant kidney and 
intestinal epithelial cells and promotes their 
anchorage-independent growth by down-regulating 
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DAPK2. Disrupts PML function and PML-NB formation 
by inhibiting RANBP2-mediated sumoylation of PML 
(PubMed:17524503, PubMed:18077326, 
PubMed:18086858, PubMed:18957423, 
PubMed:21262353, PubMed:22647378, 
PubMed:22699938, PubMed:22155184). Promotes 
neurogenesis by maintaining sympathetic neuroblasts 
within the cell cycle (By similarity). 
STITCH CTSB p07858 Enzyme Cathepsin B Thiol protease which is believed to participate in 
intracellular degradation and turnover of proteins. 
Has also been implicated in tumor invasion and 
metastasis. 
STITCH CTSL1 p07711 Enzyme Cathepsin L1 Important for the overall degradation of proteins in 
lysosomes. 
STITCH CXCL10 p02778 Chemotatic C-X-C motif chemokine 10 Chemotactic for monocytes and T-lymphocytes. Binds 
to CXCR3. 
Both CYP11B1 p15538 Metabolic 
enzmye 
Cytochrome P450 11B1, 
mitochondrial 
Has steroid 11-beta-hydroxylase activity. In addition 
to this activity, the 18 or 19-hydroxylation of steroids 
and the aromatization of androstendione to estrone 
have also been ascribed to cytochrome P450 XIB. 
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Both CYP17A1 p05093 Metabolic 
enzmye 
Steroid 17-alpha-
hydroxylase/17,20 lyase 
Conversion of pregnenolone and progesterone to 
their 17-alpha-hydroxylated products and 
subsequently to dehydroepiandrosterone (DHEA) and 
androstenedione. Catalyzes both the 17-alpha-
hydroxylation and the 17,20-lyase reaction. Involved 
in sexual development during fetal life and at puberty 
Both CYP19A1 p11511 Metabolic 
enzmye 
Aromatase Catalyzes the formation of aromatic C18 estrogens 
from C19 androgens. 
STITCH CYP1A1 p04798 Metabolic 
enzmye 
Cytochrome P450 1A1 Cytochromes P450 are a group of heme-thiolate 
monooxygenases. In liver microsomes, this enzyme is 
involved in an NADPH-dependent electron transport 
pathway. It oxidizes a variety of structurally unrelated 
compounds, including steroids, fatty acids, and 
xenobiotics. 
Both CYP1A2 p05177 Metabolic 
enzmye 
Cytochrome P450 1A2 Cytochromes P450 are a group of heme-thiolate 
monooxygenases. In liver microsomes, this enzyme is 
involved in an NADPH-dependent electron transport 
pathway. It oxidizes a variety of structurally unrelated 
compounds, including steroids, fatty acids, and 
xenobiotics. Most active in catalyzing 2-hydroxylation. 
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Caffeine is metabolized primarily by cytochrome 
CYP1A2 in the liver through an initial N3-
demethylation. Also acts in the metabolism of 
aflatoxin B1 and acetaminophen. Participates in the 
bioactivation of carcinogenic aromatic and 
heterocyclic amines. Catalizes the N-hydroxylation of 
heterocyclic amines and the O-deethylation of 
phenacetin. 
STITCH CYP2A13 q16696 Metabolic 
enzmye 
Cytochrome P450 2A13 Exhibits a coumarin 7-hydroxylase activity. Active in 
the metabolic activation of 
hexamethylphosphoramide, N,N-dimethylaniline, 2'-
methoxyacetophenone, N-
nitrosomethylphenylamine, and the tobacco-specific 
carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone. Possesses phenacetin O-deethylation 
activity. 
Both CYP2A6 p11509 Metabolic 
enzmye 
Cytochrome P450 2A6 Exhibits a high coumarin 7-hydroxylase activity. Can 
act in the hydroxylation of the anti-cancer drugs 
cyclophosphamide and ifosphamide. Competent in 
the metabolic activation of aflatoxin B1. Constitutes 
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the major nicotine C-oxidase. Acts as a 1,4-cineole 2-
exo-monooxygenase. Possesses low phenacetin O-
deethylation activity. 
Both CYP2B6 p20813 Metabolic 
enzmye 
Cytochrome P450 2B6 Cytochromes P450 are a group of heme-thiolate 
monooxygenases. In liver microsomes, this enzyme is 
involved in an NADPH-dependent electron transport 
pathway. It oxidizes a variety of structurally unrelated 
compounds, including steroids, fatty acids, and 
xenobiotics. Acts as a 1,4-cineole 2-exo-
monooxygenase. 
Both CYP2C18 p33260 Metabolic 
enzmye 
Cytochrome P450 2C18 Cytochromes P450 are a group of heme-thiolate 
monooxygenases. In liver microsomes, this enzyme is 
involved in an NADPH-dependent electron transport 
pathway. It oxidizes a variety of structurally unrelated 
compounds, including steroids, fatty acids, and 
xenobiotics. 
STITCH CYP2C19 p33261 Metabolic 
enzmye 
Cytochrome P450 2C19 Responsible for the metabolism of a number of 
therapeutic agents such as the anticonvulsant drug S-
mephenytoin, omeprazole, proguanil, certain 
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barbiturates, diazepam, propranolol, citalopram and 
imipramine. 
Both CYP2C8 p10632 Metabolic 
enzmye 
Cytochrome P450 2C8 Cytochromes P450 are a group of heme-thiolate 
monooxygenases. In liver microsomes, this enzyme is 
involved in an NADPH-dependent electron transport 
pathway. It oxidizes a variety of structurally unrelated 
compounds, including steroids, fatty acids, and 
xenobiotics. In the epoxidation of arachidonic acid it 
generates only 14,15- and 11,12-cis-
epoxyeicosatrienoic acids. It is the principal enzyme 
responsible for the metabolism the anti-cancer drug 
paclitaxel (taxol) 
Both CYP2C9 p11712 Metabolic 
enzmye 
Cytochrome P450 2C9 Cytochromes P450 are a group of heme-thiolate 
monooxygenases. In liver microsomes, this enzyme is 
involved in an NADPH-dependent electron transport 
pathway. It oxidizes a variety of structurally unrelated 
compounds, including steroids, fatty acids, and 
xenobiotics. This enzyme contributes to the wide 
pharmacokinetics variability of the metabolism of 
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drugs such as S-warfarin, diclofenac, phenytoin, 
tolbutamide and losartan. 
STITCH CYP2D6 p10635 Metabolic 
enzmye 
Cytochrome P450 2D6 Responsible for the metabolism of many drugs and 
environmental chemicals that it oxidizes. It is involved 
in the metabolism of drugs such as antiarrhythmics, 
adrenoceptor antagonists, and tricyclic 
antidepressants. 
STITCH CYP2D7P1 no entry       
STITCH CYP2E1 p05181 Metabolic 
enzmye 
Cytochrome P450 2E1 Metabolizes several precarcinogens, drugs, and 
solvents to reactive metabolites. Inactivates a number 
of drugs and xenobiotics and also bioactivates many 
xenobiotic substrates to their hepatotoxic or 
carcinogenic forms. 
Both CYP3A4 p08684 Metabolic 
enzmye 
Cytochrome P450 3A4 Cytochromes P450 are a group of heme-thiolate 
monooxygenases. In liver microsomes, this enzyme is 
involved in an NADPH-dependent electron transport 
pathway. It performs a variety of oxidation reactions 
(e.g. caffeine 8-oxidation, omeprazole sulphoxidation, 
midazolam 1'-hydroxylation and midazolam 4-
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hydroxylation) of structurally unrelated compounds, 
including steroids, fatty acids, and xenobiotics. Acts as 
a 1,8-cineole 2-exo-monooxygenase. The enzyme also 
hydroxylates etoposide 
STITCH CYP3A43 q9hb55 Metabolic 
enzmye 
Cytochrome P450 3A43 Exhibits low testosterone 6-beta-hydroxylase activity. 
STITCH CYP3A5 p20815 Metabolic 
enzmye 
Cytochrome P450 3A5 Cytochrome P450 3A5 
STITCH CYP3A7 p24462 Metabolic 
enzmye 
Cytochrome P450 3A7 Cytochromes P450 are a group of heme-thiolate 
monooxygenases. In liver microsomes, this enzyme is 
involved in an NADPH-dependent electron transport 
pathway. It oxidizes a variety of structurally unrelated 
compounds, including steroids, fatty acids, and 
xenobiotics. 
SLAP CYP4A11 q02928 Metabolic 
enzmye 
Cytochrome P450 4A11 Catalyzes the omega- and (omega-1)-hydroxylation of 
various fatty acids such as laurate, myristate and 
palmitate. Has little activity toward prostaglandins A1 
and E1. Oxidizes arachidonic acid to 20-
hydroxyeicosatetraenoic acid (20-HETE). 
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STITCH DBH p09172 Enzyme Dopamine beta-
hydroxylase 
Conversion of dopamine to noradrenaline. 
SLAP DDC p20711 Enzyme Aromatic-L-amino-acid 
decarboxylase 
Catalyzes the decarboxylation of L-3,4-
dihydroxyphenylalanine (DOPA) to dopamine, L-5-
hydroxytryptophan to serotonin and L-tryptophan to 
tryptamine. 
STITCH DDIT3 p35638 Regulator DNA damage-inducible 
transcript 3 protein 
Multifunctional transcription factor in ER stress 
response. Plays an essential role in the response to a 
wide variety of cell stresses and induces cell cycle 
arrest and apoptosis in response to ER stress. Plays a 
dual role both as an inhibitor of CCAAT/enhancer-
binding protein (C/EBP) function and as an activator 
of other genes. Acts as a dominant-negative regulator 
of C/EBP-induced transcription: dimerizes with 
members of the C/EBP family, impairs their 
association with C/EBP binding sites in the promoter 
regions, and inhibits the expression of C/EBP 
regulated genes. Positively regulates the transcription 
of TRIB3, IL6, IL8, IL23, TNFRSF10B/DR5, 
PPP1R15A/GADD34, BBC3/PUMA, BCL2L11/BIM and 
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ERO1L. Negatively regulates; expression of BCL2 and 
MYOD1, ATF4-dependent transcriptional activation of 
asparagine synthetase (ASNS), CEBPA-dependent 
transcriptional activation of hepcidin (HAMP) and 
CEBPB-mediated expression of peroxisome 
proliferator-activated receptor gamma (PPARG). 
Inhibits the canonical Wnt signaling pathway by 
binding to TCF7L2/TCF4, impairing its DNA-binding 
properties and repressing its transcriptional activity. 
Plays a regulatory role in the inflammatory response 
through the induction of caspase-11 (CASP4/CASP11) 
which induces the activation of caspase-1 (CASP1) and 
both these caspases increase the activation of pro-
IL1B to mature IL1B which is involved in the 
inflammatory response. 
STITCH DGCR2 p98153 Receptor Integral membrane protein 
DGCR2/IDD 
Putative adhesion receptor, that could be involved in 
cell-cell or cell-matrix interactions required for normal 
cell differentiation and migration. 
SLAP DHFR p00374 Enzyme Dihydrofolate reductase Key enzyme in folate metabolism. Contributes to the 
de novo mitochondrial thymidylate biosynthesis 
Appendix 2: Consolidated list of proteins 
232 
 
pathway. Catalyzes an essential reaction for de novo 
glycine and purine synthesis, and for DNA precursor 
synthesis. Binds its own mRNA and that of DHFRL1. 
STITCH DIABLO q9nr28 Regulator Diablo homolog, 
mitochondrial 
Promotes apoptosis by activating caspases in the 
cytochrome c/Apaf-1/caspase-9 pathway. Acts by 
opposing the inhibitory activity of inhibitor of 
apoptosis proteins (IAP). Inhibits the activity of 
BIRC6/bruce by inhibiting its binding to caspases. 
Isoform 3 attenuates the stability and apoptosis-
inhibiting activity of XIAP/BIRC4 by promoting 
XIAP/BIRC4 ubiquitination and degradation through 
the ubiquitin-proteasome pathway. Isoform 3 also 
disrupts XIAP/BIRC4 interacting with processed 
caspase-9 and promotes caspase-3 activation. Isoform 
1 is defective in the capacity to down-regulate the 
XIAP/BIRC4 abundance. 
STITCH DIF uncertain       
STITCH DIO1 p49895 Enzyme Type I iodothyronine 
deiodinase 
Responsible for the deiodination of T4 (3,5,3',5'-
tetraiodothyronine) into T3 (3,5,3'-triiodothyronine) 
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and of T3 into T2 (3,3'-diiodothyronine). Plays a role in 
providing a source of plasma T3 by deiodination of T4 
in peripheral tissues such as liver and kidney. 
STITCH DIO2 q92813 Enzyme Type II iodothyronine 
deiodinase 
Responsible for the deiodination of T4 (3,5,3',5'-
tetraiodothyronine) into T3 (3,5,3'-triiodothyronine). 
Essential for providing the brain with appropriate 
levels of T3 during the critical period of development. 
STITCH DIO3 p55073 Enzyme Type III iodothyronine 
deiodinase 
Responsible for the deiodination of T4 (3,5,3',5'-
tetraiodothyronine) into RT3 (3,3',5'-triiodothyronine) 
and of T3 (3,5,3'-triiodothyronine) into T2 (3,3'-
diiodothyronine). RT3 and T2 are inactive metabolites. 
May play a role in preventing premature exposure of 
developing fetal tissues to adult levels of thyroid 
hormones. Can regulate circulating fetal thyroid 
hormone concentrations throughout gestation. 
Essential role for regulation of thyroid hormone 
inactivation during embryological development. 
STITCH DPH2 q9bqc3   Diphthamide biosynthesis 
protein 2 
Required for the first step in the synthesis of 
diphthamide, a post-translational modification of 
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histidine which occurs in translation elongation factor 
2 (EEF2). 
STITCH DPH3 q96fx2   DPH3 homolog Essential for the first step in the synthesis of 
diphthamide, a post-translational modification of 
histidine which occurs in elongation factor 2 (EEF2) 
and which can be ADP-ribosylated by diphtheria toxin 
and by Pseudomonas exotoxin A (Eta). 
SLAP DRD1 p21728 Receptor D(1A) dopamine receptor Dopamine receptor whose activity is mediated by G 
proteins which activate adenylyl cyclase. 
Both DRD2 p14416 Receptor D(2) dopamine receptor Dopamine receptor whose activity is mediated by G 
proteins which inhibit adenylyl cyclase. 
SLAP DRD3 p35462 Receptor D(3) dopamine receptor Dopamine receptor whose activity is mediated by G 
proteins which inhibit adenylyl cyclase. Promotes cell 
proliferation. 
SLAP DRD4 p21917 Receptor D(4) dopamine receptor Dopamine receptor responsible for neuronal signaling 
in the mesolimbic system of the brain, an area of the 
brain that regulates emotion and complex behavior. 
Its activity is mediated by G proteins which inhibit 
adenylyl cyclase. Modulates the circadian rhythm of 
contrast sensitivity by regulating the rhythmic 
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expression of NPAS2 in the retinal ganglion cells (By 
similarity). 
SLAP DRD5 p21918 Receptor D(1B) dopamine receptor Dopamine receptor whose activity is mediated by G 
proteins which activate adenylyl cyclase. 
STITCH EGFR p00533 Kinase Epidermal growth factor 
receptor 
Receptor tyrosine kinase binding ligands of the EGF 
family and activating several signaling cascades to 
convert extracellular cues into appropriate cellular 
responses. Known ligands include EGF, TGFA/TGF-
alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, 
epiregulin/EREG and HBEGF/heparin-binding EGF. 
Ligand binding triggers receptor homo- and/or 
heterodimerization and autophosphorylation on key 
cytoplasmic residues. The phosphorylated receptor 
recruits adapter proteins like GRB2 which in turn 
activates complex downstream signaling cascades. 
Activates at least 4 major downstream signaling 
cascades including the RAS-RAF-MEK-ERK, PI3 kinase-
AKT, PLCgamma-PKC and STATs modules. May also 
activate the NF-kappa-B signaling cascade. Also 
directly phosphorylates other proteins like RGS16, 
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activating its GTPase activity and probably coupling 
the EGF receptor signaling to the G protein-coupled 
receptor signaling. Also phosphorylates MUC1 and 
increases its interaction with SRC and CTNNB1/beta-
catenin.  
Isoform 2 may act as an antagonist of EGF action. 
STITCH EGR1 p18146 Regulator Early growth response 
protein 1 
Transcriptional regulator. Recognizes and binds to the 
DNA sequence 5'-CGCCCCCGC-3'(EGR-site). Activates 
the transcription of target genes whose products are 
required for mitogenesis and differentiation. 
STITCH ENSG00000167494 no entry       
STITCH ENSG00000168937 no entry       
STITCH ENSG00000204490 no entry       
STITCH ENSG00000228978 no entry       
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STITCH EPHX1 p07099 Enzyme Epoxide hydrolase 1 Biotransformation enzyme that catalyzes the 
hydrolysis of arene and aliphatic epoxides to less 
reactive and more water soluble dihydrodiols by the 
trans addition of water. 
SLAP EPHX2 p34913 Enzyme Bifunctional epoxide 
hydrolase 2 
Bifunctional enzyme. The C-terminal domain has 
epoxide hydrolase activity and acts on epoxides 
(alkene oxides, oxiranes) and arene oxides. Plays a 
role in xenobiotic metabolism by degrading 
potentially toxic epoxides. Also determines steady-
state levels of physiological mediators. The N-terminal 
domain has lipid phosphatase activity, with the 
highest activity towards threo-9,10-phosphonooxy-
hydroxy-octadecanoic acid, followed by erythro-9,10-
phosphonooxy-hydroxy-octadecanoic acid, 12-
phosphonooxy-octadec-9Z-enoic acid, 12-
phosphonooxy-octadec-9E-enoic acid, and p-
nitrophenyl phospate. 
STITCH EPX p11678 Immune 
functions 
Eosinophil peroxidase Mediates tyrosine nitration of secondary granule 
proteins in mature resting eosinophils. Shows 
significant inhibitory activity towards Mycobacterium 
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tuberculosis H37Rv by inducing bacterial 
fragmentation and lysis. 
STITCH ERBB2 p04626 Kinase Receptor tyrosine-protein 
kinase erbB-2 
Protein tyrosine kinase that is part of several cell 
surface receptor complexes, but that apparently 
needs a coreceptor for ligand binding. Essential 
component of a neuregulin-receptor complex, 
although neuregulins do not interact with it alone. 
GP30 is a potential ligand for this receptor. Regulates 
outgrowth and stabilization of peripheral 
microtubules (MTs). Upon ERBB2 activation, the 
MEMO1-RHOA-DIAPH1 signaling pathway elicits the 
phosphorylation and thus the inhibition of GSK3B at 
cell membrane. This prevents the phosphorylation of 
APC and CLASP2, allowing its association with the cell 
membrane. In turn, membrane-bound APC allows the 
localization of MACF1 to the cell membrane, which is 
required for microtubule capture and stabilization. 
In the nucleus is involved in transcriptional regulation. 
Associates with the 5'-TCAAATTC-3' sequence in the 
PTGS2/COX-2 promoter and activates its 
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transcription. Implicated in transcriptional activation 
of CDKN1A; the function involves STAT3 and SRC. 
Involved in the transcription of rRNA genes by RNA 
Pol I and enhances protein synthesis and cell growth. 
SLAP ESR1 p03372 Receptor Estrogen receptor Nuclear hormone receptor. The steroid hormones and 
their receptors are involved in the regulation of 
eukaryotic gene expression and affect cellular 
proliferation and differentiation in target tissues. 
Ligand-dependent nuclear transactivation involves 
either direct homodimer binding to a palindromic 
estrogen response element (ERE) sequence or 
association with other DNA-binding transcription 
factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, 
to mediate ERE-independent signaling. Ligand binding 
induces a conformational change allowing subsequent 
or combinatorial association with multiprotein 
coactivator complexes through LXXLL motifs of their 
respective components. Mutual transrepression 
occurs between the estrogen receptor (ER) and NF-
kappa-B in a cell-type specific manner. Decreases NF-
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kappa-B DNA-binding activity and inhibits NF-kappa-B-
mediated transcription from the IL6 promoter and 
displace RELA/p65 and associated coregulators from 
the promoter. Recruited to the NF-kappa-B response 
element of the CCL2 and IL8 promoters and can 
displace CREBBP. Present with NF-kappa-B 
components RELA/p65 and NFKB1/p50 on ERE 
sequences. Can also act synergistically with NF-kappa-
B to activate transcription involving respective 
recruitment adjacent response elements; the function 
involves CREBBP. Can activate the transcriptional 
activity of TFF1. Also mediates membrane-initiated 
estrogen signaling involving various kinase cascades. 
Isoform 3 is involved in activation of NOS3 and 
endothelial nitric oxide production. Isoforms lacking 
one or several functional domains are thought to 
modulate transcriptional activity by competitive 
ligand or DNA binding and/or heterodimerization with 
the full length receptor. Essential for MTA1-mediated 
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transcriptional regulation of BRCA1 and BCAS3. 
Isoform 3 can bind to ERE and inhibit isoform 1. 
STITCH FASLG p48023 Immune 
functions 
Tumor necrosis factor 
ligand superfamily member 
6 
Cytokine that binds to TNFRSF6/FAS, a receptor that 
transduces the apoptotic signal into cells. May be 
involved in cytotoxic T-cell mediated apoptosis and in 
T-cell development. TNFRSF6/FAS-mediated apoptosis 
may have a role in the induction of peripheral 
tolerance, in the antigen-stimulated suicide of mature 
T-cells, or both. Binding to the decoy receptor 
TNFRSF6B/DcR3 modulates its effects. 
The FasL intracellular domain (FasL ICD) cytoplasmic 
form induces gene transcription inhibition. 
STITCH FASN p49327 Enzyme Fatty acid synthase Fatty acid synthetase catalyzes the formation of long-
chain fatty acids from acetyl-CoA, malonyl-CoA and 
NADPH. This multifunctional protein has 7 catalytic 
activities and an acyl carrier protein. 
SLAP FGF1 p05230 Regulator Fibroblast growth factor 1 Plays an important role in the regulation of cell 
survival, cell division, angiogenesis, cell differentiation 
and cell migration. Functions as potent mitogen in 
vitro. 
Appendix 2: Consolidated list of proteins 
242 
 
SLAP FGF2 p09038 Regulator Fibroblast growth factor 2 Plays an important role in the regulation of cell 
survival, cell division, angiogenesis, cell differentiation 
and cell migration. Functions as potent mitogen in 
vitro. 
STITCH FMO3 p31513 Metabolism Dimethylaniline 
monooxygenase [N-oxide-
forming] 3 
Involved in the oxidative metabolism of a variety of 
xenobiotics such as drugs and pesticides. It N-
oxygenates primary aliphatic alkylamines as well as 
secondary and tertiary amines. Plays an important 
role in the metabolism of trimethylamine (TMA), via 
the production of TMA N-oxide (TMAO). Is also able to 
perform S-oxidation when acting on sulfide 
compounds. 
SLAP FPR1 p21462 Receptor fMet-Leu-Phe receptor High affinity receptor for N-formyl-methionyl peptides 
(fMLP), which are powerful neutrophil chemotactic 
factors (PubMed:2161213, PubMed:2176894, 
PubMed:10514456, PubMed:15153520). Binding of 
fMLP to the receptor stimulates intracellular calcium 
mobilization and superoxide anion release 
(PubMed:2161213, PubMed:1712023, 
PubMed:15153520). This response is mediated via a 
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G-protein that activates a phosphatidylinositol-
calcium second messenger system (PubMed:1712023, 
PubMed:10514456). 
STITCH G6PD p11413 Enzyme Glucose-6-phosphate 1-
dehydrogenase 
Catalyzes the rate-limiting step of the oxidative 
pentose-phosphate pathway, which represents a 
route for the dissimilation of carbohydrates besides 
glycolysis. The main function of this enzyme is to 
provide reducing power (NADPH) and pentose 
phosphates for fatty acid and nucleic acid synthesis. 
STITCH GDF15 q99988 Cytokine Growth/differentiation 
factor 15 
cytokine activity, transforming growth factor beta 
receptor binding  
STITCH GNAT3 a8mtj3   Guanine nucleotide-
binding protein G(t) 
subunit alpha-3 
Guanine nucleotide-binding protein (G protein) alpha 
subunit playing a prominent role in bitter and sweet 
taste transduction as well as in umami (monosodium 
glutamate, monopotassium glutamate, and inosine 
monophosphate) taste transduction. Transduction by 
this alpha subunit involves coupling of specific cell-
surface receptors with a cGMP-phosphodiesterase; 
Activation of phosphodiesterase lowers intracellular 
levels of cAMP and cGMP which may open a cyclic 
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nucleotide-suppressible cation channel leading to 
influx of calcium, ultimately leading to release of 
neurotransmitter. Indeed, denatonium and strychnine 
induce transient reduction in cAMP and cGMP in taste 
tissue, whereas this decrease is inhibited by GNAT3 
antibody. Gustducin heterotrimer transduces 
response to bitter and sweet compounds via 
regulation of phosphodiesterase for alpha subunit, as 
well as via activation of phospholipase C for beta and 
gamma subunits, with ultimate increase inositol 
trisphosphate and increase of intracellular Calcium. 
GNAT3 can functionally couple to taste receptors to 
transmit intracellular signal: receptor heterodimer 
TAS1R2/TAS1R3 senses sweetness and 
TAS1R1/TAS1R3 transduces umami taste, whereas the 
T2R family GPCRs act as bitter sensors. Functions also 
as lumenal sugar sensors in the gut to control the 
expression of the Na+-glucose transporter SGLT1 in 
response to dietaty sugar, as well as the secretion of 
Glucagon-like peptide-1, GLP-1 and glucose-
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dependent insulinotropic polypeptide, GIP. Thus, may 
modulate the gut capacity to absorb sugars, with 
implications in malabsorption syndromes and diet-
related disorders including diabetes and obesity. 
STITCH GNLY p27749 Immune 
functions 
Granulysin Antimicrobial protein that kills intracellular 
pathogens. Active against a broad range of microbes, 
including Gram-positive and Gram-negative bacteria, 
fungi, and parasites. Kills Mycobacterium tuberculosis. 
SLAP GRIN2B q13224 Receptor Glutamate receptor 
ionotropic, NMDA 2B 
NMDA receptor subtype of glutamate-gated ion 
channels with high calcium permeability and voltage-
dependent sensitivity to magnesium. Mediated by 
glycine. In concert with DAPK1 at extrasynaptic sites, 
acts as a central mediator for stroke damage. Its 
phosphorylation at Ser-1303 by DAPK1 enhances 
synaptic NMDA receptor channel activity inducing 
injurious Ca2+ influx through them, resulting in an 
irreversible neuronal death (By similarity). 
SLAP GSTA1 p08263 Metabolism Glutathione S-transferase 
A1 
Conjugation of reduced glutathione to a wide number 
of exogenous and endogenous hydrophobic 
electrophiles. 
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Both GSTM1 p09488 Metabolism Glutathione S-transferase 
Mu 1 
Conjugation of reduced glutathione to a wide number 
of exogenous and endogenous hydrophobic 
electrophiles. 
SLAP GSTP1 p09211 Metabolism Glutathione S-transferase 
P 
Conjugation of reduced glutathione to a wide number 
of exogenous and endogenous hydrophobic 
electrophiles. Regulates negatively CDK5 activity via 
p25/p35 translocation to prevent neurodegeneration. 
STITCH HDAC3 o15379 Enzyme Histone deacetylase 3 Responsible for the deacetylation of lysine residues 
on the N-terminal part of the core histones (H2A, H2B, 
H3 and H4), and some other non-histone substrates. 
Histone deacetylation gives a tag for epigenetic 
repression and plays an important role in 
transcriptional regulation, cell cycle progression and 
developmental events. Histone deacetylases act via 
the formation of large multiprotein complexes. 
Participates in the BCL6 transcriptional repressor 
activity by deacetylating the H3 'Lys-27' (H3K27) on 
enhancer elements, antagonizing EP300 
acetyltransferase activity and repressing proximal 
gene expression. Probably participates in the 
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regulation of transcription through its binding to the 
zinc-finger transcription factor YY1; increases YY1 
repression activity. Required to repress transcription 
of the POU1F1 transcription factor. Acts as a 
molecular chaperone for shuttling phosphorylated 
NR2C1 to PML bodies for sumoylation 
(PubMed:21444723, PubMed:23911289). Contributes, 
together with XBP1 isoform 1, to the activation of 
NFE2L2-mediated HMOX1 transcription factor gene 
expression in a PI3K/mTORC2/Akt-dependent signaling 
pathway leading to endothelial cell (EC) survival under 
disturbed flow/oxidative stress 
STITCH HIF1A q16665 Regulator Hypoxia-inducible factor 1-
alpha 
Functions as a master transcriptional regulator of the 
adaptive response to hypoxia. Under hypoxic 
conditions, activates the transcription of over 40 
genes, including erythropoietin, glucose transporters, 
glycolytic enzymes, vascular endothelial growth 
factor, HILPDA, and other genes whose protein 
products increase oxygen delivery or facilitate 
metabolic adaptation to hypoxia. Plays an essential 
Appendix 2: Consolidated list of proteins 
248 
 
role in embryonic vascularization, tumor angiogenesis 
and pathophysiology of ischemic disease. Binds to 
core DNA sequence 5'-[AG]CGTG-3' within the 
hypoxia response element (HRE) of target gene 
promoters. Activation requires recruitment of 
transcriptional coactivators such as CREBPB and 
EP300. Activity is enhanced by interaction with both, 
NCOA1 or NCOA2. Interaction with redox regulatory 
protein APEX seems to activate CTAD and potentiates 
activation by NCOA1 and CREBBP. Involved in the 
axonal distribution and transport of mitochondria in 
neurons during hypoxia. 
STITCH HLA-C q29963 Immune 
functions 
HLA class I 
histocompatibility antigen, 
Cw-6 alpha chain 
Involved in the presentation of foreign antigens to the 
immune system. 
STITCH HMBS p08397 Enzmye Porphobilinogen 
deaminase 
Tetrapolymerization of the monopyrrole PBG into the 
hydroxymethylbilane pre-uroporphyrinogen in several 
discrete steps. 
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SLAP HNMT p50135 Metabolism Histamine N-
methyltransferase 
Inactivates histamine by N-methylation. Plays an 
important role in degrading histamine and in 
regulating the airway response to histamine. 
STITCH HPRT1 p00492 Enzmye Hypoxanthine-guanine 
phosphoribosyltransferase 
Converts guanine to guanosine monophosphate, and 
hypoxanthine to inosine monophosphate. Transfers 
the 5-phosphoribosyl group from 5-
phosphoribosylpyrophosphate onto the purine. Plays 
a central role in the generation of purine nucleotides 
through the purine salvage pathway 
SLAP HRH1 p35367 Receptor Histamine H1 receptor In peripheral tissues, the H1 subclass of histamine 
receptors mediates the contraction of smooth 
muscles, increase in capillary permeability due to 
contraction of terminal venules, and catecholamine 
release from adrenal medulla, as well as mediating 
neurotransmission in the central nervous system. 
SLAP HRH2 p25021 Receptor Histamine H2 receptor The H2 subclass of histamine receptors mediates 
gastric acid secretion. Also appears to regulate 
gastrointestinal motility and intestinal secretion. 
Possible role in regulating cell growth and 
differentiation. The activity of this receptor is 
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mediated by G proteins which activate adenylyl 
cyclase and, through a separate G protein-dependent 
mechanism, the phosphoinositide/protein kinase 
(PKC) signaling pathway (By similarity). 
SLAP HRH3 q9y5n1 Receptor Histamine H3 receptor The H3 subclass of histamine receptors could mediate 
the histamine signals in CNS and peripheral nervous 
system. Signals through the inhibition of adenylate 
cyclase and displays high constitutive activity 
(spontaneous activity in the absence of agonist). 
Agonist stimulation of isoform 3 neither modified 
adenylate cyclase activity nor induced intracellular 
calcium mobilization. 
SLAP HRH4 q9h3n8 Receptor Histamine H4 receptor The H4 subclass of histamine receptors could mediate 
the histamine signals in peripheral tissues. Displays a 
significant level of constitutive activity (spontaneous 
activity in the absence of agonist). 
STITCH HSD3B2 p26439 Enzmye 3 beta-hydroxysteroid 
dehydrogenase/Delta 5--
>4-isomerase type 2 
3-beta-HSD is a bifunctional enzyme, that catalyzes 
the oxidative conversion of Delta(5)-ene-3-beta-
hydroxy steroid, and the oxidative conversion of 
ketosteroids. The 3-beta-HSD enzymatic system plays 
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a crucial role in the biosynthesis of all classes of 
hormonal steroids. 
STITCH HSPA5 p11021 Structural 78 kDa glucose-regulated 
protein 
Probably plays a role in facilitating the assembly of 
multimeric protein complexes inside the endoplasmic 
reticulum. Involved in the correct folding of proteins 
and degradation of misfolded proteins via its 
interaction with DNAJC10, probably to facilitate the 
release of DNAJC10 from its substrate. 
SLAP HTR1A p08908 Receptor 5-hydroxytryptamine 
receptor 1A 
G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin). Also functions as a receptor for various 
drugs and psychoactive substances. Ligand binding 
causes a conformation change that triggers signaling 
via guanine nucleotide-binding proteins (G proteins) 
and modulates the activity of down-stream effectors, 
such as adenylate cyclase. Beta-arrestin family 
members inhibit signaling via G proteins and mediate 
activation of alternative signaling pathways. Signaling 
inhibits adenylate cyclase activity and activates a 
phosphatidylinositol-calcium second messenger 
system that regulates the release of Ca2+ ions from 
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intracellular stores. Plays a role in the regulation of 5-
hydroxytryptamine release and in the regulation of 
dopamine and 5-hydroxytryptamine metabolism. 
Plays a role in the regulation of dopamine and 5-
hydroxytryptamine levels in the brain, and thereby 
affects neural activity, mood and behavior. Plays a 
role in the response to anxiogenic stimuli. 
SLAP HTR1B p28222 Receptor 5-hydroxytryptamine 
receptor 1B 
G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin). Also functions as a receptor for ergot 
alkaloid derivatives, various anxiolytic and 
antidepressant drugs and other psychoactive 
substances, such as lysergic acid diethylamide (LSD). 
Ligand binding causes a conformation change that 
triggers signaling via guanine nucleotide-binding 
proteins (G proteins) and modulates the activity of 
down-stream effectors, such as adenylate cyclase. 
Signaling inhibits adenylate cyclase activity. Arrestin 
family members inhibit signaling via G proteins and 
mediate activation of alternative signaling pathways. 
Regulates the release of 5-hydroxytryptamine, 
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dopamine and acetylcholine in the brain, and thereby 
affects neural activity, nociceptive processing, pain 
perception, mood and behavior. Besides, plays a role 
in vasoconstriction of cerebral arteries. 
SLAP HTR1D p28221 Receptor 5-hydroxytryptamine 
receptor 1D 
G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin). Also functions as a receptor for ergot 
alkaloid derivatives, various anxiolytic and 
antidepressant drugs and other psychoactive 
substances. Ligand binding causes a conformation 
change that triggers signaling via guanine nucleotide-
binding proteins (G proteins) and modulates the 
activity of down-stream effectors, such as adenylate 
cyclase. Signaling inhibits adenylate cyclase activity. 
Regulates the release of 5-hydroxytryptamine in the 
brain, and thereby affects neural activity. May also 
play a role in regulating the release of other 
neurotransmitters. May play a role in 
vasoconstriction. 
SLAP HTR1E p28566 Receptor 5-hydroxytryptamine 
receptor 1E 
G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin). Also functions as a receptor for various 
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alkaloids and psychoactive substances. Ligand binding 
causes a conformation change that triggers signaling 
via guanine nucleotide-binding proteins (G proteins) 
and modulates the activity of down-stream effectors, 
such as adenylate cyclase. Signaling inhibits adenylate 
cyclase activity. 
SLAP HTR1F p30939 Receptor 5-hydroxytryptamine 
receptor 1F 
G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin). Also functions as a receptor for various 
alkaloids and psychoactive substances. Ligand binding 
causes a conformation change that triggers signaling 
via guanine nucleotide-binding proteins (G proteins) 
and modulates the activity of down-stream effectors, 
such as adenylate cyclase. Signaling inhibits adenylate 
cyclase activity. 
SLAP HTR2A p28223 Receptor 5-hydroxytryptamine 
receptor 2A 
G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin). Also functions as a receptor for various 
drugs and psychoactive substances, including 
mescaline, psilocybin, 1-(2,5-dimethoxy-4-
iodophenyl)-2-aminopropane (DOI) and lysergic acid 
diethylamide (LSD). Ligand binding causes a 
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conformation change that triggers signaling via 
guanine nucleotide-binding proteins (G proteins) and 
modulates the activity of down-stream effectors. 
Beta-arrestin family members inhibit signaling via G 
proteins and mediate activation of alternative 
signaling pathways. Signaling activates phospholipase 
C and a phosphatidylinositol-calcium second 
messenger system that modulates the activity of 
phosphatidylinositol 3-kinase and promotes the 
release of Ca2+ ions from intracellular stores. Affects 
neural activity, perception, cognition and mood. Plays 
a role in the regulation of behavior, including 
responses to anxiogenic situations and psychoactive 
substances. Plays a role in intestinal smooth muscle 
contraction, and may play a role in arterial 
vasoconstriction. 
SLAP HTR2B p41595 Receptor 5-hydroxytryptamine 
receptor 2B 
G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin). Also functions as a receptor for various 
ergot alkaloid derivatives and psychoactive 
substances. Ligand binding causes a conformation 
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change that triggers signaling via guanine nucleotide-
binding proteins (G proteins) and modulates the 
activity of down-stream effectors. Beta-arrestin family 
members inhibit signaling via G proteins and mediate 
activation of alternative signaling pathways. Signaling 
activates a phosphatidylinositol-calcium second 
messenger system that modulates the activity of 
phosphatidylinositol 3-kinase and down-stream 
signaling cascades and promotes the release of Ca2+ 
ions from intracellular stores. Plays a role in the 
regulation of dopamine and 5-hydroxytryptamine 
release, 5-hydroxytryptamine uptake and in the 
regulation of extracellular dopamine and 5-
hydroxytryptamine levels, and thereby affects neural 
activity. May play a role in the perception of pain. 
Plays a role in the regulation of behavior, including 
impulsive behavior. Required for normal proliferation 
of embryonic cardiac myocytes and normal heart 
development. Protects cardiomyocytes against 
apoptosis. Plays a role in the adaptation of pulmonary 
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arteries to chronic hypoxia. Plays a role in 
vasoconstriction. Required for normal osteoblast 
function and proliferation, and for maintaining normal 
bone density. Required for normal proliferation of the 
interstitial cells of Cajal in the intestine. 
SLAP HTR2C p28335 Receptor 5-hydroxytryptamine 
receptor 2C 
G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin). Also functions as a receptor for various 
drugs and psychoactive substances, including ergot 
alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-
aminopropane (DOI) and lysergic acid diethylamide 
(LSD). Ligand binding causes a conformation change 
that triggers signaling via guanine nucleotide-binding 
proteins (G proteins) and modulates the activity of 
down-stream effectors. Beta-arrestin family members 
inhibit signaling via G proteins and mediate activation 
of alternative signaling pathways. Signaling activates a 
phosphatidylinositol-calcium second messenger 
system that modulates the activity of 
phosphatidylinositol 3-kinase and down-stream 
signaling cascades and promotes the release of Ca2+ 
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ions from intracellular stores. Regulates neuronal 
activity via the activation of short transient receptor 
potential calcium channels in the brain, and thereby 
modulates the activation of pro-opiomelacortin 
neurons and the release of CRH that then regulates 
the release of corticosterone. Plays a role in the 
regulation of appetite and eating behavior, responses 
to anxiogenic stimuli and stress. Plays a role in insulin 
sensitivity and glucose homeostasis. 
SLAP HTR3A p46098 Receptor 5-hydroxytryptamine 
receptor 3A 
This is one of the several different receptors for 5-
hydroxytryptamine (serotonin), a biogenic hormone 
that functions as a neurotransmitter, a hormone, and 
a mitogen. This receptor is a ligand-gated ion channel, 
which when activated causes fast, depolarizing 
responses in neurons. It is a cation-specific, but 
otherwise relatively nonselective, ion channel. 
SLAP HTR4 q13639 Receptor 5-hydroxytryptamine 
receptor 4 
This is one of the several different receptors for 5-
hydroxytryptamine (serotonin), a biogenic hormone 
that functions as a neurotransmitter, a hormone, and 
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a mitogen. The activity of this receptor is mediated by 
G proteins that stimulate adenylate cyclase. 
SLAP HTR6 p50406 Receptor 5-hydroxytryptamine 
receptor 6 
This is one of the several different receptors for 5-
hydroxytryptamine (serotonin), a biogenic hormone 
that functions as a neurotransmitter, a hormone, and 
a mitogen. The activity of this receptor is mediated by 
G proteins that stimulate adenylate cyclase. It has a 
high affinity for tricyclic psychotropic drugs (By 
similarity). Controls pyramidal neurons migration 
during corticogenesis, through the regulation of CDK5 
activity (By similarity). Is an activator of TOR signaling  
SLAP HTR7 p34969 Receptor 5-hydroxytryptamine 
receptor 7 
This is one of the several different receptors for 5-
hydroxytryptamine (serotonin), a biogenic hormone 
that functions as a neurotransmitter, a hormone, and 
a mitogen. The activity of this receptor is mediated by 
G proteins that stimulate adenylate cyclase. 
STITCH ICAM1 p05362 Structural Intercellular adhesion 
molecule 1 
ICAM proteins are ligands for the leukocyte adhesion 
protein LFA-1 (integrin alpha-L/beta-2). During 
leukocyte trans-endothelial migration, ICAM1 
engagement promotes the assembly of endothelial 
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apical cups through ARHGEF26/SGEF and RHOG 
activation. In case of rhinovirus infection acts as a 
cellular receptor for the virus. 
STITCH IDO1 p14902 Enzyme Indoleamine 2,3-
dioxygenase 1 
Catalyzes the cleavage of the pyrrol ring of tryptophan 
and incorporates both atoms of a molecule of oxygen. 
STITCH IGF1R p08069 Kinase Insulin-like growth factor 1 
receptor 
Receptor tyrosine kinase which mediates actions of 
insulin-like growth factor 1 (IGF1). Binds IGF1 with 
high affinity and IGF2 and insulin (INS) with a lower 
affinity. The activated IGF1R is involved in cell growth 
and survival control. IGF1R is crucial for tumor 
transformation and survival of malignant cell. Ligand 
binding activates the receptor kinase, leading to 
receptor autophosphorylation, and tyrosines 
phosphorylation of multiple substrates, that function 
as signaling adapter proteins including, the insulin-
receptor substrates (IRS1/2), Shc and 14-3-3 proteins. 
Phosphorylation of IRSs proteins lead to the activation 
of two main signaling pathways: the PI3K-AKT/PKB 
pathway and the Ras-MAPK pathway. The result of 
activating the MAPK pathway is increased cellular 
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proliferation, whereas activating the PI3K pathway 
inhibits apoptosis and stimulates protein synthesis. 
Phosphorylated IRS1 can activate the 85 kDa 
regulatory subunit of PI3K (PIK3R1), leading to 
activation of several downstream substrates, 
including protein AKT/PKB. AKT phosphorylation, in 
turn, enhances protein synthesis through mTOR 
activation and triggers the antiapoptotic effects of 
IGFIR through phosphorylation and inactivation of 
BAD. In parallel to PI3K-driven signaling, recruitment 
of Grb2/SOS by phosphorylated IRS1 or Shc leads to 
recruitment of Ras and activation of the ras-MAPK 
pathway. In addition to these two main signaling 
pathways IGF1R signals also through the Janus 
kinase/signal transducer and activator of transcription 
pathway (JAK/STAT). Phosphorylation of JAK proteins 
can lead to phosphorylation/activation of signal 
transducers and activators of transcription (STAT) 
proteins. In particular activation of STAT3, may be 
essential for the transforming activity of IGF1R. The 
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JAK/STAT pathway activates gene transcription and 
may be responsible for the transforming activity. JNK 
kinases can also be activated by the IGF1R. IGF1 
exerts inhibiting activities on JNK activation via 
phosphorylation and inhibition of MAP3K5/ASK1, 
which is able to directly associate with the IGF1R. 
When present in a hybrid receptor with INSR, binds 
IGF1. PubMed:12138094 shows that hybrid receptors 
composed of IGF1R and INSR isoform Long are 
activated with a high affinity by IGF1, with low affinity 
by IGF2 and not significantly activated by insulin, and 
that hybrid receptors composed of IGF1R and INSR 
isoform Short are activated by IGF1, IGF2 and insulin. 
In contrast, PubMed:16831875 shows that hybrid 
receptors composed of IGF1R and INSR isoform Long 
and hybrid receptors composed of IGF1R and INSR 
isoform Short have similar binding characteristics, 
both bind IGF1 and have a low affinity for insulin. 
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STITCH IKBKB o14920 Kinase Inhibitor of nuclear factor 
kappa-B kinase subunit 
beta 
Serine kinase that plays an essential role in the NF-
kappa-B signaling pathway which is activated by 
multiple stimuli such as inflammatory cytokines, 
bacterial or viral products, DNA damages or other 
cellular stresses. Acts as part of the canonical IKK 
complex in the conventional pathway of NF-kappa-B 
activation and phosphorylates inhibitors of NF-kappa-
B on 2 critical serine residues. These modifications 
allow polyubiquitination of the inhibitors and 
subsequent degradation by the proteasome. In turn, 
free NF-kappa-B is translocated into the nucleus and 
activates the transcription of hundreds of genes 
involved in immune response, growth control, or 
protection against apoptosis. In addition to the NF-
kappa-B inhibitors, phosphorylates several other 
components of the signaling pathway including 
NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, 
as well as IKK-related kinases TBK1 and IKBKE. IKK-
related kinase phosphorylations may prevent the 
overproduction of inflammatory mediators since they 
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exert a negative regulation on canonical IKKs. Also 
phosphorylates other substrates including NCOA3, 
BCL10 and IRS1. Within the nucleus, acts as an 
adapter protein for NFKBIA degradation in UV-
induced NF-kappa-B activation. 
STITCH IL10 p22301 Immune 
functions 
Interleukin-10 Inhibits the synthesis of a number of cytokines, 
including IFN-gamma, IL-2, IL-3, TNF and GM-CSF 
produced by activated macrophages and by helper T-
cells. 
STITCH IL1A p01583 Immune 
functions 
Interleukin-1 alpha Produced by activated macrophages, IL-1 stimulates 
thymocyte proliferation by inducing IL-2 release, B-
cell maturation and proliferation, and fibroblast 
growth factor activity. IL-1 proteins are involved in the 
inflammatory response, being identified as 
endogenous pyrogens, and are reported to stimulate 
the release of prostaglandin and collagenase from 
synovial cells. 
Both IL1B p01584 Immune 
functions 
Interleukin-1 beta Produced by activated macrophages, IL-1 stimulates 
thymocyte proliferation by inducing IL-2 release, B-
cell maturation and proliferation, and fibroblast 
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growth factor activity. IL-1 proteins are involved in the 
inflammatory response, being identified as 
endogenous pyrogens, and are reported to stimulate 
the release of prostaglandin and collagenase from 
synovial cells. 
STITCH IL6 p05231 Immune 
functions 
Interleukin-6 Cytokine with a wide variety of biological functions. It 
is a potent inducer of the acute phase response. Plays 
an essential role in the final differentiation of B-cells 
into Ig-secreting cells Involved in lymphocyte and 
monocyte differentiation. Acts on B-cells, T-cells, 
hepatocytes, hematopoietic progenitor cells and cells 
of the CNS. Required for the generation of T(H)17 
cells. Also acts as a myokine. It is discharged into the 
bloodstream after muscle contraction and acts to 
increase the breakdown of fats and to improve insulin 
resistance. It induces myeloma and plasmacytoma 
growth and induces nerve cells differentiation. 
STITCH ILK q13418 Kinase Integrin-linked protein 
kinase 
Receptor-proximal protein kinase regulating integrin-
mediated signal transduction. May act as a mediator 
of inside-out integrin signaling. Focal adhesion protein 
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part of the complex ILK-PINCH. This complex is 
considered to be one of the convergence points of 
integrin- and growth factor-signaling pathway. Could 
be implicated in mediating cell architecture, adhesion 
to integrin substrates and anchorage-dependent 
growth in epithelial cells. Phosphorylates beta-1 and 
beta-3 integrin subunit on serine and threonine 
residues, but also AKT1 and GSK3B. 
STITCH IMPA1 p29218 Enzyme Inositol monophosphatase 
1 
Responsible for the provision of inositol required for 
synthesis of phosphatidylinositol and 
polyphosphoinositides and has been implicated as the 
pharmacological target for lithium action in brain. Has 
broad substrate specificity and can use myo-inositol 
monophosphates, myo-inositol 1,3-diphosphate, myo-
inositol 1,4-diphosphate, scyllo-inositol-phosphate, D-
galactose 1-phosphate, glucose-1-phosphate, glucose-
6-phosphate, fructose-1-phosphate, beta-
glycerophosphate, and 2'-AMP as substrates. 
STITCH INS p01308 Hormone Insulin Insulin decreases blood glucose concentration. It 
increases cell permeability to monosaccharides, 
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amino acids and fatty acids. It accelerates glycolysis, 
the pentose phosphate cycle, and glycogen synthesis 
in liver. 
STITCH ITGA2 p17301 Receptor Integrin alpha-2 Integrin alpha-2/beta-1 is a receptor for laminin, 
collagen, collagen C-propeptides, fibronectin and E-
cadherin. It recognizes the proline-hydroxylated 
sequence G-F-P-G-E-R in collagen. It is responsible for 
adhesion of platelets and other cells to collagens, 
modulation of collagen and collagenase gene 
expression, force generation and organization of 
newly synthesized extracellular matrix. 
Both JUN p05412 Regulator Transcription factor AP-1 Transcription factor that recognizes and binds to the 
enhancer heptamer motif 5'-TGA[CG]TCA-3'. 
Promotes activity of NR5A1 when phosphorylated by 
HIPK3 leading to increased steroidogenic gene 
expression upon cAMP signaling pathway stimulation. 
STITCH KCNA5 p22460 Ion channel Potassium voltage-gated 
channel subfamily A 
member 5 
Voltage-gated potassium channel that mediates 
transmembrane potassium transport in excitable 
membranes. Forms tetrameric potassium-selective 
channels through which potassium ions pass in 
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accordance with their electrochemical gradient. The 
channel alternates between opened and closed 
conformations in response to the voltage difference 
across the membrane. Can form functional 
homotetrameric channels and heterotetrameric 
channels that contain variable proportions of KCNA1, 
KCNA2, KCNA4, KCNA5, and possibly other family 
members as well; channel properties depend on the 
type of alpha subunits that are part of the channel 
(PubMed:12130714). Channel properties are 
modulated by cytoplasmic beta subunits that regulate 
the subcellular location of the alpha subunits and 
promote rapid inactivation (PubMed:12130714). 
Homotetrameric channels display rapid activation and 
slow inactivation (PubMed:8505626, 
PubMed:12130714). May play a role in regulating the 
secretion of insulin in normal pancreatic islets. 
Isoform 2 exhibits a voltage-dependent recovery from 
inactivation and an excessive cumulative inactivation 
(PubMed:11524461). 
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Both KCNH2 q12809 Ion channel Potassium voltage-gated 
channel subfamily H 
member 2 
Pore-forming (alpha) subunit of voltage-gated 
inwardly rectifying potassium channel. Channel 
properties are modulated by cAMP and subunit 
assembly. Mediates the rapidly activating component 
of the delayed rectifying potassium current in heart 
(IKr). Isoforms USO have no channel activity by 
themself, but modulates channel characteristics by 
forming heterotetramers with other isoforms which 
are retained intracellularly and undergo ubiquitin-
dependent degradation. 
STITCH KCNK18 q7z418 Ion channel Potassium channel 
subfamily K member 18 
Outward rectifying potassium channel. Produces 
rapidly activating outward rectifier K+ currents. May 
function as background potassium channel that sets 
the resting membrane potential. Channel activity is 
directly activated by calcium signal. Activated by the 
G(q)-protein coupled receptor pathway. The calcium 
signal robustly activates the channel via calcineurin, 
whereas the anchoring of 14-3-3/YWHAH interferes 
with the return of the current to the resting state 
after activation. Inhibited also by arachidonic acid and 
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other naturally occurring unsaturated free fatty acids. 
Channel activity is also enhanced by volatile 
anesthetics, such as isoflurane. Appears to be the 
primary target of hydroxy-alpha-sanshool, an 
ingredient of Schezuan pepper. May be involved in 
the somatosensory function with special respect to 
pain sensation (By similarity) 
SLAP KCNMA1 q12791 Ion channel Calcium-activated 
potassium channel subunit 
alpha-1 
Potassium channel activated by both membrane 
depolarization or increase in cytosolic Ca2+ that 
mediates export of K+. It is also activated by the 
concentration of cytosolic Mg2+. Its activation 
dampens the excitatory events that elevate the 
cytosolic Ca2+ concentration and/or depolarize the cell 
membrane. It therefore contributes to repolarization 
of the membrane potential. Plays a key role in 
controlling excitability in a number of systems, such as 
regulation of the contraction of smooth muscle, the 
tuning of hair cells in the cochlea, regulation of 
transmitter release, and innate immunity. In smooth 
muscles, its activation by high level of Ca2+, caused by 
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ryanodine receptors in the sarcoplasmic reticulum, 
regulates the membrane potential. In cochlea cells, its 
number and kinetic properties partly determine the 
characteristic frequency of each hair cell and thereby 
helps to establish a tonotopic map. Kinetics of 
KCNMA1 channels are determined by alternative 
splicing, phosphorylation status and its combination 
with modulating beta subunits. Highly sensitive to 
both iberiotoxin (IbTx) and charybdotoxin (CTX). 
SLAP KCNQ1 p51787 Ion channel Potassium voltage-gated 
channel subfamily KQT 
member 1 
Probably important in cardiac repolarization. 
Associates with KCNE1 (MinK) to form the I(Ks) 
cardiac potassium current. Elicits a rapidly activating, 
potassium-selective outward current. Muscarinic 
agonist oxotremorine-M strongly suppresses 
KCNQ1/KCNE1 current in CHO cells in which cloned 
KCNQ1/KCNE1 channels were coexpressed with M1 
muscarinic receptors. May associate also with KCNE3 
(MiRP2) to form the potassium channel that is 
important for cyclic AMP-stimulated intestinal 
secretion of chloride ions, which is reduced in cystic 
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fibrosis and pathologically stimulated in cholera and 
other forms of secretory diarrhea. 
STITCH LEF1 q9uju2 Regulator Lymphoid enhancer-
binding factor 1 
Participates in the Wnt signaling pathway. Activates 
transcription of target genes in the presence of 
CTNNB1 and EP300. May play a role in hair cell 
differentiation and follicle morphogenesis. TLE1, TLE2, 
TLE3 and TLE4 repress transactivation mediated by 
LEF1 and CTNNB1. Regulates T-cell receptor alpha 
enhancer function. Binds DNA in a sequence-specific 
manner. PIAG antagonizes both Wnt-dependent and 
Wnt-independent activation by LEF1 (By similarity). 
Isoform 3 lacks the CTNNB1 interaction domain and 
may be an antagonist for Wnt signaling. Isoform 5 
transcriptionally activates the fibronectin promoter, 
binds to and represses transcription from the E-
cadherin promoter in a CTNNB1-independent 
manner, and is involved in reducing cellular 
aggregation and increasing cell migration of 
pancreatic cancer cells. Isoform 1 transcriptionally 
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activates MYC and CCND1 expression and enhances 
proliferation of pancreatic tumor cells. 
SLAP MAOA p21397 Enzyme Amine oxidase [flavin-
containing] A 
Catalyzes the oxidative deamination of biogenic and 
xenobiotic amines and has important functions in the 
metabolism of neuroactive and vasoactive amines in 
the central nervous system and peripheral tissues. 
MAOA preferentially oxidizes biogenic amines such as 
5-hydroxytryptamine (5-HT), norepinephrine and 
epinephrine. 
Both MAPK1 p28482 Kinase Mitogen-activated protein 
kinase 1 
Serine/threonine kinase which acts as an essential 
component of the MAP kinase signal transduction 
pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 
MAPKs which play an important role in the MAPK/ERK 
cascade. They participate also in a signaling cascade 
initiated by activated KIT and KITLG/SCF. Depending 
on the cellular context, the MAPK/ERK cascade 
mediates diverse biological functions such as cell 
growth, adhesion, survival and differentiation through 
the regulation of transcription, translation, 
cytoskeletal rearrangements. The MAPK/ERK cascade 
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plays also a role in initiation and regulation of meiosis, 
mitosis, and postmitotic functions in differentiated 
cells by phosphorylating a number of transcription 
factors. About 160 substrates have already been 
discovered for ERKs. Many of these substrates are 
localized in the nucleus, and seem to participate in 
the regulation of transcription upon stimulation. 
However, other substrates are found in the cytosol as 
well as in other cellular organelles, and those are 
responsible for processes such as translation, mitosis 
and apoptosis. Moreover, the MAPK/ERK cascade is 
also involved in the regulation of the endosomal 
dynamics, including lysosome processing and 
endosome cycling through the perinuclear recycling 
compartment (PNRC); as well as in the fragmentation 
of the Golgi apparatus during mitosis. The substrates 
include transcription factors (such as ATF2, BCL6, 
ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements 
(such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, 
SORBS3 or STMN1), regulators of apoptosis (such as 
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BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), 
regulators of translation (such as EIF4EBP1) and a 
variety of other signaling-related molecules (like 
ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such 
as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, 
RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, 
MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, 
MAPKAPK3 or MAPKAPK5) and phosphatases (such as 
DUSP1, DUSP4, DUSP6 or DUSP16) are other 
substrates which enable the propagation the 
MAPK/ERK signal to additional cytosolic and nuclear 
targets, thereby extending the specificity of the 
cascade. Mediates phosphorylation of TPR in respons 
to EGF stimulation. May play a role in the spindle 
assembly checkpoint. Phosphorylates PML and 
promotes its interaction with PIN1, leading to PML 
degradation. 
Acts as a transcriptional repressor. Binds to a 
[GC]AAA[GC] consensus sequence. Repress the 
expression of interferon gamma-induced genes. 
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Seems to bind to the promoter of CCL5, DMP1, IFIH1, 
IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and 
STAT1. Transcriptional activity is independent of 
kinase activity. 
SLAP MAPK12 p53778 Kinase Mitogen-activated protein 
kinase 12 
Serine/threonine kinase which acts as an essential 
component of the MAP kinase signal transduction 
pathway. MAPK12 is one of the four p38 MAPKs 
which play an important role in the cascades of 
cellular responses evoked by extracellular stimuli such 
as proinflammatory cytokines or physical stress 
leading to direct activation of transcription factors 
such as ELK1 and ATF2. Accordingly, p38 MAPKs 
phosphorylate a broad range of proteins and it has 
been estimated that they may have approximately 
200 to 300 substrates each. Some of the targets are 
downstream kinases such as MAPKAPK2, which are 
activated through phosphorylation and further 
phosphorylate additional targets. Plays a role in 
myoblast differentiation and also in the down-
regulation of cyclin D1 in response to hypoxia in 
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adrenal cells suggesting MAPK12 may inhibit cell 
proliferation while promoting differentiation. 
Phosphorylates DLG1. Following osmotic shock, 
MAPK12 in the cell nucleus increases its association 
with nuclear DLG1, thereby causing dissociation of 
DLG1-SFPQ complexes. This function is independent 
of its catalytic activity and could affect mRNA 
processing and/or gene transcription to aid cell 
adaptation to osmolarity changes in the environment. 
Regulates UV-induced checkpoint signaling and repair 
of UV-induced DNA damage and G2 arrest after 
gamma-radiation exposure. MAPK12 is involved in the 
regulation of SLC2A1 expression and basal glucose 
uptake in L6 myotubes; and negatively regulates 
SLC2A4 expression and contraction-mediated glucose 
uptake in adult skeletal muscle. C-Jun (JUN) 
phosphorylation is stimulated by MAPK14 and 
inhibited by MAPK12, leading to a distinct AP-1 
regulation. MAPK12 is required for the normal 
kinetochore localization of PLK1, prevents 
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chromosomal instability and supports mitotic cell 
viability. MAPK12-signaling is also positively regulating 
the expansion of transient amplifying myogenic 
precursor cells during muscle growth and 
regeneration. 
Both MAPK14 q16539 Kinase Mitogen-activated protein 
kinase 14 
Serine/threonine kinase which acts as an essential 
component of the MAP kinase signal transduction 
pathway. MAPK14 is one of the four p38 MAPKs 
which play an important role in the cascades of 
cellular responses evoked by extracellular stimuli such 
as proinflammatory cytokines or physical stress 
leading to direct activation of transcription factors. 
Accordingly, p38 MAPKs phosphorylate a broad range 
of proteins and it has been estimated that they may 
have approximately 200 to 300 substrates each. Some 
of the targets are downstream kinases which are 
activated through phosphorylation and further 
phosphorylate additional targets. RPS6KA5/MSK1 and 
RPS6KA4/MSK2 can directly phosphorylate and 
activate transcription factors such as CREB1, ATF1, the 
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NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, 
but can also phosphorylate histone H3 and the 
nucleosomal protein HMGN1. RPS6KA5/MSK1 and 
RPS6KA4/MSK2 play important roles in the rapid 
induction of immediate-early genes in response to 
stress or mitogenic stimuli, either by inducing 
chromatin remodeling or by recruiting the 
transcription machinery. On the other hand, two 
other kinase targets, MAPKAPK2/MK2 and 
MAPKAPK3/MK3, participate in the control of gene 
expression mostly at the post-transcriptional level, by 
phosphorylating ZFP36 (tristetraprolin) and ELAVL1, 
and by regulating EEF2K, which is important for the 
elongation of mRNA during translation. MKNK1/MNK1 
and MKNK2/MNK2, two other kinases activated by 
p38 MAPKs, regulate protein synthesis by 
phosphorylating the initiation factor EIF4E2. MAPK14 
interacts also with casein kinase II, leading to its 
activation through autophosphorylation and further 
phosphorylation of TP53/p53. In the cytoplasm, the 
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p38 MAPK pathway is an important regulator of 
protein turnover. For example, CFLAR is an inhibitor of 
TNF-induced apoptosis whose proteasome-mediated 
degradation is regulated by p38 MAPK 
phosphorylation. In a similar way, MAPK14 
phosphorylates the ubiquitin ligase SIAH2, regulating 
its activity towards EGLN3. MAPK14 may also inhibit 
the lysosomal degradation pathway of autophagy by 
interfering with the intracellular trafficking of the 
transmembrane protein ATG9. Another function of 
MAPK14 is to regulate the endocytosis of membrane 
receptors by different mechanisms that impinge on 
the small GTPase RAB5A. In addition, clathrin-
mediated EGFR internalization induced by 
inflammatory cytokines and UV irradiation depends 
on MAPK14-mediated phosphorylation of EGFR itself 
as well as of RAB5A effectors. Ectodomain shedding of 
transmembrane proteins is regulated by p38 MAPKs 
as well. In response to inflammatory stimuli, p38 
MAPKs phosphorylate the membrane-associated 
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metalloprotease ADAM17. Such phosphorylation is 
required for ADAM17-mediated ectodomain shedding 
of TGF-alpha family ligands, which results in the 
activation of EGFR signaling and cell proliferation. 
Another p38 MAPK substrate is FGFR1. FGFR1 can be 
translocated from the extracellular space into the 
cytosol and nucleus of target cells, and regulates 
processes such as rRNA synthesis and cell growth. 
FGFR1 translocation requires p38 MAPK activation. In 
the nucleus, many transcription factors are 
phosphorylated and activated by p38 MAPKs in 
response to different stimuli. Classical examples 
include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, 
TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are 
emerging as important modulators of gene expression 
by regulating chromatin modifiers and remodelers. 
The promoters of several genes involved in the 
inflammatory response, such as IL6, IL8 and IL12B, 
display a p38 MAPK-dependent enrichment of histone 
H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-
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stimulated myeloid cells. This phosphorylation 
enhances the accessibility of the cryptic NF-kappa-B-
binding sites marking promoters for increased NF-
kappa-B recruitment. Phosphorylates CDC25B and 
CDC25C which is required for binding to 14-3-3 
proteins and leads to initiation of a G2 delay after 
ultraviolet radiation. Phosphorylates TIAR following 
DNA damage, releasing TIAR from GADD45A mRNA 
and preventing mRNA degradation. The p38 MAPKs 
may also have kinase-independent roles, which are 
thought to be due to the binding to targets in the 
absence of phosphorylation. Protein O-Glc-N-
acylation catalyzed by the OGT is regulated by 
MAPK14, and, although OGT does not seem to be 
phosphorylated by MAPK14, their interaction 
increases upon MAPK14 activation induced by glucose 
deprivation. This interaction may regulate OGT 
activity by recruiting it to specific targets such as 
neurofilament H, stimulating its O-Glc-N-acylation. 
Required in mid-fetal development for the growth of 
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embryo-derived blood vessels in the labyrinth layer of 
the placenta. Also plays an essential role in 
developmental and stress-induced erythropoiesis, 
through regulation of EPO gene expression. Isoform 
MXI2 activation is stimulated by mitogens and 
oxidative stress and only poorly phosphorylates ELK1 
and ATF2. Isoform EXIP may play a role in the early 
onset of apoptosis. Phosphorylates S100A9 at 'Thr-
113'. 
SLAP MAPK14 q16539 Kinase Mitogen-activated protein 
kinase 14 
Serine/threonine kinase which acts as an essential 
component of the MAP kinase signal transduction 
pathway. MAPK14 is one of the four p38 MAPKs 
which play an important role in the cascades of 
cellular responses evoked by extracellular stimuli such 
as proinflammatory cytokines or physical stress 
leading to direct activation of transcription factors. 
Accordingly, p38 MAPKs phosphorylate a broad range 
of proteins and it has been estimated that they may 
have approximately 200 to 300 substrates each. Some 
of the targets are downstream kinases which are 
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activated through phosphorylation and further 
phosphorylate additional targets. RPS6KA5/MSK1 and 
RPS6KA4/MSK2 can directly phosphorylate and 
activate transcription factors such as CREB1, ATF1, the 
NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, 
but can also phosphorylate histone H3 and the 
nucleosomal protein HMGN1. RPS6KA5/MSK1 and 
RPS6KA4/MSK2 play important roles in the rapid 
induction of immediate-early genes in response to 
stress or mitogenic stimuli, either by inducing 
chromatin remodeling or by recruiting the 
transcription machinery. On the other hand, two 
other kinase targets, MAPKAPK2/MK2 and 
MAPKAPK3/MK3, participate in the control of gene 
expression mostly at the post-transcriptional level, by 
phosphorylating ZFP36 (tristetraprolin) and ELAVL1, 
and by regulating EEF2K, which is important for the 
elongation of mRNA during translation. MKNK1/MNK1 
and MKNK2/MNK2, two other kinases activated by 
p38 MAPKs, regulate protein synthesis by 
Appendix 2: Consolidated list of proteins 
285 
 
phosphorylating the initiation factor EIF4E2. MAPK14 
interacts also with casein kinase II, leading to its 
activation through autophosphorylation and further 
phosphorylation of TP53/p53. In the cytoplasm, the 
p38 MAPK pathway is an important regulator of 
protein turnover. For example, CFLAR is an inhibitor of 
TNF-induced apoptosis whose proteasome-mediated 
degradation is regulated by p38 MAPK 
phosphorylation. In a similar way, MAPK14 
phosphorylates the ubiquitin ligase SIAH2, regulating 
its activity towards EGLN3. MAPK14 may also inhibit 
the lysosomal degradation pathway of autophagy by 
interfering with the intracellular trafficking of the 
transmembrane protein ATG9. Another function of 
MAPK14 is to regulate the endocytosis of membrane 
receptors by different mechanisms that impinge on 
the small GTPase RAB5A. In addition, clathrin-
mediated EGFR internalization induced by 
inflammatory cytokines and UV irradiation depends 
on MAPK14-mediated phosphorylation of EGFR itself 
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as well as of RAB5A effectors. Ectodomain shedding of 
transmembrane proteins is regulated by p38 MAPKs 
as well. In response to inflammatory stimuli, p38 
MAPKs phosphorylate the membrane-associated 
metalloprotease ADAM17. Such phosphorylation is 
required for ADAM17-mediated ectodomain shedding 
of TGF-alpha family ligands, which results in the 
activation of EGFR signaling and cell proliferation. 
Another p38 MAPK substrate is FGFR1. FGFR1 can be 
translocated from the extracellular space into the 
cytosol and nucleus of target cells, and regulates 
processes such as rRNA synthesis and cell growth. 
FGFR1 translocation requires p38 MAPK activation. In 
the nucleus, many transcription factors are 
phosphorylated and activated by p38 MAPKs in 
response to different stimuli. Classical examples 
include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, 
TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are 
emerging as important modulators of gene expression 
by regulating chromatin modifiers and remodelers. 
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The promoters of several genes involved in the 
inflammatory response, such as IL6, IL8 and IL12B, 
display a p38 MAPK-dependent enrichment of histone 
H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-
stimulated myeloid cells. This phosphorylation 
enhances the accessibility of the cryptic NF-kappa-B-
binding sites marking promoters for increased NF-
kappa-B recruitment. Phosphorylates CDC25B and 
CDC25C which is required for binding to 14-3-3 
proteins and leads to initiation of a G2 delay after 
ultraviolet radiation. Phosphorylates TIAR following 
DNA damage, releasing TIAR from GADD45A mRNA 
and preventing mRNA degradation. The p38 MAPKs 
may also have kinase-independent roles, which are 
thought to be due to the binding to targets in the 
absence of phosphorylation. Protein O-Glc-N-
acylation catalyzed by the OGT is regulated by 
MAPK14, and, although OGT does not seem to be 
phosphorylated by MAPK14, their interaction 
increases upon MAPK14 activation induced by glucose 
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deprivation. This interaction may regulate OGT 
activity by recruiting it to specific targets such as 
neurofilament H, stimulating its O-Glc-N-acylation. 
Required in mid-fetal development for the growth of 
embryo-derived blood vessels in the labyrinth layer of 
the placenta. Also plays an essential role in 
developmental and stress-induced erythropoiesis, 
through regulation of EPO gene expression. Isoform 
MXI2 activation is stimulated by mitogens and 
oxidative stress and only poorly phosphorylates ELK1 
and ATF2. Isoform EXIP may play a role in the early 
onset of apoptosis. Phosphorylates S100A9 at 'Thr-
113'. 
STITCH MAPK3 p27361 Kinase Mitogen-activated protein 
kinase 3 
Serine/threonine kinase which acts as an essential 
component of the MAP kinase signal transduction 
pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 
MAPKs which play an important role in the MAPK/ERK 
cascade. They participate also in a signaling cascade 
initiated by activated KIT and KITLG/SCF. Depending 
on the cellular context, the MAPK/ERK cascade 
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mediates diverse biological functions such as cell 
growth, adhesion, survival and differentiation through 
the regulation of transcription, translation, 
cytoskeletal rearrangements. The MAPK/ERK cascade 
plays also a role in initiation and regulation of meiosis, 
mitosis, and postmitotic functions in differentiated 
cells by phosphorylating a number of transcription 
factors. About 160 substrates have already been 
discovered for ERKs. Many of these substrates are 
localized in the nucleus, and seem to participate in 
the regulation of transcription upon stimulation. 
However, other substrates are found in the cytosol as 
well as in other cellular organelles, and those are 
responsible for processes such as translation, mitosis 
and apoptosis. Moreover, the MAPK/ERK cascade is 
also involved in the regulation of the endosomal 
dynamics, including lysosome processing and 
endosome cycling through the perinuclear recycling 
compartment (PNRC); as well as in the fragmentation 
of the Golgi apparatus during mitosis. The substrates 
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include transcription factors (such as ATF2, BCL6, 
ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements 
(such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, 
SORBS3 or STMN1), regulators of apoptosis (such as 
BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), 
regulators of translation (such as EIF4EBP1) and a 
variety of other signaling-related molecules (like 
ARHGEF2, FRS2 or GRB10). Protein kinases (such as 
RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, 
RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, 
RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or 
MAPKAPK5) and phosphatases (such as DUSP1, 
DUSP4, DUSP6 or DUSP16) are other substrates which 
enable the propagation the MAPK/ERK signal to 
additional cytosolic and nuclear targets, thereby 
extending the specificity of the cascade. 
STITCH MAPK8 p45983 Kinase Mitogen-activated protein 
kinase 8 
Serine/threonine-protein kinase involved in various 
processes such as cell proliferation, differentiation, 
migration, transformation and programmed cell 
death. Extracellular stimuli such as proinflammatory 
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cytokines or physical stress stimulate the stress-
activated protein kinase/c-Jun N-terminal kinase 
(SAP/JNK) signaling pathway. In this cascade, two dual 
specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 
phosphorylate and activate MAPK8/JNK1. In turn, 
MAPK8/JNK1 phosphorylates a number of 
transcription factors, primarily components of AP-1 
such as JUN, JDP2 and ATF2 and thus regulates AP-1 
transcriptional activity. Phosphorylates the replication 
licensing factor CDT1, inhibiting the interaction 
between CDT1 and the histone H4 acetylase HBO1 to 
replication origins. Loss of this interaction abrogates 
the acetylation required for replication initiation. 
Promotes stressed cell apoptosis by phosphorylating 
key regulatory factors including p53/TP53 and Yes-
associates protein YAP1. In T-cells, MAPK8 and 
MAPK9 are required for polarized differentiation of T-
helper cells into Th1 cells. Contributes to the survival 
of erythroid cells by phosphorylating the antagonist of 
cell death BAD upon EPO stimulation. Mediates 
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starvation-induced BCL2 phosphorylation, BCL2 
dissociation from BECN1, and thus activation of 
autophagy. Phosphorylates STMN2 and hence 
regulates microtubule dynamics, controlling neurite 
elongation in cortical neurons. In the developing 
brain, through its cytoplasmic activity on STMN2, 
negatively regulates the rate of exit from multipolar 
stage and of radial migration from the ventricular 
zone. Phosphorylates several other substrates 
including heat shock factor protein 4 (HSF4), the 
deacetylase SIRT1, ELK1, or the E3 ligase ITCH. 
Phosphorylates the CLOCK-ARNTL/BMAL1 
heterodimer and plays a role in the regulation of the 
circadian clock (PubMed:22441692). 
JNK1 isoforms display different binding patterns: 
beta-1 preferentially binds to c-Jun, whereas alpha-1, 
alpha-2, and beta-2 have a similar low level of binding 
to both c-Jun or ATF2. However, there is no 
correlation between binding and phosphorylation, 
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which is achieved at about the same efficiency by all 
isoforms. 
STITCH MC2R q01818 Receptor Adrenocorticotropic 
hormone receptor 
Receptor for corticotropin (ACTH). This receptor is 
mediated by G proteins (G(s)) which activate 
adenylate cyclase (cAMP). 
STITCH MDK p21741 Signalling Midkine Developmentally regulated, secreted growth factor 
homologous to pleiotrophin (PTN), which has heparin 
binding activity. Binds anaplastic lymphoma kinase 
(ALK) which induces ALK activation and subsequent 
phosphorylation of the insulin receptor substrate 
(IRS1), followed by the activation of mitogen-
activated protein kinase (MAPK) and PI3-kinase, and 
the induction of cell proliferation. Involved in 
neointima formation after arterial injury, possibly by 
mediating leukocyte recruitment. Also involved in 
early fetal adrenal gland development (By similarity). 
STITCH MGMT p16455 Immune 
functions 
Methylated-DNA--protein-
cysteine methyltransferase 
Involved in the cellular defense against the biological 
effects of O6-methylguanine (O6-MeG) in DNA. 
Repairs alkylated guanine in DNA by stoichiometrically 
transferring the alkyl group at the O-6 position to a 
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cysteine residue in the enzyme. This is a suicide 
reaction: the enzyme is irreversibly inactivated. 
STITCH MLXIPL q9np71 Regulator Carbohydrate-responsive 
element-binding protein 
Transcriptional repressor. Binds to the canonical and 
non-canonical E box sequences 5'-CACGTG-3' (By 
similarity). 
SLAP MMP1 p03956 Enzyme Interstitial collagenase Cleaves collagens of types I, II, and III at one site in the 
helical domain. Also cleaves collagens of types VII and 
X. In case of HIV infection, interacts and cleaves the 
secreted viral Tat protein, leading to a decrease in 
neuronal Tat's mediated neurotoxicity. 
SLAP MMP11 p24347   Stromelysin-3 May play an important role in the progression of 
epithelial malignancies. 
SLAP MMP13 p45452 Enzyme Collagenase 3 Plays a role in the degradation of extracellular matrix 
proteins including fibrillar collagen, fibronectin, TNC 
and ACAN. Cleaves triple helical collagens, including 
type I, type II and type III collagen, but has the highest 
activity with soluble type II collagen. Can also degrade 
collagen type IV, type XIV and type X. May also 
function by activating or degrading key regulatory 
proteins, such as TGFB1 and CTGF. Plays a role in 
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wound healing, tissue remodeling, cartilage 
degradation, bone development, bone mineralization 
and ossification. Required for normal embryonic bone 
development and ossification. Plays a role in the 
healing of bone fractures via endochondral 
ossification. Plays a role in wound healing, probably 
by a mechanism that involves proteolytic activation of 
TGFB1 and degradation of CTGF. Plays a role in 
keratinocyte migration during wound healing. May 
play a role in cell migration and in tumor cell invasion. 
SLAP MMP14 p50281 Regulator Matrix metalloproteinase-
14 
Seems to specifically activate progelatinase A. May 
thus trigger invasion by tumor cells by activating 
progelatinase A on the tumor cell surface. May be 
involved in actin cytoskeleton reorganization by 
cleaving PTK7. Acts as a positive regulator of cell 
growth and migration via activation of MMP15. 
Involved in the formation of the fibrovascular tissues 
in association with pro-MMP2. 
SLAP MMP2 p08253   72 kDa type IV collagenase Ubiquitinous metalloproteinase that is involved in 
diverse functions such as remodeling of the 
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vasculature, angiogenesis, tissue repair, tumor 
invasion, inflammation, and atherosclerotic plaque 
rupture. As well as degrading extracellular matrix 
proteins, can also act on several nonmatrix proteins 
such as big endothelial 1 and beta-type CGRP 
promoting vasoconstriction. Also cleaves KISS at a Gly-
|-Leu bond. Appears to have a role in myocardial cell 
death pathways. Contributes to myocardial oxidative 
stress by regulating the activity of GSK3beta. Cleaves 
GSK3beta in vitro. Involved in the formation of the 
fibrovascular tissues in association with MMP14.PEX, 
the C-terminal non-catalytic fragment of MMP2, 
posseses anti-angiogenic and anti-tumor properties 
and inhibits cell migration and cell adhesion to FGF2 
and vitronectin. Ligand for integrinv/beta3 on the 
surface of blood vessels.Isoform 2: Mediates the 
proteolysis of CHUK/IKKA and initiates a primary 
innate immune response by inducing mitochondrial-
nuclear stress signaling with activation of the pro-
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inflammatory NF-kappaB, NFAT and IRF 
transcriptional pathways. 
SLAP MMP3 p08254   Stromelysin-1 Can degrade fibronectin, laminin, gelatins of type I, III, 
IV, and V; collagens III, IV, X, and IX, and cartilage 
proteoglycans. Activates procollagenase. 
Both MMP7 p09237   Matrilysin Degrades casein, gelatins of types I, III, IV, and V, and 
fibronectin. Activates procollagenase. 
Both MMP8 p22894   Neutrophil collagenase Can degrade fibrillar type I, II, and III collagens. 
Both MMP9 p14780 Enzyme Matrix metalloproteinase-
9 
May play an essential role in local proteolysis of the 
extracellular matrix and in leukocyte migration. Could 
play a role in bone osteoclastic resorption. Cleaves 
KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V 
collagen into large C-terminal three quarter fragments 
and shorter N-terminal one quarter fragments. 
Degrades fibronectin but not laminin or Pz-peptide 
STITCH MPO p05164 Enzyme Myeloperoxidase Part of the host defense system of 
polymorphonuclear leukocytes. It is responsible for 
microbicidal activity against a wide range of 
organisms. In the stimulated PMN, MPO catalyzes the 
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production of hypohalous acids, primarily 
hypochlorous acid in physiologic situations, and other 
toxic intermediates that greatly enhance PMN 
microbicidal activity. 
STITCH MTHFR p42898 Enzyme Methylenetetrahydrofolate 
reductase 
Catalyzes the conversion of 5,10-
methylenetetrahydrofolate to 5-
methyltetrahydrofolate, a co-substrate for 
homocysteine remethylation to methionine. 
STITCH NAT2 p11245 Enzyme Arylamine N-
acetyltransferase 2 
Participates in the detoxification of a plethora of 
hydrazine and arylamine drugs. Catalyzes the N- or O-
acetylation of various arylamine and heterocyclic 
amine substrates and is able to bioactivate several 
known carcinogens. 
Both NFKB1 p19838 Regulator Nuclear factor NF-kappa-B 
p105 subunit 
NF-kappa-B is a pleiotropic transcription factor 
present in almost all cell types and is the endpoint of 
a series of signal transduction events that are initiated 
by a vast array of stimuli related to many biological 
processes such as inflammation, immunity, 
differentiation, cell growth, tumorigenesis and 
apoptosis. NF-kappa-B is a homo- or heterodimeric 
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complex formed by the Rel-like domain-containing 
proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, 
REL and NFKB2/p52 and the heterodimeric p65-p50 
complex appears to be most abundant one. The 
dimers bind at kappa-B sites in the DNA of their target 
genes and the individual dimers have distinct 
preferences for different kappa-B sites that they can 
bind with distinguishable affinity and specificity. 
Different dimer combinations act as transcriptional 
activators or repressors, respectively. NF-kappa-B is 
controlled by various mechanisms of post-
translational modification and subcellular 
compartmentalization as well as by interactions with 
other cofactors or corepressors. NF-kappa-B 
complexes are held in the cytoplasm in an inactive 
state complexed with members of the NF-kappa-B 
inhibitor (I-kappa-B) family. In a conventional 
activation pathway, I-kappa-B is phosphorylated by I-
kappa-B kinases (IKKs) in response to different 
activators, subsequently degraded thus liberating the 
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active NF-kappa-B complex which translocates to the 
nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-
p50 complexes are transcriptional activators. The NF-
kappa-B p50-p50 homodimer is a transcriptional 
repressor, but can act as a transcriptional activator 
when associated with BCL3. NFKB1 appears to have 
dual functions such as cytoplasmic retention of 
attached NF-kappa-B proteins by p105 and generation 
of p50 by a cotranslational processing. The 
proteasome-mediated process ensures the 
production of both p50 and p105 and preserves their 
independent function, although processing of 
NFKB1/p105 also appears to occur post-
translationally. p50 binds to the kappa-B consensus 
sequence 5'-GGRNNYYCC-3', located in the enhancer 
region of genes involved in immune response and 
acute phase reactions. In a complex with MAP3K8, 
NFKB1/p105 represses MAP3K8-induced MAPK 
signaling; active MAP3K8 is released by proteasome-
dependent degradation of NFKB1/p105. 
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Both NFKB2 q00653 Regulator Nuclear factor NF-kappa-B 
p100 subunit 
NF-kappa-B is a pleiotropic transcription factor 
present in almost all cell types and is the endpoint of 
a series of signal transduction events that are initiated 
by a vast array of stimuli related to many biological 
processes such as inflammation, immunity, 
differentiation, cell growth, tumorigenesis and 
apoptosis. NF-kappa-B is a homo- or heterodimeric 
complex formed by the Rel-like domain-containing 
proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, 
REL and NFKB2/p52. The dimers bind at kappa-B sites 
in the DNA of their target genes and the individual 
dimers have distinct preferences for different kappa-B 
sites that they can bind with distinguishable affinity 
and specificity. Different dimer combinations act as 
transcriptional activators or repressors, respectively. 
NF-kappa-B is controlled by various mechanisms of 
post-translational modification and subcellular 
compartmentalization as well as by interactions with 
other cofactors or corepressors. NF-kappa-B 
complexes are held in the cytoplasm in an inactive 
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state complexed with members of the NF-kappa-B 
inhibitor (I-kappa-B) family. In a conventional 
activation pathway, I-kappa-B is phosphorylated by I-
kappa-B kinases (IKKs) in response to different 
activators, subsequently degraded thus liberating the 
active NF-kappa-B complex which translocates to the 
nucleus. In a non-canonical activation pathway, the 
MAP3K14-activated CHUK/IKKA homodimer 
phosphorylates NFKB2/p100 associated with RelB, 
inducing its proteolytic processing to NFKB2/p52 and 
the formation of NF-kappa-B RelB-p52 complexes. The 
NF-kappa-B heterodimeric RelB-p52 complex is a 
transcriptional activator. The NF-kappa-B p52-p52 
homodimer is a transcriptional repressor. NFKB2 
appears to have dual functions such as cytoplasmic 
retention of attached NF-kappa-B proteins by p100 
and generation of p52 by a cotranslational processing. 
The proteasome-mediated process ensures the 
production of both p52 and p100 and preserves their 
independent function. p52 binds to the kappa-B 
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consensus sequence 5'-GGRNNYYCC-3', located in the 
enhancer region of genes involved in immune 
response and acute phase reactions. p52 and p100 
are respectively the minor and major form; the 
processing of p100 being relatively poor. Isoform p49 
is a subunit of the NF-kappa-B protein complex, which 
stimulates the HIV enhancer in synergy with p65. In 
concert with RELB, regulates the circadian clock by 
repressing the transcriptional activator activity of the 
CLOCK-ARNTL/BMAL1 heterodimer. 
STITCH NFKBIA p25963 Regulator NF-kappa-B inhibitor alpha Inhibits the activity of dimeric NF-kappa-B/REL 
complexes by trapping REL dimers in the cytoplasm 
through masking of their nuclear localization signals. 
On cellular stimulation by immune and 
proinflammatory responses, becomes phosphorylated 
promoting ubiquitination and degradation, enabling 
the dimeric RELA to translocate to the nucleus and 
activate transcription. 
STITCH NFKBIZ q2byh8 Regulator NF-kappa-B inhibitor zeta Involved in regulation of NF-kappa-B transcription 
factor complexes. Inhibits NF-kappa-B activity without 
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affecting its nuclear translocation upon stimulation. 
Inhibits DNA-binding of RELA and NFKB1/p50, and of 
the NF-kappa-B p65-p50 heterodimer and the NF-
kappa-B p50-p50 homodimer. Seems also to activate 
NF-kappa-B-mediated transcription. In vitro, upon 
association with NFKB1/p50 has transcriptional 
activation activity and, together with NFKB1/p50 and 
RELA, is recruited to LCN2 promoters. Promotes 
transcription of LCN2 and DEFB4. Is recruited to IL-6 
promoters and activates IL-6 but decreases TNF-alpha 
production in response to LPS. Seems to be involved 
in the induction of inflammatory genes activated 
through TLR/IL-1 receptor signaling. May promote 
apoptosis (By similarity) 
SLAP NISCH q9y2i1 Receptor Nischarin Acts either as the functional imidazoline-1 receptor 
(I1R) candidate or as a membrane-associated 
mediator of the I1R signaling. Binds numerous 
imidazoline ligands that induces initiation of cell-
signaling cascades triggering to cell survival, growth 
and migration. Its activation by the agonist 
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rilmenidine induces an increase in phosphorylation of 
mitogen-activated protein kinases MAPK1 and MAPK3 
in rostral ventrolateral medulla (RVLM) neurons that 
exhibited rilmenidine-evoked hypotension (By 
similarity). Blocking its activation with efaroxan 
abolished rilmenidine-induced mitogen-activated 
protein kinase phosphorylation in RVLM neurons (By 
similarity). Acts as a modulator of Rac-regulated signal 
transduction pathways (By similarity). Suppresses 
Rac1-stimulated cell migration by interacting with 
PAK1 and inhibiting its kinase activity (By similarity). 
Also blocks Pak-independent Rac signaling by 
interacting with RAC1 and inhibiting Rac1-stimulated 
NF-kB response element and cyclin D1 promoter 
activation (By similarity). Inhibits also LIMK1 kinase 
activity by reducing LIMK1 'Tyr-508' phosphorylation 
(By similarity). Inhibits Rac-induced cell migration and 
invasion in breast and colon epithelial cells (By 
similarity). Inhibits lamellipodia formation, when 
overexpressed (By similarity). Plays a role in 
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protection against apoptosis. Involved in association 
with IRS4 in the enhancement of insulin activation of 
MAPK1 and MAPK3. When overexpressed, induces a 
redistribution of cell surface ITGA5 integrin to 
intracellular endosomal structures. 
STITCH NOS1 p29475 Enzyme Nitric oxide synthase, brain Produces nitric oxide (NO) which is a messenger 
molecule with diverse functions throughout the body. 
In the brain and peripheral nervous system, NO 
displays many properties of a neurotransmitter. 
Probably has nitrosylase activity and mediates 
cysteine S-nitrosylation of cytoplasmic target proteins 
such SRR. 
STITCH NOS2 p35228 Enzyme Nitric oxide synthase, 
inducible 
Produces nitric oxide (NO) which is a messenger 
molecule with diverse functions throughout the body. 
In macrophages, NO mediates tumoricidal and 
bactericidal actions. Also has nitrosylase activity and 
mediates cysteine S-nitrosylation of cytoplasmic 
target proteins such COX2. 
STITCH NOS3 p60323 Regulator Nanos homolog 3 Plays a role in the maintenance of the 
undifferentiated state of germ cells regulating the 
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spermatogonia cell cycle and inducing a prolonged 
transit in G1 phase. Affects cell proliferation probably 
by repressing translation of specific mRNAs. Maintains 
the germ cell lineage by suppressing both Bax-
dependent and -independent apoptotic pathways. 
Essential in the early stage embryo to protect the 
migrating primordial germ cells (PGCs) from 
apoptosis. 
Both NR1I2 o75469 Regulator Nuclear receptor subfamily 
1 group I member 2 
Nuclear receptor that binds and is activated by variety 
of endogenous and xenobiotic compounds. 
Transcription factor that activates the transcription of 
multiple genes involved in the metabolism and 
secretion of potentially harmful xenobiotics, drugs 
and endogenous compounds. Activated by the 
antibiotic rifampicin and various plant metabolites, 
such as hyperforin, guggulipid, colupulone, and 
isoflavones. Response to specific ligands is species-
specific. Activated by naturally occurring steroids, 
such as pregnenolone and progesterone. Binds to a 
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response element in the promoters of the CYP3A4 
and ABCB1/MDR1 genes. 
Both NR1I3 q14994 Enzyme Nuclear receptor subfamily 
1 group I member 3 
Binds and transactivates the retinoic acid response 
elements that control expression of the retinoic acid 
receptor beta 2 and alcohol dehydrogenase 3 genes. 
Transactivates both the phenobarbital responsive 
element module of the human CYP2B6 gene and the 
CYP3A4 xenobiotic response element. 
Both NR3C1 p04150 Receptor Glucocorticoid receptor Receptor for glucocorticoids (GC). Has a dual mode of 
action: as a transcription factor that binds to 
glucocorticoid response elements (GRE), both for 
nuclear and mitochondrial DNA, and as a modulator 
of other transcription factors. Affects inflammatory 
responses, cellular proliferation and differentiation in 
target tissues. Could act as a coactivator for STAT5-
dependent transcription upon growth hormone (GH) 
stimulation and could reveal an essential role of 
hepatic GR in the control of body growth. Involved in 
chromatin remodeling. May play a negative role in 
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adipogenesis through the regulation of lipolytic and 
antilipogenic genes expression. 
SLAP NR3C2 p08235 Receptor Mineralocorticoid receptor Receptor for both mineralocorticoids (MC) such as 
aldosterone and glucocorticoids (GC) such as 
corticosterone or cortisol. Binds to mineralocorticoid 
response elements (MRE) and transactivates target 
genes. The effect of MC is to increase ion and water 
transport and thus raise extracellular fluid volume and 
blood pressure and lower potassium levels 
STITCH ODC1 p11926 Enzyme Ornithine decarboxylase Key enzyme of polyamine biosynthesis that converts 
ornithine into putrescine, which is the precursor for 
the polyamines, spermidine and spermine 
SLAP OPRK1 p41145 Receptor Kappa-type opioid receptor G-protein coupled opioid receptor that functions as 
receptor for endogenous alpha-neoendorphins and 
dynorphins, but has low affinity for beta-endorphins. 
Also functions as receptor for various synthetic 
opioids and for the psychoactive diterpene salvinorin 
A. Ligand binding causes a conformation change that 
triggers signaling via guanine nucleotide-binding 
proteins (G proteins) and modulates the activity of 
Appendix 2: Consolidated list of proteins 
310 
 
down-stream effectors, such as adenylate cyclase. 
Signaling leads to the inhibition of adenylate cyclase 
activity. Inhibits neurotransmitter release by reducing 
calcium ion currents and increasing potassium ion 
conductance. Plays a role in the perception of pain. 
Plays a role in mediating reduced physical activity 
upon treatment with synthetic opioids. Plays a role in 
the regulation of salivation in response to synthetic 
opioids. May play a role in arousal and regulation of 
autonomic and neuroendocrine functions. 
SLAP OPRM1 p35372 Receptor Mu-type opioid receptor Receptor for endogenous opioids such as beta-
endorphin and endomorphin. Receptor for natural 
and synthetic opioids including morphine, heroin, 
DAMGO, fentanyl, etorphine, buprenorphin and 
methadone. Agonist binding to the receptor induces 
coupling to an inactive GDP-bound heterotrimeric G-
protein complex and subsequent exchange of GDP for 
GTP in the G-protein alpha subunit leading to 
dissociation of the G-protein complex with the free 
GTP-bound G-protein alpha and the G-protein beta-
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gamma dimer activating downstream cellular 
effectors. The agonist- and cell type-specific activity is 
predominantly coupled to pertussis toxin-sensitive 
G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 
and GNAO1 isoforms Alpha-1 and Alpha-2, and to a 
lesser extend to pertussis toxin-insensitive G alpha 
proteins GNAZ and GNA15. They mediate an array of 
downstream cellular responses, including inhibition of 
adenylate cyclase activity and both N-type and L-type 
calcium channels, activation of inward rectifying 
potassium channels, mitogen-activated protein kinase 
(MAPK), phospholipase C (PLC), 
phosphoinositide/protein kinase (PKC), 
phosphoinositide 3-kinase (PI3K) and regulation of 
NF-kappa-B. Also couples to adenylate cyclase 
stimulatory G alpha proteins. The selective temporal 
coupling to G-proteins and subsequent signaling can 
be regulated by RGSZ proteins, such as RGS9, RGS17 
and RGS4. Phosphorylation by members of the GPRK 
subfamily of Ser/Thr protein kinases and association 
Appendix 2: Consolidated list of proteins 
312 
 
with beta-arrestins is involved in short-term receptor 
desensitization. Beta-arrestins associate with the 
GPRK-phosphorylated receptor and uncouple it from 
the G-protein thus terminating signal transduction. 
The phosphorylated receptor is internalized through 
endocytosis via clathrin-coated pits which involves 
beta-arrestins. The activation of the ERK pathway 
occurs either in a G-protein-dependent or a beta-
arrestin-dependent manner and is regulated by 
agonist-specific receptor phosphorylation. Acts as a 
class A G-protein coupled receptor (GPCR) which 
dissociates from beta-arrestin at or near the plasma 
membrane and undergoes rapid recycling. Receptor 
down-regulation pathways are varying with the 
agonist and occur dependent or independent of G-
protein coupling. Endogenous ligands induce rapid 
desensitization, endocytosis and recycling whereas 
morphine induces only low desensitization and 
endocytosis. Heterooligomerization with other GPCRs 
can modulate agonist binding, signaling and 
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trafficking properties. Involved in neurogenesis. 
Isoform 12 couples to GNAS and is proposed to be 
involved in excitatory effects. Isoform 16 and isoform 
17 do not bind agonists but may act through 
oligomerization with binding-competent OPRM1 
isoforms and reduce their ligand binding activity. 
STITCH ORM1 p02763 Transport Alpha-1-acid glycoprotein 1 Functions as transport protein in the blood stream. 
Binds various ligands in the interior of its beta-barrel 
domain. Also binds synthetic drugs and influences 
their distribution and availability in the body. Appears 
to function in modulating the activity of the immune 
system during the acute-phase reaction. 
STITCH ORM2 p19652 Transport Alpha-1-acid glycoprotein 2 Functions as transport protein in the blood stream. 
Binds various hydrophobic ligands in the interior of its 
beta-barrel domain. Also binds synthetic drugs and 
influences their distribution and availability. Appears 
to function in modulating the activity of the immune 
system during the acute-phase reaction 
STITCH PARP1 p09874 Enzyme Poly [ADP-ribose] 
polymerase 1 
Involved in the base excision repair (BER) pathway, by 
catalyzing the poly(ADP-ribosyl)ation of a limited 
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number of acceptor proteins involved in chromatin 
architecture and in DNA metabolism. This 
modification follows DNA damages and appears as an 
obligatory step in a detection/signaling pathway 
leading to the reparation of DNA strand breaks. 
Mediates the poly(ADP-ribosyl)ation of APLF and 
CHFR. Positively regulates the transcription of MTUS1 
and negatively regulates the transcription of 
MTUS2/TIP150. With EEF1A1 and TXK, forms a 
complex that acts as a T-helper 1 (Th1) cell-specific 
transcription factor and binds the promoter of IFN-
gamma to directly regulate its transcription, and is 
thus involved importantly in Th1 cytokine production. 
Required for PARP9 and DTX3L recruitment to DNA 
damage sites. PARP1-dependent PARP9-DTX3L-
mediated ubiquitination promotes the rapid and 
specific recruitment of 53BP1/TP53BP1, 
UIMC1/RAP80, and BRCA1 to DNA damage sites. 
STITCH PCNA p12004 Regulator Proliferating cell nuclear 
antigen 
Auxiliary protein of DNA polymerase delta and is 
involved in the control of eukaryotic DNA replication 
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by increasing the polymerase's processibility during 
elongation of the leading strand. Induces a robust 
stimulatory effect on the 3'-5' exonuclease and 3'-
phosphodiesterase, but not apurinic-apyrimidinic (AP) 
endonuclease, APEX2 activities. Has to be loaded onto 
DNA in order to be able to stimulate APEX2. Plays a 
key role in DNA damage response (DDR) by being 
conveniently positioned at the replication fork to 
coordinate DNA replication with DNA repair and DNA 
damage tolerance pathways. Acts as a loading 
platform to recruit DDR proteins that allow 
completion of DNA replication after DNA damage and 
promote postreplication repair: Monoubiquitinated 
PCNA leads to recruitment of translesion (TLS) 
polymerases, while 'Lys-63'-linked polyubiquitination 
of PCNA is involved in error-free pathway and 
employs recombination mechanisms to synthesize 
across the lesion. 
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Both PDPK1 o15530 Kinase 3-phosphoinositide-
dependent protein kinase 
1 
Serine/threonine kinase which acts as a master 
kinase, phosphorylating and activating a subgroup of 
the AGC family of protein kinases. Its targets include: 
protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), 
p70 ribosomal protein S6 kinase (RPS6KB1), p90 
ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and 
RPS6KA3), cyclic AMP-dependent protein kinase 
(PRKACA), protein kinase C (PRKCD and PRKCZ), serum 
and glucocorticoid-inducible kinase (SGK1, SGK2 and 
SGK3), p21-activated kinase-1 (PAK1), protein kinase 
PKN (PKN1 and PKN2). Plays a central role in the 
transduction of signals from insulin by providing the 
activating phosphorylation to PKB/AKT1, thus 
propagating the signal to downstream targets 
controlling cell proliferation and survival, as well as 
glucose and amino acid uptake and storage. 
Negatively regulates the TGF-beta-induced signaling 
by: modulating the association of SMAD3 and SMAD7 
with TGF-beta receptor, phosphorylating SMAD2, 
SMAD3, SMAD4 and SMAD7, preventing the nuclear 
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translocation of SMAD3 and SMAD4 and the 
translocation of SMAD7 from the nucleus to the 
cytoplasm in response to TGF-beta. Activates PPARG 
transcriptional activity and promotes adipocyte 
differentiation. Activates the NF-kappa-B pathway via 
phosphorylation of IKKB. The tyrosine phosphorylated 
form is crucial for the regulation of focal adhesions by 
angiotensin II. Controls proliferation, survival, and 
growth of developing pancreatic cells. Participates in 
the regulation of Ca2+ entry and Ca2+-activated K+ 
channels of mast cells. Essential for the motility of 
vascular endothelial cells (ECs) and is involved in the 
regulation of their chemotaxis. Plays a critical role in 
cardiac homeostasis by serving as a dual effector for 
cell survival and beta-adrenergic response. Plays an 
important role during thymocyte development by 
regulating the expression of key nutrient receptors on 
the surface of pre-T cells and mediating Notch-
induced cell growth and proliferative responses. 
Provides negative feedback inhibition to toll-like 
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receptor-mediated NF-kappa-B activation in 
macrophages. Isoform 3 is catalytically inactive. 
SLAP PGR uncertain       
SLAP PLA2G4A p47712 Enzyme Cytosolic phospholipase A2 Selectively hydrolyzes arachidonyl phospholipids in 
the sn-2 position releasing arachidonic acid. Together 
with its lysophospholipid activity, it is implicated in 
the initiation of the inflammatory response. 
STITCH PLAU p00749 Enzyme Urokinase-type 
plasminogen activator 
Specifically cleaves the zymogen plasminogen to form 
the active enzyme plasmin. 
SLAP PNMT p11086 Enzyme Phenylethanolamine N-
methyltransferase 
Converts noradrenaline to adrenaline. 
STITCH PNP p00491 Enzyme Purine nucleoside 
phosphorylase 
The purine nucleoside phosphorylases catalyze the 
phosphorolytic breakdown of the N-glycosidic bond in 
the beta-(deoxy)ribonucleoside molecules, with the 
formation of the corresponding free purine bases and 
pentose-1-phosphate 
STITCH POMC p01189 Signalling Pro-opiomelanocortin ACTH stimulates the adrenal glands to release 
cortisol. 
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MSH (melanocyte-stimulating hormone) increases the 
pigmentation of skin by increasing melanin 
production in melanocytes. 
Beta-endorphin and Met-enkephalin are endogenous 
opiates. 
SLAP PPARA q07869 Regulator Peroxisome proliferator-
activated receptor alpha 
Ligand-activated transcription factor. Key regulator of 
lipid metabolism. Activated by the endogenous ligand 
1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine 
(16:0/18:1-GPC). Activated by oleylethanolamide, a 
naturally occurring lipid that regulates satiety. 
Receptor for peroxisome proliferators such as 
hypolipidemic drugs and fatty acids. Regulates the 
peroxisomal beta-oxidation pathway of fatty acids. 
Functions as transcription activator for the ACOX1 and 
P450 genes. Transactivation activity requires 
heterodimerization with RXRA and is antagonized by 
NR2C2. May be required for the propagation of clock 
information to metabolic pathways regulated by 
PER2. 
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Both PPARD q03181 Receptor Peroxisome proliferator-
activated receptor delta 
Ligand-activated transcription factor. Receptor that 
binds peroxisome proliferators such as hypolipidemic 
drugs and fatty acids. Has a preference for poly-
unsaturated fatty acids, such as gamma-linoleic acid 
and eicosapentanoic acid. Once activated by a ligand, 
the receptor binds to promoter elements of target 
genes. Regulates the peroxisomal beta-oxidation 
pathway of fatty acids. Functions as transcription 
activator for the acyl-CoA oxidase gene. Decreases 
expression of NPC1L1 once activated by a ligand. 
Both PPARG p37231 Regulator Peroxisome proliferator-
activated receptor gamma 
Nuclear receptor that binds peroxisome proliferators 
such as hypolipidemic drugs and fatty acids. Once 
activated by a ligand, the nuclear receptor binds to 
DNA specific PPAR response elements (PPRE) and 
modulates the transcription of its target genes, such 
as acyl-CoA oxidase. It therefore controls the 
peroxisomal beta-oxidation pathway of fatty acids. 
Key regulator of adipocyte differentiation and glucose 
homeostasis. ARF6 acts as a key regulator of the 
tissue-specific adipocyte P2 (aP2) enhancer. Acts as a 
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critical regulator of gut homeostasis by suppressing 
NF-kappa-B-mediated proinflammatory responses. 
Plays a role in the regulation of cardiovascular 
circadian rhythms by regulating the transcription of 
ARNTL/BMAL1 in the blood vessels (By similarity) 
STITCH PPIG q13427 Regulator Peptidyl-prolyl cis-trans 
isomerase G 
PPIases accelerate the folding of proteins. It catalyzes 
the cis-trans isomerization of proline imidic peptide 
bonds in oligopeptides. May be implicated in the 
folding, transport, and assembly of proteins. May play 
an important role in the regulation of pre-mRNA 
splicing. 
STITCH PRB3 q04118 Receptor Basic salivary proline-rich 
protein 3 
Acts as a receptor for the Gram-negative bacterium 
F.nucleatum. 
SLAP PRKACA p17612 Kinase cAMP-dependent protein 
kinase catalytic subunit 
alpha 
Phosphorylates a large number of substrates in the 
cytoplasm and the nucleus. Regulates the abundance 
of compartmentalized pools of its regulatory subunits 
through phosphorylation of PJA2 which binds and 
ubiquitinates these subunits, leading to their 
subsequent proteolysis. Phosphorylates CDC25B, 
ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA 
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and VASP. RORA is activated by phosphorylation. 
Required for glucose-mediated adipogenic 
differentiation increase and osteogenic differentiation 
inhibition from osteoblasts. Involved in the regulation 
of platelets in response to thrombin and collagen; 
maintains circulating platelets in a resting state by 
phosphorylating proteins in numerous platelet 
inhibitory pathways when in complex with NF-kappa-
B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), 
but thrombin and collagen disrupt these complexes 
and free active PRKACA stimulates platelets and leads 
to platelet aggregation by phosphorylating VASP. 
Prevents the antiproliferative and anti-invasive effects 
of alpha-difluoromethylornithine in breast cancer cells 
when activated. RYR2 channel activity is potentiated 
by phosphorylation in presence of luminal Ca2+, 
leading to reduced amplitude and increased 
frequency of store overload-induced Ca2+ release 
(SOICR) characterized by an increased rate of Ca2+ 
release and propagation velocity of spontaneous Ca2+ 
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waves, despite reduced wave amplitude and resting 
cytosolic Ca2+. PSMC5/RPT6 activation by 
phosphorylation stimulates proteasome. Negatively 
regulates tight junctions (TJs) in ovarian cancer cells 
via CLDN3 phosphorylation. NFKB1 phosphorylation 
promotes NF-kappa-B p50-p50 DNA binding. Involved 
in embryonic development by down-regulating the 
Hedgehog (Hh) signaling pathway that determines 
embryo pattern formation and morphogenesis. 
Prevents meiosis resumption in prophase-arrested 
oocytes via CDC25B inactivation by phosphorylation. 
May also regulate rapid eye movement (REM) sleep in 
the pedunculopontine tegmental (PPT). 
Phosphorylates APOBEC3G and AICDA. Isoform 2 
phosphorylates and activates ABL1 in sperm flagellum 
to promote spermatozoa capacitation. 
STITCH PTEN p60484 Enzyme Phosphatidylinositol 3,4,5-
trisphosphate 3-
phosphatase and dual-
Tumor suppressor. Acts as a dual-specificity protein 
phosphatase, dephosphorylating tyrosine-, serine- 
and threonine-phosphorylated proteins. Also acts as a 
lipid phosphatase, removing the phosphate in the D3 
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specificity protein 
phosphatase 
position of the inositol ring from phosphatidylinositol 
3,4,5-trisphosphate, phosphatidylinositol 3,4-
diphosphate, phosphatidylinositol 3-phosphate and 
inositol 1,3,4,5-tetrakisphosphate with order of 
substrate preference in vitro PtdIns(3,4,5)P3 > 
PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid 
phosphatase activity is critical for its tumor 
suppressor function. Antagonizes the PI3K-AKT/PKB 
signaling pathway by dephosphorylating 
phosphoinositides and thereby modulating cell cycle 
progression and cell survival. The unphosphorylated 
form cooperates with AIP1 to suppress AKT1 
activation. Dephosphorylates tyrosine-
phosphorylated focal adhesion kinase and inhibits cell 
migration and integrin-mediated cell spreading and 
focal adhesion formation. Plays a role as a key 
modulator of the AKT-mTOR signaling pathway 
controlling the tempo of the process of newborn 
neurons integration during adult neurogenesis, 
including correct neuron positioning, dendritic 
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development and synapse formation. May be a 
negative regulator of insulin signaling and glucose 
metabolism in adipose tissue. The nuclear 
monoubiquitinated form possesses greater apoptotic 
potential, whereas the cytoplasmic nonubiquitinated 
form induces less tumor suppressive ability. In motile 
cells, suppresses the formation of lateral pseudopods 
and thereby promotes cell polarization and directed 
movement. 
Isoform alpha: Functional kinase, like isoform 1 it 
antagonizes the PI3K-AKT/PKB signaling pathway. 
Plays a role in mitochondrial energetic metabolism by 
promoting COX activity and ATP production, via 
collaboration with isoform 1 in increasing protein 
levels of PINK1. 
SLAP PTGER1 p34995 Receptor Prostaglandin E2 receptor 
EP1 subtype 
Receptor for prostaglandin E2 (PGE2). The activity of 
this receptor is mediated by G(q) proteins which 
activate a phosphatidylinositol-calcium second 
messenger system. May play a role as an important 
modulator of renal function. Implicated the smooth 
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muscle contractile response to PGE2 in various 
tissues. 
SLAP PTGER2 p43116 Receptor Prostaglandin E2 receptor 
EP2 subtype 
Receptor for prostaglandin E2 (PGE2). The activity of 
this receptor is mediated by G(s) proteins that 
stimulate adenylate cyclase. The subsequent raise in 
intracellular cAMP is responsible for the relaxing 
effect of this receptor on smooth muscle. 
SLAP PTGER3 p43115 Receptor Prostaglandin E2 receptor 
EP3 subtype 
Receptor for prostaglandin E2 (PGE2); the EP3 
receptor may be involved in inhibition of gastric acid 
secretion, modulation of neurotransmitter release in 
central and peripheral neurons, inhibition of sodium 
and water reabsorption in kidney tubulus and 
contraction in uterine smooth muscle. The activity of 
this receptor can couple to both the inhibition of 
adenylate cyclase mediated by G-I proteins, and to an 
elevation of intracellular calcium. The various 
isoforms have identical ligand binding properties but 
can interact with different second messenger systems 
(By similarity). 
Appendix 2: Consolidated list of proteins 
327 
 
Both PTGER4 p35408 Receptor Prostaglandin E2 receptor 
EP4 subtype 
Receptor for prostaglandin E2 (PGE2). The activity of 
this receptor is mediated by G(s) proteins that 
stimulate adenylate cyclase. Has a relaxing effect on 
smooth muscle. May play an important role in 
regulating renal hemodynamics, intestinal epithelial 
transport, adrenal aldosterone secretion, and uterine 
function. 
Both PTGS1 p23219 Enzyme Prostaglandin G/H 
synthase 1 
Converts arachidonate to prostaglandin H2 (PGH2), a 
committed step in prostanoid synthesis. Involved in 
the constitutive production of prostanoids in 
particular in the stomach and platelets. In gastric 
epithelial cells, it is a key step in the generation of 
prostaglandins, such as prostaglandin E2 (PGE2), 
which plays an important role in cytoprotection. In 
platelets, it is involved in the generation of 
thromboxane A2 (TXA2), which promotes platelet 
activation and aggregation, vasoconstriction and 
proliferation of vascular smooth muscle cells. 
Both PTGS2 p35354 Enzyme Prostaglandin G/H 
synthase 2 
Converts arachidonate to prostaglandin H2 (PGH2), a 
committed step in prostanoid synthesis. Constitutively 
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expressed in some tissues in physiological conditions, 
such as the endothelium, kidney and brain, and in 
pathological conditions, such as in cancer. PTGS2 is 
responsible for production of inflammatory 
prostaglandins. Up-regulation of PTGS2 is also 
associated with increased cell adhesion, phenotypic 
changes, resistance to apoptosis and tumor 
angiogenesis. In cancer cells, PTGS2 is a key step in 
the production of prostaglandin E2 (PGE2), which 
plays important roles in modulating motility, 
proliferation and resistance to apoptosis. 
STITCH PTH p01270 Hormone Parathyroid hormone PTH elevates calcium level by dissolving the salts in 
bone and preventing their renal excretion. Stimulates 
[1-14C]-2-deoxy-D-glucose (2DG) transport and 
glycogen synthesis in osteoblastic cells. 
STITCH RALBP1 q15311 Structural RalA-binding protein 1 Can activate specifically hydrolysis of GTP bound to 
RAC1 and CDC42, but not RALA. Mediates ATP-
dependent transport of S-(2,4-dinitrophenyl)-
glutathione (DNP-SG) and doxorubicin (DOX) and is 
the major ATP-dependent transporter of glutathione 
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conjugates of electrophiles (GS-E) and DOX in 
erythrocytes. Can catalyze transport of glutathione 
conjugates and xenobiotics, and may contribute to 
the multidrug resistance phenomenon. Serves as a 
scaffold protein that brings together proteins forming 
an endocytotic complex during interphase and also 
with CDK1 to switch off endocytosis, One of its 
substrates would be EPN1/Epsin. 
STITCH RELA q04206 Regulator Transcription factor p65 NF-kappa-B is a pleiotropic transcription factor 
present in almost all cell types and is the endpoint of 
a series of signal transduction events that are initiated 
by a vast array of stimuli related to many biological 
processes such as inflammation, immunity, 
differentiation, cell growth, tumorigenesis and 
apoptosis. NF-kappa-B is a homo- or heterodimeric 
complex formed by the Rel-like domain-containing 
proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, 
REL and NFKB2/p52 and the heterodimeric p65-p50 
complex appears to be most abundant one. The 
dimers bind at kappa-B sites in the DNA of their target 
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genes and the individual dimers have distinct 
preferences for different kappa-B sites that they can 
bind with distinguishable affinity and specificity. 
Different dimer combinations act as transcriptional 
activators or repressors, respectively. NF-kappa-B is 
controlled by various mechanisms of post-
translational modification and subcellular 
compartmentalization as well as by interactions with 
other cofactors or corepressors. NF-kappa-B 
complexes are held in the cytoplasm in an inactive 
state complexed with members of the NF-kappa-B 
inhibitor (I-kappa-B) family. In a conventional 
activation pathway, I-kappa-B is phosphorylated by I-
kappa-B kinases (IKKs) in response to different 
activators, subsequently degraded thus liberating the 
active NF-kappa-B complex which translocates to the 
nucleus. NF-kappa-B heterodimeric p65-p50 and p65-
c-Rel complexes are transcriptional activators. The NF-
kappa-B p65-p65 complex appears to be involved in 
invasin-mediated activation of IL-8 expression. The 
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inhibitory effect of I-kappa-B upon NF-kappa-B the 
cytoplasm is exerted primarily through the interaction 
with p65. p65 shows a weak DNA-binding site which 
could contribute directly to DNA binding in the NF-
kappa-B complex. Associates with chromatin at the 
NF-kappa-B promoter region via association with 
DDX1. Essential for cytokine gene expression in T-cells 
(PubMed:15790681). 
STITCH REN p00797 Enzyme Renin Renin is a highly specific endopeptidase, whose only 
known function is to generate angiotensin I from 
angiotensinogen in the plasma, initiating a cascade of 
reactions that produce an elevation of blood pressure 
and increased sodium retention by the kidney. 
SLAP ROCK1 q13464 Kinase Rho-associated protein 
kinase 1 
Protein kinase which is a key regulator of actin 
cytoskeleton and cell polarity. Involved in regulation 
of smooth muscle contraction, actin cytoskeleton 
organization, stress fiber and focal adhesion 
formation, neurite retraction, cell adhesion and 
motility via phosphorylation of DAPK3, GFAP, LIMK1, 
LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. 
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Phosphorylates FHOD1 and acts synergistically with it 
to promote SRC-dependent non-apoptotic plasma 
membrane blebbing. Phosphorylates JIP3 and 
regulates the recruitment of JNK to JIP3 upon UVB-
induced stress. Acts as a suppressor of inflammatory 
cell migration by regulating PTEN phosphorylation and 
stability. Acts as a negative regulator of VEGF-induced 
angiogenic endothelial cell activation. Required for 
centrosome positioning and centrosome-dependent 
exit from mitosis. Plays a role in terminal erythroid 
differentiation. May regulate closure of the eyelids 
and ventral body wall by inducing the assembly of 
actomyosin bundles. Promotes keratinocyte terminal 
differentiation. Involved in osteoblast compaction 
through the fibronectin fibrillogenesis cell-mediated 
matrix assembly process, essential for osteoblast 
mineralization. 
SLAP ROCK2 o75116 Kinase Rho-associated protein 
kinase 2 
Protein kinase which is a key regulator of actin 
cytoskeleton and cell polarity. Involved in regulation 
of smooth muscle contraction, actin cytoskeleton 
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organization, stress fiber and focal adhesion 
formation, neurite retraction, cell adhesion and 
motility via phosphorylation of ADD1, BRCA2, CNN1, 
EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, 
PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. 
Acts as a negative regulator of VEGF-induced 
angiogenic endothelial cell activation. Positively 
regulates the activation of p42/MAPK1-p44/MAPK3 
and of p90RSK/RPS6KA1 during myogenic 
differentiation. Plays an important role in the timely 
initiation of centrosome duplication. Inhibits 
keratinocyte terminal differentiation. May regulate 
closure of the eyelids and ventral body wall through 
organization of actomyosin bundles. Plays a critical 
role in the regulation of spine and synaptic properties 
in the hippocampus. Plays an important role in 
generating the circadian rhythm of the aortic 
myofilament Ca2+ sensitivity and vascular contractility 
by modulating the myosin light chain 
phosphorylation. 
Appendix 2: Consolidated list of proteins 
334 
 
STITCH S100A4 p26447   Protein S100-A4 calcium ion binding; RAGE receptor binding; poly(A) 
RNA binding 
STITCH SAT1 p21673 Enzyme Diamine acetyltransferase 
1 
Enzyme which catalyzes the acetylation of 
polyamines. Substrate specificity: norspermidine = 
spermidine >> spermine > N(1)-acetylspermine > 
putrescine. This highly regulated enzyme allows a fine 
attenuation of the intracellular concentration of 
polyamines. Also involved in the regulation of 
polyamine transport out of cells. Acts on 1,3-
diaminopropane, 1,5-diaminopentane, putrescine, 
spermidine (forming N(1)- and N(8)-
acetylspermidine), spermine, N(1)-acetylspermidine 
and N(8)-acetylspermidine. 
Both SCN10A q9y5y9 Ion channel Sodium channel protein 
type 10 subunit alpha 
Tetrodotoxin-resistant channel that mediates the 
voltage-dependent sodium ion permeability of 
excitable membranes. Assuming opened or closed 
conformations in response to the voltage difference 
across the membrane, the protein forms a sodium-
selective channel through which sodium ions may 
pass in accordance with their electrochemical 
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gradient. Plays a role in neuropathic pain 
mechanisms. 
Both SCN11A q9ui33 Ion channel Sodium channel protein 
type 11 subunit alpha 
This protein mediates the voltage-dependent sodium 
ion permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
forms a sodium-selective channel through which 
sodium ions may pass in accordance with their 
electrochemical gradient. It is a tetrodotoxin-resistant 
sodium channel isoform. Also involved, with the 
contribution of the receptor tyrosine kinase NTRK2, in 
rapid BDNF-evoked neuronal depolarization. 
Both SCN1A p35498 Ion channel Sodium channel protein 
type 1 subunit alpha 
Mediates the voltage-dependent sodium ion 
permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
forms a sodium-selective channel through which Na+ 
ions may pass in accordance with their 
electrochemical gradient. 
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Both SCN1B q079699 Ion channel Sodium channel subunit 
beta-1 
Crucial in the assembly, expression, and functional 
modulation of the heterotrimeric complex of the 
sodium channel. The subunit beta-1 can modulate 
multiple alpha subunit isoforms from brain, skeletal 
muscle, and heart. Its association with neurofascin 
may target the sodium channels to the nodes of 
Ranvier of developing axons and retain these channels 
at the nodes in mature myelinated axons. 
Isoform 2: Cell adhesion molecule that plays a critical 
role in neuronal migration and pathfinding during 
brain development. Stimulates neurite outgrowth. 
Both SCN2A q99250 Ion channel Sodium channel protein 
type 2 subunit alpha 
Mediates the voltage-dependent sodium ion 
permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
forms a sodium-selective channel through which Na+ 
ions may pass in accordance with their 
electrochemical gradient. 
Both SCN2B o60939 Ion channel Sodium channel subunit 
beta-2 
Crucial in the assembly, expression, and functional 
modulation of the heterotrimeric complex of the 
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sodium channel. The subunit beta-2 causes an 
increase in the plasma membrane surface area and in 
its folding into microvilli. Interacts with TNR may play 
a crucial role in clustering and regulation of activity of 
sodium channels at nodes of Ranvier (By similarity). 
Both SCN3A q9ny46 Ion channel Sodium channel protein 
type 3 subunit alpha 
Mediates the voltage-dependent sodium ion 
permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
forms a sodium-selective channel through which Na+ 
ions may pass in accordance with their 
electrochemical gradient. 
SLAP SCN3B q9ny72 Ion channel Sodium channel subunit 
beta-3 
Modulates channel gating kinetics. Causes unique 
persistent sodium currents. Inactivates the sodium 
channel opening more slowly than the subunit beta-1. 
Its association with neurofascin may target the 
sodium channels to the nodes of Ranvier of 
developing axons and retain these channels at the 
nodes in mature myelinated axons (By similarity). 
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Both SCN4A p35499 Ion channel Sodium channel protein 
type 4 subunit alpha 
This protein mediates the voltage-dependent sodium 
ion permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
forms a sodium-selective channel through which Na+ 
ions may pass in accordance with their 
electrochemical gradient. This sodium channel may be 
present in both denervated and innervated skeletal 
muscle. 
SLAP SCN4B q8iwt1 Ion channel Sodium channel subunit 
beta-4 
Modulates channel gating kinetics. Causes negative 
shifts in the voltage dependence of activation of 
certain alpha sodium channels, but does not affect 
the voltage dependence of inactivation. Modulates 
the suceptibility of the sodium channel to inhibition 
by toxic peptides from spider, scorpion, wasp and sea 
anemone venom. 
Both SCN5A q14524 Ion channel Sodium channel protein 
type 5 subunit alpha 
This protein mediates the voltage-dependent sodium 
ion permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
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forms a sodium-selective channel through which Na+ 
ions may pass in accordance with their 
electrochemical gradient. It is a tetrodotoxin-resistant 
Na+ channel isoform. This channel is responsible for 
the initial upstroke of the action potential. Channel 
inactivation is regulated by intracellular calcium 
levels. 
STITCH SCN7A q01118 Ion channel Sodium channel protein 
type 7 subunit alpha 
Mediates the voltage-dependent sodium ion 
permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
forms a sodium-selective channel through which Na+ 
ions may pass in accordance with their 
electrochemical gradient. 
STITCH SCN8A q9uqd0 Ion channel Sodium channel protein 
type 8 subunit alpha 
Mediates the voltage-dependent sodium ion 
permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
forms a sodium-selective channel through which Na+ 
ions may pass in accordance with their 
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electrochemical gradient. In macrophages and 
melanoma cells, isoform 5 may participate in the 
control of podosome and invadopodia formation 
Both SCN9A q15858 Ion channel Sodium channel protein 
type 9 subunit alpha 
Mediates the voltage-dependent sodium ion 
permeability of excitable membranes. Assuming 
opened or closed conformations in response to the 
voltage difference across the membrane, the protein 
forms a sodium-selective channel through which Na+ 
ions may pass in accordance with their 
electrochemical gradient. It is a tetrodotoxin-sensitive 
Na+ channel isoform. Plays a role in pain mechanisms, 
especially in the development of inflammatory pain 
(By similarity). 
STITCH SERPINA7 p05543 Transport Thyroxine-binding globulin Major thyroid hormone transport protein in serum. 
STITCH SHBG p04278 Transport Sex hormone-binding 
globulin 
Functions as an androgen transport protein, but may 
also be involved in receptor mediated processes. Each 
dimer binds one molecule of steroid. Specific for 5-
alpha-dihydrotestosterone, testosterone, and 17-
beta-estradiol. Regulates the plasma metabolic 
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clearance rate of steroid hormones by controlling 
their plasma concentration. 
SLAP SLC12A1 q13621 Transport Solute carrier family 12 
member 1 
Electrically silent transporter system. Mediates 
sodium and chloride reabsorption. Plays a vital role in 
the regulation of ionic balance and cell volume. 
SLAP SLC12A3 p55017 Transport Solute carrier family 12 
member 3 
Key mediator of sodium and chloride reabsorption in 
this nephron segment, accounting for a significant 
fraction of renal sodium reabsorption. 
STITCH SLC22A1 o15245 Transport Solute carrier family 22 
member 1 
Translocates a broad array of organic cations with 
various structures and molecular weights including 
the model compounds 1-methyl-4-phenylpyridinium 
(MPP), tetraethylammonium (TEA), N-1-
methylnicotinamide (NMN), 4-(4-
(dimethylamino)styryl)-N-methylpyridinium (ASP), the 
endogenous compounds choline, guanidine, 
histamine, epinephrine, adrenaline, noradrenaline 
and dopamine, and the drugs quinine, and metformin. 
The transport of organic cations is inhibited by a 
broad array of compounds like 
tetramethylammonium (TMA), cocaine, lidocaine, 
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NMDA receptor antagonists, atropine, prazosin, 
cimetidine, TEA and NMN, guanidine, cimetidine, 
choline, procainamide, quinine, tetrabutylammonium, 
and tetrapentylammonium. Translocates organic 
cations in an electrogenic and pH-independent 
manner. Translocates organic cations across the 
plasma membrane in both directions. Transports the 
polyamines spermine and spermidine. Transports 
pramipexole across the basolateral membrane of the 
proximal tubular epithelial cells. The choline transport 
is activated by MMTS. Regulated by various 
intracellular signaling pathways including inhibition by 
protein kinase A activation, and endogenously 
activation by the calmodulin complex, the calmodulin-
dependent kinase II and LCK tyrosine kinase. 
STITCH SLC22A11 q9nsa0 Transport Solute carrier family 22 
member 11 
Mediates saturable uptake of estrone sulfate, 
dehydroepiandrosterone sulfate and related 
compounds. 
STITCH SLC22A2 o15244 Transport Solute carrier family 22 
member 2 
Mediates tubular uptake of organic compounds from 
circulation. Mediates the influx of agmatine, 
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dopamine, noradrenaline (norepinephrine), serotonin, 
choline, famotidine, ranitidine, histamin, creatinine, 
amantadine, memantine, acriflavine, 4-[4-
(dimethylamino)-styryl]-N-methylpyridinium ASP, 
amiloride, metformin, N-1-methylnicotinamide 
(NMN), tetraethylammonium (TEA), 1-methyl-4-
phenylpyridinium (MPP), cimetidine, cisplatin and 
oxaliplatin. Cisplatin may develop a nephrotoxic 
action. Transport of creatinine is inhibited by 
fluoroquinolones such as DX-619 and LVFX. This 
transporter is a major determinant of the anticancer 
activity of oxaliplatin and may contribute to antitumor 
specificity. 
Both SLC22A6 q4u2r8 Transport Solute carrier family 22 
member 6 
Involved in the renal elimination of endogenous and 
exogenous organic anions. Functions as organic anion 
exchanger when the uptake of one molecule of 
organic anion is coupled with an efflux of one 
molecule of endogenous dicarboxylic acid (glutarate, 
ketoglutarate, etc). Mediates the sodium-
independent uptake of 2,3-dimercapto-1-
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propanesulfonic acid (DMPS) (By similarity). Mediates 
the sodium-independent uptake of p-aminohippurate 
(PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-
'deoxythymidine (AZT), cimetidine (CMD), 2,4-
dichloro-phenoxyacetate (2,4-D), hippurate (HA), 
indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-
4-methyl-5-propyl-2-furanpropionate (CMPF), 
cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) 
guanine (PMEG), 9-(2-phosphonylmethoxyethyl) 
diaminopurine (PMEDAP) and edaravone sulfate. PAH 
uptake is inhibited by p-
chloromercuribenzenesulphonate (PCMBS), diethyl 
pyrocarbonate (DEPC), sulindac, diclofenac, 
carprofen, glutarate and okadaic acid (By similarity). 
PAH uptake is inhibited by benzothiazolylcysteine 
(BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine 
S-conjugates S-dichlorovinylcysteine (DCVC), 
furosemide, steviol, phorbol 12-myristate 13-acetate 
(PMA), calcium ionophore A23187, benzylpenicillin, 
furosemide, indomethacin, bumetamide, losartan, 
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probenecid, phenol red, urate, and alpha-
ketoglutarate. 
STITCH SLC22A7 q9y694 Transport Solute carrier family 22 
member 7 
Mediates sodium-independent multispecific organic 
anion transport. Transport of prostaglandin E2, 
prostaglandin F2, tetracycline, bumetanide, estrone 
sulfate, glutarate, dehydroepiandrosterone sulfate, 
allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, 
salicylate, ethotrexate, and alpha-ketoglutarate. 
STITCH SLC22A8 q8tcc7 Transport Solute carrier family 22 
member 8 
Plays an important role in the excretion/detoxification 
of endogenous and exogenous organic anions, 
especially from the brain and kidney. Involved in the 
transport basolateral of steviol, fexofenadine. 
Transports benzylpenicillin (PCG), estrone-3-sulfate 
(E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate 
(2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and 
ochratoxin (OTA). 
STITCH SLC2A6 q9ugq3 Transport Solute carrier family 2, 
facilitated glucose 
transporter member 6 
Facilitative glucose transporter; binds cytochalasin B 
with low affinity. 
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STITCH SLC2A9 q9nrm0 Transport Solute carrier family 2, 
facilitated glucose 
transporter member 9 
Transport urate and fructose. May have a role in the 
urate reabsorption by proximal tubules. Also 
transports glucose at low rate 
STITCH SLC46A1 q96nt5 Transport Proton-coupled folate 
transporter 
Has been shown to act both as an intestinal proton-
coupled high-affinity folate transporter and as an 
intestinal heme transporter which mediates heme 
uptake from the gut lumen into duodenal epithelial 
cells. The iron is then released from heme and may be 
transported into the bloodstream. Dietary heme iron 
is an important nutritional source of iron. Shows a 
higher affinity for folate than heme. 
SLAP SLC6A2 p23975 Transport Sodium-dependent 
noradrenaline transporter 
Amine transporter. Terminates the action of 
noradrenaline by its high affinity sodium-dependent 
reuptake into presynaptic terminals. 
SLAP SLC6A3 q01959 Transport Sodium-dependent 
dopamine transporter 
Amine transporter. Terminates the action of 
dopamine by its high affinity sodium-dependent 
reuptake into presynaptic terminals. 
SLAP SLC6A4 p31645 Transport Sodium-dependent 
serotonin transporter 
Serotonin transporter whose primary function in the 
central nervous system involves the regulation of 
serotonergic signaling via transport of serotonin 
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molecules from the synaptic cleft back into the pre-
synaptic terminal for re-utilization. Plays a key role in 
mediating regulation of the availability of serotonin to 
other receptors of serotonergic systems. Terminates 
the action of serotonin and recycles it in a sodium-
dependent manner. 
STITCH SLC7A11 q9upy5 Transport Cystine/glutamate 
transporter 
Sodium-independent, high-affinity exchange of 
anionic amino acids with high specificity for anionic 
form of cystine and glutamate. 
STITCH SLCO1C1 q9nyb5 Transport Solute carrier organic 
anion transporter family 
member 1C1 
Mediates the Na+-independent high affinity transport 
of organic anions such as the thyroid hormones 
thyroxine (T4) and rT3. Other potential substrates, 
such as triiodothyronine (T3), 17-beta-glucuronosyl 
estradiol, estrone-3-sulfate and sulfobromophthalein 
(BSP) are transported with much lower efficiency. 
May play a signifiant role in regulating T4 flux into and 
out of the brain (By similarity) 
STITCH SP1 p08047 Regulator Transcription factor Sp1 Transcription factor that can activate or repress 
transcription in response to physiological and 
pathological stimuli. Binds with high affinity to GC-rich 
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motifs and regulates the expression of a large number 
of genes involved in a variety of processes such as cell 
growth, apoptosis, differentiation and immune 
responses. Highly regulated by post-translational 
modifications (phosphorylations, sumoylation, 
proteolytic cleavage, glycosylation and acetylation). 
Binds also the PDGFR-alpha G-box promoter. May 
have a role in modulating the cellular response to 
DNA damage. Implicated in chromatin remodeling. 
Plays a role in the recruitment of SMARCA4/BRG1 on 
the c-FOS promoter. Plays an essential role in the 
regulation of FE65 gene expression. In complex with 
ATF7IP, maintains telomerase activity in cancer cells 
by inducing TERT and TERC gene expression. Isoform 3 
is a stronger activator of transcription than isoform 1. 
Positively regulates the transcription of the core clock 
component ARNTL/BMAL1. 
STITCH SRC p12931 Kinase Proto-oncogene tyrosine-
protein kinase Src 
Non-receptor protein tyrosine kinase which is 
activated following engagement of many different 
classes of cellular receptors including immune 
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response receptors, integrins and other adhesion 
receptors, receptor protein tyrosine kinases, G 
protein-coupled receptors as well as cytokine 
receptors. Participates in signaling pathways that 
control a diverse spectrum of biological activities 
including gene transcription, immune response, cell 
adhesion, cell cycle progression, apoptosis, migration, 
and transformation. Due to functional redundancy 
between members of the SRC kinase family, 
identification of the specific role of each SRC kinase is 
very difficult. SRC appears to be one of the primary 
kinases activated following engagement of receptors 
and plays a role in the activation of other protein 
tyrosine kinase (PTK) families. Receptor clustering or 
dimerization leads to recruitment of SRC to the 
receptor complexes where it phosphorylates the 
tyrosine residues within the receptor cytoplasmic 
domains. Plays an important role in the regulation of 
cytoskeletal organization through phosphorylation of 
specific substrates such as AFAP1. Phosphorylation of 
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AFAP1 allows the SRC SH2 domain to bind AFAP1 and 
to localize to actin filaments. Cytoskeletal 
reorganization is also controlled through the 
phosphorylation of cortactin (CTTN). When cells 
adhere via focal adhesions to the extracellular matrix, 
signals are transmitted by integrins into the cell 
resulting in tyrosine phosphorylation of a number of 
focal adhesion proteins, including PTK2/FAK1 and 
paxillin (PXN). In addition to phosphorylating focal 
adhesion proteins, SRC is also active at the sites of 
cell-cell contact adherens junctions and 
phosphorylates substrates such as beta-catenin 
(CTNNB1), delta-catenin (CTNND1), and plakoglobin 
(JUP). Another type of cell-cell junction, the gap 
junction, is also a target for SRC, which 
phosphorylates connexin-43 (GJA1). SRC is implicated 
in regulation of pre-mRNA-processing and 
phosphorylates RNA-binding proteins such as 
KHDRBS1. Also plays a role in PDGF-mediated tyrosine 
phosphorylation of both STAT1 and STAT3, leading to 
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increased DNA binding activity of these transcription 
factors. Involved in the RAS pathway through 
phosphorylation of RASA1 and RASGRF1. Plays a role 
in EGF-mediated calcium-activated chloride channel 
activation. Required for epidermal growth factor 
receptor (EGFR) internalization through 
phosphorylation of clathrin heavy chain (CLTC and 
CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin 
(ARRB1 and ARRB2) desensitization through 
phosphorylation and activation of ADRBK1, leading to 
beta-arrestin phosphorylation and internalization. Has 
a critical role in the stimulation of the CDK20/MAPK3 
mitogen-activated protein kinase cascade by 
epidermal growth factor. Might be involved not only 
in mediating the transduction of mitogenic signals at 
the level of the plasma membrane but also in 
controlling progression through the cell cycle via 
interaction with regulatory proteins in the nucleus. 
Plays an important role in osteoclastic bone 
resorption in conjunction with PTK2B/PYK2. Both the 
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formation of a SRC-PTK2B/PYK2 complex and SRC 
kinase activity are necessary for this function. 
Recruited to activated integrins by PTK2B/PYK2, 
thereby phosphorylating CBL, which in turn induces 
the activation and recruitment of phosphatidylinositol 
3-kinase to the cell membrane in a signaling pathway 
that is critical for osteoclast function. Promotes 
energy production in osteoclasts by activating 
mitochondrial cytochrome C oxidase. Phosphorylates 
DDR2 on tyrosine residues, thereby promoting its 
subsequent autophosphorylation. Phosphorylates 
RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-
284' and CBL on 'Tyr-731'. Enhances DDX58/RIG-I-
elicited antiviral signaling. Phosphorylates PDPK1 at 
'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 
at 'Tyr-128'. Phosphorylates CBLC at multiple tyrosine 
residues, phosphorylation at 'Tyr-341' activates CBLC 
E3 activity. 
STITCH SST p61278 Hormone Somatostatin Somatostatin inhibits the release of somatotropin. 
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STITCH ST6GAL1 p15907 Transport Beta-galactoside alpha-2,6-
sialyltransferase 1 
Transfers sialic acid from CMP-sialic acid to galactose-
containing acceptor substrates. 
STITCH STAR p49675 Regulator Steroidogenic acute 
regulatory protein, 
mitochondrial 
Plays a key role in steroid hormone synthesis by 
enhancing the metabolism of cholesterol into 
pregnenolone. Mediates the transfer of cholesterol 
from the outer mitochondrial membrane to the inner 
mitochondrial membrane where it is cleaved to 
pregnenolone. 
STITCH STAT3 p40763 Immune 
functions 
Signal transducer and 
activator of transcription 3 
Signal transducer and transcription activator that 
mediates cellular responses to interleukins, KITLG/SCF 
and other growth factors. May mediate cellular 
responses to activated FGFR1, FGFR2, FGFR3 and 
FGFR4. Binds to the interleukin-6 (IL-6)-responsive 
elements identified in the promoters of various acute-
phase protein genes. Activated by IL31 through 
IL31RA. Cytoplasmic STAT3 represses 
macroautophagy by inhibiting EIF2AK2/PKR activity. 
Plays an important role in host defense in methicillin-
resistant S.aureus lung infection by regulating the 
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expression of the antimicrobial lectin REG3G (By 
similarity). 
STITCH SULT1E1 p49888 Enzyme Estrogen sulfotransferase Sulfotransferase that utilizes 3'-phospho-5'-adenylyl 
sulfate (PAPS) as sulfonate donor to catalyze the 
sulfate conjugation of estradiol and estrone. May play 
a role in the regulation of estrogen receptor activity 
by metabolizing free estradiol. Maximally sulfates 
beta-estradiol and estrone at concentrations of 20 
nM. Also sulfates dehydroepiandrosterone, 
pregnenolone, ethinylestradiol, equalenin, 
diethylstilbesterol and 1-naphthol, at significantly 
higher concentrations; however, cortisol, 
testosterone and dopamine are not sulfated. 
STITCH TAS2R1 q9nyw7 Receptor Taste receptor type 2 
member 1 
Receptor that may play a role in the perception of 
bitterness and is gustducin-linked. May play a role in 
sensing the chemical composition of the 
gastrointestinal content. The activity of this receptor 
may stimulate alpha gustducin, mediate PLC-beta-2 
activation and lead to the gating of TRPM5. 
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STITCH TAS2R10 q9ntw0 Receptor Taste receptor type 2 
member 10 
Gustducin-coupled strychnine receptor implicated in 
the perception of bitter compounds in the oral cavity 
and the gastrointestinal tract. Signals through PLCB2 
and the calcium-regulated cation channel TRPM5. 
STITCH TAS2R14 q9nyv8 Receptor Taste receptor type 2 
member 14 
Receptor that may play a role in the perception of 
bitterness and is gustducin-linked. May play a role in 
sensing the chemical composition of the 
gastrointestinal content. The activity of this receptor 
may stimulate alpha gustducin, mediate PLC-beta-2 
activation and lead to the gating of TRPM5 (By 
similarity). 
STITCH TAS2R30 p59541 Receptor Taste receptor type 2 
member 30 
Receptor that may play a role in the perception of 
bitterness and is gustducin-linked. May play a role in 
sensing the chemical composition of the 
gastrointestinal content. The activity of this receptor 
may stimulate alpha gustducin, mediate PLC-beta-2 
activation and lead to the gating of TRPM5 (By 
similarity). 
STITCH TAS2R38 p59533 Receptor Taste receptor type 2 
member 38 
Receptor that may play a role in the perception of 
bitterness and is gustducin-linked. May play a role in 
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sensing the chemical composition of the 
gastrointestinal content. The activity of this receptor 
may stimulate alpha gustducin, mediate PLC-beta-2 
activation and lead to the gating of TRPM5 (By 
similarity). 
STITCH TAS2R4 q9nyw5 Receptor Taste receptor type 2 
member 4 
Gustducin-coupled receptor for denatonium and N(6)-
propyl-2-thiouracil implicated in the perception of 
bitter compounds in the oral cavity and the 
gastrointestinal tract. Signals through PLCB2 and the 
calcium-regulated cation channel TRPM5. In airway 
epithelial cells, binding of denatonium increases the 
intracellular calcium ion concentration and stimulates 
ciliary beat frequency. 
STITCH TBXAS1 p24557 Enzyme Thromboxane-A synthase heme binding; monooxygenase activity; 
thromboxane-A synthase activity; iron ion binding; 
oxidoreductased activity, actining on paired donors, 
with incorporation or reduction of molecular oxygen 
STITCH TFAP2A p05549 Regulator Transcription factor AP-2-
alpha 
Sequence-specific DNA-binding protein that interacts 
with inducible viral and cellular enhancer elements to 
regulate transcription of selected genes. AP-2 factors 
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bind to the consensus sequence 5'-GCCNNNGGC-3' 
and activate genes involved in a large spectrum of 
important biological functions including proper eye, 
face, body wall, limb and neural tube development. 
They also suppress a number of genes including 
MCAM/MUC18, C/EBP alpha and MYC. AP-2-alpha is 
the only AP-2 protein required for early 
morphogenesis of the lens vesicle. Together with the 
CITED2 coactivator, stimulates the PITX2 P1 promoter 
transcription activation. Associates with chromatin to 
the PITX2 P1 promoter region. 
STITCH TG p01266   Thyroglobulin Precursor of the iodinated thyroid hormones 
thyroxine (T4) and triiodothyronine (T3). 
STITCH THRA p10827 Receptor Thyroid hormone receptor 
alpha 
Nuclear hormone receptor that can act as a repressor 
or activator of transcription. High affinity receptor for 
thyroid hormones, including triiodothyronine and 
thyroxine. 
STITCH TMSB10 p63313 Structural Thymosin beta-10 Plays an important role in the organization of the 
cytoskeleton. Binds to and sequesters actin 
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monomers (G actin) and therefore inhibits actin 
polymerization (By similarity) 
Both TNF p01375 Signalling Tumor necrosis factor Cytokine that binds to TNFRSF1A/TNFR1 and 
TNFRSF1B/TNFBR. It is mainly secreted by 
macrophages and can induce cell death of certain 
tumor cell lines. It is potent pyrogen causing fever by 
direct action or by stimulation of interleukin-1 
secretion and is implicated in the induction of 
cachexia, Under certain conditions it can stimulate 
cell proliferation and induce cell differentiation. 
Impairs regulatory T-cells (Treg) function in individuals 
with rheumatoid arthritis via FOXP3 
dephosphorylation. Upregulates the expression of 
protein phosphatase 1 (PP1), which dephosphorylates 
the key 'Ser-418' residue of FOXP3, thereby 
inactivating FOXP3 and rendering Treg cells 
functionally defective (PubMed:23396208). 
The TNF intracellular domain (ICD) form induces IL12 
production in dendritic cells. 
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STITCH TNFRSF10B o14763 Receptor Tumour necrosis factor 
receptor superfamily 
member 10B 
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The 
adapter molecule FADD recruits caspase-8 to the 
activated receptor. The resulting death-inducing 
signaling complex (DISC) performs caspase-8 
proteolytic activation which initiates the subsequent 
cascade of caspases (aspartate-specific cysteine 
proteases) mediating apoptosis. Promotes the 
activation of NF-kappa-B. Essential for ER stress-
induced apoptosis. 
STITCH TNFRSF1B p20333 Receptor Tumour necrosis factor 
receptor superfamily 
member 1B 
Receptor with high affinity for TNFSF2/TNF-alpha and 
approximately 5-fold lower affinity for homotrimeric 
TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 
complex recruits the apoptotic suppressors BIRC2 and 
BIRC3 to TNFRSF1B/TNFR2. This receptor mediates 
most of the metabolic effects of TNF-alpha. Isoform 2 
blocks TNF-alpha-induced apoptosis, which suggests 
that it regulates TNF-alpha function by antagonizing 
its biological activity. 
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STITCH TNFSF10 p50591 Signalling Tumour necrosis factor 
ligand superfamily member 
10 
Cytokine that binds to TNFRSF10A/TRAILR1, 
TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, 
TNFRSF10D/TRAILR4 and possibly also to 
TNFRSF11B/OPG. Induces apoptosis. Its activity may 
be modulated by binding to the decoy receptors 
TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and 
TNFRSF11B/OPG that cannot induce apoptosis. 
SLAP TP53 p04637 Regulator Cellular tumor antigen p53 Acts as a tumor suppressor in many tumor types; 
induces growth arrest or apoptosis depending on the 
physiological circumstances and cell type. Involved in 
cell cycle regulation as a trans-activator that acts to 
negatively regulate cell division by controlling a set of 
genes required for this process. One of the activated 
genes is an inhibitor of cyclin-dependent kinases. 
Apoptosis induction seems to be mediated either by 
stimulation of BAX and FAS antigen expression, or by 
repression of Bcl-2 expression. In cooperation with 
mitochondrial PPIF is involved in activating oxidative 
stress-induced necrosis; the function is largely 
independent of transcription. Induces the 
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transcription of long intergenic non-coding RNA p21 
(lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 
participates in TP53-dependent transcriptional 
repression leading to apoptosis and seem to have to 
effect on cell-cycle regulation. Implicated in Notch 
signalling cross-over. Prevents CDK7 kinase activity 
when associated to CAK complex in response to DNA 
damage, thus stopping cell cycle progression. Isoform 
2 enhances the transactivation activity of isoform 1 
from some but not all TP53-inducible promoters. 
Isoform 4 suppresses transactivation activity and 
impairs growth suppression mediated by isoform 1. 
Isoform 7 inhibits isoform 1-mediated apoptosis. 
Regulates the circadian clock by repressing CLOCK-
ARNTL/BMAL1-mediated transcriptional activation of 
PER2 
SLAP TPH1 p17752 Enzyme Tryptophan 5-hydroxylase 
1 
amino acid binding; iron ion binding; tryptophan 5-
monoxygenase activity 
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STITCH TPO p07202 Enzyme Thyroid peroxidase Iodination and coupling of the hormonogenic 
tyrosines in thyroglobulin to yield the thyroid 
hormones T3 and T4. 
STITCH TRH p20396 Regulator Pro-thyrotropin-releasing 
hormone 
Functions as a regulator of the biosynthesis of TSH in 
the anterior pituitary gland and as a 
neurotransmitter/ neuromodulator in the central and 
peripheral nervous systems. May promote hair shaft 
elongation, prolong the hair cycle growth phase 
(anagen) and antagonized its termination by TGFB2. 
May also increase proliferation and inhibited 
apoptosis of hair matrix keratinocytes 
STITCH TSHR p16473 Receptor Thyrotropin receptor Receptor for thyrothropin. Plays a central role in 
controlling thyroid cell metabolism. The activity of this 
receptor is mediated by G proteins which activate 
adenylate cyclase. Also acts as a receptor for 
thyrostimulin (GPA2+GPB5). 
STITCH UGT1A3 p35503 Metabolism UDP-
glucuronosyltransferase 1-
3 
UDPGT is of major importance in the conjugation and 
subsequent elimination of potentially toxic 
xenobiotics and endogenous compounds. Isoform 2 
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lacks transferase activity but acts as a negative 
regulator of isoform 1. 
STITCH UGT1A4 p22310 Metabolism UDP-
glucuronosyltransferase 1-
4 
UDPGT is of major importance in the conjugation and 
subsequent elimination of potentially toxic 
xenobiotics and endogenous compounds. This isoform 
glucuronidates bilirubin IX-alpha to form both the IX-
alpha-C8 and IX-alpha-C12 monoconjugates and 
diconjugate. Isoform 2 lacks transferase activity but 
acts as a negative regulator of isoform 1 (By 
similarity). 
STITCH UGT2B7 p16662 Metabolism UDP-
glucuronosyltransferase 
2B7 
UDPGT is of major importance in the conjugation and 
subsequent elimination of potentially toxic 
xenobiotics and endogenous compounds. 
Its unique specificity for 3,4-catechol oestrogens and 
oestriol suggests it may play an important role in 
regulating the level and activity of these potent and 
active oestrogen metabolites. Is also active with 
androsterone, hyodeoxycholic acid and 
tetrachlorocatechol (in vitro). 
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STITCH VEGFA p15692   Vascular endothelial 
growth factor A 
Growth factor active in angiogenesis, vasculogenesis 
and endothelial cell growth. Induces endothelial cell 
proliferation, promotes cell migration, inhibits 
apoptosis and induces permeabilisation of blood 
vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 
receptors, heparan sulfate and heparin. 
NRP1/Neuropilin-1 binds isoforms VEGF-165 and 
VEGF-145. Isoform VEGF165B binds to KDR but does 
not activate downstream signalling pathways, does 
not activate angiogenesis and inhibits tumour growth. 
STITCH VEGFC p49767   Vascular endothelial 
growth factor C 
Growth factor active in angiogenesis, and endothelial 
cell growth, stimulating their proliferation and 
migration and also has effects on the permeability of 
blood vessels. May function in angiogenesis of the 
venous and lymphatic vascular systems during 
embryogenesis, and also in the maintenance of 
differentiated lymphatic endothelium in adults. Binds 
and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) 
receptors. 
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STITCH XDH p47989 Regulator Xanthine 
dehydrogenase/oxidase 
Key enzyme in purine degradation. Catalyses the 
oxidation of hypoxanthine to xanthine. Catalyses the 
oxidation of xanthine to uric acid. Contributes to the 
generation of reactive oxygen species. Has also low 
oxidase activity towards aldehydes (in vitro). 
STITCH YWHAE p62258 Regulator 14-3-3 protein epsilon Adapter protein implicated in the regulation of a large 
spectrum of both general and specialized signaling 
pathways. Binds to a large number of partners, 
usually by recognition of a phosphoserine or 
phosphothreonine motif. Binding generally results in 
the modulation of the activity of the binding partner. 
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11 Appendix 3: Results of SLAP 
11.1 Allopurinol 
target p value   
IL1B 0.7284   
 
11.2 Carbamazepine 
target p value 
  
HTR2B 5.5773114665e-05 
HTR2A 8.22392383655e-05 
DRD2 9.20315383451e-05 
CYP2C9 1e-04 
SCN2A 1e-04 
SCN3A 1e-04 
CYP3A4 2e-04 
DRD3 2e-04 
HTR2C 2e-04 
CYP1A2 3e-04 
DRD5 3e-04 
ABCC1 4e-04 
DRD4 4e-04 
ABCB1  5e-04 
HTR7 5e-04 
DRD1 6e-04 
PGR 6e-04 
CYP2A6 8e-04 
ABCC2 0.001 
HTR1A 0.001 
CYP2B6 0.0011 
CYP2C8 0.0011 
NR3C2 0.0011 
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target p value 
KCNH2 0.0012 
HTR1B  0.0013 
HTR1F  0.0013 
HTR1D 0.0017 
AR 0.0018 
SCN10A 0.0018 
HTR4 0.0019 
ABCG2  0.0023 
HRH1 0.0023 
SCN5A 0.0029 
NR1I2  0.003 
SLC6A4  0.0032 
CYP2C18 0.0037 
JUN 0.0037 
SCN4A 0.0037 
FPR1 0.0038 
CYP17A1 0.0039 
GSTA1 0.0041 
GSTM1 0.0042 
SCN1A 0.0043 
HTR1E 0.0047 
NFKB1  0.0049 
CHRNA7 0.005 
ESR1 0.0054 
HTR3A 0.0062 
EPHX2 0.0064 
TP53 0.0064 
CYP19A1 0.0069 
NR1I3  0.0069 
NFKB2  0.007 
PTGS2 0.0075 
ADRA2A  0.0081 
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target p value 
CYP11B1 0.0084 
PTGS1 0.0087 
GSTP1 0.0092 
HTR6 0.0094 
SCN9A 0.0094 
MAOA  0.0095 
ABCB11  0.0099 
NR3C1 0.0099 
 
11.3 Celecoxib 
target p value 
  
CA1 3.19476265354e-06 
CA2 5.55073451469e-06 
PTGS2 1.40995423594e-05 
CA9 1.49023706417e-05 
CA12 2.40337858337e-05 
CA14 2.50867494557e-05 
CA4 2.59960900877e-05 
CA5A 3.12292726893e-05 
CA5B 3.1998151108e-05 
CA7 3.60611733822e-05 
CA13 5.50738672461e-05 
PTGS1 6.04181918484e-05 
PPARA 6.31778502987e-05 
ADRA2A  6.45500039546e-05 
HTR1D 6.99928488774e-05 
ADRA2C 7.52018764707e-05 
ADRA2B 7.59544860616e-05 
HTR1B  7.66886409999e-05 
AKT2  1e-04 
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CA3 1e-04 
CASP7 1e-04 
CDK4 1e-04 
CNR1 1e-04 
DRD2 1e-04 
HTR1F  1e-04 
HTR2A 1e-04 
HTR2C  1e-04 
CHRM3 2e-04 
CHRM4 2e-04 
DRD1 2e-04 
DRD3 2e-04 
DRD5 2e-04 
CNR2 3e-04 
DRD4 3e-04 
HRH1 3e-04 
HTR1A 3e-04 
HTR7 3e-04 
CASP1 4e-04 
CDK2 4e-04 
CHRM1 4e-04 
HTR2B  4e-04 
HRH2 5e-04 
PPARD 5e-04 
ALOX5  6e-04 
MMP2 6e-04 
CYP3A4 8e-04 
CHRM2 9e-04 
HTR1E 9e-04 
HTR6 9e-04 
MMP1 9e-04 
HRH4 0.001 
HTR4 0.0011 
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KCNH2 0.0011 
MMP8 0.0011 
PTGER4 0.0011 
NISCH  0.0014 
ADRA1A  0.0017 
MAPK12 0.0017 
CYP1A2 0.0018 
PNMT 0.0018 
BCL2  0.0019 
CA11 0.0019 
CYP2C9 0.0019 
HTR3A 0.002 
MMP13 0.0021 
MMP3 0.0022 
CA8 0.0023 
PTGER3 0.0023 
ADAM17  0.0026 
PTGER1 0.0027 
SLC6A4  0.0027 
CA10 0.0028 
HRH3 0.0028 
TPH1 0.0029 
NFKB1  0.003 
MMP14 0.0038 
ADRA1B 0.0039 
TP53 0.0039 
BCL2L1  0.0044 
ABCC2 0.0045 
NFKB2  0.0045 
ADRA1D  0.0046 
ABCB1  0.0047 
ROCK1 0.0051 
ADRB2  0.0053 
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SLC22A6  0.0055 
ADRB1  0.0061 
CHRM5 0.0061 
CYP2C8 0.0061 
AKT1  0.0064 
FGF1  0.0065 
CHRNA7 0.0066 
SLC12A1  0.0066 
ASL 0.0067 
CCND1 0.0068 
CYP2B6 0.0068 
PRKACA 0.0068 
CASP3 0.007 
FGF2  0.0073 
PGR 0.0077 
TNF  0.008 
MAPK1 0.0082 
MMP7 0.0082 
SLC12A3  0.0082 
IL1B  0.0083 
MMP11 0.0083 
KCNMA1 0.0091 
ROCK2 0.0091 
DDC 0.0096 
HNMT 0.0097 
SCN1A 0.0099 
PLA2G4A  0.01 
CYP19A1 0.0115 
PDPK1 0.0131 
MMP9 0.0136 
PPARG 0.017 
CCL2  0.0181 
SLC6A3  0.0183 
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GSTP1 0.0213 
CCR5 0.022 
AR 0.0269 
MAPK14 0.0287 
PTGER2 0.0288 
ABCC4 0.0355 
OPRM1 0.0492 
OPRK1 0.0692 
 
11.4 Clavulanic acid 
No Targets Predicted 
11.5 Flucloxacillin 
No Targets Predicted 
11.6 Lamotrigine 
target p value 
  
SCN2A 9.70053876914e-06 
SCN1A 1.21165483008e-05 
SCN3A 1.26338520879e-05 
SCN5A 1e-04 
SCN10A 7e-04 
SCN4A 8e-04 
SCN9A 0.0011 
SCN4B 0.0014 
CYP3A4 0.0015 
SCN2B 0.0016 
SCN1B 0.0017 
HRH1 0.0018 
SCN11A 0.0019 
SCN3B 0.0021 
HRH3 0.0024 
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HTR2A 0.0024 
CACNA1I 0.0027 
ABCC1 0.0028 
KCNH2 0.0028 
CACNA1C  0.0039 
CACNA1H 0.0041 
ABCB1  0.0043 
CACNA1G 0.0049 
SLC6A4  0.0049 
DRD2 0.0053 
HTR2C  0.0056 
SLC6A2  0.0059 
CACNA1D 0.007 
GRIN2B  0.0076 
ABCC2 0.0077 
CCR5 0.0082 
CACNA1S  0.0083 
SLC6A3  0.0087 
ABCG2  0.0088 
DRD1 0.0088 
ADRA1A  0.0091 
CALM1  0.0093 
FPR1 0.0093 
CACNA1F  0.0094 
KCNQ1 0.0098 
DHFR  0.4712 
 
11.7 Nevirapine 
No targets predicted 
11.8 Phenytoin 
target p value 
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SCN2A 2.31001566489e-05 
SCN1A 3.03887677753e-05 
SCN3A 3.21342523509e-05 
CYP3A4 7.26175587376e-05 
CYP2C9 1e-04 
SCN5A 2e-04 
CYP1A2 3e-04 
ABCC1 9e-04 
CYP2B6 9e-04 
ABCB1  0.0011 
CYP2A6 0.0012 
SCN10A 0.0014 
SCN4A 0.0015 
KCNH2 0.0018 
SCN4B 0.0018 
SCN2B 0.0019 
SCN1B 0.002 
CYP2C8 0.0021 
SCN3B 0.0023 
SCN9A 0.0023 
ABCC2 0.0036 
HRH1 0.0042 
PGR 0.0047 
SCN11A 0.0047 
ABCG2  0.0052 
EPHX2 0.0053 
CACNA1H 0.0069 
CACNA1I 0.0075 
CACNA1C  0.0079 
NR1I2  0.008 
CYP19A1 0.0085 
CYP4A11 0.0085 
CACNA1G 0.0087 
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FPR1 0.0088 
CYP17A1 0.0092 
 
11.9 Propylthiouracil 
No targets predicted. 
11.10 Sulfasalazine 
target p value 
  
CA4 1.61694131162e-06 
CA2 4.98441516594e-06 
CA1 6.0048935786e-06 
CA9 7.60332405514e-06 
CA12 5.53898608426e-05 
CA5A 2e-04 
CA5B 2e-04 
NFKB1  2e-04 
CA14 3e-04 
CA7 6e-04 
CA13 8e-04 
JUN 0.001 
CA3 0.0021 
TPH1 0.0067 
CA11 0.0079 
MMP8 0.0093 
IL1B  0.0846 
NFKB2  0.4083 
 
11.11 Sulindac 
No targets predicted. 
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12 Appendix 4: Results from STITCH 4.0 
12.1 Allopurinol 
 
Predicted Functional Partners: 
 
XDH xanthine dehydrogenase; This enzyme can be converted 
from the dehydrogenase form (D) to the oxi [...] 
(1333 aa) 
0.996 
 
HPRT1 hypoxanthine phosphoribosyltransferase 1 (218 aa) 0.988 
 
MPO myeloperoxidase; Part of the host defense system of 
polymorphonuclear leukocytes. It is respons [...] (745 aa) 
0.915 
 
PNP purine nucleoside phosphorylase (289 aa) 0.914 
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AOX1 aldehyde oxidase 1 (1338 aa) 0.905 
 
DIF Tumor necrosis factor Precursor (TNF-alpha)(Tumor 
necrosis factor ligand superfamily member 2)( [...] 
(233 aa) 
0.835 
 
CRP C-reactive protein, pentraxin-related; Displays several 
functions associated with host defense- [...] (224 aa) 
0.834 
 
TNF tumor necrosis factor (TNF superfamily, member 2); 
Cytokine that binds to TNFRSF1A/TNFR1 and TN [...] 
(233 aa) 
0.827 
 
ENSG00000228978 Tumor necrosis factor (TNF superfamily, member 2) 
Fragment (171 aa) 
0.825 
 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase); May have [...] 
(604 aa) 
0.823 
 
IL10 interleukin 10; Inhibits the synthesis of a number of 
cytokines, including IFN-gamma, IL-2, IL- [...] (178 aa) 
0.819 
 
SLC2A9 solute carrier family 2 (facilitated glucose transporter), 
member 9; Transport urate and fructo [...] (540 aa) 
0.819 
 
SLC22A7 solute carrier family 22 (organic anion transporter), 
member 7; Mediates sodium-independent mul [...] 
(548 aa) 
0.800 
 
SLC2A6 solute carrier family 2 (facilitated glucose transporter), 
member 6; Facilitative glucose trans [...] (507 aa) 
0.800 
 
PARP1 poly (ADP-ribose) polymerase 1; Involved in the base 
excision repair (BER) pathway, by catalyzi [...] (1014 aa) 
0.800 
 
HIF1A hypoxia inducible factor 1, alpha subunit (basic helix-
loop-helix transcription factor); Functi [...] (826 aa) 
0.800 
 
SLC22A8 solute carrier family 22 (organic anion transporter), 
member 8; Plays an important role in the [...] (542 aa) 
0.800 
 
MLXIPL MLX interacting protein-like; Transcriptional repressor. 
Binds to the canonical and non-canonic [...] (852 aa) 
0.800 
 
CXCL10 chemokine (C-X-C motif) ligand 10; Chemotactic for 
monocytes and T-lymphocytes. Binds to CXCR3 (98 aa) 
0.800 
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CRH corticotropin releasing hormone; This hormone from 
hypothalamus regulates the release of cortic [...] (196 aa) 
0.800 
 
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b; 
Receptor for the cytotoxic ligand TNFSF [...] (440 aa) 
0.800 
 
IDO1 indoleamine 2,3-dioxygenase 1; Catalyzes the cleavage 
of the pyrrol ring of tryptophan and inco [...] (403 aa) 
0.800 
 
FASLG Fas ligand (TNF superfamily, member 6); Cytokine that 
binds to TNFRSF6/FAS, a receptor that tra [...] (281 aa) 
0.719 
 
NOS1 nitric oxide synthase 1 (neuronal); Produces nitric oxide 
(NO) which is a messenger molecule wi [...] (1434 aa) 
0.504 
 
APRT adenine phosphoribosyltransferase; Catalyzes a salvage 
reaction resulting in the formation of A [...] (180 aa) 
0.453 
 
NOS2 nitric oxide synthase 2, inducible; Produces nitric oxide 
(NO) which is a messenger molecule wi [...] (1153 aa) 
0.446 
 
NOS3 nitric oxide synthase 3 (endothelial cell); Produces nitric 
oxide (NO) which is implicated in v [...] (1203 aa) 
0.420 
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12.2 Carbamazepine 
 
Predicted Functional Partners: 
 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.989 
 
CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6; 
Cytochromes P450 are a group of heme-thi [...] (491 aa) 
0.984 
 
CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2; 
Cytochromes P450 are a group of heme-thi [...] (516 aa) 
0.969 
 
SCN3A sodium channel, voltage-gated, type III, alpha subunit; Mediates 
the voltage-dependent sodium i [...] (2000 aa) 
0.951 
 
CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19; 
Responsible for the metabolism of a num [...] (490 aa) 
0.930 
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CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9; 
Cytochromes P450 are a group of heme-thi [...] (490 aa) 
0.930 
 
IMPA1 inositol(myo)-1(or 4)-monophosphatase 1; Responsible for the 
provision of inositol required for [...] (336 aa) 
0.929 
 
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic); Biotransformation 
enzyme that catalyzes the hydro [...] (455 aa) 
0.927 
 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5; 
Cytochromes P450 are a group of heme-thi [...] (502 aa) 
0.921 
 
CYP2C8 cytochrome P450, family 2, subfamily C, polypeptide 8; 
Cytochromes P450 are a group of heme-thi [...] (490 aa) 
0.921 
 
CYP3A7 cytochrome P450, family 3, subfamily A, polypeptide 7; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.912 
 
SHBG sex hormone-binding globulin; Functions as an androgen transport 
protein, but may also be invol [...] (402 aa) 
0.911 
 
CYP2C18 cytochrome P450, family 2, subfamily C, polypeptide 18; 
Cytochromes P450 are a group of heme-th [...] (490 aa) 
0.900 
 
CYP3A43 cytochrome P450, family 3, subfamily A, polypeptide 43; Exhibits 
low testosterone 6-beta-hydrox [...] (504 aa) 
0.900 
 
SCN1A sodium channel, voltage-gated, type I, alpha subunit; Mediates the 
voltage-dependent sodium ion [...] (1998 aa) 
0.880 
 
SCN8A sodium channel, voltage gated, type VIII, alpha subunit; Mediates 
the voltage-dependent sodium [...] (1980 aa) 
0.873 
 
SCN4A sodium channel, voltage-gated, type IV, alpha subunit; This 
protein mediates the voltage-depend [...] (1836 aa) 
0.860 
 
PPIG peptidylprolyl isomerase G (cyclophilin G); PPIases accelerate the 
folding of proteins. It cata [...] (754 aa) 
0.860 
 
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene [...] (1255 aa) 
0.840 
 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1; 
Energy-dependent efflux pump responsibl [...] (1280 aa) 
0.836 
 
POMC proopiomelanocortin; ACTH stimulates the adrenal glands to 
release cortisol (267 aa) 
0.831 
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SCN7A sodium channel, voltage-gated, type VII, alpha; Mediates the 
voltage-dependent sodium ion perme [...] (1682 aa) 
0.828 
 
SCN10A sodium channel, voltage-gated, type X, alpha subunit; This protein 
mediates the voltage-depende [...] (1956 aa) 
0.827 
 
BDNF brain-derived neurotrophic factor; During development, promotes 
the survival and differentiatio [...] (329 aa) 
0.827 
 
SST somatostatin; Somatostatin inhibits the release of somatotropin 
(116 aa) 
0.823 
 
UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7; UDPGT is 
of major importance in the conju [...] (529 aa) 
0.819 
 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2; 
Mediates hepatobiliary excretion of nu [...] (1545 aa) 
0.818 
 
TFAP2A transcription factor AP-2 alpha (activating enhancer binding 
protein 2 alpha); Sequence-specifi [...] (437 aa) 
0.814 
 
SCN5A sodium channel, voltage-gated, type V, alpha subunit; This protein 
mediates the voltage-depende [...] (2016 aa) 
0.813 
 
SCN11A sodium channel, voltage-gated, type XI, alpha subunit; This 
protein mediates the voltage-depend [...] (1791 aa) 
0.800 
 
HDAC3 histone deacetylase 3; Responsible for the deacetylation of lysine 
residues on the N-terminal p [...] (428 aa) 
0.800 
 
RALBP1 ralA binding protein 1; Can activate specifically hydrolysis of GTP 
bound to RAC1 and CDC42, bu [...] (655 aa) 
0.800 
 
NR1I2 nuclear receptor subfamily 1, group I, member 2; Nuclear receptor 
that binds and is activated b [...] (473 aa) 
0.742 
 
CYP17A1 cytochrome P450, family 17, subfamily A, polypeptide 1; 
Conversion of pregnenolone and progeste [...] (508 aa) 
0.700 
 
HSD3B2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 2; 3-beta-HSD is a b [...] (372 aa) 
0.700 
 
GSTM1 glutathione S-transferase mu 1; Conjugation of reduced 
glutathione to a wide number of exogenou [...] (218 aa) 
0.700 
 
HMBS hydroxymethylbilane synthase; Tetrapolymerization of the 
monopyrrole PBG into the hydroxymethyl [...] (361 aa) 
0.700 
Appendix 4: Results from STITCH 4.0 
382 
 
 
ORM2 orosomucoid 2; Appears to function in modulating the activity of 
the immune system during the a [...] (201 aa) 
0.583 
 
ORM1 orosomucoid 1; Appears to function in modulating the activity of 
the immune system during the a [...] (201 aa) 
0.583 
 
SCN9A sodium channel, voltage-gated, type IX, alpha subunit; Mediates 
the voltage-dependent sodium io [...] (1977 aa) 
0.489 
 
SCN1B sodium channel, voltage-gated, type I, beta; Crucial in the 
assembly, expression, and functiona [...] (268 aa) 
0.432 
 
SCN2B sodium channel, voltage-gated, type II, beta; Crucial in the 
assembly, expression, and function [...] (215 aa) 
0.413 
 
12.3 Celecoxib 
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Predicted Functional Partners: 
 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase); May have [...] (604 aa) 
0.999 
 
PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase); May play [...] (599 aa) 
0.997 
 
CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9; 
Cytochromes P450 are a group of heme-thi [...] (490 aa) 
0.987 
 
VEGFA vascular endothelial growth factor A; Growth factor active in 
angiogenesis, vasculogenesis and [...] (412 aa) 
0.984 
 
CASP3 caspase 3, apoptosis-related cysteine peptidase; Involved in the 
activation cascade of caspases [...] (277 aa) 
0.983 
 
PDPK1 3-phosphoinositide dependent protein kinase-1; Phosphorylates 
and activates not only PKB/AKT, b [...] (556 aa) 
0.968 
 
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4; 
May be an organic anion pump relevant [...] (1325 aa) 
0.958 
 
AKT1 v-akt murine thymoma viral oncogene homolog 1; General 
protein kinase capable of phosphorylatin [...] (480 aa) 
0.956 
 
CASP8 caspase 8, apoptosis-related cysteine peptidase; Most upstream 
protease of the activation casca [...] (538 aa) 
0.951 
 
CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1; 
Catalyzes the formation of aromatic C18 [...] (503 aa) 
0.941 
 
PCNA proliferating cell nuclear antigen; This protein is an auxiliary 
protein of DNA polymerase delt [...] (261 aa) 
0.914 
 
MAPK14 mitogen-activated protein kinase 14; Responds to activation by 
environmental stress, pro- infla [...] (360 aa) 
0.908 
 
CA9 carbonic anhydrase IX; Reversible hydration of carbon dioxide. 
Participates in pH regulation. M [...] (459 aa) 
0.907 
 
CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6; 
Responsible for the metabolism of many d [...] (497 aa) 
0.906 
 
CASP9 caspase 9, apoptosis-related cysteine peptidase; Involved in the 
activation cascade of caspases [...] (416 aa) 
0.900 
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CA2 carbonic anhydrase II; Essential for bone resorption and 
osteoclast differentiation (By similar [...] (260 aa) 
0.900 
 
CA12 carbonic anhydrase XII; Reversible hydration of carbon dioxide 
(354 aa) 
0.900 
 
EGFR epidermal growth factor receptor (erythroblastic leukemia viral 
(v-erb-b) oncogene homolog, avi [...] (1210 aa) 
0.873 
 
CCND1 cyclin D1; Essential for the control of the cell cycle at the G1/S 
(start) transition (295 aa) 
0.865 
 
CA5B inactivation escape 2 (non-protein coding); Reversible 
hydration of carbon dioxide (317 aa) 
0.858 
 
CA6 carbonic anhydrase VI; Reversible hydration of carbon dioxide. 
Its role in saliva is unknown (308 aa) 
0.857 
 
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b; 
Receptor for the cytotoxic ligand TNFSF [...] (440 aa) 
0.852 
 
CA13 carbonic anhydrase XIII; Reversible hydration of carbon 
dioxide (262 aa) 
0.852 
 
DIF Tumor necrosis factor Precursor (TNF-alpha)(Tumor necrosis 
factor ligand superfamily member 2)( [...] (233 aa) 
0.846 
 
DDIT3 DNA-damage-inducible transcript 3; Inhibits the DNA-binding 
activity of C/EBP and LAP by formin [...] (169 aa) 
0.845 
 
GDF15 growth differentiation factor 15 (308 aa) 0.845 
 
PPARG peroxisome proliferator-activated receptor gamma; Receptor 
that binds peroxisome proliferators [...] (505 aa) 
0.845 
 
DGCR2 DiGeorge syndrome critical region gene 2; Putative adhesion 
receptor, that could be involved in [...] (550 aa) 
0.844 
 
CYP2C8 cytochrome P450, family 2, subfamily C, polypeptide 8; 
Cytochromes P450 are a group of heme-thi [...] (490 aa) 
0.839 
 
ALOX5 arachidonate 5-lipoxygenase; Catalyzes the first step in 
leukotriene biosynthesis, and thereby [...] (674 aa) 
0.839 
 
CFLAR CASP8 and FADD-like apoptosis regulator; Apoptosis 
regulator protein which may function as a cr [...] (480 aa) 
0.838 
 
IL6 interleukin 6 (interferon, beta 2); Cytokine with a wide variety 
of biological functions. It is [...] (212 aa) 
0.834 
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MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase); May play [...] (707 aa) 
0.833 
 
TNF tumor necrosis factor (TNF superfamily, member 2); Cytokine 
that binds to TNFRSF1A/TNFR1 and TN [...] (233 aa) 
0.831 
 
JUN jun oncogene; Transcription factor that recognizes and binds to 
the enhancer heptamer motif 5'- [...] (331 aa) 
0.828 
 
FASN fatty acid synthase; Fatty acid synthetase catalyzes the 
formation of long- chain fatty acids f [...] (2511 aa) 
0.827 
 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1); May be the 
important intermediate by which p5 [...] (164 aa) 
0.827 
 
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1; 
Mediates export of organic anions and [...] (1531 aa) 
0.824 
 
CAV1 caveolin 1, caveolae protein, 22kDa; May act as a scaffolding 
protein within caveolar membranes [...] (178 aa) 
0.824 
 
CDK2 cyclin-dependent kinase 2; Involved in the control of the cell 
cycle. Interacts with cyclins A, [...] (298 aa) 
0.824 
 
VEGFC vascular endothelial growth factor C; Growth factor active in 
angiogenesis, and endothelial cel [...] (420 aa) 
0.823 
 
INS insulin; Insulin decreases blood glucose concentration. It 
increases cell permeability to monos [...] (200 aa) 
0.822 
 
ALB albumin; Serum albumin, the main protein of plasma, has a 
good binding capacity for water, Ca(2 [...] (609 aa) 
0.819 
 
SP1 Sp1 transcription factor; Transcription factor that can activate or 
repress transcription in re [...] (785 aa) 
0.819 
 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.818 
 
PLAU plasminogen activator, urokinase; Specifically cleave the 
zymogen plasminogen to form the activ [...] (431 aa) 
0.817 
 
ICAM1 intercellular adhesion molecule 1; ICAM proteins are ligands 
for the leukocyte adhesion protein [...] (532 aa) 
0.817 
 
IGF1R insulin-like growth factor 1 receptor; This receptor binds 
insulin-like growth factor 1 (IGF1) [...] (1367 aa) 
0.816 
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AR androgen receptor; Steroid hormone receptors are ligand-
activated transcription factors that re [...] (920 aa) 
0.814 
 
IL1A interleukin 1, alpha; Produced by activated macrophages, IL-1 
stimulates thymocyte proliferatio [...] (271 aa) 
0.814 
 
12.4 Clavulanic acid 
 
Predicted Functional Partners: 
 
CD59 CD59 molecule, complement regulatory protein; Potent inhibitor of 
the complement membrane attac [...] (128 aa) 
0.800 
 
CD248 CD248 molecule, endosialin; May play a role in tumor angiogenesis 
(757 aa) 
0.544 
 
CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase 
(phosphatidylinositol synthase); Catalyz [...] (213 aa) 
0.522 
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12.5 Flucloxacillin 
 
Predicted Functional Partners: 
 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.800 
 
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1; 
Transfers sialic acid from the donor of su [...] (406 aa) 
0.671 
 
HLA-C major histocompatibility complex, class I, C; Involved in 
the presentation of foreign antigens [...] (366 aa) 
0.445 
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12.6 Lamotrigine 
 
Predicted Functional Partners: 
 
SCN2A sodium channel, voltage-gated, type II, alpha subunit; Mediates the 
voltage-dependent sodium io [...] (2005 aa) 
0.870 
 
SCN1A sodium channel, voltage-gated, type I, alpha subunit; Mediates the 
voltage-dependent sodium ion [...] (1998 aa) 
0.849 
 
UGT1A4 UDP glucuronosyltransferase 1 family, polypeptide A4; UDPGT is 
of major importance in the conju [...] (534 aa) 
0.847 
 
SCN10A sodium channel, voltage-gated, type X, alpha subunit; This protein 
mediates the voltage-depende [...] (1956 aa) 
0.840 
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SCN8A sodium channel, voltage gated, type VIII, alpha subunit; Mediates 
the voltage-dependent sodium [...] (1980 aa) 
0.836 
 
SCN3A sodium channel, voltage-gated, type III, alpha subunit; Mediates 
the voltage-dependent sodium i [...] (2000 aa) 
0.835 
 
UGT1A3 UDP glucuronosyltransferase 1 family, polypeptide A3; UDPGT is 
of major importance in the conju [...] (534 aa) 
0.831 
 
SCN7A sodium channel, voltage-gated, type VII, alpha; Mediates the 
voltage-dependent sodium ion perme [...] (1682 aa) 
0.828 
 
SCN4A sodium channel, voltage-gated, type IV, alpha subunit; This 
protein mediates the voltage-depend [...] (1836 aa) 
0.827 
 
SCN9A sodium channel, voltage-gated, type IX, alpha subunit; Mediates 
the voltage-dependent sodium io [...] (1977 aa) 
0.820 
 
KCNK18 potassium channel, subfamily K, member 18; Outward rectifying 
potassium channel. Produces rapid [...] (384 aa) 
0.819 
 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1; 
Energy-dependent efflux pump responsibl [...] (1280 aa) 
0.814 
 
SCN5A sodium channel, voltage-gated, type V, alpha subunit; This protein 
mediates the voltage-depende [...] (2016 aa) 
0.800 
 
SCN11A sodium channel, voltage-gated, type XI, alpha subunit; This 
protein mediates the voltage-depend [...] (1791 aa) 
0.800 
 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.750 
 
DRD2 dopamine receptor D2; This is one of the five types (D1 to D5) of 
receptors for dopamine. The a [...] (443 aa) 
0.729 
 
DBH dopamine beta-hydroxylase (dopamine beta-monooxygenase); 
Conversion of dopamine to noradrenalin [...] (617 aa) 
0.700 
 
CYP17A1 cytochrome P450, family 17, subfamily A, polypeptide 1; 
Conversion of pregnenolone and progeste [...] (508 aa) 
0.700 
 
HSD3B2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 2; 3-beta-HSD is a b [...] (372 aa) 
0.700 
 
MC2R melanocortin 2 receptor (adrenocorticotropic hormone); Receptor 
for ACTH. This receptor is medi [...] (297 aa) 
0.700 
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CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6; 
Cytochromes P450 are a group of heme-thi [...] (491 aa) 
0.700 
 
CYP2A6 cytochrome P450, family 2, subfamily A, polypeptide 7; 
Cytochromes P450 are a group of heme-thi [...] (494 aa) 
0.700 
 
KCNH2 potassium voltage-gated channel, subfamily H (eag-related), 
member 2; Pore-forming (alpha) subu [...] (1159 aa) 
0.700 
 
CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1; 
Catalyzes the formation of aromatic C18 [...] (503 aa) 
0.700 
 
CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 1; 
Metabolizes several precarcinogens, drug [...] (493 aa) 
0.700 
 
NR3C1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid 
receptor); Receptor for glucoco [...] (778 aa) 
0.700 
 
GNLY granulysin; Antimicrobial protein that kills intracellular pathogens. 
Active against a broad ra [...] (145 aa) 
0.587 
 
12.7 Nevirapine 
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Predicted Functional Partners: 
 
CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6; 
Cytochromes P450 are a group of heme-thi [...] (491 aa) 
0.969 
 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.862 
 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5; 
Cytochromes P450 are a group of heme-thi [...] (502 aa) 
0.831 
 
CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6; 
Responsible for the metabolism of many d [...] (497 aa) 
0.825 
 
CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9; 
Cytochromes P450 are a group of heme-thi [...] (490 aa) 
0.823 
 
CYP2A6 cytochrome P450, family 2, subfamily A, polypeptide 7; 
Cytochromes P450 are a group of heme-thi [...] (494 aa) 
0.814 
 
INS insulin; Insulin decreases blood glucose concentration. It increases 
cell permeability to monos [...] (200 aa) 
0.814 
 
CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2; 
Cytochromes P450 are a group of heme-thi [...] (516 aa) 
0.813 
 
CYP3A7 cytochrome P450, family 3, subfamily A, polypeptide 7; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.800 
 
IL6 interleukin 6 (interferon, beta 2); Cytokine with a wide variety of 
biological functions. It is [...] (212 aa) 
0.700 
 
CD4 CD4 molecule; Accessory protein for MHC class-II antigen/T-cell 
receptor interaction. May regul [...] (458 aa) 
0.549 
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12.8 Phenytoin 
 
Predicted Functional Partners: 
 
CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9; 
Cytochromes P450 are a group of heme-thi [...] (490 aa) 
0.992 
 
CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19; 
Responsible for the metabolism of a num [...] (490 aa) 
0.989 
 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.987 
 
CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6; 
Cytochromes P450 are a group of heme-thi [...] (491 aa) 
0.971 
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CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6; 
Responsible for the metabolism of many d [...] (497 aa) 
0.940 
 
ALB albumin; Serum albumin, the main protein of plasma, has a good 
binding capacity for water, Ca(2 [...] (609 aa) 
0.925 
 
CYP2C18 cytochrome P450, family 2, subfamily C, polypeptide 18; 
Cytochromes P450 are a group of heme-th [...] (490 aa) 
0.925 
 
CYP2A13 cytochrome P450, family 2, subfamily A, polypeptide 13; 
Exhibits a coumarin 7-hydroxylase activ [...] (494 aa) 
0.913 
 
SHBG sex hormone-binding globulin; Functions as an androgen 
transport protein, but may also be invol [...] (402 aa) 
0.909 
 
SCN1A sodium channel, voltage-gated, type I, alpha subunit; Mediates 
the voltage-dependent sodium ion [...] (1998 aa) 
0.879 
 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5; 
Cytochromes P450 are a group of heme-thi [...] (502 aa) 
0.861 
 
CYP2C8 cytochrome P450, family 2, subfamily C, polypeptide 8; 
Cytochromes P450 are a group of heme-thi [...] (490 aa) 
0.860 
 
SCN4A sodium channel, voltage-gated, type IV, alpha subunit; This 
protein mediates the voltage-depend [...] (1836 aa) 
0.856 
 
SCN8A sodium channel, voltage gated, type VIII, alpha subunit; 
Mediates the voltage-dependent sodium [...] (1980 aa) 
0.850 
 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1; 
Energy-dependent efflux pump responsibl [...] (1280 aa) 
0.850 
 
PTH parathyroid hormone; PTH elevates calcium level by dissolving 
the salts in bone and preventing [...] (115 aa) 
0.849 
 
SCN3A sodium channel, voltage-gated, type III, alpha subunit; Mediates 
the voltage-dependent sodium i [...] (2000 aa) 
0.841 
 
INS insulin; Insulin decreases blood glucose concentration. It 
increases cell permeability to monos [...] (200 aa) 
0.836 
 
NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, zeta; Involved in [...] (718 aa) 
0.833 
 
CYP3A7 cytochrome P450, family 3, subfamily A, polypeptide 7; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.825 
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SCN7A sodium channel, voltage-gated, type VII, alpha; Mediates the 
voltage-dependent sodium ion perme [...] (1682 aa) 
0.824 
 
SCN10A sodium channel, voltage-gated, type X, alpha subunit; This 
protein mediates the voltage-depende [...] (1956 aa) 
0.819 
 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2; 
Mediates hepatobiliary excretion of nu [...] (1545 aa) 
0.819 
 
SST somatostatin; Somatostatin inhibits the release of somatotropin 
(116 aa) 
0.819 
 
SCN5A sodium channel, voltage-gated, type V, alpha subunit; This 
protein mediates the voltage-depende [...] (2016 aa) 
0.813 
 
SLCO1C1 solute carrier organic anion transporter family, member 1C1; 
Mediates the Na(+)-independent hig [...] (712 aa) 
0.810 
 
SCN11A sodium channel, voltage-gated, type XI, alpha subunit; This 
protein mediates the voltage-depend [...] (1791 aa) 
0.800 
 
CYP11B1 cytochrome P450, family 11, subfamily B, polypeptide 1; Has 
steroid 11-beta-hydroxylase activit [...] (503 aa) 
0.800 
 
SCN1B sodium channel, voltage-gated, type I, beta; Crucial in the 
assembly, expression, and functiona [...] (268 aa) 
0.789 
 
SCN2A sodium channel, voltage-gated, type II, alpha subunit; Mediates 
the voltage-dependent sodium io [...] (2005 aa) 
0.770 
 
NR1I3 nuclear receptor subfamily 1, group I, member 3; Binds and 
transactivates the retinoic acid res [...] (357 aa) 
0.764 
 
NR1I2 nuclear receptor subfamily 1, group I, member 2; Nuclear 
receptor that binds and is activated b [...] (473 aa) 
0.747 
 
NOS1 nitric oxide synthase 1 (neuronal); Produces nitric oxide (NO) 
which is a messenger molecule wi [...] (1434 aa) 
0.738 
 
IL1A interleukin 1, alpha; Produced by activated macrophages, IL-1 
stimulates thymocyte proliferatio [...] (271 aa) 
0.733 
 
CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1; 
Catalyzes the formation of aromatic C18 [...] (503 aa) 
0.716 
 
CTSL1 cathepsin L1; Important for the overall degradation of proteins in 
lysosomes (333 aa) 
0.700 
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CTSB cathepsin B; Thiol protease which is believed to participate in 
intracellular degradation and t [...] (339 aa) 
0.700 
 
MGMT O-6-methylguanine-DNA methyltransferase; Involved in the 
cellular defense against the biologica [...] (238 aa) 
0.700 
 
MAPK3 mitogen-activated protein kinase 3; Involved in both the initiation 
and regulation of meiosis, [...] (379 aa) 
0.700 
 
KCNH2 potassium voltage-gated channel, subfamily H (eag-related), 
member 2; Pore-forming (alpha) subu [...] (1159 aa) 
0.700 
 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha; Inhibits t [...] (317 aa) 
0.700 
 
MAPK1 mitogen-activated protein kinase 1; Involved in both the initiation 
and regulation of meiosis, [...] (360 aa) 
0.700 
 
DPH3 DPH3, KTI11 homolog (S. cerevisiae); Essential for the first step 
in the synthesis of diphthami [...] (82 aa) 
0.464 
 
CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 1; 
Metabolizes several precarcinogens, drug [...] (493 aa) 
0.455 
 
DPH2 DPH2 homolog (S. cerevisiae); Required for the first step in the 
synthesis of diphthamide, a po [...] (489 aa) 
0.454 
 
CYP2D7P1 cytochrome P450, family 2, subfamily D, polypeptide 7 
pseudogene 1 (497 aa) 
0.422 
 
PPIG peptidylprolyl isomerase G (cyclophilin G); PPIases accelerate 
the folding of proteins. It cata [...] (754 aa) 
0.416 
 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor); 
Integrin alpha-2/beta-1 is a rece [...] (1181 aa) 
0.404 
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12.9 Propylthiouracil 
 
Predicted Functional Partners: 
 
TPO thyroid peroxidase; Iodination and coupling of the hormonogenic 
tyrosines in thyroglobulin to y [...] (933 aa) 
0.987 
 
MPO myeloperoxidase; Part of the host defense system of 
polymorphonuclear leukocytes. It is respons [...] (745 aa) 
0.984 
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DIO1 deiodinase, iodothyronine, type I; Responsible for the 
deiodination of T4 (3,5,3',5'- tetraiodo [...] (249 aa) 
0.978 
 
TG thyroglobulin; Precursor of the iodinated thyroid hormones 
thyroxine (T4) and triiodothyronine [...] (2768 aa) 
0.932 
 
DIO2 deiodinase, iodothyronine, type II; Responsible for the 
deiodination of T4 (3,5,3',5'- tetraiod [...] (273 aa) 
0.904 
 
DIO3 deiodinase, iodothyronine, type III; Responsible for the 
deiodination of T4 (3,5,3',5'- tetraio [...] (278 aa) 
0.903 
 
CD79A CD79a molecule, immunoglobulin-associated alpha; Required in 
cooperation with CD79B for initiat [...] (226 aa) 
0.900 
 
ODC1 ornithine decarboxylase 1 (461 aa) 0.818 
 
CRH corticotropin releasing hormone; This hormone from 
hypothalamus regulates the release of cortic [...] (196 aa) 
0.810 
 
G6PD glucose-6-phosphate dehydrogenase; Produces pentose sugars for 
nucleic acid synthesis and main [...] (545 aa) 
0.800 
 
DBH dopamine beta-hydroxylase (dopamine beta-monooxygenase); 
Conversion of dopamine to noradrenalin [...] (617 aa) 
0.800 
 
PRB3 proline-rich protein BstNI subfamily 3; Acts as a receptor for the 
Gram-negative bacterium F.nu [...] (309 aa) 
0.800 
 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1; 
Cytochromes P450 are a group of heme-thi [...] (512 aa) 
0.800 
 
PTEN phosphatase and tensin homolog; Tumor suppressor. Acts as a 
dual-specificity protein phosphatas [...] (403 aa) 
0.800 
 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4; 
Cytochromes P450 are a group of heme-thi [...] (503 aa) 
0.800 
 
STAR steroidogenic acute regulatory protein; Plays a key role in steroid 
hormone synthesis by enhanc [...] (285 aa) 
0.800 
 
REN renin; Renin is a highly specific endopeptidase, whose only 
known function is to generate angio [...] (406 aa) 
0.800 
 
KCNA5 potassium voltage-gated channel, shaker-related subfamily, 
member 5; Mediates the voltage-depen [...] (613 aa) 
0.800 
 
TMSB10 thymosin beta 10; Plays an important role in the organization of 
the cytoskeleton. Binds to and [...] (44 aa) 
0.800 
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EPX eosinophil peroxidase; Mediates tyrosine nitration of secondary 
granule proteins in mature rest [...] (715 aa) 
0.800 
 
TAS2R14 taste receptor, type 2, member 14; Receptor that may play a role 
in the perception of bitternes [...] (317 aa) 
0.728 
 
TAS2R10 taste receptor, type 2, member 10; Gustducin-coupled strychnine 
receptor implicated in the perc [...] (307 aa) 
0.716 
 
TAS2R38 taste receptor, type 2, member 38; Receptor that may play a role 
in the perception of bitternes [...] (333 aa) 
0.690 
 
TSHR thyroid stimulating hormone receptor; Receptor for thyrothropin. 
Plays a central role in contro [...] (764 aa) 
0.653 
 
GNAT3 guanine nucleotide binding protein, alpha transducing 3; Guanine 
nucleotide-binding protein (G [...] (354 aa) 
0.637 
 
TAS2R4 taste receptor, type 2, member 4; Gustducin-coupled receptor for 
denatonium and N(6)- propyl-2- [...] (299 aa) 
0.604 
 
TAS2R1 taste receptor, type 2, member 1; Receptor that may play a role in 
the perception of bitterness [...] (299 aa) 
0.576 
 
TRH thyrotropin-releasing hormone; Functions as a regulator of the 
biosynthesis of TSH in the anter [...] (242 aa) 
0.503 
 
TAS2R30 taste receptor, type 2, member 46; Receptor that may play a role 
in the perception of bitternes [...] (299 aa) 
0.476 
 
SERPINA7 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 7; Major thyr [...] (415 aa) 
0.424 
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12.10 Sulfasalazine 
 
Predicted Functional Partners: 
 
CRP C-reactive protein, pentraxin-related; Displays several 
functions associated with host defense- [...] (224 aa) 
0.931 
 
NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase); 
Participates in the detoxification of a [...] (290 aa) 
0.917 
 
MPO myeloperoxidase; Part of the host defense system of 
polymorphonuclear leukocytes. It is respons [...] (745 aa) 
0.915 
 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, alpha; Inhibits t [...] (317 aa) 
0.915 
Appendix 4: Results from STITCH 4.0 
400 
 
 
ENSG00000204490 Tumor necrosis factor Precursor (TNF-alpha)(Tumor 
necrosis factor ligand superfamily member 2)( [...] 
(233 aa) 
0.900 
 
ALOX5 arachidonate 5-lipoxygenase; Catalyzes the first step in 
leukotriene biosynthesis, and thereby [...] (674 aa) 
0.900 
 
IL1B interleukin 1, beta; Produced by activated macrophages, 
IL-1 stimulates thymocyte proliferation [...] (269 aa) 
0.852 
 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase); May have [...] 
(604 aa) 
0.831 
 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 
2; Xenobiotic transporter that may play an i [...] (655 aa) 
0.831 
 
SLC46A1 solute carrier family 46 (folate transporter), member 1; 
Has been shown to act both as an intes [...] (459 aa) 
0.817 
 
SLC7A11 solute carrier family 7, (cationic amino acid transporter, 
y+ system) member 11; Sodium-indepen [...] (501 aa) 
0.816 
 
NFKB2 nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 2 (p49/p100); NF-kappa-B is [...] (900 aa) 
0.814 
 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase); May play [...] 
(707 aa) 
0.809 
 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 2; Mediates hepatobiliary excretion of nu [...] 
(1545 aa) 
0.800 
 
CHUK conserved helix-loop-helix ubiquitous kinase; Acts as 
part of the IKK complex in the convention [...] (745 aa) 
0.800 
 
PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin 
G/H synthase and cyclooxygenase); May play [...] 
(599 aa) 
0.800 
 
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-
cells, kinase beta; Acts as part of the [...] (756 aa) 
0.800 
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PPARG peroxisome proliferator-activated receptor gamma; 
Receptor that binds peroxisome proliferators [...] 
(505 aa) 
0.800 
 
ACAT1 acetyl-Coenzyme A acetyltransferase 1; Plays a major 
role in ketone body metabolism (427 aa) 
0.800 
 
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase; Bifunctiona [...] 
(592 aa) 
0.800 
 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5; 
Cytochromes P450 are a group of heme-thi [...] (502 aa) 
0.800 
 
ICAM1 intercellular adhesion molecule 1; ICAM proteins are 
ligands for the leukocyte adhesion protein [...] (532 aa) 
0.787 
 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 
(avian); NF-kappa-B is a pleiotropic trans [...] (551 aa) 
0.751 
 
MTHFR 5,10-methylenetetrahydrofolate reductase (NADPH); 
Catalyzes the conversion of 5,10- methylenete [...] 
(656 aa) 
0.729 
 
THRA thyroid hormone receptor, alpha (erythroblastic leukemia 
viral (v-erb-a) oncogene homolog, avia [...] (490 aa) 
0.719 
 
CASP3 caspase 3, apoptosis-related cysteine peptidase; Involved 
in the activation cascade of caspases [...] (277 aa) 
0.715 
 
HIF1A hypoxia inducible factor 1, alpha subunit (basic helix-
loop-helix transcription factor); Functi [...] (826 aa) 
0.700 
 
CASP9 caspase 9, apoptosis-related cysteine peptidase; Involved 
in the activation cascade of caspases [...] (416 aa) 
0.700 
 
TBXAS1 thromboxane A synthase 1 (platelet) (534 aa) 0.700 
 
ALOX5AP arachidonate 5-lipoxygenase-activating protein; Required 
for leukotriene biosynthesis by ALOX5 [...] (161 aa) 
0.583 
 
ALOX15B arachidonate 15-lipoxygenase, type B; Converts 
arachidonic acid exclusively to 15S- hydroperoxy [...] 
(676 aa) 
0.583 
 
ALOX15 arachidonate 15-lipoxygenase; Converts arachidonic acid 
to 15S- hydroperoxyeicosatetraenoic aci [...] (662 aa) 
0.583 
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NOS2 nitric oxide synthase 2, inducible; Produces nitric oxide 
(NO) which is a messenger molecule wi [...] (1153 aa) 
0.561 
 
ENSG00000168937 Putative uncharacterized protein ENSP00000305638 
Fragment (68 aa) 
0.561 
 
ENSG00000167494 Putative uncharacterized protein ENSP00000300983 
Fragment (115 aa) 
0.561 
 
TNFRSF1B tumor necrosis factor receptor superfamily, member 1B; 
Receptor with high affinity for TNFSF2/T [...] (461 aa) 
0.529 
 
12.11 Sulindac 
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Predicted Functional Partners: 
 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase); May have [...] (604 aa) 
0.996 
 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa; Involved 
in the regulation of cell adhesi [...] (781 aa) 
0.984 
 
FMO3 flavin containing monooxygenase 3; Involved in the oxidative 
metabolism of a variety of xenobio [...] (532 aa) 
0.981 
 
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta; Acts as part of the [...] (756 aa) 
0.979 
 
PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase); May play [...] (599 aa) 
0.972 
 
BAX BCL2-associated X protein; Accelerates programmed cell death 
by binding to, and antagonizing th [...] (218 aa) 
0.950 
 
CASP3 caspase 3, apoptosis-related cysteine peptidase; Involved in the 
activation cascade of caspases [...] (277 aa) 
0.924 
 
RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian); 
NF-kappa-B is a pleiotropic trans [...] (551 aa) 
0.921 
 
CCND1 cyclin D1; Essential for the control of the cell cycle at the G1/S 
(start) transition (295 aa) 
0.921 
 
PPARD peroxisome proliferator-activated receptor delta; Ligand-
activated transcription factor. Recept [...] (441 aa) 
0.911 
 
REN renin; Renin is a highly specific endopeptidase, whose only 
known function is to generate angio [...] (406 aa) 
0.909 
 
GDF15 growth differentiation factor 15 (308 aa) 0.855 
 
BIRC5 baculoviral IAP repeat-containing 5; Component of the 
chromosomal passenger complex (CPC), a co [...] (165 aa) 
0.852 
 
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b; 
Receptor for the cytotoxic ligand TNFSF [...] (440 aa) 
0.852 
 
CASP8 caspase 8, apoptosis-related cysteine peptidase; Most upstream 
protease of the activation casca [...] (538 aa) 
0.843 
 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1); May be the 
important intermediate by which p5 [...] (164 aa) 
0.833 
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EGFR epidermal growth factor receptor (erythroblastic leukemia viral 
(v-erb-b) oncogene homolog, avi [...] (1210 aa) 
0.831 
 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1; 
Cytochromes P450 are a group of heme-thi [...] (512 aa) 
0.824 
 
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene [...] (1255 aa) 
0.823 
 
SAT1 spermidine/spermine N1-acetyltransferase 1; Enzyme which 
catalyzes the acetylation of polyamine [...] (171 aa) 
0.818 
 
DIABLO diablo homolog (Drosophila); Promotes apoptosis by activating 
caspases in the cytochrome c/Apaf [...] (239 aa) 
0.818 
 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine); Degrades 
casein, gelatins of types I, III, IV, [...] (267 aa) 
0.816 
 
EGR1 early growth response 1; Transcriptional regulator. Recognizes 
and binds to the DNA sequence 5' [...] (543 aa) 
0.812 
 
S100A4 S100 calcium binding protein A4 (101 aa) 0.800 
 
SP1 Sp1 transcription factor; Transcription factor that can activate or 
repress transcription in re [...] (785 aa) 
0.800 
 
HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa); 
Probably plays a role in facilit [...] (654 aa) 
0.800 
 
C8orf4 Uncharacterized protein C8orf4 (Thyroid cancer protein 1)(TC-
1); May decrease apoptosis (106 aa) 
0.800 
 
LEF1 lymphoid enhancer-binding factor 1; Participates in the Wnt 
signaling pathway. Activates transc [...] (399 aa) 
0.800 
 
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, epsilon polypeptide; Ad [...] (255 aa) 
0.800 
 
ILK integrin-linked kinase; Receptor-proximal protein kinase 
regulating integrin- mediated signal t [...] (452 aa) 
0.770 
 
PTGER4 prostaglandin E receptor 4 (subtype EP4); Receptor for 
prostaglandin E2 (PGE2). The activity of [...] (488 aa) 
0.757 
 
CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2; 
Cytochromes P450 are a group of heme-thi [...] (516 aa) 
0.754 
 
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1; NF-kappa-B is a pleiotrop [...] (969 aa) 
0.748 
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TNFSF10 tumor necrosis factor (ligand) superfamily, member 10; 
Cytokine that binds to TNFRSF10A/TRAILR1 [...] (281 aa) 
0.747 
 
MDK midkine (neurite growth-promoting factor 2); Has heparin 
binding activity, and growth promoting [...] (143 aa) 
0.737 
 
AKR1C1 aldo-keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1; 20-alpha (3-alpha)-hydrox [...] (323 aa) 
0.731 
 
AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding protein [...] (323 aa) 
0.731 
 
AKR1C3 aldo-keto reductase family 1, member C3 (3-alpha 
hydroxysteroid dehydrogenase, type II); Cataly [...] (323 aa) 
0.731 
 
PARP1 poly (ADP-ribose) polymerase 1; Involved in the base excision 
repair (BER) pathway, by catalyzi [...] (1014 aa) 
0.728 
 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha; Inhibits t [...] (317 aa) 
0.728 
 
MAPK3 mitogen-activated protein kinase 3; Involved in both the 
initiation and regulation of meiosis, [...] (379 aa) 
0.727 
 
STAT3 signal transducer and activator of transcription 3 (acute-phase 
response factor); Transcription [...] (770 aa) 
0.726 
 
MAPK8 mitogen-activated protein kinase 8; Responds to activation by 
environmental stress and pro- inf [...] (427 aa) 
0.724 
 
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
(avian) (536 aa) 
0.722 
 
SLC22A6 solute carrier family 22 (organic anion transporter), member 6; 
Involved in the renal eliminati [...] (563 aa) 
0.712 
 
SLC22A7 solute carrier family 22 (organic anion transporter), member 7; 
Mediates sodium-independent mul [...] (548 aa) 
0.712 
 
SLC22A1 solute carrier family 22 (organic cation transporter), member 1; 
Translocates a broad array of [...] (554 aa) 
0.712 
 
SLC22A2 solute carrier family 22 (organic cation transporter), member 2; 
Mediates tubular uptake of org [...] (555 aa) 
0.712 
 
SLC22A11 solute carrier family 22 (organic anion/urate transporter), 
member 11; Mediates saturable uptak [...] (550 aa) 
0.712 
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SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1; May 
control the level of the estroge [...] (294 aa) 
0.710 
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Table 13.1  SMARTS Atomic Primitives, taken from the SMARTS theory manual(204). 
Symbol Symbol name Atomic property 
requirements 
Default 
*  wildcard any atom (no default) 
a aromatic aromatic (no default) 
A aliphatic aliphatic  (no default) 
D<n> degree <n> explicit connections exactly one 
H<n> total-H-count <n> attached hydrogens exactly one1 
h<n> implicit-H-
count 
<n> implicit hydrogens at least one 
R<n> ring 
membership 
in <n> SSSR rings any ring atom 
r<n>  ring size in smallest SSSR ring of size 
<n> 
any ring atom 
v<n> valence total bond order <n>  exactly one2 
X<n> connectivity <n> total connections exactly one2 
x<n> ring 
connectivity 
<n> total ring connections at least one2 
- <n> negative charge -<n> charge -1 charge (-- is -2, etc) 
+<n> positive charge +<n> formal charge +1 charge (++ is +2, etc) 
#n atomic number atomic number <n> (no default)2 
@ chirality anticlockwise anticlockwise, default 
class2 
@@ chirality clockwise clockwise, default class2 
@<c><n> chirality chiral class <c> chirality <n> (nodefault) 
@<c><n>? chiral or unspec chirality <c><n> or 
unspecified 
(no default) 
<n> atomic mass explicit atomic mass unspecified mass 
 
Table 13.2 SMARTS Bond Primitives, taken from the SMARTS theory manual(204). 
Symbol Atomic property requirements 
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-  single bond (aliphatic) 
/ directional bond "up" 
\ directional bond "down" 
/? directional bond "up or unspecified" 
\? directional bond "down or unspecified" 
= double bond 
#  triple bond 
:  aromatic bond 
~ any bond (wildcard) 
@ any ring bond 
 
Table 13.3 SMARTS Logical Operators, taken from the SMARTS theory manual(204). 
Symbol Expression Meaning 
exclamation !e1 not e1 
ampersand e1&e2 a1 and e2 (high precedence) 
comma e1,e2 e1 or e2 
semicolon  e1;e2 a1 and e2 (low precedence) 
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14 Appendix 6: Definitions of the pharmacophore features included 
in the genernation of pharmacophore hypotheses. 
 
Feature group Feature definition (SMARTS)  Feature 
type 
Hydrogen bond 
acceptor 
[N;X1]#[#6] 
 
vector 
 [N;X1]#CC 
 
vector 
 [N;X2](=C~[C,c])C 
 
vector 
 [N;X2](O)=N[a] 
 
vector 
 [N;X2](=N-O)[a] 
 
vector 
 [n;X2]1ccccc1 
 
vector 
 [n;X2]([a])([a]) 
 
vector 
 [N;X2](=C~[C,c])(~[*]) 
 
vector 
 [N;X3](C)(C)[N;X3]C 
 
vector 
 [N;X2](=C)(~[*]) 
 
vector 
 [N;X2](~[C,c])=[N;X2] 
 
vector 
 [n;X2]1c[nH]cc1  vector 
 O=[S;X4](=O)([!#8])([!#8])  vector 
 [O;X2]C  vector 
 [O;X2]N  vector 
 [O;X1]=[C,c]  vector 
 o  vector 
 [O;X2](C)C  vector 
 [O;X2]c1ncccc1  vector 
 [O;X2]~[a]  vector 
 O=PO([!#1])  vector 
 [O;X2]  vector 
 [S;X2](C)C  vector 
 [S;X2](=C)N  vector 
 O=C[O-,OH]  point 
 [O-,OH]C(=O)  point 
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Feature group Feature definition (SMARTS)  Feature 
type 
 [nH]([a])[a]  point 
 [#7;X3][*]=[O,S]  point 
 [N;X3](C)(C)[C;X3]  point 
 [N;X3][a]  point 
 N(=N=N)[#6]  point 
 [NH2](C(=O)[NH2])  point 
 [NH](C=O)(C=O)  point 
 [NH2](S(=O)(=O)[#6])[#6]  point 
 [NH](S(=O)(=O)[#6])[#6]  point 
 n1c([NH2])ccnc1([NH2])  point 
Hydrogen bond donor [#1][O;X2]  vector 
 [#1]S[#6]  vector 
 [#1][C;X2]#[C;X2]  vector 
 [#1][NX3]C(=[NX2])[#6]  vector 
 [#1][#7]  vector 
 [#1]OC(=O)  point 
 [#1]O[S;X3]=O  point 
 [#1]O[S;X4](=O)(=O)  point 
 [#1]O[P;X3]=O  point 
 [#1]O[P;X4]=O  point 
 [#1]n1nnnc1  point 
 [#1]N([S;X4](=O)(=O))(C(F)(F)(F))  point 
 [#1]([NH2;X3,NH3]([#6;X4]))  point 
 [#1]([NH;X3,NH2]([#6;X4])([#6;X4]))  point 
 [#1]([NH;X4]([#6;X4])([#6;X4])([#6;X4]))  point 
 [#1][NX3]C(=[NX2])[NX3]  point 
 [#1][NX3]C(=[NX3+])  point 
 [#1][NX3+]=C[NH2]  point 
 [#1][NX3]C(=[NX2])  point 
 [#1][NX3][#6](=[NX2,NX3+])[#6]  point 
Hydrophobic [a]F  group 
 [a]Cl  group 
 [a]Br  group 
 [a]I  group 
 [a]C(F)(F)(F)  group 
 [a][CH2]C(F)(F)(F)  group 
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Feature group Feature definition (SMARTS)  Feature 
type 
 [a]O[CH3]  group 
 [a]S[CH3]  group 
 [a]OC(F)(F)(F)  group 
 C(F)(F)(F)  group 
 F  group 
 Cl  group 
 Br  group 
 I  group 
 default_aromatic_surface  group 
 default_aliphatic_surface  group 
 C[S;X2]C  group 
 [S;X2]CC  group 
 [S;X2]C  group 
Positive [NX3][#6](=[NX2,NX3+])[#6]  group 
 [NX2,NX3+]=[#6]([NH;X3])([NH;X3])  group 
 [NX2,NX3+]=[#6]([NX3])([NX3])  group 
 n1c([NH2])ccnc1([NH2])  group 
 [NX2,NX3+]=C([NX3])c1ccccc1  group 
 [NH2;X3,NH3]([#6;X4])  group 
 [NH;X3,NH2]([#6;X4])([#6;X4])  group 
 [NX3,NH]([#6;X4])([#6;X4])([#6;X4])  group 
 N1CCCCC1  group 
 [+]  group 
Negative O=C[O-]  group 
 O=C[OH]  group 
 [S;X4](=O)(=O)([OH])  group 
 [S;X4](=O)(=O)([O-])  group 
 [S;X3](=O)([OH])  group 
 [S;X3](=O)([O-])  group 
 [P;X4](=O)([OH])([OH])  group 
 [P;X4](=O)([OH])([O-])  group 
 [P;X4](=O)([O-])  group 
 [P;X4](=O)([OH])  group 
 n1nc[nH]n1  group 
 n1ncnn1  group 
 [#1]N([S;X4](=O)(=O))(C(F)(F)(F))  group 
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Feature group Feature definition (SMARTS)  Feature 
type 
 [-]  group 
Armomatic ring default_aromatic_vector  group 
 default_aromatic_surface  group 
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15 Appendix 7: List of DrugBank molecules which match the 
toxicophore hypothesis 
Table 15.1 List of DrugBank molecules that match the toxicophore hypothesis as determined by the Phase Advanced 
Pharmacophore Screening tool using an Intersite Distance Matching Tolerance of 0.5Å. 
Drug name 
(1n)-4-n-butoxyphenylsulfonyl-(2r)-n-hydroxycarboxamido-(4s)-methanesulfonylamino-
pyrrolidine 
(1r)-n,6-dihydroxy-7-methoxy-2-[(4-methoxyphenyl)sulfonyl]-1,2,3,4-
tetrahydroisoquinoline-1-carboxamide 
(2e)-3-(3,4-dihydroxyphenyl)-n-[2-(4-hydroxyphenyl)ethyl]acrylamide 
(2r)-({4-[amino(imino)methyl]phenyl}amino){5-ethoxy-2-fluoro-3-[(3r)-tetrahydrofuran-3-
yloxy]phenyl}aceticacid 
(2r)-2-amino-3,3,3-trifluoro-n-hydroxy-2-{[(4-
phenoxyphenyl)sulfonyl]methyl}propanamide 
(2r)-amino(3,5-dihydroxyphenyl)acetic acid 
(2r)-amino(4-hydroxyphenyl)acetic acid 
(2s)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9h-purin-2-yl}amino)-3-
methylbutan-1-ol 
(2s)-2-{[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino}-3-methylbutan-1-ol 
(2s)-amino(4-hydroxyphenyl)acetic acid 
(2s)-hydroxy(4-hydroxyphenyl)ethanoic acid 
(2s,3s)-3-formyl-2-({[(4-nitrophenyl)sulfonyl]amino}methyl)pentanoic acid 
(2s,3s)-trans-dihydroquercetin 
(2-sulfanyl-3-phenylpropanoyl)-phe-tyr 
(3r,5z,8s,9s,11e)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro-1h-2-
benzoxacyclotetradecine-1,7(8h)-dione 
(3s,6s)-3,6-bis(4-hydroxybenzyl)piperazine-2,5-dione 
(4-hydroxymaltosephenyl)glycine 
(4r)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one 
(4r,5r)-5-amino-1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one 
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Drug name 
(5-{3-[5-(piperidin-1-ylmethyl)-1h-indol-2-yl]-1h-indazol-6-yl}-2h-1,2,3-triazol-4-
yl)methanol 
(5-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-1,2-dideoxy-ribofuranose-5-monophosphate 
(r)-1-para-nitro-phenyl-2-azido-ethanol 
[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydro-2-furanyl]methyl 
sulfamate 
[2-cytidylate-o'-phosphonyloxyl]-ethyl-trimethyl-ammonium 
[4-(4-hydroxy-benzyl)-2-(2-hydroxy-1-methyl-ethyl)-5-oxo-imidazolidin-1-yl]-acetic acid 
[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetic acid 
{(2z)-4-amino-2-[(4-methoxyphenyl)imino]-2,3-dihydro-1,3-thiazol-5-yl}(4-
methoxyphenyl)methanone 
1-((2-hydroxyethoxy)methyl)-5-(3-(benzyloxy)benzyl)pyrimidine-2,4(1h,3h)-dione 
1-((2-hydroxyethoxy)methyl)-5-(phenylthio)pyrimidine-2,4(1h,3h)-dione 
1-(2-hydroxyethyloxymethyl)-6-phenyl thiothymine 
1-(3-o-phosphono-beta-l-arabinofuranosyl)pyrimidine-2,4(1h,3h)-dione 
1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-cyanopyrazin-2-yl)urea 
1-(5-chloro-2-methoxyphenyl)-3-{6-[2-(dimethylamino)-1-methylethoxy]pyrazin-2-yl}urea 
1-(5'-phospho-beta-d-ribofuranosyl)barbituric acid 
1-[2-(4-ethoxy-3-fluoropyridin-2-yl)ethyl]-3-(5-methylpyridin-2-yl)thiourea 
10-propargyl-5,8-dideazafolic acid 
1-benzyl-3-(4-methoxy-benzenesulfonyl)-6-oxo-hexahydro-pyrimidine-4-carboxylic acid 
hydroxyamide 
1-deaza-adenosine 
1-o-[p-nitrophenyl]-beta-d-galactopyranose 
2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl dihydrogen phosphate 
2,4-dinitrophenyl 2-deoxy-2-fluoro-beta-d-allopyranoside 
2-[2-(4-chloro-phenylsulfanyl)-acetylamino]-3-(4-guanidino-phenyl)-propionamide 
2-[5-methanesulfonylamino-2-(4-aminophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-n-(3,3,3-
trifluoro-1-isopropyl-2-oxopropyl)acetamide 
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Drug name 
2-{1-[2-(2-amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-2-oxo-ethyl}-5,5-dimethyl-
thiazolidine-4-carboxylic acid 
2-{1-[2-amino-2-(4-hydroxy-phenyl)-acetylamino]-2-oxo-ethyl}-5,5-dimethyl-thiazolidine-
4-carboxylic acid 
2-{4-[4-(4-chloro-phenoxy)-benzenesulfonyl]-tetrahydro-pyran-4-yl}-n-hydroxy-acetamide 
2'-5'dideoxyuridine 
2-amino-3-(1-hydroperoxy-1h-indol-3-yl)propan-1-ol 
2-amino-adenosine 
2-chlorodideoxyadenosine 
2'-deoxycytidine 
2'-deoxycytidine-5'-monophosphate 
2'-deoxycytidine-5'-triphosphate 
2'-deoxyuridine 
2'-deoxyuridine 5'-alpha,beta-imido-diphosphate 
2'-deoxyuridine 5'-alpha,beta-imido-triphosphate 
2-fluoro-2'-deoxyadenosine 
2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7h-pyrrolo[2,3-
d]pyrimidin-4-yl]amino}benzamide 
2-hydroxy-5-({1-[(2-naphthyloxy)methyl]-3-oxoprop-1-enyl}amino)tyrosine 
2-hydroxy-5-({1-[(4-methylphenoxy)methyl]-3-oxoprop-1-enyl}amino)-l-tyrosine 
2-hydroxy-5-(2-mercapto-ethylsulfamoyl)-benzoic acid 
2-hydroxy-5-{[(1e)-2-phenylethylidene]amino}-l-tyrosine 
2-mercapto-n-[1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-
yl]acetamide 
2-methyl-2-(4-{[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-
yl}carbonyl)amino]methyl}phenoxy)propanoic acid 
2-methylthio-n6-isopentenyl-adenosine-5'-monophosphate 
2-ribofuranosyl-3-iodo-2,3-dihydro-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine 
3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one 
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Drug name 
3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1h-
indole 
3-amino-6-hydroxy-tyrosine 
3-chloro-4-hydroxyphenylglycine 
3-deaza-adenosine 
3-deazacytidine 
3'-deoxy 3'-amino adenosine-5'-diphosphate 
3-deoxyguanosine 
3-fluorotyrosine 
3-iodo-tyrosine 
3'-oxo-adenosine 
3'-uridinemonophosphate 
4-[(7-oxo-7h-thiazolo[5,4-e]indol-8-ylmethyl)-amino]-n-pyridin-2-yl-benzenesulfonamide 
4-{[(1r,2s)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-
(trifluoromethyl)benzonitrile 
4-amino-n-[(2-sulfanylethyl)carbamoyl]benzenesulfonamide 
4-hydroxyphenylglycine 
4-methylumbelliferyl-alpha-d-glucose 
4-nitrophenyl-ara 
5-(6-amino-9h-purin-9-yl)-4-hydroxytetrahydrofuran-3-yl dihydrogen phosphate 
5'-[[2-(aminooxy)ethyl]methylsulfonio]-5'-deoxy-adenosine 
5-[4-(1-carboxymethyl-2-oxo-propylcarbamoyl)-benzylsulfamoyl]-2-hydroxy-benzoic acid 
5'-{[4-(aminooxy)butyl](methyl)amino}-5'-deoxy-8-ethenyladenosine 
5-{3-[3-(2,4-dichloro-benzoyl)-ureido]-2-methyl-phenoxy}-pentanoic acid 
5-bromo-2'-deoxyuridine-5'-monophosphate 
5-bromo-cytidinemonophosphate 
5-bromo-n[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide 
5-bromovinyldeoxyuridine 
5-chloro-n-((1r,2s)-2-(4-(2-oxopyridin-1(2h)-yl)benzamido) cyclopentyl)thiophene-2-
carboxamide 
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Drug name 
5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide 
5'-deoxy-5'-(methylthio)-tubercidin 
5-fluoro-2'-deoxyuridine-5'-monophosphate 
5-fluorouridine 
5-formyl-6-hydrofolic acid 
5-hydroxynaphthalene-1-sulfonamide 
5-iodo-2'-deoxyuridine-5'-monophosphate 
5-iodotubercidin 
5-methyl-2'-deoxypseudouridine 
5-methylcytidine-5'-monophosphate 
5-methyluridine 5'-monophosphate 
5--monophosphate-9-beta-d-ribofuranosyl xanthine 
'5'-o-(n-(l-alanyl)-sulfamoyl)adenosine 
5'-o-(n-(l-cysteinyl)-sulfamoyl)adenosine 
5'-o-(n-(l-threonyl)-sulfamoyl)adenosine 
5'-o-(n-ethyl-sulfamoyl)adenosine 
5'-s-ethyl-5'-thioadenosine 
6-(2,6-dibromophenyl)pyrido[2,3-d]pyrimidine-2,7-diamine 
6-(2,6-dichlorophenyl)-2-{[3-(hydroxymethyl)phenyl]amino}-8-methylpyrido[2,3-
d]pyrimidin-7(8h)-one 
6-(2,6-dimethoxyphenyl)pyrido[2,3-d]pyrimidine-2,7-diamine 
6,7-dioxo-5h-8-ribitylaminolumazine 
6-aza-ump 
6-carbamimidoyl-4-(3-hydroxy-2-methyl-benzoylamino)-naphthalene-2-carboxylic acid 
methyl ester 
6-chloro-n-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-
carboxamide 
6-hydroxy-7,8-dihydro purine nucleoside 
6-o-phosphoryl inosine monophosphate 
7-(2,5-dihydropyrrol-1-yl)-6-phenyl-pyrido[6,5-d]pyrimidin-2-amine 
Appendix 7: List of DrugBank molecules which match the toxicophore hypothesis 
418 
 
Drug name 
7-(5-deoxy-beta-d-ribofuranosyl)-5-iodo-7h-pyrrolo[2,3-d]pyrimidin-4-amine 
7-alpha-d-ribofuranosyl-2-aminopurine-5'-phosphate 
7-alpha-d-ribofuranosyl-purine-5'-phosphate 
7-amino-2-tert-butyl-4-{[2-(1h-imidazol-4-yl)ethyl]amino}pyrido[2,3-d]pyrimidine-6-
carboxamide 
7-carboxy-5-hydroxy-12,13-dihydro-6h-indolo[2,3-a]pyrrolo[3,4-c]carbazole 
7-methylguanosine 
7n-methyl-8-hydroguanosine-5'-monophosphate 
8-bromo-adenosine-5'-monophosphate 
8-oxo-2'-deoxy-guanosine-5'-monophosphate 
9-beta-d-xylofuranosyl-adenine 
Acebutolol 
Acyclovir 
Acylated ceftazidime 
Adamantane-1-carboxylic acid-5-dimethylamino-naphthalene-1-sulfonylamino-butyl-
amide 
Adenosine 
Adenosine monophosphate 
Adenosine phosphonoacetic acid 
Adenosine-3'-5'-diphosphate 
Adenosine-5'-(dithio)phosphate 
Adenosine-5'-phosphosulfate 
Adenosine-5'-propylphosphate 
Adenosyl-ornithine 
Adenylosuccinic acid 
Al5927 
Alizapride 
Alpha-adenosine monophosphate 
Alpha-methylene adenosine monophosphate 
Alpha-n-dichloroacetyl-p-aminophenylserinol 
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Drug name 
Amiloride 
Aminacrine 
Aminophosphonic acid-guanylate ester 
Amoxicillin 
Anisomycin 
Arbutamine 
Arformoterol 
Aspartyl-adenosine-5'-monophosphate 
Balanol analog 1 
Balanol analog 2 
Balsalazide 
Bambuterol 
Bentiromide 
Benzoyl-tyrosine-alanine-methyl ketone 
Biopterin 
Bitolterol 
Bromamphenicol 
Bvdu-mp 
Capecitabine 
Carbidopa 
Carteolol 
Cefadroxil 
Cefdinir 
Cefotaxime group 
Cefprozil 
Ceftibuten 
Chloramphenicol 
Chloramphenicol succinate 
Chloroprocaine 
Cidofovir 
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Drug name 
Clenbuterol 
Cordycepin triphosphate 
Cp-coeleneterazine 
Cyclic adenosine monophosphate 
Cyclouridine 
Cytarabine 
Cytidine 5'-diphosphoglycerol 
Cytidine-2'-monophosphate 
Cytidine-3'-monophosphate 
Cytidine-5'-diphosphate 
Cytidine-5'-monophosphate 
Cytidine-5'-triphosphate 
Cytosine arabinose-5'-phosphate 
Dansylamide 
Deoxythymidine 
Deoxyuridine-5'-diphosphate 
Deoxyuridine-5'-triphosphate 
Dibucaine 
Didanosine 
Dipivefrin 
Droxidopa 
D-tyrosine 
Dyphylline 
Emtricitabine 
Epinephrine 
Esomeprazole 
Fenoterol 
Flavoxate 
Floxuridine 
Fludarabine 
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Drug name 
Folic acid 
Formoterol 
Ganciclovir 
Guanosine-3'-monophosphate 
Guanosine-5'-diphosphate 
Histidyl-adenosine monophosphate 
Honh-benzylmalonyl-l-alanylglycine-p-nitroanilide 
Idoxuridine 
Indacaterol 
Inosinic acid 
Iodo-willardiine 
Isoetharine 
Isoproterenol 
Labetalol 
Lamivudine 
Levodopa 
Levonordefrin 
L-tyrosinamide 
L-tyrosine 
Ly374571 
Melphalan 
Metaraminol 
Methoxamine 
Methyl 3-chloro-2-{3-[(2,5-dihydroxy-4-methoxyphenyl)amino]-3-oxopropyl}-4,6-
dihydroxybenzoate 
Methyldopa 
Metoclopramide 
Metyrosine 
Midodrine 
Mirabegron  
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Drug name 
Moxalactam derivative 
N-(1,4-dihydro-5h-tetrazol-5-ylidene)-9-oxo-9h-xanthene-2-sulfonamide 
N-(1-adamantyl)-n'-(4-guanidinobenzyl)urea 
N-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea 
N-(3,5-dimethoxyphenyl)imidodicarbonimidic diamide 
N(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid 
N-(4-aminobutanoyl)-s-(4-methoxybenzyl)-l-cysteinylglycine 
N-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea 
N-(7-carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide 
N-(cyclopropylmethyl)-4-(methyloxy)-3-({5-[3-(3-pyridinyl)phenyl]-1,3-oxazol-2-
yl}amino)benzenesulfonamide 
N-[(2r,3s)-3-amino-2-hydroxy-4-phenylbutyl]-4-methoxy-2,3,6-
trimethylbenzenesulfonamide 
N-[(4-methoxyphenyl)sulfonyl]-d-alanine 
N-[[3-fluoro-4-ethoxy-pyrid-2-yl]ethyl]-n'-[5-chloro-pyridyl]-thiourea 
N-[[3-fluoro-4-ethoxy-pyrid-2-yl]ethyl]-n'-[5-nitrilomethyl-pyridyl]-thiourea 
N-[1-(aminomethyl)cyclopropyl]-3-(benzylsulfonyl)-n~2~-[(1s)-2,2,2-trifluoro-1-(4-
hydroxyphenyl)ethyl]-l-alaninamide 
N-[2-(5-methyl-4h-1,2,4-triazol-3-yl)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine 
N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-
2-fluorophenyl}acetamide 
N-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide 
N-[4-({[5-(dimethylamino)-1-naphthyl]sulfonyl}amino)butyl]-3-sulfanylpropanamide 
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1h-indazol-3-yl]-2-(4-piperidin-1-ylphenyl)acetamide 
N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide 
N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-d-tryptophan 
N-{3-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-allyl}-2,3-dihydroxy-5-
nitro-benzamide 
N~2~-[(benzyloxy)carbonyl]-n-[(1s,2s)-2-hydroxy-1-(4-hydroxybenzyl)propyl]-l-
leucinamide 
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Drug name 
N~4~-methyl-n~4~-(3-methyl-1h-indazol-6-yl)-n~2~-(3,4,5-trimethoxyphenyl)pyrimidine-
2,4-diamine 
N6-isopentenyl-adenosine-5'-monophosphate 
N7-methyl-guanosine-5'-monophosphate 
N-acetyl-p-nitrophenylserinol 
Naratriptan 
Nelarabine 
Neopterin 
N-hydroxy 1n(4-methoxyphenyl)sulfonyl-4-(z,e-n-methoxyimino)pyrrolidine-2r-
carboxamide 
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonyl-piperazine-2-carboxamide 
N-hydroxy-2(r)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide 
hydrochloride 
N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2h-pyran-4-
carboxamide 
N-hydroxy-4-(methyl{[5-(2-pyridinyl)-2-thienyl]sulfonyl}amino)benzamide 
N-isobutyl-n-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid 
Nitrofurantoin 
N'-l-seryl-3'-amino-(3'-deoxy)-adenosine 
Norepinephrine 
Orciprenaline 
Orotidine-5'-monophosphate 
P-aminophenyl-alpha-d-galactopyranoside 
Pantoyl adenylate 
Para-nitrobenzyl glutaryl glycinic acid 
Pd173955 
Phenylephrine 
Phenyl-uridine-5'-diphosphate 
Phosphomethylphosphonic acid adenosyl ester 
Phosphomethylphosphonic acid guanosyl ester 
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Drug name 
Phosphonotyrosine 
Phosphoric acid mono-[3,4-dihydroxy-5-(5-hydroxy-benzoimidazol-1-yl)tetrahydro-furan-
2-ylmethyl] ester 
Phosphoric acid mono-[3-amino-5-(5-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-
tetrahydro-furan-2-ylmethyl] ester 
Phosporic acid mono-[3,4-dihydroxy-5-(5-methoxy-benzoimidazol-1-yl)-tetrahydro-furan-
2-ylmethyl] ester 
Pindolol 
Pioglitazone 
Pirbuterol 
Procaine 
Procaterol 
Pseudouridine-5'-monophosphate 
Puromycin 
Puromycin aminonucleoside-5'-monophosphate 
Rabeprazole 
Regadenoson 
Riboflavin 
Riboflavin monophosphate 
Ritodrine 
Rosiglitazone 
S-(p-nitrobenzyl)glutathione 
S-adenosyl-1,8-diamino-3-thiooctane 
S-adenosyl-l-homocysteine 
S-adenosylmethionine 
Sotalol 
Sulfacytine 
Sulfamerazine 
Sulfamethazine 
Sulfametopyrazine 
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Drug name 
Sulfapyridine 
Telbivudine 
Terbutaline 
Thymidine-5'- diphosphate 
Thymidine-5'-(dithio)phosphate 
Thymidine-5'-triphosphate 
Triamterene 
Trifluridine 
Tubercidin 
Tyrosinal 
Uridine 5'-triphosphate 
Uridine-5'-diphosphate 
Uridine-5'-monophosphate 
Valaciclovir 
Valganciclovir 
Vidarabine 
Way-151693 
Zalcitabine 
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Table 15.2 List of DrugBank molecules that match the toxicophore hypothesis as determined by the Pharmer program 
using a feature radii of 0.5Å. 
Drug name 
1-(2-hydroxyethyloxymethyl)-6-phenyl thiothymine 
1-((2-hydroxyethoxy)methyl)-5-(phenylthio)pyrimidine-2,4(1h,3h)-dione 
1-((2-hydroxyethoxy)methyl)-5-benzylpyrimidine-2,4(1h,3h)-dione 
1-benzyl-3-(4-methoxy-benzenesulfonyl)-6-oxo-hexahydro-pyrimidine-4-carboxylic acid 
hydroxyamide 
2'-5'dideoxyuridine 
2'-deoxyguanosine-5'-diphosphate 
2'-deoxyuridine 
2-hydroxy-5-({1-[(2-naphthyloxy)methyl]-3-oxoprop-1-enyl}amino)tyrosine 
2-hydroxy-5-({1-[(4-methylphenoxy)methyl]-3-oxoprop-1-enyl}amino)-l-tyrosine 
3-(2-chlorophenyl)-1-(2-{[(1s)-2-hydroxy-1,2-dimethylpropyl]amino}pyrimidin-4-yl)-1-(4-
methoxyphenyl)urea 
3-amino-6-hydroxy-tyrosine 
5--monophosphate-9-beta-d-ribofuranosyl xanthine 
5-bromovinyldeoxyuridine 
5-methyl-2'-deoxypseudouridine 
5-methyluridine 5'-monophosphate 
6-aza-ump 
6-hydroxy-1,6-dihydro purine nucleoside 
6-hydroxy-7,8-dihydro purine nucleoside 
6-o-phosphoryl inosine monophosphate 
7-methylguanosine 
7n-methyl-8-hydroguanosine-5'-diphosphate 
7n-methyl-8-hydroguanosine-5'-monophosphate 
8-benzyl-2-hydroperoxy-2-(4-hydroxy-benzyl)-6-(4-hydroxy-phenyl)-2h-imidazo[1,2-
a]pyrazin-3-one 
9-deazainosine-2',3'-o-ethylidenephosphonate 
(1r)-n,6-dihydroxy-7-methoxy-2-[(4-methoxyphenyl)sulfonyl]-1,2,3,4-
tetrahydroisoquinoline-1-carboxamide 
Appendix 7: List of DrugBank molecules which match the toxicophore hypothesis 
427 
 
Drug name 
(1n)-4-n-butoxyphenylsulfonyl-(2r)-n-hydroxycarboxamido-(4s)-methanesulfonylamino-
pyrrolidine 
(2e)-3-(3,4-dihydroxyphenyl)-2-iminopropanoic acid 
(2r)-n-hydroxy-2-[(3s)-3-methyl-3-{4-[(2-methylquinolin-4-yl)methoxy]phenyl}-2-
oxopyrrolidin-1-yl]propanamide 
(2s)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid 
Aminophosphonic acid-guanylate ester 
Amoxicillin 
Benzoyl-tyrosine-alanine-methyl ketone 
Balanol analog 1 
Carbidopa 
Cefprozil 
Deoxythymidine 
Dyclonine 
Guanosine-2',3'-o-methylidenephosphonate 
Guanosine 
Guanosine-2'-monophosphate 
Guanosine-3'-monophosphate 
Guanosine-5'-diphosphate 
Guanosine-5'-monophosphate 
Indacaterol 
Inosinic acid 
Moxalactam (hydrolyzed) 
N7-methyl-guanosine-5'-monophosphate 
N-(sulfanylacetyl)tyrosylprolylmethioninamide 
N-hydroxy 1n(4-methoxyphenyl)sulfonyl-4-(z,e-n-methoxyimino)pyrrolidine-2r-
carboxamide 
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonyl-piperazine-2-carboxamide 
N-[1-(aminomethyl)cyclopropyl]-3-(benzylsulfonyl)-n~2~-[(1s)-2,2,2-trifluoro-1-(4-
hydroxyphenyl)ethyl]-l-alaninamide 
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Drug name 
N-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide 
Neopterin 
Puromycin 
Phenyl-uridine-5'-diphosphate 
Phosphomethylphosphonic acid guanosyl ester 
Riboflavin 
Riboflavin monophosphate 
Sulfasalazine 
Uridine 
Valganciclovir 
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16 Appendix 8: A549 Cell Culture 
16.1 Preparation of Feeding Media 
A549 FEEDING MEDIA: The human alveolar epithelial cell line (A549) was purchased from 
American Type Culture Collection (ATCC, Manassas, VA) and was cultured in Ham’s F-12 
medium (Invitrogen, Carlsbad, CA) supplemented with penicillin (100 U/ml), streptomycin 
(100 µg/ml), and fetal bovine serum to a final concentration of 10%. Prepare ~ 500 mL of 
A549 FEEDING MEDIA by adding 11 mL pencillin-streptomycin 50X liquid (Invitrogen, 
Carlsbad, CA: C/N 15070-063) and 55.5 mL of heat-inactivated (56 C for 30 minutes) fetal 
bovine serum (Interpath, VIC, Australia) to 500 mL of F-12K Medium ((Invitrogen: C/N 
21127-022). 
16.2 Thawing Cells 
1. Retrieve vials from liquid nitrogen storage and hold in the 37oC water bath to 
thaw as quickly as possible. 
2. Thoroughly clean the outside of the vial with 80% ethanol. 
3. Add the ~ 1 mL of thawed cell suspension to 9 mL of A549 FEEDING MEDIA. 
Centrifuge at 1100 r.p.m. for 2 minutes. 
4. Remove supernatant by suction and add 10 mL of A549 FEEDING MEDIA and add 
to a 10 cm dish 
5. Incubate cells at 37oC, 5% CO2 overnight. 
6. On the following day, aspirate the media and add fresh 10 mL A549 FEEDING 
MEDIA (to remove DMSO and cellular debris). 
7. When cells are ready to split, ensure that you split at least 2 plates of the thawed 
culture, to refreeze therefore ensuring maintenance of stock cultures at low 
passage number. 
16.3 Freezing down cells  
To prepare stock cultures, plate cells so that they will be ~ 80% confluent on the day they 
will be frozen down. 
1. For each 10 cm plate to be frozen down, prepare a cryovial as follows 
Label each vial with cell line, initials, date and passage number 
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Add 100 μL of FBS 
Add 100 μL of sterile DMSO 
2. Trypsinize and centrifuge cells as in Appendix 4. 
3. Resuspend cell pellet in 800 μL of A549 FEEDING MEDIA. 
4. Transfer suspended cells to the pre-prepared cryo-vial and gently mix. 
5. Place cryovials in a foam rack and cover with a second foam rack. 
6. Transfer foam rack to the –80oC freezer for at least 24 hours. 
7. Transfer samples from the –80oC freezer to the liquid nitrogen long term 
storage. 
16.4 Splitting cells 
N.B. Cells should be split 1/3 two times per week (e.g. Monday and Thursday or Tuesday and 
Friday). 
1. To split cells, suction off media and wash 10 cm plates with 2 x 5 mL of sterile 
PBS (Sigma: C/N D-8537). 
2. Suction off sterile PBS and replace with 2.5 mL of Trypsin-EDTA (Sigma: C/N T-
3924) and incubate at 37oC for ~ 2 minutes. Check cell detachment 
microscopically and agitate to facilitate detachment, if necessary. 
3. Add 2.5 mL of A549 FEEDING MEDIA and aspirate cells by gently pipetting 
(transfer solution to a 15 mL sterile centrifuge tube). 
4. Centrifuge at 1100 r.p.m. for 2 minutes. 
5. Remove supernatant by suction and resuspend cells in 3 mL of A549 FEEDING 
MEDIA. 
6. Transfer 1 mL of cells to 9 mL A549 FEEDING MEDIA in new 10 cm dishes.   
16.5 Plating Cells  
1. To trypsinize 10 cm dishes, suction off media and wash with 2 x 5 mL of sterile 
PBS. 
2. Suction off sterile PBS and replace with 2.5 mL of Trypsin-EDTA and incubate at 
37oC for ~ 2 minutes. Check cell attachment microscopically and agitate to 
facilitate detachment, if necessary. 
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3. Add 2.5 mL of A549 FEEDING MEDIA and transfer solution to a 15 mL sterile 
centrifuge tube. 
4. Centrifuge at 1100 r.p.m. for 2 minutes. 
5. Remove supernatant by suction and resuspend cells in 5 mL of relevant FEEDING 
MEDIA. 
6. Dilute 20 µL of this cell solution with 20 L of trypan blue solution and count 5 
squares on both sides of a haemocytometer. Average result, then multiply by 2 
(dilution factor), then multiply by 104. This is the number of cells/mL. Use 10X 
magnification. 
7. Plate cells according to experimental need, i.e. for Western blotting and RT-PCR 
in 6-wells (prepare 250,000 cells/mL in A549 FEEDING MEDIA so that when 2 mL 
is added to 6 well dishes 500,000 cells/well is achieved). 
TYPE PLATING DENSITY MEDIA PER WELL 
96-well 6,400 cells/well 0.1 mL 
6-well 500,000 cells/well 2 mL 
 
 
